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Summary
Each year, the American Heart Association (AHA), in conjunction with the Centers for 
Disease Control and Prevention, the National Institutes of Health, and other government 
agencies, brings together the most up-to-date statistics on heart disease, stroke, other 
vascular diseases, and their risk factors and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update is a valuable resource for researchers, clinicians, 
healthcare policy makers, media professionals, the lay public, and many others who seek the 
best national data available on heart disease, stroke, and other cardiovascular disease–related 
morbidity and mortality and the risks, quality of care, medical procedures and operations, 
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and costs associated with the management of these diseases in a single document. Indeed, 
since 1999, the Statistical Update has been cited >10 500 times in the literature, based on 
citations of all annual versions. In 2011 alone, the various Statistical Updates were cited 
≈1500 times (data from ISI Web of Science). In recent years, the Statistical Update has 
undergone some major changes with the addition of new chapters and major updates across 
multiple areas, as well as increasing the number of ways to access and use the information 
assembled.
For this year’s edition, the Statistics Committee, which produces the document for the AHA, 
updated all of the current chapters with the most recent nationally representative data and 
inclusion of relevant articles from the literature over the past year. This year’s edition also 
implements a new chapter organization to reflect the spectrum of cardiovascular health 
behaviors and health factors and risks, as well as subsequent complicating conditions, 
disease states, and outcomes. Also, the 2013 Statistical Update contains new data on the 
monitoring and benefits of cardiovascular health in the population, with additional new 
focus on evidence-based approaches to changing behaviors, implementation strategies, and 
implications of the AHA’s 2020 Impact Goals. Below are a few highlights from this year’s 
Update.
The 2013 Update Expands Data Coverage of the Epidemic of Poor Cardiovascular Health 
Behaviors and Their Antecedents and Consequences
• Adjusted population attributable fractions for cardiovascular disease (CVD) 
mortality were as follows1: 40.6% (95% confidence interval [CI], 24.5–54.6) for 
high blood pressure; 13.7% (95% CI, 4.8–22.3) for smoking; 13.2% (95% CI, 
3.5–29.2) for poor diet; 11.9% (95% CI, 1.3–22.3) for insufficient physical 
activity; and 8.8% (95% CI, 2.1–15.4) for abnormal glucose levels.
• Despite 4 decades of progress, in 2011, among Americans ≥18 years of age, 
21.3% of men and 16.7% of women continued to be cigarette smokers. In 2011, 
18.1% of students in grades 9 through 12 reported current cigarette use.
• The percentage of the nonsmoking population with detectable serum cotinine 
(indicating exposure to secondhand smoke) declined from 52.5% in 1999 to 2000 
to 40.1% in 2007 to 2008, with declines higher for those 3 to 11 years of age 
(−53.6%) and those 12 to 19 years of age (−46.5%) than for those 20 years of 
age and older (−36.7%).
• The proportion of youth (≤18 years of age) who report engaging in no regular 
physical activity is high, and the proportion increases with age. In 2011, among 
adolescents in grades 9 through 12, 17.7% of girls and 10.0% of boys reported 
that they had not engaged in ≥60 minutes of moderate-to-vigorous physical 
activity, defined as any activity that increased heart rate or breathing rate, even 
once in the previous 7 days, despite recommendations that children engage in 
such activity 7 days per week.
• Thirty two percent of adults reported engaging in no aerobic leisure-time 
physical activity.
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• Data from the National Health and Nutrition Examination Survey (NHANES) 
indicate that between 1971 and 2004, average total energy consumption among 
US adults increased by 22% in women (from 1542 to 1886 kcal/d) and by 10% 
in men (from 2450 to 2693 kcal/d).
• The increases in calories consumed during this time period are attributable 
primarily to greater average carbohydrate intake, in particular, of starches, 
refined grains, and sugars. Other specific changes related to increased caloric 
intake in the United States include larger portion sizes, greater food quantity and 
calories per meal, and increased consumption of sugar-sweetened beverages, 
snacks, commercially prepared (especially fast food) meals, and higher energy-
density foods.
• The estimated prevalence of overweight and obesity in US adults (≥20 years of 
age) is 154.7 million, which represents 68.2% of this group in 2010. Fully 34.6% 
of US adults are obese (body mass index ≥30 kg/m2). Men and women of all 
race/ethnic groups in the population are affected by the epidemic of overweight 
and obesity.
• Among children 2 to 19 years of age, 31.8% are overweight and obese (which 
represents 23.9 million children) and 16.9% are obese (12.7 million children). 
Mexican American boys and girls and African American girls are 
disproportionately affected. Over the past 3 decades, the prevalence of obesity in 
children 6 to 11 years of age has increased from ≈4% to >20%.
• Obesity (body mass index ≥30 kg/m2) is associated with marked excess mortality 
in the US population. Even more notable is the excess morbidity associated with 
overweight and obesity in terms of risk factor development and incidence of 
diabetes mellitus, CVD end points (including coronary heart disease, stroke, and 
heart failure), and numerous other health conditions, including asthma, cancer, 
end-stage renal disease, degenerative joint disease, and many others.
Prevalence and Control of Cardiovascular Health Factors and Risks Remains an Issue for 
Many Americans
• An estimated 31.9 million adults ≥20 years of age have total serum cholesterol 
levels ≥240 mg/dL, with a prevalence of 13.8%.
• Based on 2007 to 2010 data, 33.0% of US adults ≥20 years of age have 
hypertension. This represents 78 million US adults with hypertension. The 
prevalence of hypertension is nearly equal between men and women. African 
American adults have among the highest prevalence of hypertension (44%) in the 
world.
• Among hypertensive adults, ≈82% are aware of their condition and 75% are 
using antihypertensive medication, but only 53% of those with documented 
hypertension have their condition controlled to target levels.
• In 2010, an estimated 19.7 million Americans had diagnosed diabetes mellitus, 
representing 8.3% of the adult population. An additional 8.2 million had 
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undiagnosed diabetes mellitus, and 38.2% had prediabetes, with abnormal fasting 
glucose levels. African Americans, Mexican Americans, Hispanic/Latino 
individuals, and other ethnic minorities bear a strikingly disproportionate burden 
of diabetes mellitus in the United States.
• The prevalence of diabetes mellitus is increasing dramatically over time, in 
parallel with the increases in prevalence of overweight and obesity.
• On the basis of NHANES 2003–2006 data, the age-adjusted prevalence of 
metabolic syndrome, a cluster of major cardiovascular risk factors related to 
overweight/obesity and insulin resistance, is ≈34% (35.1% among men and 
32.6% among women).
Rates of Death Attributable to CVD Have Declined, but the Burden of Disease Remains 
High
• The 2009 overall rate of death attributable to CVD (International Classification 
of Diseases, 10th Revision, codes I00–I99) was 236.1 per 100 000. The rates 
were 281.4 per 100 000 for white males, 387.0 per 100 000 for black males, 
190.4 per 100 000 for white females, and 267.9 per 100 000 for black females.
• From 1999 to 2009, the relative rate of death attributable to CVD declined by 
32.7%. Yet in 2009, CVD (I00–I99; Q20–Q28) still accounted for 32.3% (787 
931) of all 2 437 163 deaths, or 1 of every 3 deaths in the United States.
• On the basis of 2009 death rate data, >2150 Americans die of CVD each day, an 
average of 1 death every 40 seconds. About 153 000 Americans who died of 
CVD (I00–I99) in 2009 were <65 years of age. In 2009, 34% of deaths 
attributable to CVD occurred before the age of 75 years, which is well before the 
average life expectancy of 78.5 years.
• Coronary heart disease alone caused ≈1 of every 6 deaths in the United States in 
2009. In 2009, 386 324 Americans died of coronary heart disease. Each year, an 
estimated ≈635 000 Americans have a new coronary attack (defined as first 
hospitalized myocardial infarction or coronary heart disease death) and ≈280 000 
have a recurrent attack. It is estimated that an additional 150 000 silent first 
myocardial infarctions occur each year. Approximately every 34 seconds, 1 
American has a coronary event, and approximately every 1 minute, an American 
will die of one.
• From 1999 to 2009, the relative rate of stroke death fell by 36.9% and the actual 
number of stroke deaths declined by 23.0%. Yet each year, ≈795 000 people 
continue to experience a new or recurrent stroke (ischemic or hemorrhagic). 
Approximately 610 000 of these are first attacks, and 185 000 are recurrent 
attacks. In 2009, stroke caused ≈1 of every 19 deaths in the United States. On 
average, every 40 seconds, someone in the United States has a stroke and dies of 
one approximately every 4 minutes.
• In 2009, 1 in 9 death certificates (274 601 deaths) in the United States mentioned 
heart failure. Heart failure was the underlying cause in 56 410 of those deaths in 
et al. Page 4
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2009. The number of any-mention deaths attributable to heart failure was 
approximately as high in 1995 (287 000) as it was in 2009 (275 000). 
Additionally, hospital discharges for heart failure remained essentially 
unchanged from 2000 to 2010, with first-listed discharges of 1 008 000 and 1 
023 000, respectively.
The 2013 Update Provides Critical Data About Cardiovascular Quality of Care, Procedure 
Utilization, and Costs
In light of the current national focus on healthcare utilization, costs, and quality, it is critical 
to monitor and understand the magnitude of healthcare delivery and costs, as well as the 
quality of healthcare delivery, related to CVD risk factors and conditions. The Statistical 
Update provides these critical data in several sections.
Quality-of-Care Metrics for CVDs
Quality data are available from the AHA’s “Get With The Guidelines” programs for 
coronary artery disease and heart failure and from the American Stroke Association/AHA’s 
“Get With The Guidelines” program for acute stroke. Similar data from the Veterans 
Healthcare Administration, national Medicare and Medicaid data, and Acute Coronary 
Treatment and Intervention Outcomes Network (ACTION)–“Get With The Guidelines” 
Registry data are also reviewed. These data show impressive adherence to guideline 
recommendations for many, but not all, metrics of quality of care for these hospitalized 
patients. Data are also reviewed on screening for CVD risk factor levels and control.
Cardiovascular Procedure Use and Costs
• The total number of inpatient cardiovascular operations and procedures increased 
28%, from 5 939 000 in 2000 to 7 588 000 in 2010 (National Heart, Lung, and 
Blood Institute computation based on National Center for Health Statistics 
annual data).
• The total direct and indirect cost of CVD and stroke in the United States for 2009 
is estimated to be $312.6 billion. This figure includes health expenditures (direct 
costs, which include the cost of physicians and other professionals, hospital 
services, prescribed medications, home health care, and other medical durables) 
and lost productivity that results from morbidity and premature mortality 
(indirect costs).
• By comparison, in 2008, the estimated cost of all cancer and benign neoplasms 
was $228 billion ($93 billion in direct costs, $19 billion in morbidity indirect 
costs, and $116 billion in mortality indirect costs). CVD costs more than any 
other diagnostic group.
The AHA, through its Statistics Committee, continuously monitors and evaluates sources of 
data on heart disease and stroke in the United States to provide the most current data 
available in the Statistics Update.
Finally, it must be noted that this annual Statistical Update is the product of an entire year’s 
worth of effort by dedicated professionals, volunteer physicians and scientists, and 
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outstanding AHA staff members, without whom publication of this valuable resource would 
be impossible. Their contributions are gratefully acknowledged.
Alan S. Go, MD
Melanie B. Turner, MPH
On behalf of the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of NHANES prevalence estimates are for the 
latest year of the NHANES survey being used. Extrapolations for NHANES prevalence 
estimates are based on the census resident population for 2010 because this is the most 
recent year of NHANES data used in the Statistical Update.
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1. About These Statistics
The American Heart Association (AHA) works with the Centers for Disease Control and 
Prevention’s (CDC’s) National Center for Health Statistics (NCHS); the National Heart, 
Lung, and Blood Institute (NHLBI); the National Institute of Neurological Disorders and 
Stroke (NINDS); and other government agencies to derive the annual statistics in this Heart 
Disease and Stroke Statistical Update. This chapter describes the most important sources and 
the types of data we use from them. For more details, see Chapter 25 of this document, the 
Glossary.
The surveys used are:
• Behavioral Risk Factor Surveillance System (BRFSS)— ongoing telephone 
health survey system
• Greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS)—stroke 
incidence rates and outcomes within a biracial population
• Medical Expenditure Panel Survey (MEPS)—data on specific health services 
that Americans use, how frequently they use them, the cost of these services, and 
how the costs are paid
• National Health and Nutrition Examination Survey (NHANES)—disease and 
risk factor prevalence and nutrition statistics
• National Health Interview Survey (NHIS)—disease and risk factor prevalence
• National Hospital Discharge Survey (NHDS)—hospital inpatient discharges and 
procedures (discharged alive, dead, or status unknown)
• National Ambulatory Medical Care Survey (NAMCS)— physician office visits
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• National Home and Hospice Care Survey (NHHCS)—staff, services, and 
patients of home health and hospice agencies
• National Hospital Ambulatory Medical Care Survey (NHAMCS)—hospital 
outpatient and emergency department (ED) visits
• Nationwide Inpatient Sample of the Agency for Healthcare Research and Quality 
(AHRQ)—hospital inpatient discharges, procedures, and charges
• National Nursing Home Survey (NNHS)—nursing home residents
• National Vital Statistics System—national and state mortality data
• World Health Organization (WHO)—mortality rates by country
• Youth Risk Behavior Surveillance System (YRBSS)— health-risk behaviors in 
youth and young adults
Disease Prevalence
Prevalence is an estimate of how many people have a disease at a given point or period in 
time. The NCHS conducts health examination and health interview surveys that provide 
estimates of the prevalence of diseases and risk factors. In this Update, the health interview 
part of the NHANES is used for the prevalence of cardiovascular diseases (CVDs). 
NHANES is used more than the NHIS because in NHANES, angina pectoris (AP) is based 
on the Rose Questionnaire; estimates are made regularly for heart failure (HF); hypertension 
is based on blood pressure (BP) measurements and interviews; and an estimate can be made 
for total CVD, including myocardial infarction (MI), AP, HF, stroke, and hypertension.
Abbreviations Used in Chapter 1
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AP angina pectoris
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHS Cardiovascular Health Study
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
HD heart disease
HF heart failure
ICD International Classification of Diseases
ICD-9-CM International Classification of Diseases, Clinical Modification, 9th Revision
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ICD-10 International Classification of Diseases, 10th Revision
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHHCS National Home and Hospice Care Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institute of Neurological Disorders and Stroke
NNHS National Nursing Home Survey
PAD peripheral artery disease
WHO World Health Organization
YRBSS Youth Risk Behavior Surveillance System
See Glossary (Chapter 25) for explanation of terms.
A major emphasis of this Statistical Update is to present the latest estimates of the number 
of people in the United States who have specific conditions to provide a realistic estimate of 
burden. Most estimates based on NHANES prevalence rates are based on data collected 
from 2007 to 2010 (in most cases, these are the latest published figures). These are applied 
to census population estimates for 2010. Differences in population estimates based on 
extrapolations of rates beyond the data collection period by use of more recent census 
population estimates cannot be used to evaluate possible trends in prevalence. Trends can 
only be evaluated by comparing prevalence rates estimated from surveys conducted in 
different years.
Risk Factor Prevalence
The NHANES 2007–2010 data are used in this Update to present estimates of the 
percentage of people with high lipid values, diabetes mellitus (DM), overweight, and 
obesity. The NHIS is used for the prevalence of cigarette smoking and physical inactivity. 
Data for students in grades 9 through 12 are obtained from the YRBSS.
Incidence and Recurrent Attacks
An incidence rate refers to the number of new cases of a disease that develop in a population 
per unit of time. The unit of time for incidence is not necessarily 1 year, although we often 
discuss incidence in terms of 1 year. For some statistics, new and recurrent attacks or cases 
are combined. Our national incidence estimates for the various types of CVD are 
extrapolations to the US population from the Framingham Heart Study (FHS), the 
Atherosclerosis Risk in Communities (ARIC) study, and the Cardiovascular Health Study 
(CHS), all conducted by the NHLBI, as well as the GCNKSS, which is funded by the 
NINDS. The rates change only when new data are available; they are not computed annually. 
Do not compare the incidence or the rates with those in past editions of the Heart Disease 
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and Stroke Statistics Update (also known as the Heart and Stroke Statistical Update for 
editions before 2005). Doing so can lead to serious misinterpretation of time trends.
Mortality
Mortality data are presented according to the underlying cause of death. “Any-mention” 
mortality means that the condition was nominally selected as the underlying cause or was 
otherwise mentioned on the death certificate. For many deaths classified as attributable to 
CVD, selection of the single most likely underlying cause can be difficult when several 
major comorbidities are present, as is often the case in the elderly population. It is useful, 
therefore, to know the extent of mortality attributable to a given cause regardless of whether 
it is the underlying cause or a contributing cause (ie, its “any-mention” status). The number 
of deaths in 2009 with any mention of specific causes of death was tabulated by the NHLBI 
from the NCHS public-use electronic files on mortality.
The first set of statistics for each disease in this Update includes the number of deaths for 
which the disease is the underlying cause. Two exceptions are Chapter 9 (High Blood 
Pressure) and Chapter 19 (Cardiomyopathy and Heart Failure). High BP, or hypertension, 
increases the mortality risks of CVD and other diseases, and HF should be selected as an 
underlying cause only when the true underlying cause is not known. In this Update, 
hypertension and HF death rates are presented in 2 ways: (1) As nominally classified as the 
underlying cause and (2) as any-mention mortality.
National and state mortality data presented according to the underlying cause of death were 
computed from the mortality tables of the NCHS World Wide Web site, the Health Data 
Interactive data system of the NCHS, or the CDC compressed mortality file. Any-mention 
numbers of deaths were tabulated from the electronic mortality files of the NCHS World 
Wide Web site and from Health Data Interactive.
Population Estimates
In this publication, we have used national population estimates from the US Census Bureau 
for 2010 in the computation of morbidity data. NCHS population estimates for 2009 were 
used in the computation of death rate data. The Census Bureau World Wide Web site1 
contains these data, as well as information on the file layout.
Hospital Discharges and Ambulatory Care Visits
Estimates of the numbers of hospital discharges and numbers of procedures performed are 
for inpatients discharged from short-stay hospitals. Discharges include those discharged 
alive, dead, or with unknown status. Unless otherwise specified, discharges are listed 
according to the first-listed (primary) diagnosis, and procedures are listed according to all 
listed procedures (primary plus secondary). These estimates are from the NHDS of the 
NCHS unless otherwise noted. Ambulatory care visit data include patient visits to physician 
offices and hospital outpatient departments and EDs. Ambulatory care visit data reflect the 
first-listed (primary) diagnosis. These estimates are from NAMCS and NHAMCS of the 
NCHS.
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International Classification of Diseases
Morbidity (illness) and mortality (death) data in the United States have a standard 
classification system: the International Classification of Diseases (ICD). Approximately 
every 10 to 20 years, the ICD codes are revised to reflect changes over time in medical 
technology, diagnosis, or terminology. Where necessary for comparability of mortality 
trends across the 9th and 10th ICD revisions, comparability ratios computed by the NCHS 
are applied as noted.2 Effective with mortality data for 1999, we are using the 10th revision 
(ICD-10). It will be a few more years before the 10th revision is used for hospital discharge 
data and ambulatory care visit data, which are based on the International Classification of 
Diseases, Clinical Modification, 9th Revision (ICD-9-CM).3
Age Adjustment
Prevalence and mortality estimates for the United States or individual states comparing 
demographic groups or estimates over time either are age specific or are age adjusted to the 
2000 standard population by the direct method.4 International mortality data are age adjusted 
to the European standard.5 Unless otherwise stated, all death rates in this publication are age 
adjusted and are deaths per 100 000 population.
Data Years for National Estimates
In this Update, we estimate the annual number of new (incidence) and recurrent cases of a 
disease in the United States by extrapolating to the US population in 2010 from rates 
reported in a community- or hospital-based study or multiple studies. Age-adjusted 
incidence rates by sex and race are also given in this report as observed in the study or 
studies. For US mortality, most numbers and rates are for 2009. For disease and risk factor 
prevalence, most rates in this report are calculated from the 2007–2010 NHANES. Because 
NHANES is conducted only in the noninstitutionalized population, we extrapolated the rates 
to the total US population in 2008, recognizing that this probably underestimates the total 
prevalence, given the relatively high prevalence in the institutionalized population. The 
numbers and rates of hospital inpatient discharges for the United States are for 2010. 
Numbers of visits to physician offices, hospital EDs, and hospital outpatient departments are 
for 2010. Except as noted, economic cost estimates are for 2009.
Cardiovascular Disease
For data on hospitalizations, physician office visits, and mortality, CVD is defined according 
to ICD codes given in Chapter 25 of the present document. This definition includes all 
diseases of the circulatory system, as well as congenital CVD. Unless so specified, an 
estimate for total CVD does not include congenital CVD. Prevalence of CVD includes 
people with hypertension, heart disease (HD), stroke, peripheral artery disease (PAD), and 
diseases of the veins.
Race
Data published by governmental agencies for some racial groups are considered unreliable 
because of the small sample size in the studies. Because we try to provide data for as many 
racial groups as possible, we show these data for informational and comparative purposes.
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Contacts
If you have questions about statistics or any points made in this Update, please contact the 
AHA National Center, Office of Science & Medicine at statistics@heart.org. Direct all 
media inquiries to News Media Relations at inquiries@heart.org or 214-706-1173.
We do our utmost to ensure that this Update is error free. If we discover errors after 
publication, we will provide corrections at our World Wide Web site, http://www.heart.org/
statistics, and in the journal Circulation.
References
1. [Accessed October 29, 2012] US Census Bureau population estimates. http://www.census.gov/
popest/data/historical/2000s/index.html
2. National Center for Health Statistics. Health, United States, 2009, With Special Feature on Medical 
Technology. Hyattsville, MD: National Center for Health Statistics; 2010. http://www.cdc.gov/nchs/
data/hus/hus09.pdf [Accessed October 29, 2012]
3. National Center for Health Statistics, Centers for Medicare and Medicaid Services. [Accessed 
October 29, 2012] ICD-9-CM Official Guidelines for Coding and Reporting. 2011. http://
www.cdc.gov/nchs/data/icd9/icd9cm_guidelines_2011.pdf
4. Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 
standard. Natl Vital Stat Rep. 1998; 47:1–16. 20.
5. World Health Organization. World Health Statistics Annual. Geneva, Switzerland: World Health 
Organization; 1998. 
2. American Heart Association’s 2020 Impact Goals
See Tables 2-1 through 2-8 and Charts 2-1 through 2-12.
After achieving its major Impact Goals for 2010, the AHA created a new set of Impact Goals 
for the current decade.1 Specifically, the AHA committed to the following central 
organizational goals:
By 2020, to improve the cardiovascular health of all Americans by 20%, while 
reducing deaths from CVDs and stroke by 20%.1
These goals introduce a new concept, cardiovascular health, which is characterized by 7 
health metrics. Ideal cardiovascular health is defined by the absence of clinically manifest 
CVD together with the simultaneous presence of optimal levels of all 7 metrics, including 4 
health behaviors (not smoking and having sufficient physical activity [PA], a healthy diet 
pattern, and appropriate energy balance as represented by normal body weight) and 3 health 
factors (optimal total cholesterol, BP, and fasting blood glucose, in the absence of drug 
treatment; Table 2-1). Because a spectrum of cardiovascular health can also be envisioned 
and the ideal cardiovascular health profile is known to be rare in the US population, a 
broader spectrum of cardiovascular health can also be represented as being “ideal,” 
“intermediate,” or “poor” for each of the health behaviors and health factors.1 Table 2-1 
provides the specific definitions for ideal, intermediate, and poor cardiovascular health for 
each of the 7 metrics, both for adults (≥20 years of age) and for children (age ranges for each 
metric depending on data availability).
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This concept of cardiovascular health represents a new focus for the AHA. Three novel 
emphases are central to the AHA 2020 Impact Goals:
• An expanded focus on CVD prevention and promotion of positive 
“cardiovascular health,” rather than primarily the treatment of established CVD.
• Efforts to promote healthy behaviors (healthy diet pattern, appropriate energy 
intake, PA, and nonsmoking) and healthy biomarker levels (optimal blood lipids, 
BP, glucose levels) throughout the lifespan.
• A population-level health promotion strategy that shifts the majority of the public 
towards greater cardiovascular health in addition to targeting those individuals at 
greatest CVD risk, since healthy lifestyles in all domains are uncommon 
throughout the US population.
Beginning in 2011, and recognizing the time lag in the nationally representative US data 
sets, this chapter in the annual Statistical Update evaluates and publishes metrics and 
information to provide insights into both progress toward meeting the 2020 AHA goals and 
areas that require greater attention to meet these goals.
Abbreviations Used in Chapter 2
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DM diabetes mellitus
FDA Food and Drug Administration
HbA1c hemoglobin A1c
HBP high blood pressure
HD heart disease
HF heart failure
HR hazard ratio
IMT intima-media thickness
LDL low-density lipoprotein
MI myocardial infarction
NHANES National Health and Nutrition Examination Survey
NOMAS Northern Manhattan Study
OR odds ratio
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PA physical activity
PE physical education
SBP systolic blood pressure
SE standard error
UN United Nations
WHO World Health Organization
Cardiovascular Health: Current Prevalence
• The most up-to-date data on national prevalence of ideal, intermediate, and poor 
levels of each of the 7 cardiovascular health metrics are shown for children 
(adolescents and teens 12–19 years of age) in Chart 2-1 and for adults (≥20 years 
of age) in Chart 2-2.
• For most metrics, the prevalence of ideal levels of health behaviors and health 
factors is much higher in US children than in US adults. The major exceptions 
are diet and PA, for which the prevalence of ideal levels in children is similar (for 
PA) or worse (for diet) than in adults.
• Among children (Chart 2-1), the prevalence (unadjusted) of ideal levels of 
cardiovascular health behaviors and factors currently varies from 0% for the 
healthy diet pattern (ie, essentially no children meet at least 4 of the 5 dietary 
components) to >80% for the smoking, BP, and fasting glucose metrics. More 
than 90% of US children meet 0 or only 1 of the 5 healthy dietary components.
• Among US adults (Chart 2-2), the age-standardized prevalence of ideal levels of 
cardiovascular health behaviors and factors currently varies from 0.3% for 
having at least 4 of 5 components of the healthy diet pattern to up to 76% for 
never having smoked or being a former smoker who has quit for >12 months.
• Age-standardized and age-specific prevalence estimates for ideal cardiovascular 
health and for ideal levels of each of its components for 2007 to 2008 (baseline) 
and 2009 to 2010 are shown in Table 2-2.
– In 2009 to 2010, the prevalence of ideal levels across 6 available health 
factors and health behaviors (ie, excluding diet, for which 2009–2010 
data were not available at the time of this analysis) decreases 
dramatically from younger to older age groups. The same trend was 
seen in 2007–2008.
• Chart 2-3 displays the prevalence estimates for the population of US children 
(12–19 years of age) meeting different numbers of criteria for ideal 
cardiovascular health (out of 7 possible) in 2007 to 2008.
– Very few US children (<5%) meet only 1 or 2 criteria for ideal 
cardiovascular health.
– About half of US children meet 3 or 4 fewer criteria for ideal 
cardiovascular health, and about half meet 5 or 6 criteria.
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– Virtually no children meet all 7 criteria for ideal cardiovascular health.
– Overall distributions were similar in boys and girls.
• Charts 2-4 and 2-5 display the age-standardized prevalence estimates of US 
adults meeting different numbers of criteria for ideal cardiovascular health (out 
of 7 possible) in 2007 to 2008, overall and stratified by age, sex, and race.
– Approximately 2.5% of US adults have 0 of the 7 criteria at ideal levels, 
and another 15% meet only 1 of 7 criteria. This is much worse than 
among children.
– Most US adults (≈60%) have 2, 3, or 4 criteria at ideal cardiovascular 
health, with approximately 1 in 5 adults within each of these categories.
– Approximately 12% meet 5 metrics, 4% meet 6 metrics, and 0% meet 7 
metrics at ideal levels.
– Presence of ideal cardiovascular health is strongly age related (Chart 
2-4). Younger adults are more likely to meet greater numbers of ideal 
metrics, and older adults are much less likely. More than 60% of those 
>60 years of age have only 2 or fewer metrics at ideal levels (Chart 
2-4).
– Women tend to have more metrics at ideal levels than do men (Chart 
2-4).
– Blacks and Mexican Americans tend to have fewer metrics at ideal 
levels than whites or other races (Chart 2-5). Approximately 6 in 10 
white adults and 7 in 10 black or Mexican American adults have no 
more than 3 of 7 metrics at ideal levels (Chart 2-5).
• Chart 2-6 displays the age-standardized percentages of US adults and 
percentages of children who have 5 or more of the metrics (out of 7 possible) at 
ideal levels.
– Approximately 40% of US children 12 to 19 years of age have 5 or 
more metrics at ideal levels, with lower levels in boys (36%) than in 
girls (45%).
– In comparison, only 16% of US adults have 5 or more metrics with 
ideal levels, with lower prevalence in men (12%) than in women (21%).
– Whites had nearly twice the percentage of adults with 5 or more metrics 
with ideal levels (18%) as Mexican Americans (9.5%) or blacks (11%).
• Chart 2-7 displays the age-standardized percentages of US adults meeting 
different numbers of criteria for both poor and ideal cardiovascular health. 
Meeting the AHA 2020 Strategic Impact Goals is predicated on reducing the 
relative percentage of those with poor levels while increasing the relative 
percentage of those with ideal levels for each of the 7 metrics.
– Approximately 94% of US adults have at least 1 metric at poor levels.
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– Approximately 38% of US adults have at least 3 metrics at poor levels.
– Few US adults (<3%) have 5 or more metrics at poor levels.
– More US adults have 4 to 6 ideal metrics than 4 to 6 poor metrics.
• The prevalence of poor health behaviors and health factors and their awareness, 
treatment, and control are displayed in Table 2-3 separately for those with and 
without self-reported CVD.
– Americans with CVD are much more likely to be current or former 
smokers than Americans without CVD.
– Approximately 20% of US adults are current smokers or have quit 
recently (<12 months ago).
– As measured by self-reported data, Americans with CVD are very 
likely to have intermediate or poor levels of PA (74.1%), whereas 
Americans without CVD still commonly have such levels (58.4%). 
Furthermore, 64.5% of those with CVD and 47.3% of those without 
CVD report engaging in no moderate or vigorous activity at all.
– 79% of US adults meet 0 or only 1 of the 5 healthy diet metrics.
– Two thirds of US adults are overweight, with little difference by 
prevalent CVD. Half of all US adults with CVD and one third without 
CVD are obese.
– Hypertension is present in 28.5% of US adults without CVD and 51.0% 
of US adults with CVD. Of these, nearly all with CVD are aware of 
their hypertension (98.6%) and are receiving treatment (97.4%), but a 
much smaller proportion of those without CVD are aware (70.6%) or 
receiving treatment (61.4%).
– Both presence of hypercholesterolemia (total cholesterol ≥240 mg/dL 
or receiving medication) and DM (fasting glucose ≥125 mg/dL or 
receiving medications) and awareness and treatment of these conditions 
are similarly higher among those with CVD than among those without 
CVD.
Cardiovascular Health: Trends Over Time
• The trends over the last decade in each of the 7 cardiovascular health metrics (for 
diet, trends from 2005–2006 to 2007–2008) are shown in Chart 2-8 (for children 
12–19 years of age) and Chart 2-9 (for adults ≥20 years of age).
– Among children, there appears to be a negative trend for meeting the 
body mass index (BMI) metric and positive trends for meeting the 
smoking and total cholesterol metrics. Other metrics do not show 
consistent trends.
et al. Page 15
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
– Among adults, there appears to be a positive trend for meeting the 
smoking metric and negative trends for meeting the BMI and glucose 
metrics. Trends for other metrics appear fairly flat.
• Huffman et al2 made projections in cardiovascular health metrics to 2020 based 
on NHANES data from 1988–2008 (Chart 2-10). If current trends continue, 
estimated cardiovascular health will improve by 6%, short of the AHA’s goal of 
20%. On the basis of current trends among individual metrics, anticipated 
declines in prevalence of smoking, high cholesterol, and high BP (in men) would 
be offset by substantial increases in the prevalence of obesity and DM and small 
expected changes in ideal dietary patterns or PA.2
Cardiovascular Diseases
• In 2009, the age-standardized death rate attributable to all CVDs was 237.1 per 
100 000 (Chart 2-11), down 6% from 252.4 per 100 000 in 2007 (baseline data 
for the 2020 Impact Goals on CVD and stroke mortality).
– Death rates in 2009 attributable to stroke, HDs, and other 
cardiovascular causes were 38.9, 116.1, and 81.0 per 100 000, 
respectively.
• Data from NHANES 2009–2010 reveal that overall, 7.2% of Americans self-
reported having some type of CVD (Table 2-3), including 3.2% with coronary 
heart disease (CHD), 2.7% with stroke, and 2.0% with congestive heart failure 
(CHF) (some individuals reported more than 1 condition).
Relevance of Ideal Cardiovascular Health
Since the AHA announced its 2020 Impact Goals, several investigations have confirmed the 
importance of these metrics of cardiovascular health. Overall, these data demonstrate the 
relevance of the concept of cardiovascular health to risk of future risk factors, disease, and 
mortality, with strong inverse, stepwise association with all-cause, CVD, and ischemic HD 
mortality.
• Bambs et al3 and Folsom et al4 both described the low prevalence (<1%) of ideal 
cardiovascular health, defined as being in the ideal category of all 7 AHA metrics 
in the Heart Strategies Concentrating on Risk Evaluation and ARIC cohorts, 
respectively.
• In ARIC, a stepwise, inverse association was present between the number of 
ideal health metrics and incident CVD events (including CHD death, nonfatal 
MI, stroke, and HF) during 20 years of follow-up. For participants with 0, 1, 2, 3, 
4, 5, 6, and 7 metrics at ideal levels, the age-, sex-, and race-adjusted rates of 
incident CVD incidence were 3.21, 2.19, 1.60, 1.20, 0.86, 0.64, 0.39, and 0 per 
100 person-years, respectively.4
• Importantly, both ideal health behaviors and ideal health factors were 
independently associated with lower CVD risk in a stepwise fashion (Chart 
2-12). Thus, across any levels of health behaviors, health factors were still 
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associated with incident CVD; and across any levels of health factors, health 
behaviors were still associated with incident CVD.
• Dong et al5 demonstrated a similar strong graded, inverse relationship between 
the number of ideal cardiovascular health metrics and risk of CVD in white, 
black, and Hispanic participants of the Northern Manhattan Study (NOMAS) 
after 11 years of follow-up.
• On the basis of data from NHANES (1988–2010), a similarly low prevalence of 
ideal cardiovascular health is present across the United States: 2.0% (95% 
confidence interval [CI], 1.5%–2.5%) in 1988–1994 and 1.2% (95% CI, 0.8%–
1.9%) in 2005–2010.6
• Furthermore, a stepwise association is present between the number of ideal 
cardiovascular health metrics and risk of all-cause mortality, CVD mortality, and 
ischemic HD mortality after 14.5 years of follow-up in the United States.6 The 
adjusted hazard ratios (HRs) for individuals with 6 or 7 ideal health metrics 
compared with individuals with 0 ideal health metrics were 0.49 (95% CI, 0.33–
0.74) for all-cause mortality, 0.24 (95% CI, 0.13–0.47) for CVD mortality, and 
0.30 (95% CI, 0.13–0.68) for ischemic HD mortality.6 Ford et al7 demonstrated 
similar relationships.
• Adjusted population attributable fractions for CVD mortality were as follows6:
– 40.6% (95% CI, 24.5%–54.6%) for HBP
– 13.7% (95% CI, 4.8%–22.3%) for smoking
– 13.2% (95% CI, 3.5%–29.2%) for poor diet
– 11.9% (95% CI, 1.3%–22.3%) for insufficient PA
– 8.8% (95% CI, 2.1%–15.4%) for abnormal glucose levels
• Adjusted population attributable fractions for ischemic HD mortality were as 
follows6:
– 34.7% (95% CI, 6.6%–57.7%) for HBP
– 16.7% (95% CI, 6.4%–26.6%) for smoking
– 20.6% (95% CI, 1.2%–38.6%) for poor diet
– 7.8% (95% CI, 0%–22.2%) for insufficient PA
– 7.5% (95% CI, 3.0%–14.7%) for abnormal glucose levels
• Interestingly, based on NHANES 1999–2002, only modest intercorrelations are 
present between different cardiovascular health metrics. For example, these 
ranged from a correlation of −0.12 between PA and hemoglobin A1c (HbA1c) to 
a correlation of 0.29 between BMI and HbA1c. Thus, the 7 AHA cardiovascular 
health metrics appear interrelated, but only modestly, with substantial 
independent variation in each.7
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• The AHA cardiovascular health metrics predict future cardiometabolic risk when 
assessed in youth. In the Young Finns Study, a stepwise, inverse association was 
found between the number of ideal cardiovascular health metrics in adolescence 
(12–18 years of age) and risk of developing hypertension, dyslipidemia, or high 
carotid intima-media thickness (IMT) in adulthood after 21 years of follow-up 
(1986–2007).8 For every 1 additional ideal cardiovascular health metric present 
in adolescence, compared with either poor or intermediate levels, the age- and 
sex-adjusted odds ratios (ORs) for adult cardiometabolic outcomes were
– Hypertension: OR=0.66 (95% CI, 0.54–0.80)
– High low-density lipoprotein (LDL) cholesterol (>160 mg/dL): 
OR=0.66 (95% CI, 0.52–0.85)
– High-risk IMT (90th percentile or plaque present): OR=0.75 (95% CI, 
0.60–0.94)
Achieving the 2020 Impact Goals
• Taken together, these data continue to demonstrate both the tremendous 
relevance of the AHA 2020 Impact Goals for cardiovascular health and the 
substantial progress that will be needed to achieve these goals over the next 
decade.
• A range of complementary strategies and approaches can lead to improvements 
in cardiovascular health. These include each of the following:
– Individual-focused approaches, which target lifestyle and treatments at 
the individual level (Table 2-4).
– Health-care systems approaches, which encourage, facilitate, and 
reward efforts by providers to improve health behaviors and health 
factors (Table 2-5).
– Population approaches, which target lifestyle and treatments in schools 
or workplaces, local communities, and states, as well as throughout the 
nation (Table 2-6).
• Such approaches can focus on both (1) improving cardiovascular health among 
those who currently have less than optimal levels and (2) preserving 
cardiovascular health among those who currently have ideal levels (in particular, 
children, adolescents, and young adults) as they age.
• The metrics with the greatest potential for improvement are health behaviors, 
including diet quality, PA, and body weight. However, each of the cardiovascular 
health metrics can be improved and deserves major focus, including smoking, 
which remains the leading cause of preventable death in the United States.
• Continued emphasis is also needed on the treatment of acute CVD events and 
secondary prevention through treatment and control of health behaviors and risk 
factors.
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• For each cardiovascular health metric, modest shifts in the population 
distribution toward improved health would produce relatively large increases in 
the proportion of Americans in both ideal and intermediate categories. For 
example, on the basis of NHANES 2009–2010, the current prevalence of ideal 
levels of BP among US adults is 44.3%. To achieve the 2020 goals, a 20% 
relative improvement would require an increase in this proportion to 53.1% by 
2020 (44.3% × 1.20). On the basis of NHANES data, a reduction in population 
mean BP of just 2 mm Hg would result in 56.1% of US adults having ideal levels 
of BP, which represents a 26.8% relative improvement in this metric (Table 2-7). 
Larger population reductions in BP would lead to even larger numbers of people 
with ideal levels. Such small reductions in population BP could result from small 
health behavior changes at a population level, such as increased PA, increased 
fruit and vegetable consumption, decreased sodium intake, decreased adiposity, 
or some combination of these and other lifestyle changes, with resulting 
substantial projected decreases in CVD rates in US adults.9
• The AHA has a broad range of policy initiatives to improve cardiovascular health 
and meet the 2020 Strategic Impact Goals (Table 2-8). Future Statistical Updates 
will update these initiatives and track progress toward the 2020 Impact Goals.
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3. Smoking/Tobacco Use
See Table 3-1 and Charts 3-1 and 3-2.
Prevalence
Youth—(See Chart 3-1.)
• In 2011, in grades 9 through 12:
– 18.1% of students reported current cigarette use (on at least 1 day 
during the 30 days before the survey), 13.1% of students reported 
current cigar use, and 7.7% of students reported current smokeless 
tobacco use. Overall, 23.4% of students reported any current tobacco 
use (Youth Risk Behavior Survey [YRBS]; Chart 3-1).1
– Male students were more likely than female students to report current 
cigarette use (19.9% compared with 16.1%). Male students were also 
more likely than female students to report current cigar use (17.8% 
compared with 8.0%) and current smokeless tobacco use (12.8% 
compared with 2.2%; YRBS).1
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– Non-Hispanic white students were more likely than Hispanic or non-
Hispanic black students to report any current tobacco use, which 
includes cigarettes, cigars, or smokeless tobacco (26.5% compared with 
20.5% for Hispanic students and 15.4% for non-Hispanic black 
students; YRBS).1
• Among youths 12 to 17 years of age in 2010, 2.6 million (10.7%) used a tobacco 
product (cigarettes, cigars, or smokeless tobacco) in the past month, and 2.0 
million (8.3%) used cigarettes. Cigarette use in the past month in this age group 
declined significantly from 13.0% in 2002 to 8.3% in 2010 (National Survey on 
Drug Use and Health [NSDUH]).2
• Data from the YRBS3 for students in grades 9 to 12 indicated the following:
– The percentage of students who reported ever trying cigarettes 
remained stable from 1991 to 1999 and then declined from 70.4% in 
1999 to 44.7% in 2011.
– The percentage who reported current cigarette use (on at least 1 day in 
the 30 days before the survey) increased between 1991 and 1997 and 
then declined from 36.4% in 1997 to 18.1% in 2011.
– The percentage who reported current frequent cigarette use (smoked on 
≥20 of the 30 days before the survey) increased from 1991 to 1999 and 
then declined from 16.8% in 1999 to 6.4% in 2011.
• In 2011, 49.9% of students in grades 9 to 12 who currently smoked cigarettes 
had tried to quit smoking cigarettes during the previous 12 months. The 
prevalence of this behavior was higher among female student smokers (53.9%) 
than among male student smokers (47.0%) and among white females (54.0%) 
and Hispanic females (55.9%) than among white males (46.3%) and Hispanic 
males (44.7%; YRBS).1
Abbreviations Used in Chapter 3
AMI acute myocardial infarction
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
MEPS Medical Expenditure Panel Survey
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHIS National Health Interview Survey
NSDUH National Survey on Drug Use and Health
RR relative risk
YRBS Youth Risk Behavior Survey
Adults—(See Table 3-1 and Chart 3-2.)
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• In 2011, among adults ≥18 years of age:
– 21.3% of men and 16.7% of women were current cigarette smokers 
(NHIS).5
– The percentage of current cigarette smokers (19.0%) declined 21% 
since 1998 (24.1%).5–7
– The states with the highest percentage of current cigarette smokers were 
Kentucky (29.0%), West Virginia (28.6%), and Arkansas (27.0%). Utah 
has the lowest percentage of smokers (11.8%) (BRFSS).4
• In 2010, an estimated 69.6 million Americans ≥12 years of age were current 
(past month) users of a tobacco product (cigarettes, cigars, smokeless tobacco, or 
tobacco in pipes). The rate of current use of any tobacco product in this age 
range declined from 2007 to 2010 (from 28.6% to 27.4%; NSDUH).2
• From 1998 to 2007, cigarette smoking prevalence among adults ≥18 years of age 
decreased in 44 states and the District of Columbia. Six states had no substantial 
changes in prevalence after controlling for age, sex, and race/ethnicity (BRFSS).8
• In 2008 to 2010, among people ≥65 years of age, 9.4% of men and 9.1% of 
women were current smokers. In this age group, men were more likely than 
women to be former smokers (54.0% compared with 30.0%) on the basis of age-
adjusted estimates (NHIS).9
• In 2008 to 2010, among adults ≥18 years of age, Asian men (15.2%) and 
Hispanic men (17.3%) were less likely to be current cigarette smokers than non-
Hispanic black men (23.7%), non-Hispanic white men (23.9%), and American 
Indian or Alaska Native men (24.6%) on the basis of age-adjusted estimates 
(NHIS). Similarly, in 2008 to 2010, Asian women (5.5%) and Hispanic women 
(9.6%) were less likely to be current cigarette smokers than non-Hispanic black 
women (17.6%), non-Hispanic white women (20.9%), and American Indian or 
Alaska Native women (20.7%; NHIS).9
• In 2004 to 2006 data, adult cigarette smoking varied among Asian subgroups. 
Most Asian adults had never smoked, with rates ranging from 65% of Korean 
adults to 84% of Chinese adults. Korean adults (22%) were approximately 2 to 3 
times as likely to be current smokers as Japanese (12%), Asian Indian (7%), or 
Chinese (7%) adults on the basis of age-adjusted estimates (NHIS).10
• In 2009 to 2010, among women 15 to 44 years of age, past-month cigarette use 
was lower for those who were pregnant (16.3%) than among those who were not 
pregnant (26.7%). This pattern was found for women 18 to of age (22.7% versus 
31.2% for pregnant and nonpregnant women, respectively) and for women 26 to 
44 years of age (11.8% versus 27.0%, respectively). Among adolescents 15 to 17 
years of age, past-month cigarette use was higher for those who were pregnant 
(22.7%) than for those who were not pregnant (13.4%; NSDUH).2
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Incidence
• In 2010:
– ≈2.4 million people ≥12 years of age smoked cigarettes for the first 
time within the past 12 months, which was similar to the estimate in 
2009 (2.5 million). The 2010 estimate averages out to ≈6500 new 
cigarette smokers every day. Most new smokers (58.8%) in 2010 were 
<18 years of age when they first smoked cigarettes (NSDUH).2
– The number of new smokers <18 years of age (1.4 million) is similar to 
that in 2002 (1.3 million); however, new smokers ≥18 years of age 
increased from ≈600 000 in 2002 to 1 million in 2010 (NSDUH).2
– Among people ages 12 to 49 years of age who had started smoking 
within the past 12 months, the average age of first cigarette use was 
17.3 years, similar to the average in 2009 (17.5 years).2
• Data from 2002 to 2004 suggest that ≈1 in 5 nonsmokers 12 to 17 years of age is 
likely to start smoking. Youths in the Mexican subpopulations were significantly 
more susceptible (28.8%) to start smoking than those in non-Hispanic white 
(20.8%), non-Hispanic black (23.0%), Cuban (16.4%), Asian Indian (15.4%), 
Chinese (15.3%), and Vietnamese (13.8%) subpopulations. There was no 
significant difference in susceptibility to start smoking between boys and girls in 
any of the major populations or subpopulations (NSDUH).11
Morbidity
A 2010 report of the US Surgeon General on how tobacco causes disease summarizes an 
extensive body of literature on smoking and CVD and the mechanisms through which 
smoking is thought to cause CVD. Among its conclusions are the following:
• There is a sharp increase in CVD risk with low levels of exposure to cigarette 
smoke, including secondhand smoke, and a less rapid further increase in risk as 
the number of cigarettes per day increases.
• A meta-analysis comparing pooled data of ≈2.4 million smokers and nonsmokers 
found the relative risk (RR) ratio of smokers to nonsmokers for developing CHD 
was 25% higher in women than in men (95% CI, 1.12–1.39).12
• Current smokers have a 2 to 4 times increased risk of stroke compared with 
nonsmokers or those who have quit for >10 years.13,14
Mortality
• In 2005, tobacco smoking was the cause of ≈467 000 adult deaths (19.1%) in the 
United States. Approximately one third of these deaths were related to CVD.15
• During 2000 to 2004, ≈49 000 (11.1%) of cigarette smoking–related deaths were 
attributable to secondhand smoke.16
• Each year from 2000 to 2004, smoking caused 3.1 million years of potential life 
lost for males and 2.0 million years for females, excluding deaths attributable to 
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smoking-attributable residential fires and adult deaths attributable to secondhand 
smoke.16
• From 2000 to 2004, smoking during pregnancy resulted in an estimated 776 
infant deaths annually.16
• During 2000 to 2004, cigarette smoking resulted in an estimated 269 655 deaths 
annually among males and 173 940 deaths annually among females.16
• On average, male smokers die 13.2 years earlier than male nonsmokers, and 
female smokers die 14.5 years earlier than female nonsmokers.17
Smoking Cessation
• Smoking cessation reduces the risk of cardiovascular morbidity and mortality for 
smokers with and without CHD.
– There is no evidence to date that reducing the amount smoked by 
smoking fewer cigarettes per day reduces the risk of CVD.18
• In 2008, 64.5% of adult current smokers ≥18 years of age with a checkup during 
the preceding year reported that they had been advised to quit, which was not 
significantly different from 2002 (63.1%). Smokers between 18 and 44 years of 
age were less likely to be advised to quit than those at older ages. Women were 
more likely than men to receive advice to quit smoking (MEPS).19
Secondhand Smoke
• Data from a 2006 report of the US Surgeon General on the consequences of 
involuntary exposure to tobacco smoke20 indicate the following:
– Nonsmokers who are exposed to secondhand smoke at home or at work 
increase their risk of developing CHD by 25% to 30%.
– Short exposures to secondhand smoke can cause blood platelets to 
become stickier, damage the lining of blood vessels, and decrease 
coronary flow velocity reserves, potentially increasing the risk of an 
acute MI (AMI).
• In 2008, data from 11 states showed that the majority of people surveyed in each 
state reported having smoke-free home rules, ranging from 68.8% in West 
Virginia to 85.6% in Arizona (BRFSS).21
• As of December 31, 2010, 25 states and the District of Columbia had laws that 
prohibited smoking in indoor areas of worksites, restaurants, and bars; no states 
had such laws in 2000. As of December 31, 2010, an additional 10 states had 
laws that prohibited smoking in 1 or 2 but not all 3 venues.22
• Pooled data from 17 studies in North America, Europe, and Australasia suggest 
that smoke-free legislation can reduce the incidence of acute coronary events by 
10%.23
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• The percentage of the US nonsmoking population with detectable serum cotinine 
declined from 52.5% in 1999 to 2000 to 40.1% in 2007 to 2008, with declines 
occurring for children and adults. During 2007 to 2008, the percentage of 
nonsmokers with detectable serum cotinine was higher for those 3 to 11 years of 
age (53.6%) and those 12 to 19 years of age (46.5%) than for those ≥20 years of 
age (36.7%); the percentage was also higher for non-Hispanic blacks (55.9%) 
than for non-Hispanic whites (40.1%) and Mexican Americans (28.5%; 
NHANES).24
Cost
• Direct medical costs ($96 billion) and lost productivity costs ($97 billion) 
associated with smoking totaled an estimated $193 billion per year between 2000 
and 2004.16
• In 2008, $9.94 billion was spent on marketing cigarettes in the United States.25
• Cigarette prices have increased 283% between the early 1980s and 2011, 
resulting in decreased sales from ≈30 million packs sold in 1982 to ≈14 million 
packs sold in 2011.25
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4. Physical Inactivity
See Table 4-1 and Charts 4-1 through 4-5.
Prevalence
Youth
Inactivity: (See Chart 4-1.)
• The proportion of adolescents (grades 9–12) who report engaging in no regular 
PA is high and varies by sex and race.1
• Nationwide, 13.8% of adolescents were inactive during the previous 7 days, as 
indicated by their response that they did not participate in ≥60 minutes of any 
kind of PA that increased their heart rate and made them breathe hard on any 1 of 
the previous 7 days.1
• Girls were more likely than boys to report inactivity (17.7% versus 10.0%).1
• The prevalence of inactivity was highest among black (26.7%) and Hispanic 
(21.3%) girls, followed by white girls (13.7%), black boys (12.3%), Hispanic 
boys (10.7%), and white boys (8.5%).1
• A study of 3068 youths between 14 and 24 years of age from 1999 to 2006 found 
that the prevalence of inactivity went up with age for both boys and girls. Across 
ages, girls had a higher prevalence of physical inactivity than boys.2
• In a study of 12 812 youth 9 to 18 years of age, the PA level in boys and girls 
declined starting at the age of 13, with a significantly greater decline in activity 
among girls.3
Television/Video/Computers: (See Chart 4-2.)
In 2011:
• Nationwide, 31.1% of adolescents used a computer for activities other than 
school work (eg, videogames or other computer games) for ≥3 hours per day on 
an average school day.1
• The prevalence of using computers or watching television ≥3 hours per day was 
highest among black (41.1%) and Hispanic boys (36.3%), followed by white 
boys (33.3%), black girls (35.2%), Hispanic girls (28.3%), and white girls 
(22.6%).1
• 32.4% of adolescents watched television for ≥3 hours per day.1
• The prevalence of watching television ≥3 hours per day was highest among black 
girls (54.9%) and boys (54.4%), followed by Hispanic boys (38.4%) and girls 
(37.2%) and white boys (27.3%) and girls (23.9%).1
• Increased television time has significant nutritional associations with weight gain 
(refer to Chapter 5, Nutrition).
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Abbreviations Used in Chapter 4
BP blood pressure
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
EF ejection fraction
FMD flow-mediated dilation
HbA1c hemoglobin A1c
HBP high blood pressure
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHIS National Health Interview Survey
PA physical activity
PAD peripheral artery disease
RR relative risk
SBP systolic blood pressure
WHO World Health Organization
Activity Recommendations: (See Charts 4-3 and 4-4.)
• In 2011, the proportion of students who met activity recommendations of at least 
60 minutes of PA on 7 days of the week was 28.7% nationwide and declined 
from 9th (30.7%) to 12th (25.1%) grades. At each grade level, the proportion was 
higher in boys than in girls.1
• In 2011, more high school boys (38.3%) than girls (18.5%) self-reported having 
been physically active at least 60 minutes per day on all_7 days; self-reported 
rates of activity were higher in white (30.4%) than in black (26.0%) or Hispanic 
(26.5%) adolescents.1
• The 2010 National Youth Physical Activity and Nutrition Study showed that a 
total of 15.3% of high school students met the recommendations for aerobic 
activity, 51.0% met the recommendations for muscle-strengthening activity, and 
12.2% met the recommendations for both aerobic and muscle-strengthening 
activities.4
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• There was a marked discrepancy between the proportion of youth (ages 6–11 
years) who reported engaging in ≥60 minutes of moderate-to-vigorous PA on 
most days of the week and those who actually engaged in moderate-to-vigorous 
PA for ≥60 minutes when activity was measured objectively with accelerometers 
(ie, portable motion sensors that record and quantify the duration and intensity of 
movements) in the NHANES 2003–2004 survey.5
• On the basis of accelerometer counts per minute >2020, 42% of 6- to 11-year-
olds accumulated ≥260 minutes of moderate-to-vigorous PA on ≥5 days per 
week, whereas only 8% of 12-to 15-year-olds and 7.6% of 16- to 19-year-olds 
achieved similar counts.5
• More boys than girls met PA recommendations (≥60 minutes of moderate-to-
vigorous activity on most days of the week) as measured by accelerometry.5
Structured Activity Participation
• Despite recommendations from the National Association for Sport and Physical 
Education that schools should require daily physical education for students in 
kindergarten through 12th grade,6 only 51.8% of students attended physical 
education classes in school daily (56.7% of boys and 46.7% of girls).1
• Physical education class participation declined from the 9th through the 12th 
grades among boys and girls.1
• Little more than half (58.4%) of high school students played on at least 1 school 
or community sports team in the previous year; however, the prevalence declined 
with increasing grade level, from 61.4% in the 9th grade to 52.5% in the 12th 
grade.1
Adults
Inactivity: According to 2011 data from the NHIS, in adults ≥18 years of age:
• Thirty-two percent do not engage in leisure-time PA (“no leisure-time PA/
inactivity” refers to no sessions of light/moderate or vigorous PA of at least 10 
minutes duration per day).7
• Inactivity was higher among women than men (33.2% versus 29.9%, age-
adjusted) and increased with age from 26.1% to 33.4%, 40.0%, and 52.4% 
among adults 18 to 44, 45 to 64, 65 to 74, and ≥75 years of age, respectively.7
• Non-Hispanic black and Hispanic adults were more likely to be inactive (41.1% 
and 42.2%, respectively) than were non-Hispanic white adults (27.7%) on the 
basis of age-adjusted estimates.7
Activity Recommendations: (See Table 4-1 and Chart 4-5.)
According to 2011 data from the NHIS, in adults ≥18 years of age:
• 21.0% met the 2008 federal PA guidelines for both aerobic and strengthening 
activity, an important component of overall physical fitness.7
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• The age-adjusted proportion who reported engaging in moderate or vigorous PA 
that met the 2008 aerobic Physical Activity Guidelines for Americans (at least 
150 minutes of moderate PA or 75 minutes of vigorous PA or an equivalent 
combination each week) was 48.9%; 52.7% of men and 45.5% of women met the 
recommendations. Age-adjusted prevalence was 52.5% for non-Hispanic whites, 
41.2% for non-Hispanic blacks, and 40.1% for Hispanics.7
• The proportion of respondents who did not meet the federal PA guidelines 
increased with age from 44.1% of 18- to 44-year-olds to 72.6% of adults ≥75 
years of age.7
• Hispanic/Latino adults (59.8%) and non-Hispanic black adults (58.8%) were 
more likely to not meet the federal PA guidelines than non-Hispanic white 
(47.4%) adults, according to age-adjusted estimates.7
• The percentage of adults ≥25 years of age not meeting the full (aerobic and 
muscle-strengthening) federal PA guidelines was inversely associated with 
education; participants with no high school diploma (68.4%), a high school 
diploma (59.0%), some college (48.2%), or a bachelor’s degree or higher 
(34.0%), respectively, did not meet the full federal PA guidelines.7
• The proportion of adults ≥25 years of age who met the 2008 federal PA 
guidelines for aerobic activity was positively associated with education level: 
62.5% of those with a college degree or higher met the PA guidelines compared 
with 28.6% of adults with less than a high school diploma.7
• The proportion of adults reporting levels of PA consistent with the 2008 Physical 
Activity Guidelines for Americans remains low and decreases with age.8,9 
Thirty-three percent of respondents in a study examining awareness of current 
US PA guidelines had direct knowledge of the recommended dosage of PA (ie, 
frequency/duration).10
• The percentage of adults reporting at least 150 minutes of moderate PA or 75 
minutes of vigorous PA or an equivalent combination weekly decreased with age 
from 55.8% for adults 18 to 44 years of age to 27.4% for those ≥75 years of age, 
on the basis of the 2011 NHIS.9
• The percentage of men who engaged in both leisure-time aerobic and 
strengthening activities decreased with age, from 39.8% at age 18 to 24 years to 
11.1% at ≥75 years of age. The percentage of women who engaged in both 
leisure-time aerobic and strengthening activities also decreased with age, from 
20.7% at age 18 to 24 years to 5.3% at ≥75 years of age, on the basis of the 2011 
NHIS.9
• Using PA recommendations that existed at the time of the survey, adherence to 
PA recommendations was much lower when based on PA measured by 
accelerometer in NHANES 2003–20045:
– Among adults 20 to 59 years of age, 3.8% of men and 3.2% of women 
met recommendations to engage in moderate-to-vigorous PA 
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(accelerometer counts >2020/min) for 30 minutes (in sessions of ≥10 
minutes) on ≥5 of 7 days.
– Among those ≥60 years of age, adherence was 2.5% in men and 2.3% 
in women.
• Accelerometry data from NHANES 2003–2006 showed that men engaged in 35 
minutes of moderate activity per day, whereas for women, it was 21 minutes. 
More than 75% of moderate activity was accumulated in 1-minute bouts. Levels 
of activity declined sharply after the age of 50 years in all groups.11
• In a review examining self-reported versus actual measured PA (eg, 
accelerometers, pedometers, indirect calorimetry, double-labeled water, heart rate 
monitor), 60% of respondents self-reported higher values of activity than what 
was measured by use of direct methods.12
• Among men, self-reported PA was 44% greater than actual measured values; 
among women, self-reported activity was 138% greater than actual measured 
PA.12
Trends
Youth—In 2011:
• Among adolescents, there was a significant decrease in the prevalence of 
watching television ≥3 hours per day, from 42.8% in 1999 to 32.4%, although 
there was no significant decrease from the 2009 prevalence of 32.8%.1
• Among students nationwide, there was a significant increase in the prevalence of 
having participated in muscle-strengthening activities on ≥3 days per week, from 
47.8% in 1991 to 55.6%.1
• Nationwide, the prevalence of adolescents using computers ≥3 hours per day 
increased from 21.1% in 2005 to 24.9% in 2009 and 31.1%.1
• Among adolescents nationwide, the prevalence of attending physical education 
classes at least once per week did not increase significantly, from 48.9% in 1991 
to 51.8%.1
• The prevalence of adolescents playing at least 1 team sport in the past year 
increased from 55.1% in 1999 to 58.4%.1
Adults
• Between NHANES III (1988–1994) and NHANES 2001–2006, the non–age-
adjusted proportion of adults who engaged in >12 bouts of PA per month 
declined from 57.0% to 43.3% in men and from 49.0% to 43.3% in women.13
• The proportion of US adults who meet criteria for muscle strength has improved 
between 1998 and 2011. Annual estimates of the percentage of US adults who 
met the muscle-strengthening criteria increased from 17.7% in 1998 to 24.5% in 
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2011, and estimates of the percentage who met both the muscle-strengthening 
and aerobic criteria increased from 14.4% in 1998 to 21.0% in 2011.7,8
• A 2.3% decline in physical inactivity between 1980 and 2000 prevented or 
postponed ≈17 445 deaths (≈5%) attributable to CHD in the United States.14
CVD and Metabolic Risk Factors
Youth
• More girls (67.9%) than boys (55.7%) reported having exercised to lose weight 
or to keep from gaining weight.1
• White girls (72.2%) were more likely than black (54.2%) and Hispanic (66.3%) 
girls to report exercising to lose weight or to keep from gaining weight.1
• Total and vigorous PA are inversely correlated with body fat and the prevalence 
of obesity.15
• Among children 4 to 18 years of age, increased time in moderate-to-vigorous PA 
was associated with improvements in waist circumference, systolic BP (SBP), 
fasting triglycerides, high-density lipoprotein (HDL) cholesterol, and insulin. 
These findings were significant regardless of the amount of the children’s 
sedentary time.16
Adults
• Participants in the Diabetes Prevention Project randomized trial who met the PA 
goal of 150 minutes of PA per week were 44% less likely to develop DM after 
3.2 years of follow-up, even if they did not meet the weight-loss target.17
• Exercise for weight loss, without dietary interventions, was associated with 
significant reductions in diastolic BP (DBP; −2 mm Hg; 95% CI, −4 to −1 mm 
Hg), triglycerides (−0.2 mmol/L; 95% CI, −0.3 to −0.1 mmol/L), and fasting 
glucose (−0.2 mmol/L; 95% CI, −0.3 to −0.1 mmol/L).18
• A total of 120 to 150 minutes per week of moderate-intensity activity, compared 
with none, can reduce the risk of developing metabolic syndrome.19
• In Coronary Artery Risk Development in Young Adults (CARDIA), women who 
maintained high activity through young adulthood gained 6.1 fewer kilograms of 
weight and 3.8 fewer centimeters in waist circumference in middle age than 
those with lower activity. Highly active men gained 2.6 fewer kilograms and 3.1 
fewer centimeters than their lower-activity counterparts.20
• Self-reported low lifetime recreational activity has been associated with 
increased PAD.21
• In 3 US cohort studies, men and women who increased their PA over time gained 
less weight in the long-term, whereas those who decreased their PA over time 
gained more weight and those who maintained their current PA had intermediate 
weight gain.22
et al. Page 32
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• Among US men and women, every hour per day of increased television watching 
was associated with 0.3 pounds of greater weight gain every 4 years, whereas 
every hour per day of decreased television watching was associated with a 
similar amount of relative weight loss.22
Morbidity and Mortality
• Physical inactivity is responsible for 12.2% of the global burden of MI after 
accounting for other CVD risk factors such as cigarette smoking, DM, 
hypertension, abdominal obesity, lipid profile, no alcohol intake, and 
psychosocial factors.23
• In a meta-analysis of longitudinal studies among women, RRs of incident CHD 
were 0.83 (95% CI, 0.69–0.99), 0.77 (95% CI, 0.64–0.92), 0.72 (95% CI, 0.59–
0.87), and 0.57 (95% CI, 0.41–0.79) across increasing quintiles of PA compared 
with the lowest quintile.28
• A 2003 meta-analysis of 23 studies on the association of PA with stroke 
indicated that compared with low levels of activity, high (RR, 0.79; 95% CI, 
0.69–0.91) and moderate (RR, 0.91; 95% CI, 0.80–1.05) levels of activity were 
inversely associated with the likelihood of developing total stroke (ischemic and 
hemorrhagic).24
• With television watching as a sedentary activity, 2 hours of television per day is 
associated with an RR for type 2 DM of 1.20 (95% CI, 1.14–1.27), an RR for 
fatal or non-fatal CVD of 1.15 (95% CI, 1.06–1.23), and an RR for all-cause 
mortality of 1.13 (95% CI, 1.07–1.18). The risk for all-cause mortality further 
increases with >3 hours of television daily.25
• Longitudinal studies commonly report a graded, inverse association of PA 
amount and duration (ie, dose) with incident CHD and stroke.26
• The PA guidelines for adults cite evidence that ≈150 minutes per week of 
moderate-intensity aerobic activity, compared with none, can reduce the risk of 
CVD.27
• Adherence to PA guidelines for both aerobic and muscle-strengthening activities 
is associated with 27% lower all-cause mortality among adults without existing 
chronic conditions such as DM, cancer, MI, angina, CVD, stroke, or respiratory 
diseases and with 46% lower mortality among people with chronic 
comorbidities.28
• In the Health Professionals Follow-Up Study, for every 3-hour-per-week increase 
in vigorous-intensity activity, the multivariate RR of MI was 0.78 (95% CI, 0.61–
0.98) for men. This 22% reduction of risk can be explained in part by beneficial 
effects of PA on HDL cholesterol, vitamin D, apolipoprotein B, and HbA1c.29
• In a 20-year study of older male veterans, an inverse, graded, and independent 
association between impaired exercise capacity and all-cause mortality risk was 
found. For each increase of 1 metabolic equivalent tasks in exercise capacity, 
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mortality risk was 12% lower (HR 0.88; 95% CI, 0.86–0.90). Unfit individuals 
who improved their fitness status had a 35% lower mortality risk (HR 0.65; 95% 
CI, 0.46–0.93) than those who remained unfit.30
Secondary Prevention
• PA improves inflammatory markers in people with existing stable CHD. After a 
6-week training session, C-reactive protein levels declined by 23.7% (P<0.001), 
and plasma vascular cell adhesion molecule-1 levels declined by 10.23% 
(P<0.05); there was no difference in leukocyte count or levels of intercellular 
adhesion molecule-1.31
• In a randomized trial of patients with PAD, supervised treadmill exercise training 
and lower-extremity resistance training were each associated with significant 
improvements in functional performance and quality of life compared with a 
usual-care control group. Exercise training was additionally associated with 
improved brachial artery flow-mediated dilation (FMD), whereas resistance 
training was associated with better stair-climbing ability versus control.32
• On the basis of a meta-analysis of 34 randomized controlled trials, exercise-
based cardiac rehabilitation after MI was associated with lower rates of 
reinfarction, cardiac mortality, and overall mortality.33
• The benefit of intense exercise training for cardiac rehabilitation in people with 
HF was tested in a trial of 27 patients with stable, medically treated HF. Intense 
activity (an aerobic interval-training program 3 times per week for 12 weeks) 
was associated with a significant 35% improvement in left ventricular ejection 
fraction (EF) and decreases in pro-brain natriuretic peptide (40%), left 
ventricular end-diastolic volume (18%), and left ventricular end-systolic volume 
(25%) compared with control and endurance-training groups.34
Costs
• The economic consequences of physical inactivity are substantial. In a summary 
of WHO data sources, the economic costs of physical inactivity were estimated 
to account for 1.5% to 3.0% of total direct healthcare expenditures in developed 
countries such as the United States.35
• The 1996 MEPS was linked to self-reported activity in the 1995 NHIS. On the 
basis of a self-reported prevalence of inactivity of 47.5% and a prevalence of 
CVD of 21.5%, direct expenditures for CVD associated with inactivity were 
estimated to be $23.7 billion in 2001.36
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5. Nutrition
See Tables 5-1 and 5-2 and Charts 5-1 through 5-3.
This chapter of the update highlights national dietary consumption data, focusing on key 
foods, nutrients, dietary patterns, and other dietary factors related to cardiometabolic health. 
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It is intended to examine current intakes, trends changes in intakes, and estimated effects on 
disease to support and further stimulate efforts to monitor and improve dietary habits in 
relation to cardiovascular health.
Abbreviations Used in Chapter 5
ALA α-linoleic acid
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DHA docosahexaenoic acid
DM diabetes mellitus
EPA eicosapentaenoic acid
GFR glomerular filtration rate
GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico
HD heart disease
HDL high-density lipoprotein
HEI Healthy Eating Index
LDL low-density lipoprotein
MI myocardial infarction
n-6-PUFA ω-6-polyunsaturated fatty acid
NA not available
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
OR odds ratio
PA physical activity
PREMIER Prospective Registry Evaluating Myocardial Infarction: Events and Recovery
RR relative risk
SBP systolic blood pressure
SD standard deviation
WHI Women’s Health Initiative
Prevalence
Foods and Nutrients: Adults—See Table 5-1; NHANES 2005–2008).
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The dietary consumption by US adults of selected foods and nutrients related to 
cardiometabolic health is detailed in Table 5-1 according to sex and race or ethnic 
subgroups:
• Average consumption of whole grains by white and black men and women was 
between 0.5 and 0.8 servings per day, with only between 3% and 5% of white 
and black adults meeting guidelines of ≥3 servings per day. Average whole grain 
consumption by Mexican Americans was ≈2 servings per day, with 21% to 27% 
consuming ≥3 servings per day.
• Average fruit consumption ranged from 1.1 to 1.8 servings and per day in these 
sex and race or ethnic subgroups: 9% to 11% of whites, 6% to 7% of blacks, and 
8% to 10% of Mexican Americans met guidelines of ≥2 cups per day. When 
100% fruit juices were included, the number of servings consumed and the 
proportions of adults consuming ≥2 cups per day approximately doubled.
• Average vegetable consumption ranged from 1.3 to 2.2 servings per day; 6% to 
7% of whites, 3% of blacks, and 3% of Mexican Americans consumed ≥2.5 cups 
per day. The inclusion of vegetable juices and sauces generally produced little 
change in these consumption patterns.
• Average consumption of fish and shellfish was lowest among white women (1.2 
servings per week) and highest among black men and women (1.7 servings per 
week); ≈75% to 80% of all adults in each sex and race or ethnic subgroup 
consumed <2 servings per week. Approximately 10% to 13% of whites, 14% to 
15% of blacks, and 12% of Mexican Americans consumed ≥250 mg of 
eicosapentaenoic acid and docosahexaenoic acid per day.
• Average consumption of nuts, legumes, and seeds was ≈2 to 3 servings per week 
among white and black men and women and 6 servings per week among 
Mexican American men and women. Approximately 20% of whites, 15% of 
blacks, and 40% of Mexican Americans met guidelines of ≥4 servings per week.
• Average consumption of processed meats was lowest among Mexican American 
women (1.8 servings per week) and highest among black men (3.6 servings per 
week). Between 36% (Mexican American women) and 66% (black men) of 
adults consumed ≥1 serving per week.
• Average consumption of sugar-sweetened beverages ranged from ≈7 servings per 
week among white women to 16 servings per week among Mexican American 
men. Approximately 50% and 33% of white men and women, 73% and 65% of 
black men and women, and 76% and 62% of Mexican American men and 
women, respectively, consumed >36 oz (4.5 8-oz servings) per week.
• Average consumption of sweets and bakery desserts ranged from ≈4 servings per 
day (Mexican American men) to 7 servings per day (white men). Approximately 
two thirds of white and black men and women and half of all Mexican American 
men and women consumed >2.5 servings per week.
et al. Page 38
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• Between 33% and 50% of adults in each sex and race or ethnic subgroup 
consumed <10% of total calories from saturated fat, and between 58% and 70% 
consumed <300 mg of dietary cholesterol per day.
• Only 4% to 7% of whites, 2% to 4% of blacks, and 9% to 11% of Mexican 
Americans consumed ≥28 g of dietary fiber per day.
• Only 8% to 11% of whites, 9% to 11% of blacks, and 13% to 19% of Mexican 
Americans consumed <2.3 g of sodium per day. In 2005, the US Department of 
Health and Human Services and US Department of Agriculture recommended 
that adults in specific groups, including people with hypertension, all middle-
aged and older adults, and all blacks, should consume ≤1.5 g of sodium per day. 
In 2005 to 2006, the majority (69.2%) of US adults belonged to ≥1 of these 
specific groups in whom sodium consumption should be <1.5 g/d.1
Foods and Nutrients: Children and Teenagers—See Table 5-2; NHANES 2005–
2008).
The dietary consumption by US children and teenagers of selected foods and nutrients 
related to cardiometabolic health is detailed in Table 5-2:
• Average whole grain consumption was low, ranging from 0.4 to 0.6 servings per 
day, with <4% of all children in different age and sex subgroups meeting 
guidelines of ≥3 servings per day.
• Average fruit consumption was low and decreased with age: ≈1.5 servings per 
day in younger boys and girls (5–9 years of age), 1.3 servings per day in 
adolescent boys and girls (10–14 years of age), and 0.9 servings per day in 
teenage boys and girls (15–19 years of age). The proportion meeting guidelines 
of ≥2 cups per day was also low and decreased with age: ≈8% in those 5 to 9 
years of age, 7% to 8% in those 10 to 14 years of age, and 4% in those 15 to 19 
years of age. When 100% fruit juices were included, the number of servings 
consumed approximately doubled or tripled, and proportions consuming ≥2 cups 
per day were 29% to 36% of those 5 to 9 years of age, 22% to 26% of those 10 to 
14 years of age, and 21% to 22% of those 15 to 19 years of age.
• Average vegetable consumption was low, ranging from 0.9 to 1.1 servings per 
day, with <2% of children in different age and sex subgroups meeting guidelines 
of ≥2.5 cups per day.
• Average consumption of fish and shellfish was low, ranging between 0.5 and 0.7 
servings per week in all age and sex groups. Among all ages, only 10% to 13% 
of children teenagers consumed ≥2 servings per week.
• Average consumption of nuts, legumes, and seeds ranged from 1.3 to 1.4 
servings per week among 5- to 9-year-olds, 1.4 to 2.1 servings per week among 
10- to 14-year-olds, and 0.8 to 1.1 servings per week among 15- to 19-year-olds. 
Only between 7% and 14% of children in age and sex subgroups consumed ≥4 
servings per week.
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• Average consumption of processed meats ranged from 2.1 to 3.2 servings per 
week; was uniformly higher than the average consumption of nuts, legumes, and 
seeds; and was up to 6 times higher than the average consumption of fish and 
shellfish. Between 40% and 54% of children consumed ≥2 servings per week.
• Average consumption of sugar-sweetened beverages was higher in boys than in 
girls and was ≈8 servings per week in 5- to 9-year-olds, 11 to 13 servings per 
week in 10- to 14-year-olds, and 14 to 18 servings per week in 15- to 19-year-
olds. This was generally considerably higher than the average consumption of 
whole grains, fruits, vegetables, fish and shellfish, or nuts, legumes, and seeds. 
Only between 17% (boys 15–19 years of age) and 42% (boys and girls 5–9 years 
of age) of children consumed <4.5 servings per week.
• Average consumption of sweets and bakery desserts was ≈8 to 10 servings per 
week in 5- to 9-year-olds and 10- to 14-year-olds and 6 to 8 servings per week in 
15- to 19-year-olds. From 82% (girls 5–9 years of age) to 58% (boys 15–19 
years of age) of youths consumed >2.5 servings per week.
• Average consumption of eicosapentaenoic acid and docosahexaenoic acid was 
low, ranging from ≈45 to 75 mg/d in boys and girls at all ages. Only between 3% 
and 7% of children and teenagers at all ages consumed ≥250 mg/d.
• Average consumption of saturated fat was between 11% and 12% of calories, and 
average consumption of dietary cholesterol was ≈230 mg/d. Approximately one 
fifth to one third of children consumed <10% energy from saturated fat, and 
≈80% consumed <300 mg of dietary cholesterol per day.
• Average consumption of dietary fiber ranged from 12 to 14 g/d. Less than 2% of 
children in all different age and sex subgroups consumed ≥28 g/d.
• Average consumption of sodium ranged from 3.1 to 3.4 g/d. Between 7% and 
12% of children in different age and sex subgroups consumed <2.3 g/d.
Energy Balance—Energy balance, or consumption of total calories appropriate for needs, 
is determined by the balance of average calories consumed versus expended, with this 
balance depending on multiple factors, including calories consumed, PA, body size, age, sex, 
and underlying basal metabolic rate. Thus, one individual may consume relatively high 
calories but have negative energy balance (as a result of even greater calories expended), 
whereas another individual may consume relatively few calories but have positive energy 
balance (because of low calories expended). Given such variation, the most practical and 
reasonable method to assess energy balance in populations is to assess changes in weight 
over time (Trends section).
• Average daily caloric intake in the United States is ≈2500 and calories in adult 
men and 1800 calories in adult women (Table 5-1). In children and teenagers, 
average caloric intake is higher in boys than in girls and increases with age in 
boys (Table 5-2). Trends in energy balance are described below. The average US 
adult gains ≈1 pound per year. In an analysis of >120 000 US men and women in 
3 separate US cohorts followed up for up to 20 years, changes in intakes of 
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different foods and beverages were linked to long-term weight gain in different 
ways.2 Foods and beverages most positively linked to weight gain included poor-
quality carbohydrates, such as potatoes, refined grains (eg, white bread, white 
rice, low-fiber breakfast cereals), sweets/desserts, sugar-sweetened beverages, 
and red and processed meats. In contrast, increased consumption of several other 
foods, including nuts, whole grains, fruits, vegetables, and yogurt, was linked to 
less weight gain over time.2
• Other nutritional determinants of positive energy balance (more calories 
consumed than expended), as determined by adiposity or weight gain, include 
larger portion sizes3,4 and greater consumption of fast food and commercially 
prepared meals.5–9
• Preferences for portion size are associated with BMI, socioeconomic status, 
eating in fast-food restaurants, and television watching.10,11 Most portion sizes 
are larger at fast-food restaurants than at home or at other restaurants.12
• Between 1999 and 2004, 53% of Americans consumed an average of 1 to 3 
restaurant meals per week, and 23% consumed ≥4 restaurant meals per week.13 
Spending on food away from home, including restaurant meals, catered foods, 
and food eaten during out-of-town trips, increased from 26% of average annual 
food expenditures in 1970 to 42% in 2004.13 Macronutrient composition of the 
overall diet or of specific foods, such as percent calories from total fat, does not 
appear to be strongly associated with energy balance as ascertained by weight 
gain or loss.2,14–16 In contrast, dietary quality as characterized by higher or lower 
intakes of specific foods and beverages is associated with weight gain (see 
above).2
• Preliminary evidence suggests that consumption of trans fat may be associated 
with energy imbalance as assessed by changes in adiposity or weight, as well as 
more specific adverse effects on visceral adiposity, but such data are still 
emerging.17–19
• Other individual factors associated with positive energy balance (weight gain) 
include greater television watching (with evidence that effects are mediated by 
diet, rather than physical inactivity, including greater snacking in front of the 
television and the influence of advertising on poor food choices)2,20–24 and lower 
average sleep duration.2,25
• Randomized controlled trials of weight loss in obese individuals generally show 
modestly greater weight loss with low-carbohydrate (high-fat) diets than with 
low-fat diets at 6 months, but at 1 year, such differences diminish, and a diet that 
focuses on dietary quality and whole foods may be most successful in the long-
term.26–29
• On the basis of BRFSS data from 2003, among all American adults who are 
overweight or obese, a higher proportion are trying to lose weight if also 
diagnosed with hypertension (58% trying to lose weight), DM (60%), or both 
diseases (72%) than adults with neither condition (50%).31
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• A 2007–2008 national survey of 1082 retail stores in 19 US cities found that 
energy-dense snack foods/beverages were present in 96% of pharmacies, 94% of 
gas stations, 22% of furniture stores, 16% of apparel stores, and 29% to 65% of 
other types of stores.32
• Societal and environmental factors independently associated with energy 
imbalance (weight gain), via either increased caloric consumption or decreased 
expenditure, include education, income, race/ethnicity, and local conditions such 
as availability of grocery stores, types of restaurants, safety, parks and open 
spaces, and walking or biking paths.33–35 PA is covered in Chapter 4 of this 
update.
Dietary Patterns
In addition to individual foods and nutrients, overall dietary patterns can be used to assess 
more global dietary quality. Different dietary patterns have been defined, including the 
Healthy Eating Index (HEI), Alternative HEI, Western versus prudent dietary patterns, 
Mediterranean dietary pattern, and DASH (Dietary Approaches to Stop Hypertension)-type 
diet. The higher-monounsaturated-fat DASH–type diet is generally similar to a traditional 
Mediterranean dietary pattern.36
• In 1999 to 2004, only 19.4% of hypertensive US adults were following a DASH-
type diet (based on intake of fiber, magnesium, calcium, sodium, potassium, 
protein, total fat, saturated fat, and cholesterol). This represented a decrease from 
26.7% of hypertensive US adults in 1988 to 1994.37
• Among older US adults (≥60 years of age) in 1999 to 2002, 72% met guidelines 
for dietary cholesterol intake, but only between 18% and 32% met guidelines for 
the HEI food groups (meats, dairy, fruits, vegetables, and grains). On the basis of 
the HEI score, only 17% of older US adults consumed a good-quality diet. 
Higher HEI scores were seen in white adults and individuals with greater 
education; lower HEI scores were seen in black adults and smokers.38
Dietary Supplements
Use of dietary supplements is common in the United States among both adults and children:
• More than half (53%) of US adults in 2003 to 2006 used dietary supplements, 
with the most common supplement being multivitamins and multiminerals (40% 
of men and women reporting use).39 It has been shown that most supplements 
are taken daily and for at least 2 years. Supplement use was associated with older 
age, higher education, greater PA, wine intake, lower BMI, and white race.40
• One third (32%) of US children (birth to 18 years of age) used dietary 
supplements in 1999 to 2002, with the highest use (48.5%) occurring among 4- 
to 8-year-olds. The most common supplements were multivitamins and 
multiminerals (58% of supplement users). The primary nutrients supplemented 
(either by multivitamins and/or individual vitamins) included vitamin C (29% of 
US children), vitamin A (26%), vitamin D (26%), calcium (21%), and iron 
(19%). Supplement use was associated with higher family income, a smoke-free 
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home environment, lower child BMI, and less screen time (television, video 
games, or computers).41
• In a 2005 to 2006 telephone survey of US adults, 41.3% were making or had 
made in the past a serious weight-loss attempt. Of these, one third (33.9%) had 
used a dietary supplement for weight loss, with such use being more common in 
women (44.9%) than in men (19.8%) and in blacks (48.7%) or Hispanics 
(41.6%) than in whites (31.2%); in those with high school education or less 
(38.4%) than in those with some college or more (31.1%); and in those with 
household income less than $40 000 per year (41.8%) than in those with higher 
incomes (30.3%).42
• Multiple trials of most dietary supplements, including folate, vitamin C, and 
vitamin E, have generally shown no significant benefits for CVD risk, and even 
potential for harm.36 For example, a multicenter randomized trial in patients with 
diabetic nephropathy found that B vitamin supplementation (folic acid 2.5 mg/d, 
vitamin B6 25 mg/d, and vitamin B12 1 mg/d) decreased glomerular filtration 
rate (GFR) and increased risk of MI and stroke compared with placebo.43 Fish 
oil supplements at doses of 1 to 2 g/d have shown CVD benefits in 2 large 
randomized, open-label trials and 1 large randomized, placebo-controlled trial 
(Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico 
[GISSI]-Prevenzione, Japan Eicosapentaenoic Acid Lipid Intervention Study, 
and GISSI-HF),44–46 but other smaller trials of fish oil have not shown 
significant effects on CVD risk.47 A meta-analysis of placebo-controlled trials 
(ie, excluding the 2 large open-label trials) showed a modest benefit for CVD 
mortality but no statistically significant effects on other CVD end points.48
Trends
Energy Balance—(See Chart 5-1)
Energy balance, or consumption of total calories appropriate for needs, has been steadily 
worsening in the United States over the past several decades, as evidenced by the dramatic 
increases in overweight and obesity among both children and adults across broad cross 
sections of sex, race/ethnicity, geographic residence, and socioeconomic status.49,50,50a
• Although trends in total calories consumed are difficult to quantify exactly 
because of differing methods of serial national dietary surveys over time, 
multiple lines of evidence indicate that average total energy consumption has 
increased by at least 200 kcal/d per person in the past 3 decades.
• Data from NHANES indicate that between 1971 and 2004, average total energy 
consumption among US adults increased by 22% in women (from 1542 to 1886 
kcal/d) and by 10% in men (from 2450 to 2693 kcal/d). These increases are 
supported by data from the Nationwide Food Consumption Survey (1977–1978) 
and the Continuing Surveys of Food Intake (1989–1998).12
• The increases in calories consumed during this time period are attributable 
primarily to greater average carbohydrate intake, particularly of starches, refined 
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grains, and sugars (Foods and Nutrients section). Other specific changes related 
to increased caloric intake in the United States include larger portion sizes, 
greater food quantity and calories per meal, and increased consumption of sugar-
sweetened beverages, snacks, commercially prepared (especially fast-food) 
meals, and higher-energy-density foods.6,12,51–55
• Between 1977 and 1978 and 1994 and 1996, the average portion sizes for nearly 
all foods increased at fast-food outlets, other restaurants, and home. These 
included a 33% increase in the average portion of Mexican food (from 408 to 
541 calories), a 34% increase in the average portion of cheeseburgers (from 397 
to 533 calories), a 36% increase in the average portion of French fries (from 188 
to 256 calories), and a 70% increase in the average portion of salty snacks such 
as crackers, potato chips, pretzels, puffed rice cakes, and popcorn (from 132 to 
225 calories).12
• Among US children 2 to 7 years of age, an estimated energy imbalance of only 
110 to 165 kcal/d (the equivalent of one 12- to 16-oz bottle of soda/cola) was 
sufficient to account for the excess weight gain between 1988 and 1994 and 1999 
and 2002.56
• In a quantitative analysis using various US surveys between 1977 and 2006, the 
relations of changes in energy density, portion sizes, and number of daily eating/
drinking occasions to changes in total energy intake were assessed.57 Decreases 
in energy density were actually linked to lower total energy intake over time, 
whereas increases in both portion size and number of eating occasions were 
linked to greater energy intake.
• Among US children 2 to 18 years of age, increases in energy intake between 
1977 and 2006 (179 kcal/d) were entirely attributable to substantial increases in 
energy eaten away from home (255 kcal/d).58 The percentage of energy eaten 
away from home increased from 23.4% to 33.9% during this time, with a shift 
toward energy from fast food as the largest contributor to foods away from home 
for all age groups.
Foods and Nutrients—Several changes in foods and nutrients have occurred over time. 
Selected changes are highlighted:
Macronutrients: (See Chart 5-1)
• Starting in 1977 and continuing until the most recent dietary guidelines revision 
in 2010, a major focus of US dietary guidelines was reduction of dietary fats.58a 
During this time, average total fat consumption declined as a percent of calories 
from 36.9% to 33.4% in men and from 36.1% to 33.8% in women.13
• Dietary guidelines during this time also emphasized carbohydrate consumption 
as the base of one’s dietary pattern,59 and more recently specifies the importance 
of complex rather than refined carbohydrates58a (eg, as the base of the Food 
Guide Pyramid).59 Total carbohydrate intake increased from 42.4% to 48.2% of 
calories in men and from 45.4% to 50.6% of calories in women.13 Evaluated as 
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absolute intakes, the increase in total calories consumed during this period was 
attributable primarily to the greater consumption of carbohydrates, both as foods 
(starches and grains) and as beverages.60,61
Sugar-Sweetened Beverages: (See Chart 5-2)
• Between 1965 and 2002, the average percentage of total calories consumed from 
beverages in the United States increased from 11.8% to 21.0% of energy, which 
represents an overall absolute increase of 222 cal/d per person.54 This increase 
was largely caused by increased consumption of sugar-sweetened beverages and 
alcohol: Average consumption of fruit juices went from 20 to 39 kcal/d; of milk, 
from 125 to 94 kcal/d; of alcohol, from 26 to 99 kcal/d; of sweetened fruit 
drinks, from 13 to 38 kcal/d; and of soda/cola, from 35 to 143 kcal/d.57
• In addition to increased overall consumption, the average portion size of a single 
sugar-sweetened beverage increased by >50% between 1977 and 1996, from 
13.1 to 19.9 fl oz.12
• Among children and teenagers (2–19 years of age), the largest increases in 
consumption of sugar-sweetened beverages between 1988 to 1994 and 1999 to 
2004 were seen among black and Mexican American youths compared with 
white youths.55
Fruits and Vegetables
• Between 1994 and 2005, the average consumption of fruits and vegetables 
declined slightly, from a total of 3.4 to 3.2 servings per day. The proportions of 
men and women consuming combined fruits and vegetables ≥5 times per day 
were low (≈20% and 29%, respectively) and did not change during this period.62
Morbidity and Mortality
Effects on Cardiovascular Risk Factors—Dietary habits affect multiple 
cardiovascular risk factors, including both established risk factors (SBP, DBP, LDL 
cholesterol levels, HDL cholesterol levels, glucose levels, and obesity/weight gain) and 
novel risk factors (eg, inflammation, cardiac arrhythmias, endothelial cell function, 
triglyceride levels, lipoprotein[a] levels, and heart rate):
• A DASH dietary pattern with low sodium reduced SBP by 7.1 mm Hg in adults 
without hypertension and by 11.5 mm Hg in adults with hypertension.63
• Compared with the low-fat DASH diet, DASH-type diets that increased 
consumption of either protein or unsaturated fat had similar or greater beneficial 
effects on CVD risk factors. Compared with a baseline usual diet, each of the 
DASH-type diets, which included various percentages (27%–37%) of total fat 
and focused on whole foods such as fruits, vegetables, whole grains, and fish, as 
well as potassium and other minerals and low sodium, reduced SBP by 8 to 10 
mm Hg, DBP by 4 to 5 mm Hg, and LDL cholesterol by 12 to 14 mg/dL. The 
diets that had higher levels of protein and unsaturated fat also lowered 
triglyceride levels by 16 and 9 mg/dL, respectively.64 The DASH-type diet 
et al. Page 45
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
higher in unsaturated fat also improved glucose-insulin homeostasis compared 
with the low-fat/high-carbohydrate DASH diet.65
• In a meta-analysis of randomized controlled trials, consumption of 1% of 
calories from trans fat in place of saturated fat, monounsaturated fat, or 
polyunsaturated fat increased the ratio of total to HDL cholesterol by 0.031, 
0.054, and 0.67; increased apolipoprotein B levels by 3, 10, and 11 mg/L; 
decreased apolipoprotein A-1 levels by 7, 5, and 3 mg/L; and increased 
lipoprotein(a) levels by 3.8, 1.4, and 1.1 mg/L, respectively.66
• In meta-analyses of randomized controlled trials, consumption of 
eicosapentaenoic acid and docosahexaenoic acid for 212 weeks lowered SBP by 
2.1 mm Hg67 and lowered resting heart rate by 2.5 beats per minute.68
• In a pooled analysis of 25 randomized trials totaling 583 men and women both 
with and without hypercholesterolemia, nut consumption significantly improved 
blood lipid levels.69 For a mean consumption of 67 g of nuts per day, total 
cholesterol was reduced by 10.9 mg/dL (5.1%), LDL cholesterol by 10.2 mg/dL 
(7.4%), and the ratio of total cholesterol to HDL cholesterol by 0.24 (5.6% 
change; P<0.001 for each). Triglyceride levels were also reduced by 20.6 mg/dL 
(10.2%) in subjects with high triglycerides (2150 mg/dL). Different types of nuts 
had similar effects.69 A review of cross-sectional and prospective cohort studies 
suggests that higher intake of sugar-sweetened beverages is associated with 
greater visceral fat and higher risk of type 2 DM.70 In the Prospective Registry 
Evaluating Myocardial Infarction: Events and Recovery (PREMIER) study, a 
prospective analysis of the 810 participants indicated that a reduction in sugar-
sweetened beverages of 1 serving per day was associated with a reduction in SBP 
of 1.8 mm Hg (95% CI, 1.2–2.4 mm Hg) and a reduction in DBP of 1.1 mm Hg 
(95% CI, 0.7–1.4 mm Hg).71
• In a cross-sectional analysis among nearly 3000 adults from the United States 
and the United Kingdom, higher consumption of sugar-sweetened beverages was 
linked to higher BP (1.6 and 0.8 mm Hg higher SBP and DBP per serving per 
day, respectively, and 1.1 and 0.4 mm Hg higher SBP and DBP per serving per 
day after adjustment for weight and weight).72
• In a randomized controlled trial, compared with a low-fat diet, 2 Mediterranean 
dietary patterns that included either virgin olive oil or mixed nuts lowered SBP 
by 5.9 and 7.1 mm Hg, plasma glucose by 7.0 and 5.4 mg/dL, fasting insulin by 
16.7 and 20.4 pmol/L, the homeostasis model assessment index by 0.9 and 1.1, 
and the ratio of total to HDL cholesterol by 0.38 and 0.26 and raised HDL 
cholesterol by 2.9 and 1.6 mg/dL, respectively. The Mediterranean dietary 
patterns also lowered levels of C-reactive protein, interleukin-6, intercellular 
adhesion molecule-1, and vascular cell adhesion molecule-1.73
Effects on Cardiovascular Outcomes—Because dietary habits affect a broad range of 
established and novel risk factors, estimation of the impact of nutritional factors on 
cardiovascular health by considering only a limited number of pathways (eg, only effects on 
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lipids, BP, and obesity) will systematically underestimate or even misconstrue the actual 
total impact on cardiovascular health. Randomized controlled trials and prospective 
observational studies have been used to quantify the total effects of dietary habits on clinical 
outcomes:
Fats and Carbohydrates
• In the Women’s Health Initiative (WHI) randomized clinical trial (n=48 835), 
reduction of total fat consumption from 37.8% energy (baseline) to 24.3% energy 
(at 1 year) and 28.8% energy (at 6 years) had no effect on incidence of CHD 
(RR, 0.98; 95% CI, 0.88–1.09), stroke (RR, 1.02; 95% CI, 0.90–1.15), or total 
CVD (RR, 0.98; 95% CI, 0.92–1.05) over a mean of 8.1 years.74 This was 
consistent with null results of 4 prior randomized clinical trials and multiple 
large prospective cohort studies that indicated little effect of total fat 
consumption on CVD risk.75
• In 3 separate meta-analyses of prospective cohort studies, the largest of which 
included 21 studies with up to 2 decades of follow-up, saturated fat consumption 
overall had no significant association with incidence of CHD, stroke, or total 
CVD.76–78 In comparison, in a pooled individual-level analysis of 11 prospective 
cohort studies, the specific exchange of polyunsaturated fat consumption in place 
of saturated fat was associated with lower CHD risk, with 13% lower risk for 
each 5% energy exchange (RR, 0.87; 95% CI, 0.70–0.97).79 These findings are 
consistent with a meta-analysis of randomized controlled trials in which 
increased polyunsaturated fat consumption in place of saturated fat reduced CHD 
events, with 10% lower risk for each 5% energy exchange (RR, 0.90; 95% CI, 
0.83–0.97).80
• In a pooled analysis of individual-level data from 11 prospective cohort studies 
in the United States, Europe, and Israel that included 344 696 participants, each 
5% higher energy consumption of carbohydrate in place of saturated fat was 
associated with a 7% higher risk of CHD (RR, 1.07; 95% CI, 1.01–1.14).79 Each 
5% higher energy consumption of monounsaturated fat in place of saturated fat 
was not significantly associated with CHD risk.79
• Together these findings suggest that reducing saturated fat without specifying the 
replacement may have minimal effects on CHD risk, whereas increasing 
polyunsaturated fats from vegetable oils will reduce CHD.36
• In a meta-analysis of prospective cohort studies, each 2% of calories from trans 
fat was associated with a 23% higher risk of CHD (RR, 1.23; 95% CI, 1.11–
1.37).81
• In meta-analyses of prospective cohort studies, greater consumption of refined 
complex carbohydrates, starches, and sugars, as assessed by glycemic index or 
load, was associated with significantly higher risk of CHD and DM. When the 
highest category was compared with the lowest category, risk of CHD was 36% 
greater (glycemic load: RR, 1.36; 95% CI, 1.13–1.63), and risk of DM was 40% 
greater (glycemic index: RR, 1.40; 95% CI, 1.23–1.59).82,83
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Foods and Beverages
• In meta-analyses of prospective cohort studies, each daily serving of fruits or 
vegetables was associated with a 4% lower risk of CHD (RR, 0.96; 95% CI, 
0.93–0.99) and a 5% lower risk of stroke (RR, 0.95; 95% CI, 0.92–0.97).84,85
• In a meta-analysis of prospective cohort studies, greater whole grain intake (2.5 
compared with 0.2 servings per day) was associated with a 21% lower risk of 
CVD events (RR, 0.79; 95% CI, 0.73–0.85), with similar estimates in men and 
women and for various outcomes (CHD, stroke, and fatal CVD). In contrast, 
refined grain intake was not associated with lower risk of CVD (RR, 1.07; 95% 
CI, 0.94–1.22).86
• In a meta-analysis of 16 prospective cohort studies that included 326 572 
generally healthy individuals in Europe, the United States, China, and Japan, fish 
consumption was associated with significantly lower risk of CHD mortality.87 
Compared with no consumption, an estimated 250 mg of long-chain omega-3 
fatty acids per day was associated with 35% lower risk of CHD death (P<0.001).
• In a meta-analysis of prospective cohort and case-control studies from multiple 
countries, consumption of unprocessed red meat was not significantly associated 
with incidence of CHD. In contrast, each 50-g serving per day of processed 
meats (eg, sausage, bacon, hot dogs, deli meats) was associated with a higher 
incidence of CHD (RR, 1.42; 95% CI, 1.07–1.89).88
• In a meta-analysis of prospective cohort studies that included 442 101 
participants and 28 228 DM cases, unprocessed red meat consumption was 
associated with a higher risk of DM (RR, 1.19; 95% CI, 1.04–1.37, per 100 g/d). 
On a per g/d basis, risk of DM was nearly 7-fold higher for processed meat 
consumption (RR, 1.51; 95% CI, 1.25–1.83, per 50 g/d).89
• In a meta-analysis of 6 prospective observational studies, nut consumption was 
associated with significantly lower incidence of CHD (comparing higher to low 
intake: RR, 0.70; 95% CI, 0.57–0.82).77
• Higher consumption of dairy or milk products is associated with lower incidence 
of DM and trends toward lower risk of stroke.77,90,91 Some limited evidence 
suggests that these associations are stronger for low-fat dairy or milk than for 
other dairy products. Dairy consumption is not significantly associated with 
higher or lower risk of CHD.77,91
• Among 88 520 generally healthy women in the Nurses’ Health Study who were 
34 to 59 years of age in 1980 and were followed up from 1980–2004, regular 
consumption of sugar-sweetened beverages was independently associated with 
higher incidence of CHD, with 23% and 35% higher risk with 1 and ≥2 servings 
per day, respectively, compared with <1 per month.92 Among the 15 745 
participants in the ARIC study, the OR for developing CHD was 2.59 for 
participants who had a serum uric acid level >9.0 mg/dL and who drank >1 
sugar-sweetened soda per day.93
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Sodium and Potassium
• Lower estimated consumption of dietary sodium was not associated with lower 
CVD mortality in NHANES,94 although such findings may be limited by 
changes in behaviors that result from underlying risk (reverse causation). In a 
post hoc analysis of the Trials of Hypertension Prevention, participants 
randomized to low-sodium interventions had a 25% lower risk of CVD (RR, 
0.75; 95% CI, 0.57–0.99) after 10 to 15 years of follow-up after the original 
trials.95
• In a meta-analysis of small randomized trials of sodium reduction of ≥6 months’ 
duration, nonsignificant trends were seen toward fewer CVD events in subjects 
with normal BP (RR, 0.71; 95% CI, 0.42–1.20; n=200 events) or hypertension 
(RR, 0.84; 95% CI, 0.57–1.23; n=93 events), but the findings were not 
statistically significant, with relatively low statistical power because of the small 
numbers of events. Sodium restriction increased total mortality in trials of 
patients with CHF (RR, 2.59; 95% CI, 1.04–6.44), but these data were based on 
very few events (n=21 deaths).96
• In a meta-analysis of 13 prospective cohorts that included 177 025 participants 
and >11 000 vascular events, higher sodium consumption was associated with 
greater risk of stroke (pooled RR, 1.23; 95% CI, 1.06–1.43; P=0.007) and a trend 
toward higher risk of CVD (1.14, 0.99–1.32; P=0.07). These associations were 
greater with larger differences in sodium intake and longer follow-up.97
• In a meta-analysis of 15 prospective cohort samples that included 247 510 
participants and 7066 strokes, 3058 CHD events, and 2497 total CVD events, 
each 1.64-g/d (42 mmol/d) higher potassium intake was associated with a 21% 
lower risk of stroke (RR, 0.79; 95% CI, 0.68–0.90) and trends toward lower risk 
of CHD and total CVD.98
Dietary Patterns
• In a cohort of 380 296 US men and women, greater versus lower adherence to a 
Mediterranean dietary pattern, characterized by higher intakes of vegetables, 
legumes, nuts, fruits, whole grains, fish, and unsaturated fat and lower intakes of 
red and processed meat, was associated with a 22% lower cardiovascular 
mortality (RR, 0.78; 95% CI, 0.69–0.87).99 Similar findings have been seen for 
the Mediterranean dietary pattern and risk of incident CHD and stroke100 and for 
the DASH-type dietary pattern.101
• In a cohort of 72 113 US female nurses, a dietary pattern characterized by higher 
intakes of vegetables, fruits, legumes, fish, poultry, and whole grains was 
associated with a 28% lower cardiovascular mortality (RR, 0.72; 95% CI, 0.60–
0.87), whereas a dietary pattern characterized by higher intakes of processed 
meat, red meat, refined grains, French fries, and sweets/desserts was associated 
with a 22% higher cardiovascular mortality (RR, 1.22; 95% CI, 1.01–1.48).102 
Similar findings have been seen in other cohorts and for other outcomes, 
including development of DM and metabolic syndrome.103–109
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Impact on US Mortality
• In one report that used consistent and comparable risk assessment methods and 
nationally representative data, the mortality effects in the United States of 12 
modifiable dietary, lifestyle, and metabolic risk factors were assessed. High 
dietary salt consumption was estimated to be responsible for 102 000 annual 
deaths, low dietary omega-3 fatty acids for 84 000 annual deaths, high dietary 
trans fatty acids for 82 000 annual deaths, and low consumption of fruits and 
vegetables for 55 000 annual deaths.110
Cost
(See Chart 5-3)
The US Department of Agriculture forecast that the Consumer Price Index for all food 
would increase 3.0% to 4.0% in 2013 as retailers continued to pass on higher commodity 
and energy costs to consumers in the form of higher retail prices. The Consumer Price Index 
for food increased 3.7% in 2011. Prices for foods eaten at home increased 4.8% in 2011, 
whereas prices for foods eaten away from home increased by 1.9%.111
• The proportion of total US food expenditures for meals outside the home, as a 
share of total food dollars, increased from 27% in 1961 to 40% in 1981 to 49% 
in 2011.59
• The proportion of sales of meals and snacks from fast-food restaurants compared 
with total meals and snacks away from home increased from 5% in 1958 to 29% 
in 1982 to 36% in 2011.111
• As a proportion of income, food has become less expensive over time in the 
United States. As a share of personal disposable income, average (mean) total 
food expenditures by families and individuals have decreased from 22.3% (1949) 
to 18.1% (1961) to 14.9% (1981) to 11.3% (2011). For any given year, the share 
of disposable income spent on food is inversely proportional to absolute income. 
The share increases as absolute income levels decline.111
• Among 153 forms of fruits and vegetables priced with 2008 Nielsen Homescan 
data, price and calorie per portion of 20 fruits and vegetables were compared 
with 20 common snack foods such as cookies, chips, pastries, and crackers. 
Average price per portion of fruits and vegetables was 31 cents with an average 
of 57 calories per portion, compared with 33 cents and 183 calories per portion 
for snack foods.111
• An overview of the costs of various strategies for primary prevention of CVD 
determined that the estimated costs per year of life gained were between $9800 
and $18 000 for statin therapy, ≥$1500 for nurse screening and lifestyle advice, 
$500 to $1250 for smoking cessation, and $20 to $900 for population-based 
healthy eating.112
• Each year, >$33 billion in medical costs and $9 billion in lost productivity 
resulting from HD, cancer, stroke, and DM are attributed to poor nutrition.113–117
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• Two separate cost-effectiveness analyses estimated that population reductions in 
dietary salt would not only be cost-effective but actually cost-saving.118,119 In 1 
analysis, a 1.2 g/d reduction in dietary sodium was projected to reduce US 
annual cases of incident CHD by 60 000 to 120 000, stroke by 32 000 to 66 000, 
and total mortality by 44 000 to 92 000.119 If accomplished through a regulatory 
intervention, estimated savings in healthcare costs would be $10 to $24 billion 
annually.119 Such an intervention would be more cost-effective than using 
medications to lower BP in all people with hypertension.
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6. Overweight and Obesity
See Table 6-1 and Charts 6-1 through 6-3
Prevalence
Youth—(See Table 6-1 and Chart 6-1)
• The prevalence of overweight and obesity in children 2 to 5 years of age, based 
on a BMI-for-age value ≥85th percentile of the 2000 CDC growth charts, was 
26% for non-Hispanic white boys and 21% for non-Hispanic white girls, 31% for 
non-Hispanic black boys and 27% for non-Hispanic black girls, and 32% for 
Mexican American boys and 33% for Mexican American girls according to 
2009–2010 data from NHANES (NCHS). In children 6 to 11 years of age, the 
prevalence was 30% for non-Hispanic white boys and 25% for non-Hispanic 
white girls, 41% for non-Hispanic black boys and 44% for non-Hispanic black 
girls, and 39% for Mexican American boys and 40% for Mexican American 
girls. In children 12 to 19 years of age, the prevalence was 32% for non-Hispanic 
white boys and 28% for non-His-panic white girls, 37% for non-Hispanic black 
boys and 45% for non-Hispanic black girls, and 46% for Mexican American 
boys and 41% for Mexican American girls.2
• The prevalence of obesity in children 2 to 5 years of age, based on BMI-for-age 
values ≥95th percentile of the 2000 CDC growth charts, was 12% for non-
Hispanic white boys and 6% for non-Hispanic white girls, 21% for non-Hispanic 
black boys and 17% for non-Hispanic black girls, and 19% for Mexican 
American boys and 12% for Mexican American girls according to 2009–2010 
data from NHANES (NCHS). In children 6 to 11 years of age, the prevalence 
was 17% for non-Hispanic white boys and 11% for non-Hispanic white girls, 
30% for non-Hispanic black boys and 28% for non-Hispanic black girls, and 
22% for Mexican American boys and 22% for Mexican American girls. In 
children 12 to 19 years of age, the prevalence was 18% for non-Hispanic white 
boys and 15% for non-Hispanic white girls, 23% for non-Hispanic black boys 
and 25% for non-Hispanic black girls, and 29% for Mexican American boys and 
19% for Mexican American girls.2
• Overall, 18% of US children and adolescents 6 to 19 years of age have BMI-for-
age values ≥95th percentile of the 2000 CDC growth charts for the United States 
(NHANES [2009–2010], NCHS).2
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• NHANES 2009–2010 found that 16.9% (15.4%–18.4%) of youth aged 2 to 19 
years were obese, which was unchanged from 2007–2008. Rates of overweight 
and obesity (≥85th BMI percentile) were 39.1% for Hispanics, 39.4% for 
Mexican Americans, 27.9% for non-Hispanic whites, and 39.1% for non-
Hispanic blacks.2
• A study of >8500 4-year-olds in the Early Childhood Longitudinal Study, Birth 
Cohort (National Center for Education Statistics) found that 1 in 5 were obese. 
Almost 13% of Asian children, 16% of white children, nearly 21% of black 
children, 22% of Hispanic children, and 31% of American Indian children were 
obese. Children were considered obese if their BMI was ≥95th percentile on the 
basis of CDC BMI growth charts. For 4-year-olds, that would be a BMI of ≈18 
kg/m2.3
• Childhood sociodemographic factors may contribute to sex disparities in obesity 
prevalence. A study of data from the National Longitudinal Study of Adolescent 
Health found that parental education consistently modified sex disparity in 
blacks. The sex gap was largest in those with low parental education (16.7% of 
men compared with 45.4% of women were obese) and smallest in those with 
high parental education (28.5% of men compared with 31.4% of women were 
obese). In whites, there was little overall sex difference in obesity prevalence.4
• The obesity epidemic is disproportionally more rampant among children living in 
low-income, low-education, and higher-unemployment households, according to 
data from the National Survey of Children’s Health.5
• Data from 2011 show that American Indian/Alaskan Native youth have an 
obesity rate of 17.7%, whereas rates are 14.7% for Hispanics, 10.6% for non-
Hispanic blacks, 10.3% for non-Hispanic whites, and 9.3% for Asian/Pacific 
Islanders.6
• According to 1999–2008 NHANES survey data, lowest-income girls had an 
obesity prevalence of 17.9% compared with 13.1% among those with higher 
income; similar observations were observed for boys (20.6% versus 15.6%, 
respectively).7
• According to the US National Longitudinal Study of Adolescent Health, 1.0% of 
adolescents were severely obese in 1996 (defined as age <20 years and BMI 
≥95th sex-specific BMI-for-age growth chart or BMI ≥30 kg/m2); the majority 
(70.5%) maintained this weight status into adulthood. Obese adolescents had a 
16-fold increased risk of becoming severely obese adults compared with those 
with normal weight or those who were overweight.8
• NHANES 2003–2004 and 2005–2006 data were used to determine overweight 
and obesity prevalence in rural versus urban youth; the results showed that 39% 
of rural versus 32% of urban children had BMI >85th percentile.9
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Abbreviations Used in Chapter 6
AF atrial fibrillation
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DM diabetes mellitus
FHS Framingham Heart Study
HbA1c hemoglobin A1c
HDL high-density lipoprotein
HR hazard ratio
HUNT 2 Nord-Trøndelag Health Study
IMT intima-media thickness
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
RR relative risk
SBP systolic blood pressure
SD standard deviation
STEMI ST-segment–elevation myocardial infarction
WHO World Health Organization
Adults—(See Table 6-1 and Chart 6-2)
• According to NHANES 2007–2010 (unpublished NHLBI tabulations):
– Overall, 68% of US adults were overweight or obese (73% of men and 
64% of women).
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– Among men, Mexican-Americans (81%) and non-His-panic whites 
(73%) were more likely to be overweight or obese than non-Hispanic 
blacks (69%).
– Among women, non-Hispanic blacks (80%) and Mexican-Americans 
(78%) were more likely to be overweight or obese than non-Hispanic 
whites (60%).
– Among US adults, 35% were obese (35% of men and 36% of women).
– Among men, non-Hispanic blacks (38%) and Mexican-Americans 
(36%) were more likely to be obese than non-Hispanic whites (34%).
– Among women, non-Hispanic blacks (54%) and Mexican-Americans 
(45%) were more likely to be obese than non-Hispanic whites (33%).
• When estimates were based on self-reported height and weight in the 
BRFSS/CDC survey in 2011, the prevalence of obesity ranged from 20.7% in 
Colorado to 34.9% in Mississippi. The median percentage by state was 27.8%.10 
Additionally, no state met the Healthy People 2010 goal of reducing obesity to 
15% of adults.11
• On the basis of 2011 data on self-reported weights and heights from the 2011 
NHIS12:
– Blacks ≥18 years of age (26.4%), American Indians or Alaska Natives 
(27.6%), and whites (36.6%) were less likely than Asians (56.7%) to be 
at a healthy weight.12
– Blacks ≥18 years of age (38.9%) and American Indians or Alaska 
Natives (40.8%) were more likely to be obese than were whites (27.2%) 
and Asians (9.3%).12
• Most adults in Asian subgroups were in the healthy weight range, with rates 
ranging from 51% for Filipino adults to 68% for Chinese adults. Although the 
prevalence of obesity is low within the Asian adult population, Filipino adults 
(14%) were more than twice as likely to be obese (BMI ≥30 kg/m2) as Asian 
Indian (6%), Vietnamese (5%), or Chinese (4%) adults.13
• According to the 2008 National Healthcare Disparities Report (on the basis of 
NHANES 2003–2006)14:
– Approximately 64.8% of obese adults were told by a doctor or health 
professional that they were overweight.
– The proportion of obese adults told that they were overweight was 
significantly lower for non-Hispanic blacks (60.5%) and Mexican 
Americans (57.1%) than for non-Hispanic whites (66.4%), for middle-
income people than for high-income people (62.4% versus 70.6%), and 
for adults with less than a high school education than for those with any 
college education (59.2% versus 70.3%).14
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• As judged by an analysis of data from the Multi-Ethnic Study of Atherosclerosis 
(MESA), a large proportion of white, black, and Hispanic participants were 
overweight (60%–85%) or obese (30%–50%), whereas fewer Chinese American 
participants were overweight (33%) or obese (5%).15
• In a cross-sectional study of 7000 elderly subjects at high cardiovascular risk, 
adherence to a Mediterranean diet, moderate alcohol consumption, the 
expenditure of ≥200 kcal/d in PA, and nonsmoking were associated with a 1.3-
kg/m2 (0.9–1.7) lower BMI and a 4.3-cm (3.1–5.4) lower waist circumference 
than having ≤1 healthy lifestyle factor.16
• Among severely obese (class II or III) patients, a 1-year intensive lifestyle 
intervention of diet and PA achieved clinically significant weight loss and 
improvement in cardiometabolic factors in addition to reduction in visceral and 
hepatic fat content.17
Trends
Youth—(See Chart 6-3)
• Among infants and children between 6 and 23 months of age, the prevalence of 
high weight for recumbent length was 7% in 1976–1980 and 12% in 2003–2006 
(NHANES, NCHS).18
• The obesity epidemic in children continues to grow on the basis of recent data 
from the Bogalusa Heart Study. Compared with 1973 to 1974, the proportion of 
children 5 to 17 years of age who were obese was 5 times higher in 2008 to 
2009.19
• A comparison of NHANES 2009–2010 data with 1999–2000 data demonstrates 
an increase in obesity prevalence in male youth of 5% (OR, 1.05; 95% CI, 1.01–
1.10) but not in female youth (OR, 1.02; 95% CI, 0.98–1.07).2
Adults
• On the basis of 2009 self-reported BRFSS data, overall obesity prevalence was 
26.7% in the United States, with rates of 27.4% in men and 26.0% in women. By 
race/ethnicity, the prevalence of obesity among non-Hispanic whites was 25.2%, 
whereas it.8% among non-Hispanic blackswas 36 and 30.7% among Hispanics. 
There was an inverse association by education level: College graduates had a 
20.8% rate of obesity, whereas those who attained less than a high school 
education had an obesity prevalence of 32.9%.20
• The prevalence of obesity increased by 5.6% or ≈2.7 million people from 1997 
to 2002 among Medicare beneficiaries. By 2002, 21.4% of beneficiaries and 
39.3% of disabled beneficiaries were obese compared with 16.4% and 32.5%, 
respectively, in 1997.21
• The population attributable fraction for CHD associated with reducing current 
population mean BMI to 21 kg/m2 in the Asia-Pacific region ranged from 2% in 
India to 58% in American Samoa; the population attributable fraction for 
et al. Page 62
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ischemic stroke ranged from 3% in India to 64% in American Samoa. These data 
from 15 countries show the proportion of CVD that would be prevented if the 
population mean BMI were reduced below the current overweight cut point.22a
• The CARDIA study showed that young adults who were overweight or obese 
had lower health-related quality of life than normal-weight participants 20 years 
later. On the basis of data from the Medical Outcomes Study 12-item short-form 
health survey, overweight and obese participants had lower multivariable-
adjusted scores on the physical component summary score but not on the mental 
component summary score.22
• Forecasts through 2030 using the BRFSS 1990–2008 data set suggest that by 
2030, 51% of the population will be obese, with 11% with severe obesity, an 
increase of 33% for obesity and 130% for severe obesity.23
Morbidity
• Overweight children and adolescents are at increased risk for future adverse 
health effects, including the following24:
– Increased prevalence of traditional cardiovascular risk factors such as 
hypertension, hyperlipidemia, and DM.
– Poor school performance, tobacco use, alcohol use, premature sexual 
behavior, and poor diet.
– Other associated health conditions, such as asthma, hepatic steatosis, 
sleep apnea, stroke, some cancers (breast, colon, and kidney), 
musculoskeletal disorders, and gallbladder disease.
• According to data from the Bogalusa Heart Study and the Young Finns study, 
adolescents with high BMI in the overweight or obese range are at a 2.5-fold 
increased risk of developing metabolic syndrome, a 2.2-fold increased risk of 
high carotid IMT, and a 3.4-fold increased risk of DM in adulthood.25
• The increasing prevalence of obesity is driving an increased incidence of type 2 
DM. Data from the FHS indicate a doubling in the incidence of DM over the past 
30 years, most dramatically during the 1990s and primarily among individuals 
with a BMI >30 kg/m2.26
• Obesity was the most powerful predictor of DM in the Nurses’ Health Study. 
Women with a BMI of ≥35 kg/m2 had an RR for DM of 38.8 compared with 
women with a BMI of <23 kg/m2.27
• Obesity is also a strong predictor of sleep-disordered breathing, itself strongly 
associated with the development of CVD, as well as with myriad other health 
conditions, including numerous cancers, nonalcoholic fatty liver disease, 
gallbladder disease, musculoskeletal disorders, and reproductive abnormalities.28
• A recent meta-analysis of 15 prospective studies demonstrated the increased risk 
for Alzheimer disease or vascular dementia and any dementia was 1.35 and 1.26 
for overweight, respectively, and 2.04 and 1.64 for obesity, respectively.29
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• A randomized clinical trial of 130 severely obese adult individuals randomized to 
either 12 months of diet and PA or only 6 months of PA resulted in 12.1 and 9.9 
kg, respectively, of weight loss at 1 year, with improvements in waist 
circumference, visceral fat, BP, and insulin resistance.17
• Data from 4 Finnish cohort studies examining childhood and adult BMI with a 
mean follow-up of 23 years found that overweight or obese children who 
remained obese in adulthood had increased risks of type 2 DM, hypertension, 
dyslipidemia, and carotid atherosclerosis. However, those who became normal 
weight by adulthood had risks comparable to individuals who were never 
obese.30
• In a meta-analysis from 58 cohorts, representing 221 934 people in 17 developed 
countries with 14 297 incident CVD outcomes, BMI, waist circumference, and 
waist-to-hip ratio were only minimally associated with cardiovascular outcomes 
after controlling for baseline SBP, DM, and total and HDL cholesterol in 
addition to age, sex, and smoking status. Measures of adiposity also did not 
improve risk discrimination or reclassification when risk factor data were 
included.31
• Ten-year follow-up data from the Swedish Obese Subjects intervention study 
indicated that to maintain a favorable effect on cardiovascular risk factors, more 
than the short-term goal of 5% weight loss is needed to overcome secular trends 
and aging effects.32
• An obesity paradox has been reported, with obese patients demonstrating 
favorable outcomes in CHF, hypertension, peripheral vascular disease, and 
coronary artery disease (CAD). In the Atrial Fibrillation Follow-up Investigation 
of Rhythm Management (AFFIRM) study, a multicenter trial of atrial fibrillation 
(AF), obese patients had lower all-cause mortality (HR=0.77, P=0.01) than 
normal-weight patients after multivariable adjustment over a 3-year follow-up 
period.33
• A systematic review of prospective studies examining overweight and obesity as 
predictors of major stroke subtypes in >2 million participants over ≥4 years 
found an adjusted RR for ischemic stroke of 1.22 (1.05–1.41) in overweight 
individuals and an RR of 1.64 (1.36–1.99) for obese individuals relative to 
normal-weight individuals. RRs for hemorrhagic stroke were 1.01 (0.88–1.17) 
and 1.24 (0.99–1.54) for overweight and obese individuals, respectively. These 
risks were graded with increasing BMI and were independent of age, lifestyle, 
and other cardiovascular risk factors.34
Mortality
• Elevated childhood BMIs in the highest quartile were associated with premature 
death as an adult in a cohort of 4857 American Indian children during a median 
follow-up of 23.9 years.35
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• Among adults, obesity was associated with nearly 112 000 excess deaths (95% 
CI, 53 754–170 064) relative to normal weight in 2000. Grade I obesity (BMI 30 
to <35 kg/m2) was associated with almost 30 000 of these excess deaths (95% 
CI, 8534–68 220) and grade II to III obesity (BMI ≥35 kg/m2) with >82 000 
(95% CI, 44 843–119 289). Underweight was associated with nearly 34 000 
excess deaths (95% CI, 15 726–51 766). As other studies have found,36 
overweight (BMI 25 to <30 kg/m2) was not associated with excess deaths.37
• Overweight was associated with significantly increased mortality resulting from 
DM or kidney disease and was not associated with increased mortality resulting 
from cancer or CVD in an analysis of 2004 data from NHANES. Obesity was 
associated with significantly increased mortality caused by CVD, some cancers, 
and DM or kidney disease. Obesity was associated with 13% of CVD deaths in 
2004.38
• In a collaborative analysis of data from almost 900 000 adults in 57 prospective 
studies, mostly in western Europe and North America, overall mortality was 
lowest at a BMI of ≈22.5 to 25 kg/m2 in both sexes and at all ages, after 
exclusion of early follow-up and adjustment for smoking status. Above this 
range, each 5-kg/m2-higher BMI was associated with ≈30% higher all-cause 
mortality, and no specific cause of death was inversely associated with BMI. 
Below 22.5 to 25 kg/m2, the overall inverse association with BMI was 
predominantly related to strong inverse associations for smoking-related 
respiratory disease, and the only clearly positive association was for ischemic 
heart disease.39
• In a meta-analysis of 1.46 million white adults, over a mean follow-up period of 
10 years, all-cause mortality was lowest at BMI levels of 20.0 to 24.9 kg/m2. 
Among compared with a BMI of 22.5 to 24.9 kg/m2, the HRs for death were as 
follows: BMI 15.0 to 18.4 kg/m2, 1.47; 18.5 to 19.9 kg/m2, 1.14; 20.0 to 22.4 
kg/m2, 1.0; 25.0 to 29.925 kg/m2, 1.13; 30.0 to 34.9 kg/m2, 1.44; 35.0 to 39.9 
kg/m2, 1.88; and 40.0 to 49.9 kg/m2, 2.51. Similar estimates were observed in 
men.40
• Calculations based on NHANES data from 1978–2006 suggest that the gains in 
life expectancy from smoking cessation are beginning to be outweighed by the 
loss of life expectancy related to obesity.41
• Because of the increasing prevalence of obesity, the number of quality-adjusted 
life-years lost as a result of obesity is similar to or greater than that lost as a 
result of smoking, according to data from the BRFSS.42
• Recent estimates suggest that reductions in smoking, cholesterol, BP, and PA 
levels resulted in a gain of 2 770 500 life-years; however, these gains were 
reduced by a loss of 715 000 life-years caused by the increased prevalence of 
obesity and DM.43
• Using self-reported NHIS data with linked mortality files through 2006, the HR 
for all-cause mortality was 1.07 (95% CI, 0.91–1.26) for overweight individuals, 
et al. Page 65
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1.41 (95% CI, 1.16–1.73) for obese individuals, and 2.46 for extremely obese 
individuals (95% CI, 1.91–3.16).44
• In a comparison of 5 different anthropometric variables (BMI, waist 
circumference, hip circumference, waist-to-hip ratio, and waist-to-height ratio) in 
62 223 individuals from Norway with 12 years of follow-up from the HUNT 2 
study (Nord-Trøndelag Health Study), the risk of death per SD increase in each 
measure was 1.02 (95% CI, 0.99–1.06) for BMI, 1.10 (95% CI, 1.06–1.14) for 
waist circumference, 1.01 (95% CI, 0.97–1.05) for hip circumference, 1.15 (95% 
CI, 1.11–1.19) for waist-to-hip ratio, and 1.12 (95% CI, 1.08–1.16) for waist-to-
height ratio. For CVD mortality, the risk of death per SD increase was 1.12 (95% 
1.06–1.20) for BMI, 1.19 (1.12–1.26) for waist circumference, 1.06 (1.00–1.13) 
for hip circumference, 1.23 (95% CI, 1.16–1.30) for waist-to-hip ratio, and 1.24 
(95% CI, 1.16–1.31) for waist-to-height ratio.45
• According to data from the National Cardiovascular Data Registry, among 
patients presenting with ST-segment–elevation myocardial infarction (STEMI) 
and a BMI of at least 40 kg/m2, in-hospital mortality rates were higher for 
patients with class III obesity (OR, 1.64; 95% CI, 1.32–2.03) when class I 
obesity was used as the referent.46
• The Canadian Heart Health Surveys from 1986 to 1995 demonstrated an 
increased risk of cancer across BMI categories, with an HR of 1.34 (95% CI, 
1.01–1.78) for those with BMI 30 to 34.9 kg/m2 and an HR of 1.82 (95% CI, 
1.22–2.71) for those with BMI ≥35 kg/m2.47
• In a study of 22 203 women and men from England and Scotland, metabolically 
unhealthy obese individuals were at an increased risk of all-cause mortality 
compared with metabolically healthy obese individuals (HR, 1.72; 95% CI, 
1.23–2.41).48
Cost
• Among children and adolescents, annual hospital costs related to obesity were 
$127 million between 1997 and women, 1999.49
• According to 1 study, overall estimates show that the annual medical burden of 
obesity has increased to almost 10% of all medical spending and could amount to 
$147 billion per year in 2008 (in 2008 dollars).50
• If current trends in the growth of obesity continue, total healthcare costs 
attributable to obesity could reach $861 to $957 billion by 2030, which would 
account for 16% to 18% of US health expenditures.51
• According to NHANES I data linked to Medicare and mortality records, obese 
45-year-olds had lifetime Medicare costs of $163 000 compared with $117 000 
among those with normal weight by the time they reached 65 years of age.52
• The total excess cost related to the current prevalence of adolescent overweight 
and obesity is estimated to be $254 billion ($208 billion in lost productivity 
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secondary to premature morbidity and mortality and $46 billion in direct medical 
costs).53
• According to 2006 MEPS and 2006 BRFSS data, annual medical expenditures 
would be 6.7% to 10.7% lower in the absence of obesity.54
• According to data from the Medicare Current Beneficiary Survey from 1997–
2006, in 1997, expenditures for a Part A and Part B services beneficiary were 
$6832 for a normal-weight individual, which was more than for overweight 
($5473) or obese ($5790) individuals. However, over time, expenses increased 
more rapidly for overweight and obese individuals.55
• The costs of obesity are high: Obese people pay on average $1429 (42%) more 
for healthcare costs than normal-weight individuals. For obese beneficiaries, 
Medicare pays $1723 more, Medicaid pays $1021 more, and private insurances 
pay $1140 more than for beneficiaries who are at normal weight. Similarly, 
obese people have 46% higher inpatient costs and 27% more outpatient visits and 
spend 80% more on prescription drugs.50
Bariatric Surgery
• Patients with BMI >40 kg/m2 or >35 kg/m2 with an obesity-related comorbidity 
are eligible for gastric bypass surgery, which is typically performed as either a 
Roux-en-Y gastric bypass or a biliopancreatic diversion.
• According to the 2006 NHDS, the incidence of bariatric surgery was estimated at 
113 000 cases per year, with costs of ≈1.5 billion dollars annually.56
• Among obese Swedish patients undergoing bariatric surgery and followed up for 
up to 15 years, maximum weight loss was 32%. The risk of death was 0.76 
among those who underwent bariatric surgery compared with matched control 
subjects.57 More recent data examining MI and stroke showed that bariatric 
surgery was associated with fewer CVD deaths (HR, 0.47; 95% CI, 0.29–0.76) 
and fewer strokes (HR, 0.67; 95% CI, 0.54–0.83) than in the control group.58
• Among 641 patients followed up for 10 years compared with 627 matched 
control subjects, after 2 years of follow-up, 72% of the surgically treated patients 
versus 21% of the control patients had remission of their DM; at 10 years of 
follow-up, results were 36% and 13%, respectively. Similar results have been 
observed for hypertension, elevated triglycerides, and low HDL cholesterol.59
• According to retrospective data from the United States, among 9949 patients 
who underwent gastric bypass surgery, after a mean of 7 years, long-term 
mortality was 40% lower among the surgically treated patients than among obese 
control subjects. Specifically, cancer mortality was reduced by 60%, DM 
mortality by 92%, and CAD mortality by 56%. Non-disease death rates (eg, 
accidents, suicide) were 58% higher in the surgery group.60
• A recent retrospective cohort from the Veterans Affairs medical system showed 
that in a propensity-matched analysis, bariatric surgery was not associated with 
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reduced mortality compared with obese control subjects (time-adjusted HR, 0.94; 
95% CI, 0.64–1.39).61
• Two recent randomized controlled trials were performed that randomized 
bariatric surgery compared with intensive medical treatment among patients with 
type 2 DM. The first study randomized 150 patients and conducted 12-month 
follow-up; this study showed that glycemic control improved (6.4%) and weight 
loss was greater (29.4 versus 5.4 kg) in the surgical arm.62 The second trial 
randomized 60 patients to bariatric surgery versus medical therapy and 
conducted follow-up for 24 months. The results showed that DM remission 
occurred in 75% of the group that underwent gastric bypass surgery compared 
with 0% of those in the medical treatment arm, with HbA1c values of 6.35% in 
the surgical arm compared with 7.69% in the medical treatment arm.63
• A recent cost-effectiveness study of laparoscopic adjustable gastric banding 
showed that after 5 years, $4970 was saved in medical expenses; if indirect costs 
were included (absenteeism and presenteeism), savings increased to $6180 and 
$10 960, respectively.64
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7. Family History and Genetics
See Tables 7-1 through 7-3.
Biologically related first-degree relatives (siblings, offspring and parents) share roughly 50% 
of their genetic variation with one another. This constitutes much greater sharing of genetic 
variation than with a randomly selected person from the population, and thus, when a trait 
aggregates within a family, this lends evidence for a genetic risk factor for the trait. 
Similarly, racial/ethnic minorities are more likely to share their genetic variation within their 
demographic than with other demographics. Familial aggregation of CVD may be related to 
aggregation of specific behaviors (eg, smoking, alcohol use) or risk factors (eg, 
hypertension, DM, obesity) that may themselves have environmental and genetic 
contributors. Unlike classic mendelian genetic risk factors, usually 1 mutation directly 
causes 1 disease, a complex trait’s genetic contributors may increase risk without necessarily 
always causing the condition. The effect size of any specific contributor to risk may be small 
but widespread throughout a population, or may be large but affect only a small population, 
or may have an enhanced risk when an environmental contributor is present. Although the 
breadth of all genetic research into CVD is beyond the scope of this chapter, we present a 
summary of evidence that a genetic risk for CVD is likely, as well as a summary of evidence 
on the most consistently replicated genetic markers for HD and stroke identified to date.
Abbreviations Used in Chapter 7
AAA abdominal aortic aneurysm
ABI ankle-brachial index
AF atrial fibrillation
BMI body mass index
CAC coronary artery calcification
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CARDIoGRAM Coronary Artery Disease Genome-wide Replication and Meta-Analysis Consortium
CI confidence interval
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
FHS Framingham Heart Study
GFR glomerular filtration rate
HbA1c glycosylated hemoglobin
HD heart disease
HDL high-density lipoprotein
HF heart failure
LDL low-density lipoprotein
MI myocardial infarction
NHANES National Health and Nutrition Examination Survey
OR odds ratio
SBP systolic blood pressure
SNP single-nucleotide polymorphism
Family History
Prevalence
• Among adults ≥20 years of age, 12.6% reported having a parent or sibling with a 
heart attack or angina before the age of 50 years. The racial/ethnic breakdown is 
as follows (NHANES 2007–2010, unpublished NHLBI tabulation):
– Fr non-Hispanic whites, 12.4% for men, 14.9% for women
– For non-Hispanic blacks, 8.1% for men, 13.0% for women
– For Mexican Americans, 8.1% for men, 10.0% for women
– For other Hispanics, 8.8% for men, 12.0% for women
– For other races, 8.7% for men, 10.7% for women
• HD occurs as people age, and those without a family history whereby of HD may 
survive longer, so the prevalence of family history will vary depending on the 
age at which it is assessed. The breakdown of reported family history of heart 
attack by age in the US population as measured by NHANES is as follows 
(NHANES 2007–2010, unpublished NHLBI tabulation):
– Age 20 to 39 years, 8.4% for men, 10.3% for women
– Age 40 to 59 years, 12.8% for men, 15.3% for women
– Age 60 to 79 years, 13.7% for men, 17.5% for women
– Age ≥80 years, 9.8% for men, 13.7% for women
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• In the multigenerational FHS, only 75% of participants with a documented 
parental history of a heart attack before age 55 years reported that history when 
asked.1
Impact of Family History
• Premature paternal history of a heart attack has been shown to approximately 
double the risk of a heart attack in men and increase the risk in women by 
≈70%.2,3
• History of a heart attack in both parents increases the risk of heart attack, 
especially when 1 parent had a premature heart attack4 (Table 7-1).
• Sibling history of HD has been shown to increase the odds of HD in men and 
women by ≈50%.5
• Premature family history of angina, MI, angioplasty, or bypass surgery increased 
the lifetime risk by ≈50% for both HD (from 8.9% to 13.7%) and CVD mortality 
(from 14.1% to 21%).6
• Similarly, parental history of AF is associated with ≈80% increased odds of AF 
in men and women,7 and a history of stroke in a first-degree relative increased 
the odds of stroke in men and women by ≈50%.8
Genetics
Heart Disease
• Genome-wide association is a robust technique to identify associations between 
genotypes and phenotypes. Table 7-2 presents results from the CARDIoGRAM 
(Coronary ARteryDIsease Genome-wide Replication And Meta-analysis) 
consortium, which represents the largest genetic study of MI to date, with 22 233 
MI case subjects and 64 762 control subjects and with independent validation in 
an additional 56 682 individuals.9 Altogether, there are 23 well-replicated loci 
for MI. The ORs are modest, ranging from 1.06 to 1.51 per copy of the risk allele 
(individuals may harbor up to 2 copies of a risk allele). However, these are 
common alleles, which suggests that the attributable risk may be substantial.
• Genetic markers discovered thus far have not been shown to add to 
cardiovascular risk prediction tools beyond current models that incorporate 
family history.10 Genetic markers have also not been shown to improve 
prediction of subclinical atherosclerosis beyond traditional risk factors.11
• The most consistently replicated genetic marker for HD in European-derived 
populations is located at 9p21.3. At this single-nucleotide polymorphism, ≈27% 
of the white population is estimated to have 0 risk alleles, 50% is estimated to 
have 1 risk allele, and the remaining 23% is estimated to have 2 risk alleles.12
• The 10-year HD risk for a 65-year-old man with 2 risk alleles at 9p21.3 and no 
other traditional risk factors is ≈13.2%, whereas a similar man with 0 alleles 
would have a 10-year risk of ≈9.2%. The 10-year HD risk for a 40-year-old 
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woman with 2 alleles and no other traditional risk factors is ≈2.4%, whereas a 
similar woman with 0 alleles would have a 10-year risk of ≈1.7%.12
• Variation at the 9p21.3 region also increases the risk of HF13 and sudden death.14 
Associations have also been observed between the 9p21.3 region and coronary 
artery calcification (CAC).15,16 Additionally, stronger associations have been 
found between variation at 9p21.3 and earlier17,18 and more severe19 heart 
attacks. The biological mechanism underpinning the association of genetic 
variation in the 9p21 region with disease outcomes is still under investigation.
Stroke
• The same 9p21.3 region has also been associated with intracranial aneurysm, 
abdominal aortic aneurysm (AAA),20 and ischemic stroke.21
• For large-vessel ischemic stroke, a new association for large-vessel stroke with 
histone deacetylase 9 on chromosome 7p21.1 has been identified (>9000 
subjects) and replicated (>12 000 subjects).21
CVD Risk Factors
• Heritability is the ratio of genetically caused variation to the total variation of a 
trait or measure. Table 7-3 presents heritability estimates for standard CVD risk 
factors using data generated from the FHS. These data suggest that most CVD 
risk factors have at least moderate heritability.
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8. High Blood Cholesterol and Other Lipids
See Table 8-1 and Charts 8-1 through 8-3.
Prevalence
For information on dietary cholesterol, total fat, saturated fat, and other factors that affect 
blood cholesterol levels, see Chapter 5 (Nutrition).
Youth—(See Chart 8-1.)
• Among children 4 to 11 years of age, the mean total blood cholesterol level is 
161.9 mg/dL. For boys, it is 162.3 mg/dL; for girls, it is 161.5 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– For non-Hispanic whites, 160.9 mg/dL for boys and 161.6 mg/dL for 
girls
– For non-Hispanic blacks, 165.2 mg/dL for boys and 157.9 mg/dL for 
girls
– For Mexican Americans, 159.6 mg/dL for boys and 160.7 mg/dL for 
girls
• Among adolescents 12 to 19 years of age, the mean total blood cholesterol level 
is 158.2 mg/dL. For boys, it is 156.1 mg/dL; for girls, it is 160.3 mg/dL. The 
racial/ethnic breakdown is as follows (NHANES 2007–2010, unpublished 
NHLBI tabulation):
– For non-Hispanic whites, 156.8 mg/dL for boys and 161.1 mg/dL for 
girls
– For non-Hispanic blacks, 154.1 mg/dL for boys and 160.6 mg/dL for 
girls
– For Mexican Americans, 157.8 mg/dL for boys and 158.0 mg/dL for 
girls
• The prevalence of abnormal lipid levels among youths 12 to 19 years of age is 
20.3%; 14.2% of normal-weight youths, 22.3% of overweight youths, and 42.9% 
of obese youths have at least 1 abnormal lipid level (NHANES 1999–2006, 
NCHS).1
• Approximately 7.8% of adolescents 12 to 19 years of age have total cholesterol 
levels ≥200 mg/dL (NHANES 2007–2010, unpublished NHLBI tabulation).
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• Fewer than 1% of adolescents are potentially eligible for pharmacological 
treatment on the basis of guidelines from the American Academy of 
Pediatrics.1,2
Abbreviations Used in Chapter 8
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CVD cardiovascular diseases
DM diabetes mellitus
HD heart disease
HDL high-density lipoprotein
LDL low-density lipoprotein
Mex. Am. Mexican American
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
Adults—(See Table 8-1 and Charts 8-2 and 8-3.)
• An estimated 31.9 million adults ≥20 years of age have total serum cholesterol 
levels ≥240 mg/dL (extrapolated to 2010 by use of NCHS/NHANES 2007–2010 
data), with a prevalence of 13.8% (Table 8-1; unpublished NHLBI tabulation).
• Approximately 5.6% of adults ≥20 years of age have undiagnosed 
hypercholesterolemia3 (NHANES 2007–2010, unpublished NHLBI tabulation).
• Between the periods 1988–1994 and 1999–2002 (NHANES/NCHS), the age-
adjusted mean total serum cholesterol level of adults ≥20 years of age decreased 
from 206 to 203 mg/dL, and LDL cholesterol levels decreased from 129 to 123 
mg/dL.4
• Data from NHANES 2003–2008 (NCHS) showed the serum total crude mean 
cholesterol level in adults ≥20 years of age was 195 mg/dL for men and 201 
mg/dL for women.5
• Data from the Minnesota Heart Survey (1980–1982 to 2000–2002) showed a 
decline in age-adjusted mean total cholesterol concentrations from 5.49 and 5.38 
mmol/L for men and women, respectively, in 1980–1982 to 5.16 and 5.09 
mmol/L, respectively, in 2000–2002; however, the decline was not uniform 
across all age groups. Middle-aged to older people have shown substantial 
decreases, but younger people have shown little overall change and recently had 
increased total cholesterol values. Lipid-lowering drug use rose significantly for 
both sexes among those 35 to 74 years of age. Awareness, treatment, and control 
of hypercholesterolemia have increased; however, more than half of those at 
borderline-high risk remain unaware of their condition.6
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• According to data from NHANES 2005–2006, between the periods 1999 to 2000 
and 2005 to 2006, mean serum total cholesterol levels in adults ≥20 years of age 
declined from 204 to 199 mg/dL. This decline was observed for men ≥40 years 
of age and for women ≥60 years of age. There was little change over this time 
period for other sex/age groups. In 2005 to 2006, ≈65% of men and 70% of 
women had been screened for high cholesterol in the past 5 years, and 16% of 
adults had serum total cholesterol levels ≥240 mg/dL.7
• According to data from NHANES, from 1999 to 2006, the prevalence of elevated 
LDL cholesterol levels (as defined by levels higher than the specified Adult 
Treatment Panel III risk category) in adults ≥20 years of age has decreased by 
≈33%.8
• During the period from 1999 to 2006, 26.0% of adults had hypercholesterolemia, 
9% of adults had both hypercholesterolemia and hypertension, 1.5% of adults 
had DM and hypercholesterolemia, and 3% of adults had all 3 conditions.3
Screening
• Data from the BRFSS study of the CDC in 2011 showed that the percentage of 
adults who had been screened for high blood cholesterol in the preceding 5 years 
ranged from 66.3% in Utah to 83.7% in Massachusetts. The median percentage 
among all 50 states was 75.5%.9
• The percentage of adults who reported having had a cholesterol check increased 
from 68.6% during 1999 to 2000 to 74.8% during 2005 to 2006.10
Awareness
• Data from the BRFSS (CDC) survey in 2011 showed that among adults screened 
for high blood cholesterol, the percentage who had been told that they had high 
blood cholesterol ranged from 33.5% in Colorado to 42.3% in Mississippi. The 
median percentage among states was 38.4%.9
• Among adults with hypercholesterolemia, the percentage who had been told that 
they had high cholesterol increased from 42.0% during 1999 to 2000 to 50.4% 
during 2005 to 2006.10
Treatment
• NHANES data on the treatment of high LDL cholesterol showed an increase 
from 28.4% of individuals during 1999 to 2002 to 48.1% during 2005 to 2008.11
• Self-reported use of cholesterol-lowering medications increased from 8.2% 
during 1999 to 2000 to 14.0% during 2005 to 2006.10
Adherence
Youth—The American Academy of Pediatrics recommends screening for dyslipidemia in 
children and adolescents who have a family history of dyslipidemia or premature CVD, 
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those whose family history is unknown, and those youths with risk factors for CVD, such as 
being overweight or obese, having hypertension or DM, or being a smoker.1
Analysis of data from NHANES 1999–2006 showed that the overall prevalence of abnormal 
lipid levels among youths 12 to 19 years of age was 20.3%.1
Adults
• On the basis of data from the Third Report of the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults12:
– Fewer than half of all people who qualify for any kind of lipid-
modifying treatment for CHD risk reduction are receiving it.
– Fewer than half of even the highest-risk people (those with 
symptomatic CHD) are receiving lipid-lowering treatment.
– Only approximately one third of treated patients are achieving their 
LDL goal; <20% of patients with CHD are at their LDL goal.
• Data from NHANES 2005–2006 indicate that among those with elevated LDL 
cholesterol levels, 35.5% had not been screened previously, 24.9% were screened 
but not told they had elevated cholesterol, and 39.6% were treated inadequately.8
• There were 33.2% of adults overall during 2005–2008 in NHANES who 
achieved LDL cholesterol goals. Among adults without health insurance, only 
22.6% achieved LDL cholesterol goals; however, 82.8% of those adults with 
uncontrolled LDL cholesterol did have some form of health insurance.11
Lipid Levels
LDL (Bad) Cholesterol
Youth
• There are limited data available on LDL cholesterol for children 4 to 11 years of 
age.
• Among adolescents 12 to 19 years of age, the mean LDL cholesterol level is 89.5 
mg/dL. For boys, it is 88.6 mg/dL, and for girls, it is 90.5 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– Among non-Hispanic whites, 90.4 mg/dL for boys and 90.9 mg/dL for 
girls
– Among non-Hispanic blacks, 85.8 mg/dL for boys and 91.8 mg/dL for 
girls
– Among Mexican Americans, 90.6 mg/dL for boys and 87.1 mg/dL for 
girls
• High levels of LDL cholesterol occurred in 7.3% of male adolescents and 7.6% 
of female adolescents during 2007 to 2010.1
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Adults
• The mean level of LDL cholesterol for American adults ≥20 years of age was 
115.8 mg/dL in 2007 to 2010.8 Levels of 130 to 159 mg/dL are considered 
borderline high, levels of 160 to 189 mg/dL are classified as high, and levels of 
≥190 mg/dL are considered very high according to Adult Treatment Panel III.
• According to NHANES 2007–2010 (unpublished NHLBI tabulation):
– Among non-Hispanic whites, mean LDL cholesterol levels were 115.1 
mg/dL for men and 115.7 mg/dL for women.
– Among non-Hispanic blacks, mean LDL cholesterol levels were 115.9 
mg/dL for men and 114.2 mg/dL for women.
– Among Mexican Americans, mean LDL cholesterol levels were 119.7 
mg/dL for men and 115.0 mg/dL for women.
• The age-adjusted prevalence of high LDL cholesterol in US adults was 26.6% in 
1988 to 1994 and 25.3% in 1999 to 2004 (NHANES/NCHS). Between 1988 to 
1994 and 1999 to 2004, awareness increased from 39.2% to 63.0%, and use of 
pharmacological lipid-lowering treatment increased from 11.7% to 40.8%. LDL 
cholesterol control increased from 4.0% to 25.1% among those with high LDL 
cholesterol. In 1999 to 2004, rates of LDL cholesterol control were lower among 
adults 20 to 49 years of age than among those ≥65 years of age (13.9% versus 
30.3%, respectively), among non-Hispanic blacks and Mexican Americans than 
among non-Hispanic whites (17.2% and 16.5% versus 26.9%, respectively), and 
among men than among women (22.6% versus 26.9%, respectively).13
• Mean levels of LDL cholesterol decreased from 126.1 mg/dL during 1999 to 
2000 to 116.1 mg/dL during 2009 to 2010. The prevalence of high LDL 
cholesterol decreased from 31.5% during 1999 to 2000 to 28.2% during 2009 to 
20108 (unpublished NHLBI tabulation).
HDL (Good) Cholesterol
Youth
• Among children 4 to 11 years of age, the mean HDL cholesterol level is 53.6 
mg/dL. For boys, it is 55.1 mg/dL, and for girls, it is 51.9 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– Among non-Hispanic whites, 53.9 mg/dL for boys and 51.4 mg/dL for 
girls
– Among non-Hispanic blacks, 59.9 mg/dL for boys and 55.3 mg/dL for 
girls
– Among Mexican Americans, 53.5 mg/dL for boys and 50.5 mg/dL for 
girls
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• Among adolescents 12 to 19 years of age, the mean HDL cholesterol level is 
51.4 mg/dL. For boys, it is 49.2 mg/dL, and for girls, it is 53.6 mg/dL. The 
racial/ethnic breakdown is as follows (NHANES 2007–2010, unpublished 
NHLBI tabulation):
– Among non-Hispanic whites, 48.4 mg/dL for boys and 53.0 mg/dL for 
girls
– Among non-Hispanic blacks, 53.9 mg/dL for boys and 55.4 mg/dL for 
girls
– Among Mexican Americans, 47.5 mg/dL for boys and 53.3 mg/dL for 
girls
• Low levels of HDL cholesterol occurred in 21.7% of male adolescents and 
10.7% of female adolescents during 2007 to 20101 (NHANES 2007–2010, 
unpublished NHLBI tabulation).
Adults
• An HDL cholesterol level <40 mg/dL in adult males and <50 mg/dL in adult 
females is considered low and is a risk factor for HD and stroke. The mean level 
of HDL cholesterol for American adults ≥20 years of age is 52.5 mg/dL 
(NHANES 2007–2010, unpublished NHLBI tabulation).
• According to NHANES 2007–2010 (unpublished NHLBI tabulation):
– Among non-Hispanic whites, mean HDL cholesterol levels were 46.7 
mg/dL for men and 58.1 mg/dL for women
– Among non-Hispanic blacks, mean HDL cholesterol levels were 52.6 
mg/dL for men and 58.7 mg/dL for women
– Among Mexican Americans, mean HDL cholesterol levels were 45.4 
mg/dL for men and 53.7 mg/dL for women
Triglycerides
Youth
• There are limited data available on triglycerides for children 4 to 11 years of age.
• Among adolescents 12 to 19 years of age, the mean triglyceride level is 82.9 
mg/dL. For boys, it is 85.6 mg/dL, and for girls, it is 80.1 mg/dL. The racial/
ethnic breakdown is as follows (NHANES 2007–2010, unpublished NHLBI 
tabulation):
– Among non-Hispanic whites, 89.6 mg/dL for boys and 83.5 mg/dL for 
girls
– Among non-Hispanic blacks, 66.7 mg/dL for boys and 58.6 mg/dL for 
girls
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– Among Mexican Americans, 97.1 mg/dL for boys and 83.5 mg/dL for 
girls
– High levels of triglycerides occurred in 9.4% of male adolescents and 
6.7% of female adolescents during 2007 to 2010.1
Adults
• A fasting triglyceride level ≥150 mg/dL in adults is considered elevated and is a 
risk factor for HD and stroke. The mean level of triglycerides for American 
adults ≥20 years of age is 130.3 mg/dL (NHANES 2007–2010, unpublished 
NHLBI tabulation).
– Among men, the mean triglyceride level is 141.7 mg/dL (NHANES 
2007–2010, unpublished NHLBI tabulation). The racial/ethnic 
breakdown is as follows:
♦ 140.0 mg/dL for non-Hispanic white men
♦ 111.3 mg/dL for non-Hispanic black men
♦ 161.4 mg/dL for Mexican American men
– Among women, the mean triglyceride level is 119.1 mg/dL, with the 
following racial/ethnic breakdown:
♦ 121.5 mg/dL for non-Hispanic white women
♦ 94.4 mg/dL for non-Hispanic black women
♦ 134.1 mg/dL for Mexican American women
• Approximately 27% of adults ≥20 years of age had a triglyceride level ≥150 
mg/dL during 2007 to 201014 (NHANES 2007–2010, unpublished NHLBI 
tabulation).
• Fewer than 3% of adults with a triglyceride level ≥150 mg/dL received 
pharmacological treatment during 1999 to 2004.14
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ICD-9 401 to 404, ICD-10 I10 to I15. See Tables 9-1 and 9-2 and Charts 9-1 through 9-5.
Prevalence
(See Table 9-1 and Chart 9-1.)
• HBP is defined as:
– SBP ≥140 mm Hg or DBP ≥90 mm Hg or taking antihypertensive 
medicine, or
– Having been told at least twice by a physician or other health 
professional that one has HBP.
• One in 3 US adults has HBP (unpublished NHLBI tabulation).
• Data from NHANES 2007–2010 found that ≈6% of US adults have undiagnosed 
hypertension. Data from the 2007–2008 BRFSS, NHIS, and NHANES surveys 
found 27.8%, 28.5%, and 30.7% US adults were told they had hypertension, 
respectively.1
• An estimated 77.9 million adults ≥20 years of age have HBP, extrapolated to 
2010 with NHANES 2007–2010 data (Table 9-1).
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• NHANES data show that a higher percentage of men than women have 
hypertension until 45 years of age. From 45 to 54 and from 55 to 64 years of age, 
the percentages of men and women with hypertension are similar. After that, a 
higher percentage of women have hypertension than men (Chart 9-1).
• HBP is 2 to 3 times more common in women taking oral contraceptives, 
especially among obese and older women, than in women not taking them.2
• Data from NHANES 2005–2006 found that 29% of US adults ≥18 years of age 
were hypertensive. The prevalence of hypertension was nearly equal between 
men and women; 7% of adults had HBP but had never been told that they had 
hypertension. Among hypertensive adults, 78% were aware of their condition, 
68% were using antihypertensive medication, and 64% of those treated had their 
hypertensioncontrolled.3
• Data from the 2011 BRFSS/CDC indicate that the percentage of adults ≥18 years 
of age who had been told that they had HBP ranged from 22.9% in Utah to 
40.1% in Alabama. The median percentage was 30.8%.4
– According to NHANES data 2003–2008, among US adults with 
hypertension, 8.9% met the criteria for resistant hypertension (BP was 
≥140/90 mm Hg, and they reported using antihypertensive medications 
from 3 different drug classes or drugs from ≥4 antihypertensive drug 
classes regardless of BP). This represents 12.8% of the population 
taking antihypertensive medication.5
• According to data from NHANES 1988–1994 and 2007–2008, HBP control rates 
improved from 27.3% to 50.1%, treatment improved from 54.0% to 73.5%, and 
the control/treated rates improved from 50.6% to 72.3%.6
• Projections show that by 2030, prevalence of hypertension will increase 7.2% 
from 2013 estimates (unpublished AHA computation, based on methodology 
described by Heidenreich et al).7
Abbreviations Used in Chapter 9
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CHS Cardiovascular Health Study
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
ED emergency department
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FHS Framingham Heart Study
HBP high blood pressure
HD heart disease
ICD-9 International Classification of Diseases, 9th Revision
ICD-9-CM International Classification of Diseases, Clinical Modification, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHES National Health Examination Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institute of Neurological Disorders and Stroke
NNHS National Nursing Home Survey
PA physical activity
REGARDS REasons for Geographic And Racial Differences in Stroke study
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
WHI Women’s Health Initiative
Older Adults
• In 2009 to 2010, hypertension was among the diagnosed chronic conditions that 
were more prevalent among older (≥65 years of age) women than older men 
(57% for women, 54% for men). Ever-diagnosed conditions that were more 
prevalent among older men than older women included HD (37% for men, 26% 
for women) and DM (24% for men, 18% for women), on the basis of data from 
NHIS/NCHS.8
• The age-adjusted prevalence of hypertension (both diagnosed and undiagnosed) 
in 2003 to 2006 was 75% for older women and 65% for older men on the basis 
of data from NHANES/NCHS.9
• Data from the 2004 NNHS revealed the most frequent chronic medical condition 
among this nationally representative sample of long-term stay residents aged ≥65 
years was hypertension (53% of men and 56% of women). In men, prevalence of 
hypertension decreased with increasing age.10
• Among US adults ≥65 years of age (NHANES 1999–2004), prevalence of 
hypertension was 70.8%, awareness of hypertension was 75.9%, treatment for 
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hypertension was 69.3%, and control of hypertension was 48.8%. Women had a 
slightly higher prevalence than men and a significantly lower rate of 
hypertension control.11
Children and Adolescents
• Analysis of the National Health Examination Survey (NHES), the Hispanic 
Health and Nutrition Examination Survey, and the NHANES/NCHS surveys of 
the NCHS (1963–2002) found that the BP, pre-HBP, and HBP trends in children 
and adolescents 8 to 17 years of age moved downward from 1963 to 1988 and 
upward thereafter. Pre-HBP and HBP increased 2.3% and 1%, respectively, 
between 1988 and 1999. Increased obesity (abdominal obesity more so than 
general obesity) partially explained the HBP and pre-HBP rise from 1988 to 
1999. BP and HBP reversed their downward trends 10 years after the increase in 
the prevalence of obesity. In addition, an ethnic and sex gap appeared in 1988 for 
pre-HBP and in 1999 for HBP: Non-Hispanic blacks and Mexican Americans 
had a greater prevalence of HBP and pre-HBP than non-Hispanic whites, and the 
prevalence was greater in boys than in girls. In that study, HBP in children and 
adolescents was defined as SBP or DBP that was, on repeated measurement, 
≥95th percentile.12
• A study in Ohio of >14 000 children and adolescents 3 to 18 years of age who 
were observed at least 3 times between 1999 and 2006 found that 3.6% had 
hypertension.13 Of these, 26% had been diagnosed and 74% were undiagnosed. 
In addition, 3% of those with hypertension had stage 2 hypertension, and 41% of 
those with stage 2 hypertension were undiagnosed. Criteria for prehypertension 
were met by 485 children. Of these, 11% were diagnosed. In this study, HBP in 
children and adolescents was defined as SBP or DBP that was, on repeated 
measurement, ≥95th percentile.13
• A study from 1988–1994 through 1999–2000 of children and adolescents 8 to 17 
years of age showed that among non-Hispanic blacks, mean SBP levels increased 
by 1.6 mm Hg among girls and by 2.9 mm Hg among boys compared with non-
Hispanic whites. Among Mexican Americans, girls’ SBP increased 1.0 mm Hg 
and boys’ SBP increased 2.7 mm Hg compared with non-Hispanic whites.14
• Analysis of data from the Search for Diabetes in Youth Study (SEARCH), which 
included children 3 to 17 years of age with type 1 and type 2 DM, found the 
prevalence of elevated BP to be 5.9% among those with type 1 DM and 23.7% 
among those with type 2 DM.15
• A study of high school students in Houston, TX (mean age 15.4 years; 45.2% 
male, 49.3% Hispanic, 25.2% Caucasian, and 16.1% African American) found 
≈30% of the students had at least 1 elevated BP measurement; elevated BP was 
significantly influenced by obesity.16
• Longitudinal BP outcomes from the National Childhood Blood Pressure database 
(ages 13–15 years) were examined after a single BP measurement. Among those 
determined to have prehypertension, 14% of boys and 12% of girls had 
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hypertension 2 years later; the overall rate of progression from prehypertension 
to hypertension was ≈7%.17
Race/Ethnicity and HBP
(See Table 9-1 and Chart 9-2.)
• The prevalence of hypertension in blacks in the United States is among the 
highest in the world, and it is increasing. From 1988 to 1994 through 1999 to 
2002, the prevalence of HBP in adults increased from 35.8% to 41.4% among 
blacks, and it was particularly high among black women at 44.0%. Prevalence 
among whites also increased, from 24.3% to 28.1%.18
• Compared with whites, blacks develop HBP earlier in life, and their average BPs 
are much higher. As a result, compared with whites, blacks have a 1.3-times 
greater rate of nonfatal stroke, a 1.8-times greater rate of fatal stroke, a 1.5-times 
greater rate of death attributable to HD, and a 4.2-times greater rate of end-stage 
kidney disease (fifth and sixth reports of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure).
• Within the black community, rates of hypertension vary substantially.18,19
– Those with the highest rates are more likely to be middle-aged or older, 
less educated, overweight or obese, and physically inactive and are 
more likely to have DM.
– Those with the lowest rates are more likely to be younger but also 
overweight or obese.
– Those with uncontrolled HBP who are not taking antihypertensive 
medication tend to be male, to be younger, and to have infrequent 
contact with a physician.
• Analysis from the REasons for Geographic And Racial Differences in Stroke 
study (REGARDS) study of the NINDS suggests that efforts to raise awareness 
of prevalent hypertension among blacks apparently have been successful (31% 
greater odds in blacks relative to whites), and efforts to communicate the 
importance of receiving treatment for hypertension have been successful (69% 
greater odds among blacks relative to whites); however, substantial racial 
disparities remain with regard to the control of BP (SBP <140 mm Hg, DBP <90 
mm Hg), with the odds of control being 27% lower in blacks than in whites. In 
contrast, geographic disparities in hypertension awareness, treatment, and control 
were minimal.20
• Data from the 2011 NHIS showed that black adults ≥18 years of age were more 
likely (33.4%) to have been told on ≥2 occasions that they had hypertension than 
white adults (23.3%), American Indian/Alaska Native adults (25.8%), or Asian 
adults (18.7%).21
• The CDC analyzed death certificate data from 1995 to 2002 (any-mention 
mortality; ICD-9 codes 401–404 and ICD-10 codes I10–I13). The results 
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indicated that Puerto Rican Americans had a consistently higher hypertension-
related death rate than all other Hispanic subpopulations and non-Hispanic 
whites. The age-standardized hypertension-related mortality rate was 127.2 per 
100 000 population for all Hispanics, similar to that of non-Hispanic whites 
(135.9). The age-standardized rate for Hispanic females (118.3) was substantially 
lower than that observed for Hispanic males (135.9). Hypertension-related 
mortality rates for males were higher than rates for females for all Hispanic 
subpopulations. Puerto Rican Americans had the highest hypertension-related 
death rate among all Hispanic subpopulations (154.0); Cuban Americans had the 
lowest (82.5).22
• Some studies suggest that Hispanic Americans have rates of HBP similar to or 
lower than those of non-Hispanic white Americans. Findings from a new 
analysis of combined data from the NHIS of 2000–2002 point to a health 
disparity between black and white adults of Hispanic descent. Black Hispanics 
were at slightly greater risk than white Hispanics, although non-Hispanic black 
adults had by far the highest rate of HBP. The racial disparity among Hispanics 
also was evident in the fact that higher-income, better-educated black Hispanics 
still had a higher rate of HBP than lower-income, less-educated white 
Hispanics.23 Data from the NHLBI’s ARIC study found that hypertension was a 
particularly powerful risk factor for CHD in black people, especially black 
women.24
• Data from MESA found that being born outside the United States, speaking a 
language other than English at home, and living fewer years in the United States 
were each associated with a decreased prevalence of hypertension.25
• Filipino (27%) and Japanese (25%) adults were more likely than Chinese (17%) 
or Korean (17%) adults to have ever been told that they had hypertension.26
Mortality
(See Table 9-1.)
HBP mortality in 2009 was 61 762. Any-mention mortality in 2009 was 348 102. The 2009 
death rate was 18.5.27
• From 1999 to 2009, the death rate caused by HBP increased 17.1%, and the 
actual number of deaths rose 43.6% (AHA tabulation).27
• The 2009 overall death rate resulting from HBP was 18.5. Death rates were 17.0 
for white males, 51.6 for black males, 14.4 for white females, and 38.3 for black 
females. When any-mention mortality for 2009 was used, the overall death rate 
was 104.9. Death rates were 108.5 for white males, 219.7 for black males, 86.1 
for white females, and 163.7 for black females.
• Analysis of NHANES I and II comparing hypertensive and nonhypertensive 
individuals found a reduction in age-adjusted mortality rate of 4.6/1000 person-
years among people with hypertension compared with a reduction of 4.2/1000 
person-years among those without hypertension.28
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• Assessment of 30-year follow-up of the Hypertension Detection and Follow-up 
Program identified the long-term benefit of stepped care, as well as the increased 
survival for hypertensive African Americans.29
• Assessment of the Charleston Heart Study and Evans County Heart Study 
identified the excess burden of elevated BP for African Americans and its effect 
on long-term health outcomes.30
• Data from the Harvard Alumni Health Study found that higher BP in early 
adulthood was associated several decades later with higher risk for all-cause 
mortality, CVD mortality, and CHD mortality but not stroke mortality.31
Risk Factors
• Numerous risk factors and markers for development of hypertension, including 
age, ethnicity, family history of hypertension and genetic factors, lower 
education and socioeconomic status, greater weight, lower PA, tobacco use, 
psychosocial stressors, sleep apnea, and dietary factors (including dietary fats, 
higher sodium intake, lower potassium intake, and excessive alcohol intake), 
have been identified.
• A study of related individuals in the NHLBI’s FHS suggested that different sets 
of genes regulate BP at different ages.32
• Recent data from the Nurses’ Health Study suggest that a large proportion of 
incident hypertension in women can be prevented by controlling dietary and 
lifestyle risk factors.33
• A meta-analysis identified the benefit of a goal BP of 130/80 mm Hg for 
individuals with hypertension and type 2 DM but less evidence for treatment 
below this value.34
Aftermath
• Approximately 69% of people who have a first heart attack, 77% of those who 
have a first stroke, and 74% of those who have CHF have BP >140/90 mm Hg 
(NHLBI unpublished estimates from ARIC, CHS, and FHS Cohort and 
Offspring studies).
• Data from FHS/NHLBI indicate that recent (within the past 10 years) and remote 
antecedent BP levels may be an important determinant of risk over and above the 
current BP level.35
• Data from the FHS/NHLBI indicate that hypertension is associated with shorter 
overall life expectancy, shorter life expectancy free of CVD, and more years 
lived with CVD.36
– Total life expectancy was 5.1 years longer for normotensive men and 
4.9 years longer for normotensive women than for hypertensive people 
of the same sex at 50 years of age.
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– Compared with hypertensive men at 50 years of age, men with 
untreated BP <140/90 mm Hg survived on average 7.2 years longer 
without CVD and spent 2.1 fewer years of life with CVD. Similar 
results were observed for women.
Hospital Discharges/Ambulatory Care Visits
(See Table 9-1.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with HBP as the first-listed diagnosis increased from 457 000 to 488 000 (no 
significant difference; NCHS, NHDS). The number of all-listed discharges 
increased from 8 034 000 to 11 282 000 (NHLBI, unpublished data from the 
NHDS, 2010; diagnoses in 2010 were truncated at 7 diagnoses for comparability 
with earlier year).
• Data from the Nationwide Inpatient Sample from the years 2000 to 2007 found 
the frequency of hospitalizations for adults aged ≥18 years of age with a 
hypertensive emergency increased from 101 to 111 per 100 000 in 2007 (average 
increase of 1.11%). In contrast to the increased number of hospitalizations, the 
all-cause in-hospital mortality rate decreased during the same period from 2.8% 
to 2.6%.37
• Data from ambulatory medical care utilization estimates for 2009 showed that 
the number of visits for essential hypertension was 55 148 000. Of these, 49 966 
000 were physician office visits, 1 000 000 were ED visits, and 4 182 000 were 
outpatient department visits (NAMCS and NHAMCS, NHLBI tabulation).
• In 2010, there were 280 000 hospitalizations with a first-listed diagnosis of 
essential hypertension (ICD-9-CM code 401), but essential hypertension was 
listed as either a primary or a secondary diagnosis 11 048 000 times for 
hospitalized inpatients (unpublished data from the NHDS, NHLBI tabulation).
Awareness, Treatment, and Control
(See Table 9-2 and Charts 9-3 through 9-5.)
• Data from NHANES 2007–2010 showed that of those with hypertension who 
were ≥20 years of age, 81.5% were aware of their condition, 74.9% were under 
current treatment, 52.5% had their hypertension under control, and 47.5% did not 
have it controlled (NHLBI tabulation).
• Data from NHANES 1999–2006 showed that 11.2% of adults ≥20 years of age 
had treated and controlled BP levels.38
• Analysis of NHANES data from 1999–2004 through 2005–2006 found that there 
were substantial increases in awareness and treatment rates of hypertension. The 
control rates increased in both sexes, in non-Hispanic blacks, and in Mexican 
Americans. Among the group ≥60 years of age, awareness, treatment, and 
control rates of hypertension increased significantly.3,39
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• In NHANES 2007–2010, rates of control were lower in Mexican Americans 
(39.3%) than in non-Hispanic whites (54.9%) and non-Hispanic blacks (47.6%; 
unpublished NHLBI tabulation).
• The awareness, treatment, and control of HBP among those ≥65 years of age in 
the CHS/NHLBI improved during the 1990s. The percentages of those aware of 
and treated for HBP were higher among blacks than among whites. Prevalence 
rates with HBP under control were similar. For both groups combined, the 
control of BP to <140/90 mm Hg increased from 37% in 1990 to 49% in 1999. 
Improved control was achieved by an increase in antihypertensive medications 
per person and by an increase in the proportion of the CHS population treated for 
hypertension from 34.5% to 51.1%.40
• Data from the FHS of the NHLBI show that among those ≥80 years of age, only 
38% of men and 23% of women had BPs that met targets set forth in the 
National High Blood Pressure Education Program’s clinical guidelines. Control 
rates in men <60, 60 to 79, and ≥80 years of age were 38%, 36%, and 38%, 
respectively; for women in the same age groups, they were 38%, 28%, and 23%, 
respectively.41
• Data from the WHI observational study of nearly 100 000 postmenopausal 
women across the country enrolled between 1994 and 1998 indicate that 
although prevalence rates ranged from 27% of women 50 to 59 years of age to 
41% of women 60 to 69 years of age to 53% of women 70 to 79 years of age, 
treatment rates were similar across age groups: 64%, 65%, and 63%, 
respectively. Despite similar treatment rates, hypertension control is especially 
poor in older women, with only 29% of hypertensive women 70 to 79 years of 
age having clinic BPs <140/90 mm Hg compared with 41% and 37% of those 50 
to 59 and 60 to 69 years of age, respectively.42
• Among a cohort of postmenopausal women taking hormone replacement, 
hypertension was the most common comorbidity, with a prevalence of 34%.43
• A study of >300 women in Wisconsin showed a need for significant 
improvement in BP and LDL levels. Of the screened participants, 35% were not 
at BP goal, 32.4% were not at LDL goal, and 53.5% were not at both goals.44
• In 2005, a survey of people in 20 states conducted by the BRFSS of the CDC 
found that 19.4% of respondents had been told on ≥2 visits to a health 
professional that they had HBP. Of these, 70.9% reported changing their eating 
habits; 79.5% reduced the use of or were not using salt; 79.2% reduced the use of 
or eliminated alcohol; 68.8% were exercising; and 73.4% were taking 
antihypertensive medication.45
• On the basis of NHANES 2003–2004 data, it was found that nearly three fourths 
of adults with CVD comorbidities have hypertension. Poor control rates of 
systolic hypertension remain a principal problem that further compromises their 
already high CVD risk.46
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• According to data from NHANES 2001–2006, non-Hispanic blacks had 90% 
higher odds of poorly controlled BP than non-Hispanic whites. Among those 
who were hypertensive, non-Hispanic blacks and Mexican Americans had 40% 
higher odds of uncontrolled BP than non-Hispanic whites.47
• According to data from NHANES 1998–2008 for adults with DM, prevalence of 
hypertension increased, whereas awareness, treatment, and control improved 
during these time periods; however, for adults 20 to 44 years of age, there was no 
evidence of improvement.48
• “Resistant hypertension” is a treatment and control issue for nearly 1 in 10 
hypertensive adults. This category of HBP represents individuals with 
uncontrolled HBP despite the use of ≥3 antihypertensive medications or with BP 
controlled with the use of ≥4 medications.49,50
Cost
(See Table 9-1.)
• The estimated direct and indirect cost of HBP for 2009 is $51.0 billion (MEPS, 
NHLBI tabulation).
• Projections show that by 2030, total cost of HBP will increase to an estimated 
$343 billion (unpublished AHA computation, based on methodology described 
in Heidenreich et al7).
Prehypertension
• Prehypertension is untreated SBP of 120 to 139 mm Hg or untreated DBP of 80 
to 89 mm Hg and not having been told on 2 occasions by a physician or other 
health professional that one has hypertension.
• Data from NHANES 1999–2006 estimate that 29.7% of adults ≥20 years of age 
have prehypertension.38
• Follow-up of 9845 men and women in the FHS/NHLBI who attended 
examinations from 1978 to 1994 revealed that at 35 to 64 years of age, the 4-year 
incidence of hypertension was 5.3% for those with baseline BP <120/80 mm Hg, 
17.6% for those with SBP of 120 to 129 mm Hg or DBP of 80 to 84 mm Hg, and 
37.3% for those with SBP of 130 to 139 mm Hg or DBP of 85 to 89 mm Hg. At 
65 to 94 years of age, the 4-year incidences of hypertension were 16.0%, 25.5%, 
and 49.5% for these BP categories, respectively.51
• Data from FHS/NHLBI also reveal that prehypertension is associated with 
elevated relative and absolute risks for CVD outcomes across the age spectrum. 
Compared with normal BP (<120/80 mm Hg), prehypertension was associated 
with a 1.5- to 2-fold increased risk for major CVD events in those <60, 60 to 79, 
and ≥80 years of age. Absolute risks for major CVD associated with 
prehypertension increased markedly with age: 6-year event rates for major CVD 
were 1.5% in prehypertensive people <60 years of age, 4.9% in those 60 to 79 
years of age, and 19.8% in those ≥80 years of age.41
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• In a study of NHANES 1999–2000 (NCHS), people with prehypertension were 
more likely than those with normal BP levels to have above-normal cholesterol 
levels (≥200 mg/dL) and to be overweight or obese, whereas the probability of 
current smoking was lower. People with prehypertension were 1.65 times more 
likely to have 1 or more of these adverse risk factors than were those with normal 
BP.52
• Assessment of the REGARDS data identified high risk of prehypertension to be 
associated with increased age and black race.53
• A meta-analysis of 12 prospective cohort studies (including 518 520 participants) 
found prehypertension was associated with incident stroke. The risk was 
particularly noted in nonelderly persons and for those with BP values in the 
higher prehypertension range.54
• Prehypertension was found to be significantly associated with stroke.54
• Prehypertension was highest in blacks with other risk factors, including DM and 
elevated C-reactive protein.53
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10. Diabetes Mellitus
ICD-9 250; ICD-10 E10 to E14. See Table 10-1 and Charts 10-1 through 10-4.
Prevalence
Youths
• In SEARCH, the prevalence of DM in youths <20 years of age in 2001 in the 
United States was 1.82 cases per 1000 youths (0.79 per 1000 among youths 0–9 
years of age and 2.80 per 1000 among youths 10–19 years of age). Non-Hispanic 
white youths had the highest prevalence (1.06 per 1000) in the younger group. 
Among youths 10 to 19 years of age, black youths (3.22 per 1000) and non-
Hispanic white youths (3.18 per 1000) had the highest rates, followed by 
American Indian youths (2.28 per 1000), Hispanic youths (2.18 per 1000), and 
Asian/Pacific Islander youths (1.34 per 1000). Among younger children, type 1 
DM accounted for ≥80% of DM; among older youths, the proportion of type 2 
DM ranged from 6% (0.19 per 1000 for non-Hispanic white youths) to 76% 
(1.74 per 1000 for American Indian youths). This translates to 154 369 youths 
with physician-diagnosed DM in 2001 in the United States, for an overall 
prevalence estimate for DM in children and adolescents of ≈0.18%.1
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• Approximately 186 000 people <20 years of age have DM. Each year, ≈15 000 
people <20 years of age are diagnosed with type 1 DM. Healthcare providers are 
finding more and more children with type 2 DM, a disease usually diagnosed in 
adults ≥40 years of age. Children who develop type 2 DM are typically 
overweight or obese and have a family history of the disease. Most are American 
Indian, black, Asian, or Hispanic/Latino.2
• During the period from 2002 to 2005, 3600 youth (age <20 years) were 
diagnosed with type 2 DM annually.3
• Among adolescents 10 to 19 years of age diagnosed with DM, 57.8% of blacks 
were diagnosed with type 2 versus type 1 DM compared with 46.1% of Hispanic 
and 14.9% of white youths.4
• According to the Bogalusa Heart Study, a long-term follow-up study of youths 
aging into adulthood, youths who were prediabetic or who had DM were more 
likely to have a constellation of metabolic disorders in young adulthood (19–44 
years of age), including obesity, hypertension, dyslipidemia, and metabolic 
syndrome, all of which predispose to CHD.5
• Among youths with type 2 DM, 10.4% are overweight and 79.4% are obese.6
• According to NHANES data from 1999–2007, among US adolescents aged 12 to 
19 years, the prevalence of prediabetes and DM increased from 9% to 23%.7
• The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) 
cohort comprised youths aged 10 to 17 years (41.1% Hispanic and 31.5% non-
Hispanic black) participating in a randomized controlled study of new-onset type 
2 DM; 41.5% of participants had household income <$25 000.8 The results of 
the clinical trial demonstrated that only half of the children maintained durable 
glycemic control with monotherapy,9 a higher rate of treatment failure than 
observed in adult cohorts.
• Of 1514 SEARCH participants, 95% reported having undergone BP checks and 
88% reported lipid-level checks, whereas slightly more than two thirds (68%) 
reported having had HbA1c testing or eye examinations (66%).10
Abbreviations Used in Chapter 10
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACS acute coronary syndrome
ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled 
Evaluation
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
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CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
ESRD end-stage renal disease
FHS Framingham Heart Study
HbA1c hemoglobin A1c
HD heart disease
HDL high-density lipoprotein
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IDDM insulin-dependent diabetes mellitus
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PA physical activity
PAR population-attributable risk
RR relative risk
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
STEMI ST-segment–elevation myocardial infarction
TODAY Treatment Options for Type 2 Diabetes in Adolescents and Youth
UA unstable angina
Adults—(See Table 10-1 and Charts 10-1 through 10-3.)
• On the basis of data from NHANES 2007–2010 (unpublished NHLBI 
tabulation), an estimated 19.7 million Americans ≥20 years of age have 
physician-diagnosed DM. An additional 8.2 million adults have undiagnosed 
DM, and ≈87.3 million adults have prediabetes (eg, fasting blood glucose of 100 
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to <126 mg/dL). The prevalence of prediabetes in the US adult population is 
38%.
• The prevalence of diagnosed DM in adults ≥65 years of age was 26.9% in 2010, 
and an additional 50% (>20 million) had prediabetes based on fasting glucose, 
oral glucose tolerance testing, or HbA1c. In addition, data from NHANES 2005–
2006 show that 46% of DM cases remain undiagnosed in this group aged ≥65 
years.11
• Men ≥20 years of age have a slightly higher prevalence of DM (11.8%) than 
women (10.8%).6
• After adjustment for population age differences, 2007 to 2009 national survey 
data for people ≥20 years of age indicate that 7.1% of non-Hispanic whites, 8.4% 
of Asian Americans, 11.8% of Hispanics, and 12.6% of non-Hispanic blacks had 
diagnosed DM.3
• Compared with non-Hispanic white adults, the risk of diagnosed DM was 18% 
higher among Asian Americans, 66% higher among Hispanics/Latinos, and 77% 
higher among non-Hispanic blacks.3
• In 2004 to 2006, the prevalence of diagnosed DM was more than twice as high 
for Asian Indian adults (14%) as for Chinese (6%) or Japanese (5%) adults.12
• Type 2 DM accounts for 90% to 95% of all diagnosed cases of DM in adults.3
• On the basis of 2010 BRFSS (CDC) data, the prevalence of adults in the United 
States who reported ever having been told by a physician that they had DM 
ranged from 5.3% in Alaska to 13.2% in Alabama. The median percentage 
among all states was 8.7%.13
• The CDC analyzed data from 1994 to 2004 collected by the Indian Health 
Service that indicated that the age-adjusted prevalence per 1000 population of 
DM increased 101.2% among American Indian/Alaska Native adults <35 years 
of age (from 8.5% to 17.1%). During this time period, the prevalence of 
diagnosed DM was greater among females than males in all age groups.14
• On the basis of projections from NHANES/NCHS studies between 1984 and 
2004, the total prevalence of DM in the United States is expected to more than 
double from 2005 to 2050 (from 5.6% to 12.0%) in all age, sex, and race/
ethnicity groups. Increases are projected to be largest for the oldest age groups 
(for instance, projected to increase by 220% among those 65–74 years of age and 
by 449% among those ≥75 years of age). DM prevalence is projected to increase 
by 99% among non-Hispanic whites, by 107% among non-Hispanic blacks, and 
by 127% among Hispanics. The age/race/ethnicity group with the largest 
increase is expected to be blacks ≥75 years of age (projected increase of 
606%).15
• According to NHIS data from 1997 to 2008, the prevalence of DM was higher at 
both time points among Asian Americans (4.3%–8.2%, respectively) than among 
whites (3.8%–6.0%, respectively), with the Asian American group also having a 
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greater proportional increase (1.9- versus 1.5-fold increase). This was observed 
despite lower BMI levels (23.6 versus 26.1 kg/m2 in the earliest time period) 
among Asians.16
• The prevalence of DM for all age groups worldwide was estimated to be 2.8% in 
2000 and is projected to be 4.4% in 2030. The total number of people with DM 
is projected to rise from 171 million in 2000 to 366 million in 2030.17
• According to international survey and epidemiologic data from 2.7 million 
participants, the prevalence of DM in adults increased from 8.3% in men and 
7.5% in women in 1980 to 9.8% in men and 9.2% in women in 2008. The 
number of individuals affected with DM increased from 153 million in 1980 to 
347 million in 2008.18
Incidence
Youths
• In the SEARCH study, the incidence of DM in youths overall was 24.3 per 100 
000 person-years. Among children <10 years of age, most had type 1 DM, 
regardless of race/ethnicity. The highest rates of incident type 1 DM were 
observed in non-Hispanic white youths (18.6, 28.1, and 32.9 per 100 000 person-
years for age groups of 0–4, 5–9, and 10–14 years, respectively). Overall, type 2 
DM was relatively infrequent, with the highest rates (17.0–49.4 per 100 000 
person-years) seen among 15- to 19-year-old minority groups.4
• Of 2291 individuals <20 years of age with newly diagnosed DM, slightly more 
than half (54.5%) had autoimmune, insulin-sensitive DM, and 15.9% had 
nonautoimmune, insulin-resistant DM.19
Adults—(See Table 10-1.)
• A total of 1.9 million new cases of DM (type 1 or type 2) were diagnosed in US 
adults ≥20 years of age in 2010.3
• Data from the FHS indicate a doubling in the incidence of DM over the past 30 
years, most dramatically during the 1990s. Among adults 40 to 55 years of age in 
each decade of the 1970s, 1980s, and 1990s, the age-adjusted 8-year incidence 
rates of DM were 2.0%, 3.0%, and 3.7% among women and 2.7%, 3.6%, and 
5.8% among men, respectively. Compared with the 1970s, the age-and sex-
adjusted OR for DM was 1.40 in the 1980s and 2.05 in the 1990s (P for 
trend=0.0006). Most of the increase in absolute incidence of DM occurred in 
individuals with a BMI ≥30 kg/m2 (P for trend=0.03).20
• DM incidence in adults also varies markedly by race. Over 5 years of follow-up 
in 45- to 84-year-olds in MESA, 8.2% of the cohort developed DM. The 
cumulative incidence was highest in Hispanics (11.3%), followed by black 
(9.5%), Chinese (7.7%), and white (6.3%) participants.21
• A recent meta-analysis of television viewing, including 4 studies consisting of 
175 938 adult individuals and 6428 incident type 2 DM cases, showed that 
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among those who watched 2 hours of television per day, the RR of DM was 20% 
higher (HR, 1.20; 95% CI, 1.14–1.27).22
• Gestational diabetes complicates 2% to 10% of pregnancies and increases the 
risk of developing type 2 DM by 35% to 60%.3
Mortality
(See Table 10-1.)
DM mortality in 2009 was 68 705. Any-mention mortality in 2009 was 230 642.23
• The 2009 overall underlying-cause death rate attributable to DM was 20.9. Death 
rates per 100 000 people were 23.3 for white males, 44.2 for black males, 15.7 
for white females, and 35.9 for black females.23
• According to data from the National Diabetes Information Clearinghouse, the 
National Institute of Diabetes and Digestive and Kidney Diseases, and the 
National Institutes of Health
– At least 68% of people >65 years of age with DM die of some form of 
HD; 16% die of stroke.
– HD death rates among adults with DM are 2 to 4 times higher than the 
rates for adults without DM.3
• In a collaborative meta-analysis of 820 900 individuals from 97 prospective 
studies, DM was associated with the following risks: all-cause mortality, HR 
1.80 (95% CI, 1.71–1.90); cancer death, HR 1.25 (95% CI, 1.19–1.31); and 
vascular death, HR 2.32 (95% CI, 2.11–2.56). In particular, DM was associated 
with death attributable to the following cancers: liver, pancreas, ovary, colorectal, 
lung, bladder, and breast. A 50-year-old with DM died on average 6 years earlier 
than an individual without DM.24
• FHS/NHLBI data show that having DM significantly increased the risk of 
developing CVD (HR 2.5 for women and 2.4 for men) and of dying when CVD 
was present (HR 2.2 for women and 1.7 for men). Diabetic men and women ≥50 
years of age lived an average of 7.5 and 8.2 years less than their nondiabetic 
equivalents. The differences in life expectancy free of CVD were 7.8 and 8.4 
years, respectively.25
• Analysis of data from NHANES 1971–2000 found that men with DM 
experienced a 43% relative reduction in the age-adjusted mortality rate, which 
was similar to that of nondiabetic men. Among women with DM, however, 
mortality rates did not decrease, and the difference in mortality rates between 
diabetic and nondiabetic women doubled.26
• During 1979 to 2004, DM death rates for black youths 1 to 19 years of age were 
approximately twice those for white youths. During 2003 to 2004, the annual 
average DM death rate per 1 million youths was 2.46 for black youths and 0.91 
for white youths.27
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• Analysis of data from the FHS from 1950 to 2005 found reductions in all-cause 
and CVD mortality among men and women with and without DM. However, all-
cause and CVD mortality rates among individuals with DM remain ≈2-fold 
higher than for individuals without DM.28
• According to NHIS data from 1997 to 2006, the rate of CVD death among adults 
with DM decreased by 40% (95% CI, 23%–54%). Similarly, all-cause mortality 
decreased by 23% (95% CI, 10%–35%). Compared with adults without DM, the 
CVD mortality rate decreased by 60% and the allcause mortality rate decreased 
by 44%.29
• Among 11 927 participants with DM who were part of the Translating Research 
into Action for Diabetes study, DM was recorded on 41% of the death 
certificates as the underlying cause of death for slightly more than one tenth 
(13%). It was noted that DM was more likely to be reported as a cause of death 
among individuals who died of CVD. These findings underscore that 
underreporting of DM exists on death certificates.30
Awareness
(See Chart 10-4.)
• Analysis of NHANES/NCHS data from 1988–1994 to 2005–2006 in adults ≥20 
years of age showed that 40% of those with DM did not know they had it.11 
Although the prevalence of diagnosed DM has increased significantly over the 
past decade, the prevalence of undiagnosed DM and impaired fasting glucose has 
remained relatively stable. Minority groups remain disproportionately affected.31
• Analysis of NHANES/NCHS data collected during 2005–2008 indicated that the 
prevalence of DM was 8.2% among people ≥20 years of age. Prevalence of DM 
was defined as people who were told by a physician or other health professional 
that they have DM. Of the estimated 18.3 million adults with DM, 73.3% were 
told they had DM or were undergoing treatment, and 26.7% (5.7 million) were 
unaware of the diagnosis. Of 7.9 million people being treated (37.3% of the 
diabetic population), one third (2.6 million) had their DM under control (ie, they 
were undergoing treatment and had fasting plasma glucose <126 mg/dL), and 
25.0% (5.3 million) were being treated but did not have their DM under control 
(fasting plasma glucose ≥126 mg/dL). An estimated 13.3 million individuals 
with DM are not treated. The untreated and unaware population (5.6 million) was 
26.7% of the diabetic population (NHANES 2003–2006, NHLBI tabulation).
Aftermath
• Although the exact date of DM onset can be difficult to determine, increasing 
duration of DM diagnosis is associated with increasing CVD risk. Longitudinal 
data from FHS suggest that the risk factor–adjusted RR of CHD is 1.38 (95% CI, 
0.99–1.92) times higher and the risk for CHD death is 1.86 (95% CI, 1.17–2.93) 
times higher for each 10-year increase in duration of DM.32
• On the basis of data from the NCHS/NHIS, 1997–200533
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– The estimated number of people ≥35 years of age with DM with a self-
reported cardiovascular condition increased 36%, from 4.2 million in 
1997 to 5.7 million in 2005; however, the age-adjusted prevalence of 
self-reported CVD conditions among people with diagnosed DM who 
were ≥35 years of age decreased 11.2%, from 36.6% in 1997 to 32.5% 
in 2005.
– Age-adjusted CVD prevalence was higher among men than women, 
among whites than blacks, and among non-Hispanics than Hispanics. 
Among women, the age-adjusted prevalence decreased by 11.2%; 
among men, it did not decrease significantly. Among blacks, the age-
adjusted prevalence of self-reported CVD decreased by 25.3%; among 
whites, no significant decrease occurred; among non-Hispanics, the rate 
decreased by 12%. No clear trends were detected among Hispanics. If 
the total number of people with DM and self-reported CVD increased 
over this period but proportions with self-reported CVD declined, the 
data suggest that the mean age at which people have been diagnosed is 
decreasing, or the higher CVD mortality rate among older diabetic 
individuals is removing them from ability to self-report CVD. These 
and other data show a consistent increase over time in the United States 
of the number of people with DM and CVD.
• Data from FHS show that despite improvements in CVD morbidity and 
mortality, DM continues to be associated with incremental CVD risk. 
Participants 45 to 64 years of age from the FHS original and offspring cohorts 
who attended examinations in 1950 to 1966 (“earlier” time period) and 1977 to 
1995 (“later” time period) were followed up for incident MI, CHD death, and 
stroke. Among participants with DM, the age- and sex-adjusted CVD incidence 
rate was 286.4 per 10 000 person-years in the earlier period and 146.9 per 10 000 
person-years in the later period, a 35.4% decline. HRs for DM as a predictor of 
incident CVD were not significantly different in the earlier (risk factor–adjusted 
HR, 2.68; 95% CI, 1.88–3.82) versus later (HR, 1.96; 95% CI, 1.44–2.66) 
period.34 Thus, although there was a 50% reduction in the rate of incident CVD 
events among adults with DM, the absolute risk of CVD remained 2-fold greater 
than among people without DM.34
– Data from these earlier and later time periods in FHS also suggest that 
the increasing prevalence of DM is leading to an increasing rate of 
CVD, resulting in part from CVD risk factors that commonly 
accompany DM. The age- and sex-adjusted HR for DM as a CVD risk 
factor was 3.0 in the earlier time period and 2.5 in the later time period. 
Because the prevalence of DM has increased over time, the population 
attributable risk (PAR) for DM as a CVD risk factor increased from 
5.4% in the earlier time period to 8.7% in the later time period 
(attributable risk ratio, 1.62; P=0.04). Adjustment for CVD risk factors 
(age, sex, hypertension, current smoking, high cholesterol, and obesity) 
weakened this attributable risk ratio to 1.5 (P=0.12).35
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– Other data from FHS show that over a 30-year period, CVD among 
women with DM was 54.8% among normal-weight women but 78.8% 
among obese women. Among normal-weight men with DM, the 
lifetime risk of CVD was 78.6%, whereas it was 86.9% among obese 
men.36
• DM increases the risk of stroke, with the RR ranging from 1.8- to 6-fold 
increased risk.32,37
– DM is associated with increased ischemic stroke incidence at all ages, 
with the incremental risk associated with DM being most prominent 
before 55 years of age in blacks and before 65 years of age in whites.37
– Ischemic stroke patients with DM are younger, more likely to be black, 
and more likely to have hypertension, prior MI, and high cholesterol 
than nondiabetic patients.37
• Data from the ARIC study of the NHLBI found that the magnitude of 
incremental CHD risk associated with DM was smaller in blacks than in 
whites.38
• A subgroup analysis was conducted of patients with DM enrolled in randomized 
clinical trials that evaluated acute coronary syndrome (ACS) therapies. The data 
included 62 036 patients from Thrombolysis in Myocardial Infarction studies (46 
577 with STEMI and 15 459 with unstable angina [UA]/non–ST-segment–
elevation myocardial infarction [NSTEMI]). Of these, 17.1% had DM. Modeling 
showed that mortality at 30 days was significantly higher among patients with 
DM than among those without DM who presented with UA/NSTEMI (2.1% 
versus 1.1%; P≤0.001) and STEMI (8.5% versus 5.4%; P=0.001), with adjusted 
risks for 30-day mortality in DM versus no DM of 1.78 for UA/NSTEMI (95% 
CI, 1.24–2.56) and 1.40 (95% CI, 1.24–1.57) for STEMI. DM was also 
associated with significantly higher mortality 1 year after UA/NSTEMI or 
STEMI. By 1 year after ACS, patients with DM presenting with UA/NSTEMI 
had a risk of death that approached that of patients without DM presenting with 
STEMI (7.2% versus 8.1%).39
• Other studies show that the increased prevalence of DM is being followed by an 
increasing prevalence of CVD morbidity and mortality. New York City death 
certificate data for 1989 to 1991 and 1999 to 2001 and hospital discharge data for 
1988 to 2002 show increases in all-cause and cause-specific mortality between 
1990 and 2000, as well as in annual hospitalization rates for DM and its 
complications among patients hospitalized with AMI and/or DM. During this 
decade, all-cause and cause-specific mortality rates declined, although not for 
patients with DM; rates increased 61% and 52% for diabetic men and women, 
respectively, as did hospitalization rates for DM and its complications. The 
percentage of all AMIs occurring in patients with DM increased from 21% to 
36%, and the absolute number more than doubled, from 2951 to 6048. Although 
hospital days for AMI fell overall, for those with DM, they increased 51% (from 
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34 188 to 51 566). These data suggest that increases in DM rates threaten the 
long-established nationwide trend toward reduced coronary artery events.40
• In an analysis of provincial health claims data for adults living in Ontario, 
Canada, between 1992 and 2000, the rate of patients admitted for AMI and 
stroke decreased to a greater extent in the diabetic than the nondiabetic 
population (AMI, −15.1% versus −9.1%, P=0.0001; stroke, −24.2% versus 
−19.4%, P=0.0001). Diabetic patients experienced reductions in case fatality 
rates related to AMI and stroke similar to those without DM (−44.1% versus 
−33.2%, P=0.1; −17.1% versus −16.6%, P=0.9, respectively) and similarly 
comparable decreases in all-cause mortality. Over the same period, the number 
of DM cases increased by 165%, which translates to a marked increase in the 
proportion of CVD events occurring among patients with DM: AMI, 44.6%; 
stroke, 26.1%; AMI deaths, 17.2%; and stroke deaths, 13.2%.41
• In the same data set, the transition to a high-risk category (an event rate 
equivalent to a 10-year risk of 20% or an event rate equivalent to that associated 
with previous MI) occurred at a younger age for men and women with DM than 
for those without DM (mean difference 14.6 years). For the outcome of AMI, 
stroke, or death resulting from any cause, diabetic men and women entered the 
high-risk category at 47.9 and 54.3 years of age, respectively. The data suggest 
that DM confers a risk equivalent to aging 15 years. In North America, diverse 
data show lower rates of CVD among diabetic people, but as the prevalence of 
DM has increased, so has the absolute burden of CVD, especially among middle-
aged and older individuals.42
• DM accounted for 44% of the new cases of end-stage renal disease (ESRD) in 
2007. According to data from the US Renal Data System and BRFSS from 1996 
to 2007, the incidence rate of ESRD attributed to DM decreased from 304.5 per 
100 000 to 199.1 per 100 000.43
• According to NHANES data, the prevalence of diabetic kidney disease has 
increased from 2.2% in NHANES III to 3.3% in NHANES 2005–2008. These 
increases were observed in direct proportion to increases in DM.44
• HbA1c levels ≥6.5% can be used to diagnose DM.45 In the population-based 
ARIC study, HbA1c levels ≥6.5% had a 14-year follow-up, multivariable-
adjusted HR of 16.5 (95% CI, 14.2–19.1) for diagnosed DM and 1.95 (95% CI, 
1.53–2.48) for CHD relative to those with HbA1c <5.0%.46
• According to data from the ARIC study and NHANES III, the sensitivity and 
specificity for diagnosing DM (compared with a single fasting glucose 
measurement of ≥126 mg/dL) were 47% and 98%, respectively.
Risk Factors
• DM, especially type 2 DM, is associated with clustered risk factors for CHD, 
with a prevalence of 75% to 85% for hypertension among adults with DM, 70% 
to 80% for elevated LDL, and 60% to 70% for obesity.47
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• Aggressive treatment of hypertension is recommended for adults with DM to 
prevent cardiovascular complications. Between NHANES III (1984–1992) and 
NHANES 1999–2004, the proportion of patients with DM whose BP was treated 
increased from 76.5% to 87.8%, and the proportion whose BP was controlled 
nearly doubled (15.9% to 29.6%).48
• Aggressive treatment of hypercholesterolemia is recommended for adults with 
DM, with the cornerstone of treatment being statin therapy, which is 
recommended for all patients with DM >40 years of age independent of baseline 
cholesterol, with targeted LDL cholesterol <100 mg/dL and optimally <70 
mg/dL.49
• CHD risk factors among patients with DM remain suboptimally treated, although 
improvements have been observed over the past decade. Between 1999 and 2008, 
in up to 2623 adult participants with DM, data from NHANES showed that 
improvements were observed for the achieved targets for control of HbA1c (from 
37.0% to 55.2%), BP (from 35.2% to 51.0%), and LDL cholesterol (from 32.5% 
to 52.9%).50
• Data from the 2004 National Healthcare Disparities Report (Agency for 
Healthcare Research and Quality, US Department of Health and Human 
Services) found that only approximately one third of adults with DM received all 
5 interventions to reduce risk factors recommended for comprehensive DM care 
in 2001. The proportion receiving all 5 interventions was lower among blacks 
than whites and among Hispanics than non-Hispanic whites.51
– In multivariable models that controlled for age, sex, income, education, 
insurance, and residence location, blacks were 38% less likely and 
Hispanics were 33% less likely than their respective comparison groups 
to receive all recommended risk factor interventions in 2001.51
• In 1 large academic medical center, outpatients with type 2 DM were observed 
during an 18-month period for proportions of patients who had HbA1c levels, BP, 
or total cholesterol levels measured; who had been prescribed any drug therapy if 
HbA1c levels, SBP, or LDL cholesterol levels exceeded recommended treatment 
goals; and who had been prescribed greater-than-starting-dose therapy if these 
values were above treatment goals. Patients were less likely to have cholesterol 
levels measured (76%) than HbA1c levels (92%) or BP (99%; P<0.0001 for 
either comparison). The proportion of patients who received any drug therapy 
was greater for above-goal HbA1c (92%) than for above-goal SBP (78%) or LDL 
cholesterol (38%; P<0.0001 for each comparison). Similarly, patients whose 
HbA1c levels were above the treatment goal (80%) were more likely to receive 
greater-than-starting-dose therapy than were those who had above-goal SBP 
(62%) and LDL cholesterol levels (13%; P<0.0001).52
– Data from the same academic medical center also showed that CVD 
risk factors among women with DM were managed less aggressively 
than among men with DM. Women were less likely than men to have 
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HbA1c <7% (without CHD: adjusted OR for women versus men 0.84, 
P=0.005; with CHD: 0.63, P<0.0001). Women without CHD were less 
likely than men to be treated with lipid-lowering medication (0.82; 
P=0.01) or, when treated, to have LDL cholesterol levels <100 mg/dL 
(0.75; P=0.004) and were less likely than men to be prescribed aspirin 
(0.63; P<0.0001). Women with DM and CHD were less likely than men 
to be prescribed aspirin (0.70, P<0.0001) and, when treated for 
hypertension or hyperlipidemia, were less likely to have BP levels 
<130/80 mm Hg (0.75; P<0.0001) or LDL cholesterol levels <100 
mg/dL (0.80; P=0.006).53
• Analysis of data from the CHS of the NHLBI found that lifestyle risk factors, 
including PA level, dietary habits, smoking habits, alcohol use, and adiposity 
measures, assessed late in life, were each independently associated with risk of 
new-onset DM. Participants whose PA level and dietary, smoking, and alcohol 
habits were all in the low-risk group had an 82% lower incidence of DM than all 
other participants. When absence of adiposity was added to the other 4 low-risk 
lifestyle factors, incidence of DM was 89% lower.54
• According to 2007 data from the BRFSS, only 25% of adults with DM achieved 
recommended levels of total PA based on the 2007 American Diabetes 
Association guidelines.55
Hospitalizations
(See Table 10-1.)
Youths
• Nationwide Inpatient Sample data from 1993 to 2004 were analyzed for 
individuals 0 to 29 years of age with a diagnosis of DM. Rates of hospitalizations 
increased by 38%. Hospitalization rates were higher for females (42%) than for 
males (29%). Inflation-adjusted total charges for DM hospitalizations increased 
130%, from $1.05 billion in 1993 to $2.42 billion in 2004.56
Adults
• According to NHDS data reported by the CDC in an analysis of data from 2009, 
DM was a listed diagnosis in ≈15% of US adult hospital discharges, among 
which circulatory diseases was the most common first-listed diagnosis (26.2%; 
1.4 million discharges) and DM the second most common (12.0%; 655 000 
discharges).57
Hypoglycemia
• Hypoglycemia is a common side effect of DM treatment, typically defined as a 
blood glucose level <50 mg/dL; severe hypoglycemia is additionally defined as 
patients needing assistance to treat themselves.
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• In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation) trial, 2.1% of patients had 
an episode of severe hypoglycemia. Severe hypoglycemia was associated with an 
increased risk of major macrovascular events (HR, 2.88; 95% CI, 2.01–4.12), 
cardiovascular death (HR, 2.68; 95% CI, 1.72–4.19), and all-cause death (HR, 
2.69; 95% CI, 1.97–3.67), including nonvascular outcomes. The lack of 
specificity of hypoglycemia with vascular outcomes suggests that it might be a 
marker for susceptibility. Risk factors for hypoglycemia included older age, DM 
duration, worse renal function, lower BMI, lower cognitive function, multiple 
glucose-lowering medications, and randomization to the intensive glucose 
control arm.58
• According to data from the 2004 to 2008 MarketScan database of type 2 DM, 
which consisted of 536 581 individuals, the incidence rate of hypoglycemia was 
153.8 per 10 000 person-years and was highest in adults aged 18 to 34 years 
(218.8 per 10 000 person-years).59
• According to data from 2956 adults ≥55 years of age from the ACCORD (Action 
to Control Cardiovascular Risk in Diabetes) trial, poor cognitive function, 
defined as a 5-point poorer baseline score on the Digit Symbol Substitution Test, 
was associated with a 13% increased risk of severe hypoglycemia that required 
medical assistance.60
Cost
(See Table 10-1.)
• In 2007, the direct ($116 billion) and indirect ($58 billion) cost attributable to 
DM was $174 billion.3 These estimates include not just DM as a primary 
diagnosis but also long-term complications that are attributed to DM.61
• After adjustment for age and sex, medical costs for patients with DM were 2.3 
times higher than for people without DM.3
• A study of data from NHANES 2003–2006, Ingenix Research Data Mart, 2003–
2005 NAMCS, the 2003–2005 NHAMCS, the 2004–2005 Nationwide Inpatient 
Sample, and the 2003–2005 MEPS found that the estimated economic cost of 
undiagnosed DM in 2007 was $18 billion, including medical costs of $11 billion 
and indirect costs of $7 billion.62
• According to 2003–2005 MEPS data (household component data), reductions in 
DM and hypertension of 5% could save ≈9 billion dollars annually in the short-
term. Longer term, savings could total nearly $25 billion.63
• When the 2007 MarketScan database was used to assess costs associated with 
youths who have DM, mean annual costs per person with DM were $9061 
compared with $1468 for those without DM; 43% of this cost was for 
prescription drugs. For type 1 compared with type 2 DM, costs were $9333 
versus $5683, respectively.64
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• Using the insurance claims and MarketScan data from 7556 youths <19 years of 
age with insulin-treated DM, costs for youths with hypoglycemia were $12 850 
compared with $8970 for youths without hypoglycemia. For diabetic 
ketoacidosis, costs were $14 236 for youths with versus $8398 for youths 
without diabetic ketoacidosis.65
• The cost of hypoglycemia, according to data from 536 581 individuals with type 
2 DM from the 2004–2008 MarketScan database, was $52 223 675, which 
accounted for 1.0% of inpatient costs, 2.7% of ED costs, and 0.3% of outpatient 
costs. This resulted in a mean cost of $17 564 for an inpatient admission, $1387 
for an ED visit, and $394 for an outpatient visit.59
Type 1 DM
• Type 1 DM constitutes 5% to 10% of DM in the United States.66
• The Colorado IDDM (insulin-dependent DM) Study Registry (1978–1988) and 
SEARCH for Diabetes in Youth (2002–2004) demonstrated an increasing 
incidence of type 1 DM among Colorado youths ≤17 years of age, with a 2.3% 
(95% CI, 1.6%–3.1%) increase per year over the past 26 years.67
• Among youths with type 1 DM, the prevalence of overweight is 22.1% and the 
prevalence of obesity is 12.6%.6
• A long-term study of patients with type 1 DM that began in 1966 showed that 
over 30 years of follow-up, overall risk of mortality associated with type 1 DM 
was 7 times greater than that of the general population. Females had a 13.2-fold 
incremental mortality risk compared with a 5.0-fold increased risk in males. 
During the course of study, the incremental mortality risk associated with type 1 
DM declined from 9.3 to 5.6 times that of nondiabetic control subjects.68
• According to 30-year mortality data from Allegheny County, PA, those with type 
1 DM have a mortality rate 5.6 times higher than the general population.69
• The leading cause of death among patients with type 1 DM is CVD, which 
accounted for 22% of deaths among those in the Allegheny County, PA, type 1 
DM registry, followed by renal (20%) and infectious (18%) causes.70
• Long-term follow-up data from the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications Study Research 
Group showed that intensive versus conventional treatment in the Diabetes 
Control and Complications Trial was associated with a 42% reduced risk of CVD 
(P=0.02) and a 57% reduced risk of the composite end point (P=0.02; included 
nonfatal MI, stroke, and CVD death).71
• Observational data from the Swedish National Diabetes Register showed that 
most CVD risk factors were more adverse among patients with HbA1c between 
8.0% and 11.9% than among those with HbA1c between 5.0% and 7.9%. Per 1% 
unit increase in HbA1c, the HR of fatal and nonfatal CHD was 1.30 in 
multivariable adjusted models and 1.27 for fatal and nonfatal CVD. Among 
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patients with HbA1c 8.0% to 11.9% compared with those with HbA1c 5.0% to 
7.9%, the HR of fatal/nonfatal CHD was 1.71 and the risk of fatal/nonfatal CVD 
was 1.59.72
• Among 2787 patients from the EURODIAB Prospective Complications Study, 
age, waist-hip ratio, pulse pressure, non-HDL cholesterol, microalbuminuria, and 
peripheral and autonomic neuropathy were risk factors for all-cause, CVD, and 
non-CVD mortality.61
• Among 3610 older patients (>60 years of age) with type 1 DM, the risk of severe 
hypoglycemia was twice as high as for those <60 years of age (40.1 versus 24.3 
per 100 patient-years).73
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frequent severe hypoglycaemia in “elderly” and “old” patients with type 1 diabetes. Diabet Med. 
2012; 29:e176–e179. [PubMed: 22506989] 
11. Metabolic Syndrome
• Metabolic syndrome refers to a cluster of risk factors for CVD and type 2 DM. 
Although several different definitions for metabolic syndrome have been 
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proposed, the International Diabetes Federation, NHLBI, AHA, and others 
recently proposed a harmonized definition for metabolic syndrome.1 By this 
definition, metabolic syndrome is diagnosed when ≥3 of the following 5 risk 
factors are present (most but not all people with DM will be classified as having 
metabolic syndrome by this definition because they will have at least 2 other 
factors besides the glucose criterion; many will prefer to separate those with DM 
into a separate group for risk stratification or treatment purposes):
– Fasting plasma glucose ≥100 mg/dL or undergoing drug treatment for 
elevated glucose
– HDL cholesterol <40 mg/dL in men or <50 mg/dL in women or 
undergoing drug treatment for reduced HDL cholesterol.
– Triglycerides ≥150 mg/dL or undergoing drug treatment for elevated 
triglycerides
– Waist circumference ≥102 cm in men or ≥88 cm in women in the 
United States.
– BP ≥130 mm Hg systolic or ≥85 mm Hg diastolic or undergoing drug 
treatment for hypertension or antihypertensive drug treatment in a 
patient with a history of hypertension.
• Identification of metabolic syndrome represents a call to action for the healthcare 
provider and patient to address the underlying lifestyle-related risk factors, 
including abdominal obesity, physical inactivity, and atherogenic diet, as well as 
clinical management to address the characteristic atherogenic dyslipidemia, 
elevated BP, elevated glucose, and prothrombotic state that are common to 
people with metabolic syndrome. A multidisciplinary team of healthcare 
professionals is desirable to adequately address these multiple issues in patients 
with the metabolic syndrome.2
Abbreviations Used in Chapter 11
AF atrial fibrillation
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities
BMI body mass index
BP blood pressure
CAC coronary artery calcification
CAD coronary artery disease
CHD coronary heart disease
CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
CVD cardiovascular disease
DM diabetes mellitus
FRS Framingham Risk Score
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HDL high-density lipoprotein
HF heart failure
HR hazard ratio
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAR population attributable risk
PCI percutaneous coronary intervention
RR relative risk
WHO World Health Organization
Adults
The following estimates include many of those who have DM, in addition to those with 
metabolic syndrome without DM.
• Prevalence of metabolic syndrome varies by the definition used, with definitions 
such as that from the International Diabetes Federation that suggest lower 
thresholds for defining central obesity in European whites, Asians, and Hispanics 
resulting in higher prevalence estimates.3
• On the basis of NHANES 2003–2006 data and National Cholesterol Education 
Program/Adult Treatment Panel III guidelines, ≈34% of adults ≥20 years of age 
met the criteria for metabolic syndrome.4
• Also based on NHANES 2003–2006 data4
– The age-adjusted prevalence was 35.1% for men and 32.6% for women.
– Among men, the age-specific prevalence ranged from 20.3% among 
people 20 to 39 years of age to 40.8% for people 40 to 59 years of age 
and 51.5% for people ≥60 years of age. Among women, the age-
specific prevalence ranged from 15.6% among people 20 to 39 years of 
age to 37.2% for people 40 to 59 years of age and 54.4% for those ≥60 
years of age.
– The age-adjusted prevalences of people with metabolic syndrome were 
37.2%, 25.3%, and 33.2% for non-Hispanic white, non-Hispanic black, 
and Mexican American men, respectively. Among women, the 
percentages were 31.5%, 38.8%, and 40.6%, respectively.
– The age-adjusted prevalence was ≈53% higher among non-Hispanic 
black women than among non-Hispanic black men and ≈22% higher 
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among Mexican American women than among Mexican American 
men.
• The prevalence of metabolic syndrome is also high among immigrant Asian 
Indians, ranging between 26.8% and 38.2% depending on the definition used.5
• The prevalence of metabolic syndrome among pregnant women increased to 
26.5% during 1999 to 2004 from 17.8% during 1988 to 1994.6
• Despite its prevalence, the public’s recognition of metabolic syndrome is 
limited.7 The above estimates include many of those who have DM in addition to 
those with metabolic syndrome without DM.
Children/Adolescents
• According to the 2009 AHA scientific statement about metabolic syndrome in 
children and adolescents, metabolic syndrome should be diagnosed with caution 
in this age group because metabolic syndrome categorization in adolescents is 
not stable.8 Approximately half of the 1098 adolescent participants in the 
Princeton School District Study diagnosed with pediatric Adult Treatment Panel 
III metabolic syndrome lost the diagnosis over 3 years of follow-up.9
• Additional evidence of the instability of the diagnosis of metabolic syndrome in 
children exists. In children 6 to 17 years of age participating in research studies 
in a single clinical research hospital, the diagnosis of metabolic syndrome was 
unstable in 46% of cases after a mean of 5.6 years of follow-up.10
• On the basis of NHANES 1999–2002 data, the prevalence of metabolic 
syndrome in adolescents 12 to 19 years of age was 9.4%, which represents ≈2.9 
million people. It was 13.2% in boys, 5.3% in girls, 10.7% in whites, 5.2% in 
blacks, and 11.1% in Mexican Americans.11
• In 1999 to 2004, ≈4.5% of US adolescents 12 to 17 years of age had metabolic 
syndrome according to the definition developed by the International Diabetes 
Federation.12 In 2006, this prevalence would have represented ≈1.1 million 
adolescents 12 to 17 years of age with metabolic syndrome. It increased from 
1.2% among those 12 to 13 years of age to 7.1% among those 14 to 15 years of 
age and was higher among boys (6.7%) than girls (2.1%). Furthermore, 4.5% of 
white adolescents, 3.0% of black adolescents, and 7.1% of Mexican American 
adolescents had metabolic syndrome. The prevalence of metabolic syndrome 
remained relatively stable during successive 2-year periods: 4.5% for 1999 to 
2000, 4.4% to 4.5% for 2001 to 2002, and 3.7% to 3.9% for 2003 to 2004.
• In 1999 to 2002, among overweight or obese adolescents, 44% had metabolic 
syndrome.11 In 1988 to 1994, two thirds of all adolescents had at least 1 
metabolic abnormality.13
• Of 31 participants in the NHLBI Lipid Research Clinics Princeton Prevalence 
Study and the Princeton Follow-Up Study who had metabolic syndrome at 
baseline, 21 (68%) had metabolic syndrome 25 years later.14 After adjustment 
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for age, sex, and race, the baseline status of metabolic syndrome was 
significantly associated with an increased risk of having metabolic syndrome 
during adulthood (OR, 6.2; 95% CI, 2.8–13.8).
• In the Bogalusa Heart Study, 4 variables (BMI, homeostasis model assessment of 
insulin resistance, ratio of triglycerides to HDL cholesterol, and mean arterial 
pressure) considered to be part of the metabolic syndrome clustered together in 
blacks and whites and in children and adults.15 The degree of clustering was 
stronger among adults than among children. The clustering of rates of change in 
the components of the metabolic syndrome in blacks exceeded that in whites. 
Cardiovascular abnormalities are associated with metabolic syndrome in children 
and adolescents.16,17
Risk
Adults
• Consistent with 2 earlier meta-analyses, a recent metaanalysis of prospective 
studies concluded that metabolic syndrome increased the risk of developing 
CVD (summary RR, 1.78; 95% CI, 1.58–2.00).18 The risk of CVD tended to be 
higher in women (summary RR, 2.63) than in men (summary RR, 1.98; P=0.09). 
On the basis of results from 3 studies, metabolic syndrome remained a predictor 
of cardiovascular events after adjustment for the individual components of the 
syndrome (summary RR, 1.54; 95% CI, 1.32–1.79). A more recent meta-analysis 
among 87 studies comprising 951 083 subjects showed an even higher risk of 
CVD associated with metabolic syndrome (summary RR, 2.35; 95% CI, 2.02–
2.73), with significant increased risks (RRs ranging from 1.6 to 2.9) for all-cause 
mortality, CVD mortality, MI, and stroke, as well as for those with metabolic 
syndrome without DM.19
• In one of the earlier studies among US adults, mortality follow-up of the second 
NHANES showed a stepwise increase in risk of CHD, CVD, and total mortality 
across the spectrum of no disease, metabolic syndrome (without DM), DM, prior 
CVD, and those with CVD and DM, with an HR for CHD mortality of 2.02 
(95% CI, 1.42–2.89) associated with metabolic syndrome. Increased risk was 
seen with increased numbers of metabolic syndrome risk factors.20
• Several studies suggest that the Framingham Risk Score (FRS) is a better 
predictor of incident CVD than metabolic syndrome.21–23 In the San Antonio 
Heart Study, the area under the receiver-operating characteristic curve was 0.816 
for the FRS and 0.811 for the FRS plus the metabolic syndrome. 21 Furthermore, 
the sensitivity for CVD at a fixed specificity was significantly higher for the FRS 
than for the metabolic syndrome. In ARIC, inclusion of the metabolic syndrome 
did not improve the risk prediction achieved by the FRS.22 In the British 
Regional Heart Study, the area under the receiver-operating characteristic curve 
for the FRS was 0.73 for incident CHD during 10 years of follow-up, and the 
area under the receiver-operating characteristic curve for the number of 
metabolic syndrome components was 0.63.23 For CHD events during 20 years of 
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follow-up, the areas under the receiver-operating characteristic curves were 0.68 
for the FRS and 0.59 for the number of metabolic syndrome components.
• Estimates of RR for CVD generally increase as the number of components of 
metabolic syndrome increases.23 Compared with men without an abnormal 
component in the Framingham Offspring Study, the HRs for CVD were 1.48 
(95% CI, 0.69–3.16) for men with 1 or 2 components and 3.99 (95% CI, 1.89–
8.41) for men with ≥3 components.24 Among women, the HRs were 3.39 (95% 
CI, 1.31–8.81) for 1 or 2 components and 5.95 (95% CI, 2.20–16.11) for ≥3 
components. Compared with men without a metabolic abnormality in the British 
Regional Heart Study, the HRs were 1.74 (95% CI, 1.22–2.39) for 1 component, 
2.34 (95% CI, 1.65–3.32) for 2 components, 2.88 (95% CI, 2.02–4.11) for 3 
components, and 3.44 (95% CI, 2.35–5.03) for 4 or 5 components.23
• The cardiovascular risk associated with the metabolic syndrome varies on the 
basis of the combination of metabolic syndrome components present. Of all 
possible ways to have 3 metabolic syndrome components, the combination of 
central obesity, elevated BP, and hyperglycemia conferred the greatest risk for 
CVD (HR, 2.36; 95% CI, 1.54–3.61) and mortality (HR, 3.09; 95% CI, 1.93–
4.94) in the Framingham Offspring Study.25
• Data from the Aerobics Center Longitudinal Study indicate that risk for CVD 
mortality is increased in men without DM who have metabolic syndrome (HR, 
1.8; 95% CI, 1.5–2.0); however, among those with metabolic syndrome, the 
presence of DM is associated with even greater risk for CVD mortality (HR, 2.1; 
95% CI, 1.7–2.6).26 Analysis of data from NCHS was used to determine the 
number of disease-specific deaths attributable to all nonoptimal levels of each 
risk factor exposure by age and sex. The results of the analysis of dietary, 
lifestyle, and metabolic risk factors show that targeting a handful of risk factors 
has large potential to reduce mortality in the United States.27
• Among stable CAD patients in the COURAGE trial (Clinical Outcomes Utilizing 
Revascularization and Aggressive Drug Evaluation), the presence of metabolic 
syndrome was associated with an increased risk of death or MI (unadjusted HR, 
1.41; 95% CI, 1.15–1.73; P=0.001); however, after adjustment for its individual 
components, metabolic syndrome was no longer significantly associated with 
outcome (HR, 1.15; 95% CI, 0.79–1.68; P=0.46). Early percutaneous coronary 
intervention (PCI) in addition to medical therapy did not significantly reduce the 
risk of death or MI regardless of metabolic syndrome or DM status.28
• In the INTERHEART case-control study of 26 903 subjects from 52 countries, 
metabolic syndrome was associated with an increased risk of MI, both according 
to the WHO (OR, 2.69; 95% CI, 2.45–2.95) and International Diabetes 
Federation (OR, 2.20; 95% CI, 2.03–2.38) definitions, with a PAR of 14.5% 
(95% CI, 12.7%–16.3%) and 16.8% (95% CI, 14.8%–18.8%), respectively, and 
associations that were similar across all regions and ethnic groups. In addition, 
the presence of ≥3 risk factors with subthreshold values was associated with 
increased risk of MI (OR, 1.50; 95% CI, 1.24–1.81) compared with having 
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“normal” values. Similar results were observed when the International Diabetes 
Federation definition was used.29
• In MESA, among 6603 people aged 45 to 84 years (1686 [25%] with metabolic 
syndrome without DM and 881 [13%] with DM), subclinical atherosclerosis 
assessed by CAC was more severe in people with metabolic syndrome and DM 
than in those without these conditions, and the extent of CAC was a strong 
predictor of CHD and CVD events in these groups.30 Furthermore, the 
progression of CAC was greater in people with metabolic syndrome and DM 
than in those without.31
• In addition to CVD, the metabolic syndrome has been associated with incident 
AF32 and HF.33
• The metabolic syndrome is associated with increased healthcare use and 
healthcare-related costs among individuals with and without DM. Overall, 
healthcare costs increase by ≈24% for each additional metabolic syndrome 
component present.34
Children
• Few prospective pediatric studies have examined the future risk for CVD or DM 
according to baseline metabolic syndrome status. Data from 771 participants 6 to 
19 years of age from the NHLBI’s Lipid Research Clinics Princeton Prevalence 
Study and the Princeton Follow-Up Study showed that the risk of developing 
CVD was substantially higher among those with metabolic syndrome than 
among those without this syndrome (OR, 14.6; 95% CI, 4.8–45.3) who were 
followed up for 25 years.14
• Another analysis of 814 participants of this cohort showed that those 5 to 19 
years of age who had metabolic syndrome at baseline had an increased risk of 
having DM 25 to 30 years later compared with those who did not have the 
syndrome at baseline (OR, 11.5; 95% CI, 2.1–63.7).35
• Additional data from the Princeton Follow-Up Study, the Fels Longitudinal 
Study, and the Muscatine Study suggest that the absence of components of the 
metabolic syndrome in childhood had a high negative predictive value for the 
development of metabolic syndrome or DM in adulthood.36
Risk Factors
• In prospective or retrospective cohort studies, the following factors have been 
reported as being directly associated with incident metabolic syndrome, defined 
by one of the major definitions: age,35,37–39 low educational attainment,37,40 low 
socioeconomic status,41 smoking,40–43 low levels of PA,40–46 low levels of 
physical fitness,44,47–49 intake of soft drinks,50 intake of diet soda,51 magnesium 
intake,52 energy intake,46 carbohydrate intake,37,42,53 total fat intake,37,53 
Western dietary pattern,51 meat intake,51 intake of fried foods,51 heavy alcohol 
consumption,54 abstention from alcohol use,37 parental history of DM,35 long-
term stress at work,55 pediatric metabolicsyndrome,35 obesity or 
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BMI,37,38,42,46,56 childhood obesity,57 waist circumference,39,53,58–61 
intraabdominal fat,62 gain in weight or BMI,37,63 change in weight or 
BMI,39,42,64 weight fluctuation,65 BP,39,53,60,66 heart rate,67 homeostasis model 
assessment,58,68 fasting insulin,58 2-hour insulin,58 proinsulin,58 fasting glucose 
or hyperglycemia, 39,58,60 2-hour glucose,58 impaired glucose tolerance,58 
triglycerides,39,53,56,58–60 low HDL cholesterol,39,53,57,58,60 oxidized LDL,68 
uric acid,64,69 γ-glutamyltransferase,64,70,71 alanine transaminase,64,70,72,73 
plasminogen activator inhibitor-1,74 aldosterone,74 leptin,75 C-reactive 
protein,76,77 adipocyte–fatty acid binding protein,78 and free testosterone 
index.79
• The following factors have been reported as being inversely associated with 
incident metabolic syndrome, defined by one of the major definitions, in 
prospective or retrospective cohort studies: muscular strength,80 change in PA or 
physical fitness,42,47 alcohol intake,40,46 Mediterranean diet,81 dairy 
consumption,51 insulin sensitivity,58 ratio of aspartate aminotransferase to 
alanine transaminase,72 total testosterone,79,82,83 sex hormone–binding 
globulin,79,82,83 and Δ5-desaturase activity.84
• Furthermore, men were more likely than women to develop metabolic 
syndrome,37,39 and blacks were shown to be less likely to develop metabolic 
syndrome than whites.37
• In >6 years of follow-up in the ARIC Study, 1970 individuals (25%) developed 
metabolic syndrome, and compared with the normal-weight group (BMI <25 
kg/m2), the ORs of developing metabolic syndrome were 2.81 (95% CI, 2.50–
3.17) and 5.24 (95% CI, 4.50–6.12) for the overweight (BMI 25–30 kg/m2) and 
obese (BMI ≥30 kg/m2) groups, respectively. Compared with the lowest quartile 
of leisure-time PA, the ORs of developing metabolic syndrome were 0.80 (95% 
CI, 0.71–0.91) and 0.92 (95% CI, 0.81–1.04) for people in the highest and 
middle quartiles, respectively.85
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12. Chronic Kidney Disease
ICD-10 N18.0. See Tables 12-1 through 12-3.
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End-Stage Renal Disease
Prevalence, Incidence, and Risk—(See Tables 12-1 and 12-2.)
ESRD is a condition that is most commonly associated with DM or HBP, occurs when the 
kidneys are functioning at a very low level, and is currently defined as the receipt of chronic 
renal replacement treatment such as hemodialysis, peritoneal dialysis, or kidney 
transplantation. The ESRD population is increasing in size and cost as those with chronic 
kidney disease (CKD) transition to ESRD and as a result of changing practice patterns in the 
United States.
• Data from the 2012 annual report of the US Renal Data System showed that in 
2010:
– The prevalence of ESRD was 593 086, with 65% of these prevalent 
cases being treated with hemodialysis.1
– 114 083 new cases of ESRD were reported.1
– 16843 kidney transplants were performed.1
• Data from a large cohort of insured patients found that in addition to established 
risk factors for ESRD, lower hemoglobin levels, higher serum uric acid levels, 
self-reported history of nocturia, and family history of kidney disease are 
independent risk factors for ESRD.2
• Data from a large insured population revealed that among adults with a GFR >60 
mL·min−1·1.73 m−2 and no evidence of proteinuria or hematuria at baseline, risks 
for ESRD increased dramatically with higher baseline BP level, and in this same 
patient population, BP-associated risks were greater in men than in women and 
in blacks than in whites.3
• Compared with white patients with similar levels of kidney function, black 
patients are much more likely to progress to ESRD and are on average 10 years 
younger when they reach ESRD.4,5
• Results from a large community-based population showed that higher BMI also 
independently increased the risk of ESRD. The higher risk of ESRD with 
overweight and obesity was consistent across age, sex, and race and in the 
presence or absence of DM, hypertension, or known baseline kidney disease.6
Abbreviations Used in Chapter 12
ACTION Acute Coronary Treatment and Intervention Outcomes Network
AF atrial fibrillation
AMI acute myocardial infarction
BMI body mass index
BP blood pressure
CHD coronary heart disease
CHF congestive heart failure
CKD chronic kidney disease
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CI confidence interval
CVD cardiovascular disease
DM diabetes mellitus
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
GFR glomerular filtration rate
HBP high blood pressure
HF heart failure
ICD-10 International Classification of Diseases, 10th Revision
JNC V fifth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure
MI myocardial infarction
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
PAD peripheral arterial disease
RR relative risk
Age, Sex, Race, and Ethnicity
• The median age of the population with ESRD in 2010 varied across different 
racial/ethnic groups: 57.9 years for Native Americans, 58.1 years for blacks, 59.7 
years for Asians, and 61.2 years for whites.1
• Treatment of ESRD is more common in men than in women.1
• Blacks, Hispanics, Asian Americans, and Native Americans have higher rates of 
ESRD than do whites. However, since 2000 new ESRD rates have increased 
6.1% for whites and 2.5 percent among Asians, while rates have decreased 7.0% 
for blacks.1
Chronic Kidney Disease
Prevalence
• CKD, defined as reduced GFR, excess urinary protein excretion, or both, is a 
serious health condition and a worldwide public health problem. The incidence 
and prevalence of CKD are increasing in the United States and are associated 
with poor outcomes and a high cost to the US healthcare system. Controversy 
exists about whether CKD itself independently causes incident CVD, but it is 
clear that people with CKD, as well as those with ESRD, represent a population 
at very high risk for CVD events. In fact, individuals with CKD are more likely 
to die of CVD than to transition to ESRD. The US Renal Data System estimates 
that by 2020, >700 000 Americans will have ESRD, with >500 000 requiring 
dialysis and >250 000 receiving a transplant.
• The National Kidney Foundation Kidney Disease Outcome Quality Initiative 
developed guidelines in 2002 that provided a standardized definition for CKD. 
Prevalence estimates may differ depending on assumptions used in obtaining 
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estimates, including which equation is used to estimate GFR and methods for 
measuring proteinuria.7
• The most recent US prevalence estimates of CKD come from NHANES 1988–
1994 and 1999–2004 (NCHS) in adults ≥20 years of age8:
– The prevalence of CKD in 1999–2004 (stages I to V)9 is 13.1%. This 
represents an increase from the 10.0% prevalence estimate from 
NHANES 1988–1994 (NCHS).
– The prevalence of stage I CKD (estimated GFR [eGFR] ≥90 
mL·min−1·1.73 m−2 with kidney damage, ie, presence of albuminuria) is 
1.8%.
– The prevalence of stage II CKD (eGFR 60–89 mL·min−1·1.73 m−2 with 
kidney damage) is 3.2%.
– The prevalence of stage III CKD (eGFR 30–59 mL·min−1·1.73 m−2) is 
7.7%.
– The prevalence of stages IV and V CKD (eGFR<29 mL·min−1·1.73 
m−2) is 0.4%.
• More than 26 million people (13%) in the United States have CKD, and most are 
undiagnosed.8 Another 20 million are at increased risk for CKD.10
Demographics
• According to current definitions, the prevalence of CKD is higher with older 
age1:
– 5.7% for those 20 to 39 years of age
– 9.1% for those 40 to 59 years of age
– 35.0% for those ≥60 years of age
• CKD prevalence was greater among those with DM (40.1%) and hypertension 
(23.2%) than among those without these chronic conditions.1
• The prevalence of CKD was slightly higher among Mexican Americans (18.7%) 
and non-Hispanic blacks (19.9%) than among non-Hispanic whites (16.1%). 
This disparity was most evident for those with stage I CKD; non-Hispanic whites 
had a CKD prevalence of 4.2% compared with prevalences among Mexican 
Americans and non-Hispanic blacks of 10.2% and 9.4%, respectively.11
Risk Factors
• Many traditional CVD risk factors are also risk factors for CKD, including older 
age, male sex, hypertension, DM, smoking, and family history of CVD.
• Recent evidence suggests that BMI is associated with worsening CKD.
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– In a cohort of 652 African American individuals with hypertensive 
nephrosclerosis, BMI was independently associated with urine total 
protein and albumin excretion.12
• In addition, both the degree of CKD (ie, eGFR) and urine albumin are strongly 
associated with the progression from CKD to ESRD. Furthermore, urine albumin 
level is associated with progression to CKD across all levels of reduced eGFR.13
• Other risk factors include systemic conditions such as autoimmune diseases, 
systemic infections, and drug exposure, as well as anatomically local conditions 
such as urinary tract infections, urinary stones, lower urinary tract obstruction, 
and neoplasia. Even after adjustment for these risk factors, excess CVD risk 
remains.14
ESRD/CKD and CVD
(See Table 12-3.)
• CVD is the leading cause of death among those with ESRD, although the 
specific cardiovascular cause of death may be more likely to be arrhythmic than 
an AMI, end-stage HF, or stroke. CVD mortality is 5 to 30 times higher in 
dialysis patients than in subjects from the general population of the same age, 
sex, and race.15,16
– Individuals with less severe forms of kidney disease are also at 
significantly increased CVD risk independent of typical CVD risk 
factors.17
– CKD is a risk factor for recurrent CVD events.18
– CKD is also a risk factor for AF.19
• Studies from a broad range of cohorts demonstrate an association between 
reduced eGFR and elevated risk of CVD, CVD outcomes, and all-cause 
death17,20–25 that appears to be largely independent of other known major CVD 
risk factors.
• Although clinical practice guidelines recommend management of mineral and 
bone disorders secondary to CKD, a recent meta-analysis suggests that there is 
no consistent association between calcium and parathyroid hormone and the risk 
of death or cardiovascular events.26
• Any degree of albuminuria, starting below the microalbuminuria cutpoint, has 
been shown to be an independent risk factor for cardiovascular events, CHF 
hospitalization, PAD, and all-cause death in a wide variety of cohorts.27–32
• A recent meta-analysis of 21 published studies of albuminuria involving 105 872 
participants (730 577 person-years) from 14 studies with urine albumin/
creatinine ratio measurements and 1.1 million participants (4.7 million person-
years) from 7 studies with urine dipstick measurements showed that excess 
albuminuria or proteinuria is independently associated with a higher risk of CVD 
and all-cause mortality.33
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– People with both albuminuria/proteinuria and reduced eGFR are at 
particularly high risk for CVD, CVD outcomes, and death.34
– The exact reasons why CKD and ESRD increase the risk of CVD have 
not been completely delineated but are clearly multifactorial and likely 
involve pathological alterations in multiple organ systems and 
pathways.
• One potential explanation for the higher CVD event rate in patients with CKD is 
the low uptake of standard therapies for patients presenting with MI. In a recent 
analysis from the Acute Coronary Treatment and Intervention Outcomes 
Network (ACTION) registry, patients presenting with CKD had a substantially 
higher mortality rate. In addition, patients with CKD were less likely to receive 
standard therapies for the treatment of MI.35
Cost: ESRD
• The total annual cost of treating ESRD in the United States was $26.8 billion in 
2008, which represents nearly 6% of the total Medicare budget.1
• The total annual cost associated with CKD has not been determined accurately to 
date.
Cystatin C: Kidney Function and CVD
Serum cystatin C, another marker of kidney function, has been proposed to be a more 
sensitive indicator of kidney function than serum creatinine and creatinine-based estimating 
formulas at higher levels of GFR. It is a low-molecular-weight protein produced at a 
constant rate by all nucleated cells and appears not to be affected significantly across age, 
sex, and levels of muscle mass. Cystatin C is excreted by the kidneys, filtered through the 
glomerulus, and nearly completely reabsorbed by proximal tubular cells.36 Several equations 
have been proposed using cystatin C alone and in combination with serum creatinine to 
estimate kidney function.37,38
All-Cause Mortality—Elevated levels of cystatin C have been shown to be associated with 
increased risk for all-cause mortality in studies from a broad range of cohorts.39–41
• In addition to GFR and urine albumin-to-creatinine ratio, cystatin C provides 
incremental information for the prediction of ESRD and mortality.
– In a recent analysis of 26 643 US adults, the addition of cystatin C to 
the combination of creatinine and albumin-to-creatinine ratio resulted in 
a significant improvement in the prediction of both all-cause mortality 
and the development of ESRD.42
Cardiovascular Disease
• Data from a large national cohort found higher values of cystatin C to be 
associated with prevalent stroke, angina, and MI,43 as well as higher BMI.44
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• Elevated cystatin C was an independent risk factor for HF,45,46 PAD events,47 
clinical atherosclerosis, and subclinical measures of CVD in older adults,48 as 
well as for cardiovascular events among those with CHD.39,49
• In several diverse cohorts, elevated cystatin C has been found to be associated 
with CVD-related mortality,41,50,51 including sudden cardiac death.52
• In a recent clinical trial of 9270 patients with CKD, the effect of lipid-lowering 
therapy with simvastatin/ezetimibe was associated with a lower risk for major 
atherosclerotic events compared with placebo.53
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13. Total Cardiovascular Diseases
ICD-9 390 to 459, 745 to 747; ICD-10 I00 to I99, Q20 to Q28; see Glossary (Chapter 25) 
for details and definitions.
See Tables 13-1 through 13-4 and Charts 13-1 through 13-21.
Abbreviations Used in Chapter 13
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CABG cardiac revascularization (coronary artery bypass graft)
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
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CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CLRD chronic lower respiratory disease
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
HBP high blood pressure
HCM hypertrophic cardiomyopathy
HD heart disease
HDL high-density lipoprotein
HF heart failure
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHHCS National Home and Hospice Care Survey
NHLBI National Heart, Lung, and Blood Institute
NNHS National Nursing Home Survey
PA physical activity
PCI percutaneous coronary intervention
RR relative risk
SBP systolic blood pressure
UA unstable angina
Prevalence
(See Table 13-1 and Chart 13-1.)
An estimated 83.6 million American adults (>1 in 3) have 1 or more types of CVD. Of these, 
42.2 million are estimated to be ≥60 years of age. Total CVD includes diseases listed in the 
bullet points below, with the exception of congenital CVD. Because of overlap across 
conditions, it is not possible to add these conditions to arrive at a total of unique individuals.
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• HBP—77.9 million (defined as systolic pressure ≥140 mm Hg and/or diastolic 
pressure ≥90 mm Hg, use of antihypertensive medication, or being told at least 
twice by a physician or other health professional that one has HBP).
• CHD—15.4 million
– MI (heart attack)—7.6 million
– AP (chest pain)—7.8 million
– HF—5.1 million
– Stroke (all types)—6.8 million
– Congenital cardiovascular defects— 650 000 to 1.3 million
• The following age-adjusted prevalence estimates from the NHIS, NCHS are for 
diagnosed conditions for people ≥18 years of age in 20111:
– Among whites only, 11.1% have HD, 6.3% have CHD, 23.3% have 
hypertension, and 2.3% have had a stroke.
– Among blacks or African Americans, 10.7% have HD, 6.9% have 
CHD, 33.4% have hypertension, and 4.5% have had a stroke.
– Among Hispanics or Latinos, 8.6% have HD, 5.9% have CHD, 22.2% 
have hypertension, and 2.8% have had a stroke.
– Among Asians, 7.4% have HD, 4.3% have CHD, 18.7% have 
hypertension, and 2.7% have had a stroke.
– Among American Indians or Alaska Natives, 12.7% have HD, 7.2% 
have CHD, 25.8% have hypertension, and 4.6% have had a stroke.
– Among Native Hawaiians or other Pacific Islanders, 21.8% have 
hypertension. Statistics for the other conditions for this group are not 
shown because of unreliability.
• Asian Indian adults (9%) are ≈2-fold more likely than Korean adults (4%) to 
have ever been told they have HD, based on data for 2004 to 2006.2
• By 2030, 40.8% of the US population is projected to have some form of CVD 
(unpublished AHA computation, based on methodology described in 
Heidenreich et al3).
Incidence
(See Chart 13-2.)
• On the basis of the NHLBI’s FHS original and offspring cohort data from 1980 
to 20034
– The average annual rates of first cardiovascular events rise from 3 per 
1000 men at 35 to 44 years of age to 74 per 1000 men at 85 to 94 years 
of age. For women, comparable rates occur 10 years later in life. The 
gap narrows with advancing age.
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– Before 75 years of age, a higher proportion of CVD events attributable 
to CHD occur in men than in women, and a higher proportion of events 
attributable to stroke occur in women than in men.
• Among American Indian men 45 to 74 years of age, the incidence of CVD 
ranges from 15 to 28 per 1000 population. Among women, it ranges from 9 to 15 
per 1000.5
• Data from the FHS indicate that the subsequent lifetime risk for all CVD in 
recipients starting free of known disease is almost 2 in 3 for men and >1 in 2 for 
women at 45 years of age (Table 13-4).5a
• Analysis of FHS data among participants free of CVD at 50 years of age showed 
the lifetime risk for developing CVD was 51.7% for men and 39.2% for women. 
Median overall survival was 30 years for men and 36 years for women.6
Mortality
(See Tables 13-1 through 13-3 and Charts 13-3 through 13-18.)
ICD-10 I00 to I99, Q20 to Q28 for CVD (CVD mortality includes congenital cardiovascular 
defects); C00 to C97 for cancer; C33 to C34 for lung cancer; C50 for breast cancer; J40 to 
J47 for chronic lower respiratory disease (CLRD); G30 for Alzheimer disease; E10 to E14 
for DM; and V01 to X59, Y85 to Y86 for accidents.
• Mortality data show that CVD (I00–I99, Q20–Q28) as the listed underlying 
cause of death (including congenital cardiovascular defects) accounted for 32.3% 
(787 931) of all 2 437 163 deaths in 2009, or ≈1 of every 3 deaths in the United 
States. CVD any-mentions (1 330 137 deaths in 2009) constituted 54.6% of all 
deaths that year (NHLBI; NCHS public use data files).7
• In every year since 1900 except 1918, CVD accounted for more deaths than any 
other major cause of death in the United States.8,9
• On average, >2150 Americans die of CVD each day, an average of 1 death every 
40 seconds. CVD currently claims more lives each year than cancer and CLRD 
combined.7
• The 2009 death rate attributable to CVD (I00–I99) was 236.1 (excluding 
congenital cardiovascular defects) (NCHS).7 The rates were 281.4 for white 
males, 387.0 for black males, 190.4 for white females, and 267.9 for black 
females. From 1999 to 2009, death rates attributable to CVD (ICD-10 I00–I99) 
declined 32.7%. In the same 10-year period, the actual number of CVD deaths 
per year declined by 17.8% (AHA computation).7
• Among other causes of death in 2009, cancer caused 567 628 deaths; CLRD, 137 
353; accidents, 118 021; and Alzheimer disease, 79 003.7
• The 2009 CVD (I00–I99) death rates were 287.2 for males and 196.1 for 
females. There were 40 678 deaths attributable to breast cancer in females in 
2009; lung cancer claimed 70 389 females. Death rates for females were 22.3 for 
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breast cancer and 38.5 for lung cancer. One in 30 deaths of females was 
attributable to breast cancer, whereas 1 in 6.9 was attributable to CHD. For 
comparison, 1 in 4.5 females died of cancer, whereas 1 in 3.0 died of CVD (I0–
I99, Q20– Q28). On the basis of 2009 mortality data, CVD caused ≈1 death per 
minute among females, or 401 495 deaths. That represents approximately the 
same number of female lives that were claimed by cancer, CLRD, and Alzheimer 
disease combined (unpublished AHA tabulation).7
• Approximately 150 000 Americans died of CVD (I00–I99) in 2009 who were 
<65 years of age, and 34% of deaths attributed to CVD occurred before the age 
of 75 years,7 which is well below the average life expectancy of 78.5 years.8
• According to the NCHS, if all forms of major CVD were eliminated, life 
expectancy could rise by almost 7 years. If all forms of cancer were eliminated, 
the estimated gain could be 3 years. According to the same study, the probability 
at birth of eventually dying of major CVD (I00–I78) is 47%, and the chance of 
dying of cancer is 22%. Additional probabilities are 3% for accidents, 2% for 
DM (unrelated to CVD), and 0.7% for HIV.10
• In 2009, the leading causes of death in women ≥65 years of age were diseases of 
the heart (No. 1), cancer (No. 2), stroke (No. 3), and CLRD (No. 4). In older 
men, they were diseases of the heart (No. 1), cancer (No. 2), CLRD (No. 3), and 
stroke (No. 4).7
• A study of the decrease in US deaths attributable to CHD from 1980 to 2000 
suggests that ≈47% of the decrease was attributable to increased use of evidence-
based medical therapies and 44% to changes in risk factors in the population 
attributable to lifestyle and environmental changes.9
• Analysis of data from NCHS was used to determine the number of disease-
specific deaths attributable to all non-optimal levels of each risk factor exposure, 
by age and sex. In 2005, tobacco smoking and HBP were estimated to be 
responsible for 467 000 deaths, accounting for ≈1 in 5 or 6 deaths among US 
adults. Overweight/obesity and physical inactivity were each estimated to be 
responsible for nearly 1 in 10 deaths. High dietary salt, low dietary omega-3 fatty 
acids, and high dietary trans fatty acids were the dietary risks with the largest 
estimated excess mortality effects.10
Aftermath
• Among an estimated 45 million people with functional disabilities in the United 
States, HD, stroke, and hypertension are among the 15 leading conditions that 
caused those disabilities. Disabilities were defined as difficulty with activities of 
daily living or instrumental activities of daily living, specific functional 
limitations (except vision, hearing, or speech), and limitation in ability to do 
housework or work at a job or business.11
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Awareness of Warning Signs and Risk Factors for CVD
• Surveys conducted by the AHA in 1997, 2000, 2003, 2006, and 2009 to evaluate 
trends in women’s awareness, knowledge, and perceptions related to CVD found 
that in 2009, awareness of HD as the leading cause of death among women was 
54%, significantly higher than in 1997.12 Awareness was 66% lower among 
black and Hispanic women than among white women,13 and the racial/ethnic 
difference has not changed appreciably over time. Awareness of HD as the 
leading cause of death among women has approximately doubled among white 
and Hispanic women and tripled among black women between the first survey in 
1997 and the current 2009 survey. However, after adjustment for age and 
education level, African American, Hispanic, and Asian women were 
significantly less likely to be aware that HD/heart attack is the leading cause of 
death than white women.12 Awareness of heart attack signs was low for all racial/
ethnic and age groups surveyed.13
• A total of 875 students in 4 Michigan high schools were given a survey to obtain 
data on the perception of risk factors and other knowledge-based assessment 
questions about CVD. Accidents were rated as the greatest perceived lifetime 
health risk (39%). Nearly 17% selected CVD as the greatest lifetime risk, which 
made it the third most popular choice after accidents and cancer. When asked to 
identify the greatest cause of death for each sex, 42% correctly recognized CVD 
for men, and 14% correctly recognized CVD for women; 40% incorrectly chose 
abuse/use behavior with a substance other than cigarettes as the most important 
CVD risk behavior.14
Awareness of Cardiopulmonary Resuscitation
• Seventy-nine percent of the lay public are confident that they know what actions 
to take in a medical emergency; 98% recognize an automated external 
defibrillator as something that administers an electric shock to restore a normal 
heart beat among victims of sudden cardiac arrest; and 60% are familiar with 
cardiopulmonary resuscitation (Harris Interactive survey conducted on behalf of 
the AHA among 1132 US residents >18 years of age, January 8, 2008, through 
January 21, 2008).
Disparities in CVD Risk Factors
(See Chart 13-19.)
• Data from the 2003 CDC BRFSS survey of adults ≥18 years of age showed the 
prevalence of respondents who reported having ≥2 risk factors for HD and stroke 
was successively higher at higher age groups. The prevalence of having ≥2 risk 
factors was highest among blacks (48.7%) and American Indian/Alaska Natives 
(46.7%) and lowest among Asians (25.9%); prevalence was similar in women 
(36.4%) and men (37.8%). The prevalence of multiple risk factors ranged from 
25.9% among college graduates to 52.5% among those with less than a high 
school diploma (or its equivalent). People reporting household income of ≥$50 
000 had the lowest prevalence (28.8%), and those reporting household income of 
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<$10 000 had the highest prevalence (52.5%). Adults who reported being unable 
to work had the highest prevalence (69.3%) of ≥2 risk factors, followed by 
retired people (45.1%), unemployed adults (43.4%), homemakers (34.3%), and 
employed people (34.0%). Prevalence of ≥2 risk factors varied by state/ territory 
and ranged from 27.0% (Hawaii) to 46.2% (Kentucky). Twelve states and 2 
territories had a multiple risk factor prevalence of ≥40%: Alabama, Arkansas, 
Georgia, Indiana, Kentucky, Louisiana, Mississippi, North Carolina, Ohio, 
Oklahoma, Tennessee, West Virginia, Guam, and Puerto Rico.15
• Analysis of several data sets by the CDC showed that in adults ≥18 years of age, 
disparities were common in all risk factors examined. In men, the highest 
prevalence of obesity (29.7%) was found in Mexican Americans who had 
completed a high school education. Black women with or without a high school 
education had a high prevalence of obesity (48.4%). Hypertension prevalence 
was high among blacks (41.2%) regardless of sex or educational status. 
Hypercholesterolemia was high among white and Mexican American men and 
white women regardless of educational status. CHD and stroke were inversely 
related to education, income, and poverty status. Hospitalization for total HD and 
AMI was greater among men, but hospitalization for CHF and stroke was greater 
among women. Among Medicare enrollees, CHF hospitalization was higher 
among blacks, Hispanics, and American Indian/Alaska Natives than among 
whites, and stroke hospitalization was highest among blacks. Hospitalizations for 
CHF and stroke were highest in the southeastern United States. Life expectancy 
remains higher in women than in men and in whites than in blacks by ≈5 years. 
CVD mortality at all ages tended to be highest in blacks.16
• Analysis of >14 000 middle-aged subjects between 1987 and 2002 in the ARIC 
study sponsored by the NHLBI showed that >90% of CVD events in black 
subjects, compared with ≈70% in white subjects, appeared to be explained by 
elevated or borderline risk factors. Furthermore, the prevalence of participants 
with elevated risk factors was higher in black subjects; after accounting for 
education and known CVD risk factors, the incidence of CVD was identical in 
black and white subjects. Thus, the observed higher CVD incidence rate in black 
subjects appears to be largely attributable to a greater prevalence of elevated risk 
factors. These results suggest that the primary prevention of elevated risk factors 
might substantially impact the future incidence of CVD, and these beneficial 
effects would likely be applicable not only for white but also for black 
subjects.17
• Data from the MEPS 2004 Full-Year Data File showed that nearly 26 million US 
adults ≥18 years of age were told by a doctor that they had HD, stroke, or any 
other heart-related disease18:
– 38.6% maintained a healthy weight. Among those told that they had 
HD, 33.9% had a healthy weight compared with 39.3% who had never 
been told they had HD.
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– 78.8% did not currently smoke. Among those ever told that they had 
indicators of HD, 18.3% continued to smoke.
– More than 93% engaged in at least 1 recommended behavior for 
prevention of HD: 75.5% engaged in 1 or 2; 18% engaged in all 3; and 
6.5% did not engage in any of the recommended behaviors.
– Age-based variations:
♦ Moderate to vigorous PA ≥3 times per week varied according 
to age. Younger people (18–44 years of age) were more likely 
(59.9%) than those who were older (45–64 and ≥65 years of 
age, 55.3% and 48.5%, respectively) to engage in regular PA.
♦ A greater percentage of those 18 to 44 years of age had a 
healthy weight (43.7%) than did those 45 to 64 years of age 
and ≥65 years of age (31.4% and 37.3%, respectively).
♦ People ≥65 years of age were more likely to be current 
nonsmokers (89.7%) than were people 18 to 44 years of age 
and 45 to 64 years of age (76.1% and 77.7%, respectively).
– Race/ethnicity-based variations:
♦ Non-Hispanic whites were more likely than Hispanics or non-
Hispanic blacks to engage in moderate to vigorous PA (58.5% 
versus 51.4% and 52.5%, respectively).
♦ Non-Hispanic whites were more likely to have maintained a 
healthy weight than were Hispanics or non-Hispanic blacks 
(39.8% versus 32.1% and 29.7%, respectively).
♦ Hispanics were more likely to be nonsmokers (84.2%) than 
were non-Hispanic whites and non-Hispanic blacks (77.8% 
and 76.3%, respectively).
– Sex-based variations:
♦ Men were more likely to have engaged in moderate to 
vigorous PA ≥3 times per week than women (60.3% versus 
53.1%, respectively).
♦ Women were more likely than men to have maintained a 
healthy weight (45.1% versus 31.7%, respectively).
♦ 81.7% of women did not currently smoke, compared with 
75.7% of men.
– Variations based on education level:
♦ A greater percentage of adults with at least some college 
education engaged in moderate to vigorous PA ≥3 times per 
week (60.8%) than did those with a high school education or 
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less than a high school education (55.3% and 48.3%, 
respectively).
♦ A greater percentage of adults with at least some college 
education had a healthy weight (41.2%) than did those with a 
high school or less than high school education (36.2% and 
36.1%, respectively).
♦ There was a greater percentage of nonsmokers among those 
with a college education (85.5%) than among those with a 
high school or less than high school education (73.8% and 
69.9%, respectively).
• A study of nearly 1500 participants in the MESA study found that Hispanics 
with hypertension, hypercholesterolemia, and/or DM who speak Spanish at home 
and/or have spent less than half a year in the United States have higher SBP, LDL 
cholesterol, and fasting blood glucose, respectively, than Hispanics who speak 
English and who have lived a longer period of time in the United States.19
Family History of CVD
• A family history of CVD increases risk of CVD, with the largest increase in risk 
if the family member’s CVD was premature.20
• There is consistent evidence from multiple large-scale prospective epidemiology 
studies for a strong and significant association of a reported family history of 
premature parental CHD with incident MI or CHD in offspring. In the FHS, the 
occurrence of a validated premature atherosclerotic CVD event in either a 
parent21 or a sibling22 was associated with an ≈2-fold elevated risk for CVD, 
independent of other traditional risk factors.
• Addition of family history of premature CVD to a model that contained 
traditional risk factors provided modestly improved prognostic value in the 
FHS.21 Family history of premature MI is also an independent risk factor in 
other multivariable risk models that contain traditional risk factors in large 
cohorts of women23 and men.24
• Parental history of premature CHD is associated with increased burden of 
subclinical atherosclerosis in the coronary arteries and the abdominal aorta.25,26
• In the FHS, a parental history of validated HF was associated with a 1.7-fold 
higher risk of HF in offspring, after multivariable adjustment.27
• A family history of early-onset sudden cardiac death in a first-degree relative is 
associated with a >2-fold higher risk for sudden cardiac death in offspring on the 
basis of available case-control studies.28
• The 2004 HealthStyles survey of 4345 people in the United States indicated that 
most respondents believe that knowing their family history is important for their 
own health, but few are aware of the specific health information from relatives 
necessary to develop a family history.29
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• An accurate and complete family history may identify rare mendelian conditions 
such as hypertrophic cardiomyopathy (HCM), long-QT syndrome, or familial 
hypercholesterolemia. However, in the majority of people with a family history 
of a CVD event, a known rare mendelian condition is not identified.
• Studies are under way to determine genetic variants that may help identify 
individuals at increased risk of CVD.
Outcomes Associated With Healthy Lifestyle and Low Risk Factor Levels
Much of the literature on CVD has focused on factors associated with increasing risk for 
CVD and on factors associated with poorer outcomes in the presence of CVD; however, in 
recent years, a number of studies have defined the potential beneficial effects of healthy 
lifestyle factors and lower CVD risk factor burden on CVD outcomes and longevity. These 
studies suggest that prevention of risk factor development at younger ages may be the key to 
“successful aging,” and they highlight the need for evaluation of the potential benefits of 
intensive prevention efforts at younger and middle ages once risk factors develop to increase 
the likelihood of healthy longevity.
• Data from the Cardiovascular Lifetime Risk Pooling Project, which involved 18 
cohort studies and combined data on 257 384 black men and women and white 
men and women, indicate that at 45 years of age, participants with an optimal 
risk factor profile had a substantially lower lifetime risk of CVD events than 
those with 1 major risk factor (1.4% versus 39.6% among men, 4.1% versus 
20.2% among women). The presence of ≥2 major risk factors further increased 
life-time risk to 49.5% in men and 30.7% in women.30
• A recent study examined the association between low lifetime predicted risk for 
CVD (ie, having all optimal or near-optimal risk factor levels) and burden of 
subclinical atherosclerosis in younger adults in the CARDIA and MESA studies 
of the NHLBI. Among participants <50 years of age, nearly half had low and 
half had high predicted lifetime risks for CVD. Those with low predicted lifetime 
risk had lower prevalence and less severe amounts of coronary calcification and 
less carotid intima-media thickening, even at these younger ages, than those with 
high predicted lifetime risk. During follow-up, those with low predicted lifetime 
risk also had less progression of coronary calcium.31
• Among >7900 men and women from the FHS followed up for 111 000 person-
years, median survival was highly associated with risk factor presence and 
burden at 50 years of age. Men and women with optimal risk factors had a 
median life expectancy ≥10 years longer than those with ≥2 major risk factors at 
age 50 years.6
• In another study, FHS investigators followed up 2531 men and women who were 
examined between the ages of 40 and 50 years and observed their overall rates of 
survival and survival free of CVD to 85 years of age and beyond. Low levels of 
the major risk factors in middle age were associated with overall survival and 
morbidity-free survival to ≥85 years of age.32
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– Overall, 35.7% survived to the age of 85 years, and 22% survived to 
that age free of major morbidities.
– Factors associated with survival to the age of 85 years included female 
sex, lower SBP, lower total cholesterol, better glucose tolerance, 
absence of current smoking, and higher level of education attained. 
Factors associated with survival to the age of 85 years free of MI, UA, 
HF, stroke, dementia, and cancer were nearly identical.
– When adverse levels of 4 of these factors were present in middle age, 
<5% of men and ≈15% of women survived to 85 years of age.
• Data from the Chicago Heart Association Detection Project (1967–1973, with an 
average follow-up of 31 years) showed the following:
– In younger women (18–39 years of age) with favorable levels for all 5 
major risk factors (BP, serum cholesterol, BMI, DM, and smoking), 
future incidence of CHD and CVD is rare, and long-term and all-cause 
mortality are much lower than for those who have unfavorable or 
elevated risk factor levels at young ages. Similar findings applied to 
men in this study.33
– Participants (18–64 years of age at baseline) without a history of MI 
were investigated to determine whether traditional CVD risk factors 
were similarly associated with CVD mortality in black and white men 
and women. In general, the magnitude and direction of associations 
were similar by race. Most traditional risk factors demonstrated similar 
associations with mortality in black and white adults of the same sex. 
Small differences were primarily in the strength and not the direction of 
the association.34
– Remaining lifetime risks for CVD death were noted to increase 
substantially and in a graded fashion according to the number of risk 
factors present in middle age (40–59 years of age). However, remaining 
lifetime risks for non-CVD death also increased dramatically with 
increasing CVD risk factor burden. These data help to explain the 
markedly greater longevity experienced by those who reach middle age 
free of major CVD risk factors.35
– Presence of a greater number of risk factors in middle age is associated 
with lower scores at older ages on assessment of social functioning, 
mental health, walking, and health perception in women, with similar 
findings in men.36
– Risk factor burden in middle age is associated with better quality of life 
at follow-up in older age (≈25 years later) and lower average annual 
Medicare costs at older ages.36,37 Similarly, the existence of a greater 
number of risk factors in middle age is associated with higher average 
annual CVD-related and total Medicare costs (once Medicare eligibility 
is attained).37
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• A study of 84 129 women enrolled in the Nurses’ Health Study identified 5 
healthy lifestyle factors, including absence of current smoking, drinking half a 
glass or more of wine per day (or equivalent alcohol consumption), half an hour 
or more per day of moderate or vigorous PA, BMI <25 kg/m2, and dietary score 
in the top 40% (which included diets with lower amounts of trans fats, lower 
glycemic load, higher cereal fiber, higher marine omega-3 fatty acids, higher 
folate, and higher polyunsaturated to saturated fat ratio). When 3 of the 5 healthy 
lifestyle factors were present, the RR for CHD over a 14-year period was 57% 
lower; when 4 were present, RR was 66% lower; and when all 5 factors were 
present, RR was 83% lower.38 However, data from NHANES 1999–2002 
showed that only approximately one third of adults complied with ≥6 of the 
recommended heart-healthy behaviors. Dietary recommendations, in general, and 
daily fruit intake recommendations, in particular, were least likely to be 
followed.39
• Among individuals 70 to 90 years of age, adherence to a Mediterranean-style 
diet and greater PA are associated with 65% to 73% relatively lower rates of all-
cause mortality, as well as lower mortality rates attributable to CHD, CVD, and 
cancer.40
• Seventeen-year mortality data from the NHANES II Mortality Follow-Up Study 
indicated that the RR for fatal CHD was 51% lower for men and 71% lower for 
women with none of 3 major risk factors (hypertension, current smoking, and 
elevated total cholesterol [≥240 mg/dL]) than for those with ≥1 risk factor. Had 
all 3 major risk factors not occurred, it is hypothesized that 64% of all CHD 
deaths among women and 45% of CHD deaths in men could theoretically have 
been avoided.41
Hospital Discharges, Ambulatory Care Visits, Home Healthcare Patients, Nursing Home 
Residents, and Hospice Care Discharges
(See Table 13-1 and Charts 13-20 through 13-21.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with CVD as the first-listed diagnosis decreased from 6 294 000 to 5 802 000 
(NHDS, NHLBI tabulation). In 2010, CVD ranked highest among all disease 
categories in hospital discharges (NHDS, NHLBI tabulation).
• In 2010, there were 94 871 000 physician office visits with a primary diagnosis 
of CVD (NCHS, NAMCS, NHLBI tabulation). In 2009, there were 4 761 000 
ED visits and 7 261 000 hospital outpatient department visits with a primary 
diagnosis of CVD (NHAMCS, NHLBI tabulation).
• In 2009, ≈1 of every 6 hospital stays, or 6 million, resulted from CVD (Agency 
for Healthcare Research and Quality, Nationwide Inpatient Sample). The total 
inpatient hospital cost for CVD was $71.2 billion, approximately one fourth of 
the total cost of inpatient hospital care in the United States. The average cost per 
hospitalization was ≈41% higher than the average cost for all stays. Hospital 
admissions that originated in the ED accounted for 60.7% of all hospital stays for 
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CVD. This was 41% higher than the rate of 43.1% for all types of hospital stays; 
3.3% of patients admitted to the hospital for CVD died in the hospital, which was 
significantly higher than the average in-hospital death rate of 2.1% for all 
hospitalized patients.42
• In 2004, CAD was estimated to be responsible for 1.2 million hospital stays and 
was the most expensive condition treated. This condition resulted in >$44 billion 
in expenses. More than half of the hospital stays for CAD were among patients 
who also received PCI or coronary artery bypass graft (CABG) during their stay. 
AMI resulted in $31 billion of inpatient hospital charges for 695 000 hospital 
stays. The 1.1 million hospitalizations for CHF amounted to nearly $29 billion in 
hospital charges.43
• In 2003, ≈48.3% of inpatient hospital stays for CVD were for women, who 
accounted for 42.8% of the national cost ($187 billion) associated with these 
conditions. Although only 40% of hospital stays for AMI and CAD were for 
women, more than half of all stays for nonspecific chest pain, CHF, and stroke 
were for women. There was no difference between men and women in 
hospitalizations for cardiac dysrhythmias.44
• Circulatory disorders were the most frequent reason for admission to the hospital 
through the ED, accounting for 26.3% of all admissions through the ED. After 
pneumonia, the most common heart-related conditions (in descending order) 
were CHF, chest pain, hardening of the arteries, and heart attack, which together 
accounted for >15% of all admissions through the ED. Stroke and irregular 
heartbeat ranked seventh and eighth, respectively.45
• Among the 1.5 million nursing home residents each day in 2004, CVD was the 
leading primary diagnosis; approximately one fourth of nursing home residents 
had a primary diagnosis of CVD at admission (23.7% or 353 100 residents) or at 
the time of interview (25% or 373 000 residents) (NCHS, NNHS).46
• Among the 1.5 million home healthcare patients each day in 2007, CVD was the 
leading primary diagnosis; almost one fifth of home healthcare patients had a 
primary diagnosis of CVD at admission (18.3% or 267 300 residents) or at the 
time of interview (18.9% or 275 700 residents) (NCHS, NHHCS). The majority 
(62.9% or 918 900 patients) of home healthcare patients each day in 2007 had 
diagnosis of some type of CVD at the time of interview.47
• Among the 1.0 million patients discharged from hospice in 2007, CVD was the 
primary diagnosis for 15.8% (or 165 100 discharges) at admission and 15.9% (or 
165 700 discharges) at discharge. Half (50% or 523 000) of all hospice 
discharges had a diagnosis of some type of CVD at the time of discharge.47
Operations and Procedures
• In 2010, an estimated 7 588 000 inpatient cardiovascular operations and 
procedures were performed in the United States; 4.4 million were performed on 
males, and 3.2 million were performed on females (NHDS, NHLBI tabulation).
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Cost
• The estimated direct and indirect cost of CVD for 2009 is $312.6 billion (MEPS, 
NHLBI tabulation).
• By 2030, real (2010$) total direct medical costs of CVD are projected to increase 
to ≈$1.48 trillion (AHA computation, based on methodology described by 
Heidenreich et al3).
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14. Stroke (Cerebrovascular Disease)
ICD-9 430 to 438; ICD-10 I60 to I69. See Tables 14-1 and 14-2 and Charts 14-1 through 
14-13.
Stroke Prevalence
(See Table 14-1 and Chart 14-1.)
• An estimated 6.8 million Americans ≥20 years of age have had a stroke 
(extrapolated to 2010 using NHANES 2007–2010 data). Overall stroke 
prevalence during this period is an estimated 2.8%.
• According to data from the 2010 BRFSS (CDC), 2.7% of men and 2.6% of 
women ≥18 years of age had a history of stroke; 2.4% of non-Hispanic whites, 
3.9% of non-Hispanic blacks, 1.5% of Asian/Pacific Islanders, 2.5% of Hispanics 
(of any race), 5.9% of American Indian/Alaska Natives, and 4.1% of other races 
or multiracial people had a history of stroke.1
• Over the time period 2006–2010, data from BRFSS show that the overall self-
reported stroke prevalence did not change.1
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• Older adults, blacks, people with lower levels of education, and people living in 
the southeastern United States had higher stroke prevalence.1
• The prevalence of silent cerebral infarction is estimated to range from 6% to 
28%, with higher prevalence with increasing age.2–4 The prevalence estimates 
also vary depending on the population studied (eg, ethnicity, sex, risk factor 
profile), definition of silent cerebral infarction, and imaging technique. It has 
been estimated that 13 million people had prevalent silent stroke in the 1998 US 
population.5,6
• The prevalence of stroke-related symptoms was found to be relatively high in a 
general population free of a prior diagnosis of stroke or transient ischemic attack 
(TIA). On the basis of data from 18 462 participants enrolled in a national cohort 
study, 17.8% of the population >45 years of age reported at least 1 symptom. 
Stroke symptoms were more likely among blacks than whites, among those with 
lower income and lower educational attainment, and among those with fair to 
poor perceived health status. Symptoms also were more likely in participants 
with higher Framingham stroke risk score (REGARDS, NINDS).7
• Projections show that by 2030, an additional 4 million people will have had a 
stroke, a 21.9% increase in prevalence from 2013 (AHA computation based on 
methodology described in Heidenreich et al8).
Abbreviations Used in Chapter 14
AF atrial fibrillation
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities study
BASIC Brain Attack Surveillance in Corpus Christi
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CAS carotid artery stenting
CDC Centers for Disease Control and Prevention
CEA carotid endarterectomy
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CLRD chronic lower respiratory disease
CREST Carotid Revascularization Endarterectomy versus Stenting Trial
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
eGFR estimated glomerular filtration rate
EMS emergency medical services
FHS Framingham Heart Study
FRS Framingham Risk Score
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
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GFR glomerular filtration rate
HD heart disease
HDL high-density lipoprotein
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
ICH intracerebral hemorrhage
MCBE Medicare beneficiaries
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institutes of Neurological Disorders and Stroke
NOMAS Northern Manhattan Study
OR odds ratio
PA physical activity
PAR population attributable risk
REGARDS Reasons for Geographic and Racial Differences in Stroke study
RR relative risk
SAH subarachnoid hemorrhage
STOP Stroke Prevention Trial in Sickle Cell Anemia
SWiTCH Stroke With Transfusions Changing to Hydroxyurea
TIA transient ischemic attack
Stroke Incidence
(See Table 14-1 and Charts 14-2 through 14-5.)
• Each year, ≈795 000 people experience a new or recurrent stroke. Approximately 
610 000 of these are first attacks, and 185 000 are recurrent attacks (GCNKSS, 
NINDS, and NHLBI; GCNKSS and NINDS data for 1999 provided July 9, 2008; 
estimates compiled by NHLBI).
• Of all strokes, 87% are ischemic and 10% are intracerebral hemorrhagic strokes, 
whereas 3% are subarachnoid hemorrhage strokes (GCNKSS, NINDS, 1999).
• On average, every 40 seconds, someone in the United States has a stroke (AHA 
computation based on the latest available data).
• Each year, ≈55 000 more women than men have a stroke (GCNKSS, NINDS).9
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• Women have a higher lifetime risk of stroke than men. In the FHS, lifetime risk 
of stroke among those 55 to75 years of age was 1 in 5 for women (20% to 21%) 
and ≈1 in 6 for men (14% to 17%).10
• Women have lower age-adjusted stroke incidence than men; however, sex 
differences in stroke risk may be modified by age.11 Data from FHS demonstrate 
that compared with white men, white women 45 to 84 years of age have lower 
stroke risk than men, but this association is reversed in older ages such that 
women >85 years of age have elevated risk compared with men.12 Similarly, a 
population-based study in Sweden found stroke incidence to be lower for women 
than for men at ages 55 to 64 years, but at 75 to 85 years of age, this association 
reversed, and women had a higher incidence than men.13 Other studies report an 
excess risk of stroke in men compared with women that persists throughout the 
life course or that diminishes but does not reverse with age.14–18
• In the national REGARDS cohort, in 27 744 participants followed up for 4.4 
years (2003–2010), the overall age- and sex-adjusted black/white incidence rate 
ratio was 1.51, but for ages 45 to 54 years, it was 4.02, whereas for those ≥85 
years of age, it was 0.86.19 Similar trends for decreasing black/white incidence 
rate ratio with age were seen in the GCNKSS.20
• Analysis of data from the FHS suggests that stroke incidence is declining over 
time in this largely white cohort. Data from 1950 to 1977, 1978 to 1989, and 
1990 to 2004 showed that the age-adjusted incidence of first stroke per 1000 
person-years in each of the 3 periods was 7.6, 6.2, and 5.3 in men and 6.2, 5.8, 
and 5.1 in women, respectively. Lifetime risk for incident stroke at 65 years of 
age decreased significantly in the latest data period compared with the first, from 
19.5% to 14.5% in men and from 18.0% to 16.1% in women.21
• In a similar fashion, data from the most recent GCNKSS show that compared 
with the 1990s, when incidence rates of stroke were stable, stroke incidence in 
2005 was decreased for whites. A similar decline was not seen in blacks. These 
changes for whites were driven by a decline in ischemic strokes. There were no 
changes in incidence of ischemic stroke for blacks or of hemorrhagic strokes in 
blacks or whites.9
• The BASIC (Brain Attack Surveillance in Corpus Christi) project (NINDS) 
demonstrated an increased incidence of stroke among Mexican Americans 
compared with non-Hispanic whites in a community in southeast Texas. The 
crude 3-year cumulative incidence (2000–2002) was 16.8 per 1000 in Mexican 
Americans and 13.6 per 1000 in non-Hispanic whites. Specifically, Mexican 
Americans had a higher cumulative incidence for ischemic stroke at younger 
ages (45–59 years of age: RR, 2.04; 95% CI, 1.55–2.69; 60–74 years of age: RR, 
1.58; 95% CI, 1.31–1.91) but not at older ages (≥75 years of age: RR, 1.12; 95% 
CI, 0.94– 1.32). Mexican Americans also had a higher incidence of intracerebral 
hemorrhage and subarachnoid hemorrhage than non-Hispanic whites, adjusted 
for age.22
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• The age-adjusted incidence of first ischemic stroke per 1000 was 0.88 in whites, 
1.91 in blacks, and 1.49 in Hispanics according to data from the Northern 
Manhattan Study (NOMAS; NINDS) for 1993 to 1997. Among blacks, 
compared with whites, the relative rate of intracranial atherosclerotic stroke was 
5.85; of extracranial atherosclerotic stroke, 3.18; of lacunar stroke, 3.09; and of 
cardioembolic stroke, 1.58. Among Hispanics (primarily Cuban and Puerto 
Rican), compared with whites, the relative rate of intracranial atherosclerotic 
stroke was 5.00; of extracranial atherosclerotic stroke, 1.71; of lacunar stroke, 
2.32; and of cardioembolic stroke, 1.42.23
• Among 4507 American Indian participants without a prior stroke in the Strong 
Heart Study in 1989 to 1992, the age-and sex-adjusted incidence of stroke 
through 2004was 6.79 per 100 person-years, with 86% of incident strokes being 
ischemic.24
• In the GCNKSS, the annual incidence of anticoagulant-associated intracerebral 
hemorrhage per 100 000 people increased from 0.8 (95% CI, 0.3–1.3) in 1988 to 
1.9 (95% CI, 1.1–2.7) in 1993/1994 and 4.4 (95% CI, 3.2–5.5) in 1999 (P<0.001 
for trend). Among people ≥80 years of age, the rate of anticoagulant-associated 
intracerebral hemorrhage increased from 2.5 (95% CI, 0–7.4) in 1988 to 45.9 
(95% CI, 25.6–66.2) in 1999 (P<0.001 for trend).25
TIA: Prevalence, Incidence, and Prognosis
• In a nationwide survey of US adults, the estimated prevalence of self-reported 
physician-diagnosed TIA was 2.3%, which translates into ≈5 million people. The 
true prevalence of TIA is greater, because many patients who experience 
neurological symptoms consistent with a TIA fail to report it to their healthcare 
provider.26
• In the GCNKS, using data from 1993 and 1994, the age-, sex-, and race-adjusted 
incidence rates for TIA were 0.83 per 10 000.27 Age- and sex-adjusted incidence 
rates for TIA in Rochester, MN, were estimated at 0.68 per 1000 for the years 
1985 through 1989.28 In a more recent Italian community-based registry 
conducted in 2007 to 2009, the crude TIA incidence rate was 0.52 per 1000.29
• The prevalence of physician-diagnosed TIA increases with age.26 Incidence of 
TIA increases with age and varies by sex and race/ethnicity. Men, blacks, and 
Mexican Americans have higher rates of TIA than their female and non-Hispanic 
white counterparts.22,27,29
• Approximately 15% of all strokes are heralded by a TIA.30
• TIAs confer a substantial short-term risk of stroke, hospitalization for CVD 
events, and death. Of 1707 TIA patients evaluated in the ED of Kaiser 
Permanente Northern California, a large, integrated healthcare delivery system, 
180 (11%) experienced a stroke within 90 days. Ninety-one patients (5%) had a 
stroke within 2 days. Predictors of stroke included age >60 years, DM, focal 
et al. Page 157
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
symptoms of weakness or speech impairment, and TIA that lasted >10 
minutes.31
• Meta-analyses of cohorts of patients with TIA have shown the short-term risk of 
stroke after TIA to be ≈3% to 10% at 2 days and 9% to 17% at 90 days.32,33
• Individuals who have a TIA and survive the initial high-risk period have a 10-
year stroke risk of roughly 19% and a combined 10-year stroke, MI, or vascular 
death risk of 43% (4% per year).34
• Within 1 year of TIA, ≈12% of patients will die.27
• It is estimated that one third of episodes characterized as TIA according to the 
classic definition (ie, focal neurological deficits that resolve within 24 hours) 
would be considered infarctions on the basis of diffusion-weighted magnetic 
resonance imaging findings.35
Stroke Mortality
(See Table 14-1 and Charts 14-6 through 14-7.)
• On average, every 4 minutes, someone dies of a stroke (NCHS, NHLBI).36
• Stroke accounted for ≈1 of every 19 deaths in the United States in 2009.36
• When considered separately from other CVDs, stroke ranks No. 4 among all 
causes of death, behind diseases of the heart, cancer, and CLRD (NCHS 
mortality data). Stroke mortality as an underlying cause of death in 2009 was 128 
824; any-mention mortality in 2009 was 215 864, and the death rate was 38.9 per 
100 000.36
• From 1999 to 2009, the annual stroke death rate decreased 36.9%, and the actual 
number of stroke deaths declined 22.9% (AHA computation).36
• Conclusions about changes in stroke death rates from 1980 to 2005 are as 
follows:
– There was a greater decline in stroke death rates in men than in women, 
with a male-to-female ratio decreasing from 1.11 to 1.03 (age adjusted).
– There were greater declines in stroke death rates in men than in women 
and among people ≥65 years of age than among younger ages.37
• In examining trends in stroke mortality by census divisions between 1999 and 
2007 for people ≥45 years of age, the rate of decline varied by geographic region 
and race-ethnic group. Among black and white women and white men, rates 
declined by at least 2% annually in every census division, but among black men, 
rates declined little in the East and West South Central divisions.38
• Approximately 56% of stroke deaths in 2009 occurred out of the hospital 
(unpublished tabulation of NCHS 2009 Mortality Data Set).
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• More women than men die of stroke each year because of the larger number of 
elderly women. Women accounted for almost 60% of US stroke deaths in 2009 
(AHA tabulation).36
• From 1995 to 1998, age-standardized mortality rates for ischemic stroke, 
subarachnoid hemorrhage, and intracerebral hemorrhage were higher among 
blacks than whites. Death rates attributable to intracerebral hemorrhage also 
were higher among Asians/Pacific Islanders than among whites. All minority 
populations had higher death rates attributable to subarachnoid hemorrhage than 
did whites. Among adults 25 to 44 years of age, blacks and American Indian/
Alaska Natives had higher risk ratios for stroke mortality than did whites for all 3 
stroke subtypes. Age-standardized mortality rates for ischemic stroke and 
intracerebral hemorrhage were lower for Hispanics than for whites.39
• In 2002, death certificate data showed that the mean age at stroke death was 79.6 
years; however, males had a younger mean age at stroke death than females. 
Blacks, American Indian/Alaska Natives, and Asian/Pacific Islanders had 
younger mean ages than whites, and the mean age at stroke death was also 
younger among Hispanics than non-Hispanics.40
• A report released by the CDC in collaboration with the Centers for Medicare & 
Medicaid Services, the Atlas of Stroke Hospitalizations Among Medicare 
Beneficiaries, found that in Medicare beneficiaries over the time period 1995 to 
2002, 30-day mortality rate varied by age: 9% in patients 65 to 74 years of age, 
13.1% in those 74 to 84 years of age, and 23% in those ≥85 years of age.41
• There are substantial geographic disparities in stroke mortality, with higher rates 
in the southeastern United States, known as the “stroke belt.” This area is usually 
defined to include the 8 southern states of North Carolina, South Carolina, 
Georgia, Tennessee, Mississippi, Alabama, Louisiana, and Arkansas. These 
geographic differences have existed since at least 1940,42 and despite some 
minor shifts,43 they persist.41,44,45 Within the stroke belt, a “buckle” region 
along the coastal plain of North Carolina, South Carolina, and Georgia has been 
identified with an even higher stroke mortality rate than the remainder of the 
stroke belt.46 The overall average stroke mortality is ≈20% higher in the stroke 
belt than in the rest of the nation and ≈40% higher in the stroke buckle.
Stroke Risk Factors
(See Table 14-2 and Chart 14-8.)
For prevalence and other information on any of these specific risk factors, refer to the 
specific risk factor chapters.
High Blood Pressure—(See Chapter 9 for more information.)
• BP is a powerful determinant of risk for both ischemic stroke and intracranial 
hemorrhage.
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– Approximately 77% of those who have a first stroke have BP >140/90 
mm Hg (NHLBI unpublished estimates from ARIC, CHS, and FHS 
Cohort and Offspring studies).
– Diabetic subjects with BP <120/80 mm Hg have approximately half the 
lifetime risk of stroke of subjects with hypertension. The treatment and 
lowering of BP among diabetic hypertensive individuals was associated 
with a significant reduction in stroke risk.47
• A meta-analysis of 12 prospective cohort studies (including 518 520 participants) 
found that prehypertension is associated with incident stroke. The risk is 
particularly noted in nonelderly people and for those with BP values in the 
higher prehypertension range.48
• Prehypertension was found to be highest in blacks with other risk factors, 
including DM and elevated C-reactive protein.49
• In REGARDS (NINDS), black participants were more aware than whites of their 
hypertension and more likely to be undergoing treatment if aware of their 
diagnosis, but among those treated for hypertension, they were less likely than 
whites to have their BP controlled.50
• REGARDS (NINDS) also showed no evidence of a difference between the 
stroke belt and other regions in awareness of hypertension, but there was a trend 
for better treatment and BP control in the stroke belt region. The lack of 
substantial geographic differences in hypertension awareness and the trend 
toward better treatment and control in the stroke belt suggest that differences in 
hypertension management may not be a major contributor to the geographic 
disparity in stroke mortality.50
Diabetes Mellitus—(See Chapter 10 for more information.)
• Age-specific incidence rates and rate ratios show that DM increases ischemic 
stroke incidence at all ages, but this risk is most prominent before 55 years of age 
in blacks and before 65 years of age in whites. Ischemic stroke patients with DM 
are younger, more likely to be black, and more likely to have hypertension, MI, 
and high cholesterol than nondiabetic patients.51
• In people with history of TIA or minor stroke, impaired glucose tolerance nearly 
doubled the stroke risk compared with those with normal glucose levels and 
tripled the risks for those with DM.52
Disorders of Heart Rhythm—(See Chapter 16 for more information.)
• AF is a powerful risk factor for stroke, independently increasing risk ≈5-fold 
throughout all ages. The percentage of strokes attributable to AF increases 
steeply from 1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years of age.53,54
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• Because AF is often asymptomatic55,56 and likely frequently clinically 
undetected,57 the stroke risk attributed to AF may be substantially 
underestimated.58
• Among 2580 participants ≥65 years of age with hypertension in whom a cardiac 
rhythm device that included an atrial lead was implanted, 35% developed 
subclinical tachyarrhythmias (defined as an atrial rate ≥190 beats per minute that 
lasted at least 6 minutes). These subclinical events were independently associated 
with a 2.5-fold increased risk of ischemic stroke or systemic embolism.59
High Blood Cholesterol and Other Lipids—(See Chapter 8 for more information.)
• Data from the Honolulu Heart Program//NHLBI found that in Japanese men 71 
to 93 years of age, low concentrations of HDL cholesterol were more likely to be 
associated with a future risk of thromboembolic stroke than were high 
concentrations. 60 However, a meta-analysis of 23 studies performed in the Asia-
Pacific Region showed no significant association between low HDL and stroke 
risk.61
Smoking—(See Chapter 3 for more information.)
• Current smokers have a 2 to 4 times increased risk of stroke compared with 
nonsmokers or those who have quit for >10 years.62,63
• Cigarette smoking is a risk factor for ischemic stroke and subarachnoid 
hemorrhage, but the data for intracerebral hemorrhage are less consistent.62,63
• Smoking is perhaps the most important modifiable risk factor in preventing 
subarachnoid hemorrhage, with the highest PAR of any subarachnoid 
hemorrhage risk factor.64
• Data also support a dose-response relationship across old and young age 
groups.62,65
• Discontinuation of smoking has been shown to reduce stroke risk across sex, 
race, and age groups.65
• Exposure to secondhand smoke (also termed passive smoking or environmental 
tobacco smoke) is a risk factor for stroke. Meta-analyses have estimated a pooled 
RR of 1.25 for exposure to spousal smoking (or nearest equivalent) and risk of 
stroke. A dose-response relationship between exposure to secondhand smoke and 
stroke risk has also been reported.66,67
Physical Inactivity—(See Chapter 4 for more information.)
• In NOMAS, a prospective cohort that included white, black, and Hispanic adults 
in an urban setting followed up for a median of 9 years, moderate to vigorous PA 
was associated with an overall 35% reduction in risk of ischemic stroke 
compared with no PA.68 In this cohort, it was also found that only moderate-to 
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vigorous-intensity exercise was associated with reduced stroke incidence, 
whereas light exercise (such as walking) showed no benefit.69
• In NOMAS, higher levels of PA were associated with lower risk of silent brain 
infarcts on magnetic resonance imaging, even after adjustment for other risk 
factors potentially in the pathway of action for PA.70
• Timing of PA in relation to stroke onset has also been examined in several 
studies. In a hospital-based case-control study from Heidelberg, Germany, recent 
activity (within the prior months) was associated with reduced odds of having a 
stroke or TIA, whereas sports activity during young adulthood that was not 
continued showed no benefit.71 In a Danish case-control study, ischemic stroke 
patients were less physically active in the week preceding the stroke than age- 
and sex-matched control subjects, with the highest activity scores associated with 
the greatest reduction in odds of stroke.72
Family History and Genetics—(See Chapter 7 for more information.)
• In the FHS, a documented parental ischemic stroke by the age of 65 years was 
associated with a 3-fold increase in ischemic stroke risk in offspring, even after 
adjustment for other known stroke risk factors. The absolute magnitude of the 
increased risk was greatest in those in the highest quintile of the FRS. By age 65 
years, people in the highest FRS quintile with an early parental ischemic stroke 
had a 25% risk of stroke compared with a 7.5% risk of ischemic stroke for those 
without such a history.73
Chronic Kidney Disease—(See Chapter 12 for more information.)
• The CHS (NHLBI) showed that people with creatinine ≥1.5 mg/dL were at 
increased risk for stroke, with an adjusted HR of 1.77 (95% CI, 1.08–2.91).74 
Participants in REGARDS with a reduced eGFR were also shown to have 
increased risk of stroke symptoms,75 and a meta-analysis of >280 000 patients 
showed a 43% increased incident stroke risk among patients with a GFR <60 
mL·min−1·1.73 m−2.76
Risk Factor Issues Specific to Women
• On average, women are older at stroke onset than men (≈75 years compared with 
71 years).12
• Analysis of data from the FHS found that women with natural menopause before 
42 years of age had twice the ischemic stroke risk of women with natural 
menopause after 42 years of age.77 Investigators from the Nurse’s Health Study, 
however, did not find an association between age at natural menopause and risk 
of ischemic or hemorrhagic stroke.78
• Overall, randomized clinical trial data indicate that the use of estrogen plus 
progestin, as well as estrogen alone, increases stroke risk in postmenopausal, 
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generally healthy women and provides no protection for postmenopausal women 
with established CHD79–82 and recent stroke or TIA.83
• In a nested case-control study of the United Kingdom’s General Practice 
Research Database, the rate of stroke was not elevated when current users of 
transdermal estrogens, with or without progestins, were compared with nonusers 
(RR, 0.95; 95% CI, 0.75–1.20). This association was modified by dose such that 
stroke risk was not increased for users of low-dose (≤50 μg) estrogen patches 
(RR, 0.81; 95% CI, 0.62–1.05) but was increased for users of high-dose (>50 μg) 
patches (RR, 1.89; 95% CI, 1.15–3.11) compared with nonusers.84
• The risk of ischemic stroke or intracerebral hemorrhage during pregnancy and 
the first 6 weeks after giving birth was 2.4 times greater than for nonpregnant 
women of similar age and race, according to the Baltimore-Washington 
Cooperative Young Stroke Study. The risk of ischemic stroke during pregnancy 
was not increased during pregnancy per se but was increased 8.7-fold during the 
first 6 postpartum weeks. Intracerebral hemorrhage showed a small RR of 2.5 
during pregnancy that increased dramatically to an RR of 28.3 in the first 6 
postpartum weeks. The excess risk of stroke (all types except subarachnoid 
hemorrhage) attributable to the combined pregnancy/postpregnancy period was 
8.1 per 100 000 pregnancies.85
• In the US Nationwide Inpatient Sample from 2000 to 2001, the rate of events per 
100 000 pregnancies was 9.2 for ischemic stroke, 8.5 for intracerebral 
hemorrhage, 0.6 for cerebral venous thrombosis, and 15.9 for the ill-defined 
category of pregnancy-related cerebrovascular events, for a total rate of 34.2 per 
100 000, not including subarachnoid hemorrhage. The risk was increased in 
blacks and among older women. Death occurred during hospitalization in 4.1% 
of women with these events and in 22% of survivors after discharge to a facility 
other than home.86
• Analyses of the US Nationwide Inpatient Sample from 1994 to 1995 and from 
2006 to 2007 show a temporal increase in the proportion of pregnancy 
hospitalizations that were associated with a stroke, with a 47% increase for 
antenatal hospitalizations and an 83% increase for postpartum hospitalizations, 
but no increase for delivery hospitalizations. Increases in the prevalence of HD 
and hypertensive disorders accounted for almost all the increase in postpartum 
stroke hospitalizations but not the antenatal stroke hospitalizations.88
• Preeclampsia is a risk factor for ischemic stroke remote from pregnancy.89 The 
subsequent stroke risk of preeclampsia maybe mediated by a 3.6- to 6.1-fold 
higher later risk of hypertension and a 3.1- to 3.7-fold higher later risk of DM, 
depending on whether the preeclampsia was mild or severe.90
Sleep Apnea
• Sleep apnea is an independent risk factor for stroke, increasing the risk of stroke 
or death 2-fold.91–94
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• Increasing sleep apnea severity is associated with greater stroke risk; patients 
with severe sleep apnea have 3-to 4-fold increased odds of stroke.91,93,94
• Sleep apnea is common after stroke, occurring in two thirds to three quarters of 
poststroke patients. 95–106
• Continuous positive airway pressure improves a variety of outcomes after 
stroke.96,107–109 For example, continuous positive airway pressure reduces the 
risk of recurrent vascular events among patients with stroke (relative risk 
reduction, 81.4%; number needed to treat, 3.4).108
Awareness of Stroke Warning Signs and Risk Factors
• Correct knowledge of at least 1 stroke warning sign increased from 48% in 1995 
to 68% in 2000, with no significant improvement to 2005 (68%) on the basis of a 
telephone survey conducted in a biracial population in the greater Cincinnati/
Northern Kentucky region. Knowledge of 3 correct warning signs was low but 
increased over time: 5.4% in 1995, 12.0% in 2000, and 15.7% in 2005. 
Knowledge of at least 1 stroke risk factor increased from 59% in 1995 to 71% in 
2000, but there was no improvement to 2005 (71%). Only 3.6% of those 
surveyed were able to independently identify tissue-type plasminogen activator 
as an available drug therapy, and only 9% of these were able to identify a 
window of <3 hours for treatment.110
• In the 2009 NHIS, 51.2% of subjects were aware of 5 stroke warning symptoms 
and would first call 911 if they thought that someone was having a stroke. 
Awareness of all 5 stroke warning symptoms and calling 911 was higher among 
whites than blacks and Hispanics (55.9%, 47.1%, and 36.5%, respectively), 
women than men (53.6% versus 48.6%), and people with higher versus lower 
educational attainment (59.0% for people with a bachelor’s degree or more 
compared with 51.4% for people with a high school diploma or some college and 
36.7% for those who had not received a high school diploma; unpublished 
NHLBI tabulation).
• A study was conducted of patients admitted to an ED with possible stroke to 
determine their knowledge of the signs, symptoms, and risk factors of stroke. Of 
the 163 patients able to respond, 39% did not know a single sign or symptom. 
Patients ≥65 years of age were less likely than those <65 years old to know a 
sign or symptom of stroke (28% versus 47%), and 43% did not know a single 
risk factor. Overall, almost 40% of patients did not know the signs, symptoms, 
and risk factors for stroke.111
• In 2004, 800 adults ≥45 years of age were surveyed to assess their perceived risk 
for stroke and their history of stroke risk factors. Overall, 39% perceived 
themselves to be at risk. Younger age, current smoking, a history of DM, high 
BP, high cholesterol, HD, and stroke/TIA were independently associated with 
perceived risk for stroke. Respondents with AF were no more likely to report 
being at risk than were respondents without AF. Perceived risk for stroke 
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increased as the number of risk factors increased; however, 46% of those with ≥3 
risk factors did not perceive themselves to be at risk.112
• A study of patients who had experienced a stroke found that only 60.5% were 
able to accurately identify 1 stroke risk factor and that 55.3% were able to 
identify 1 stroke symptom. Patients’ median delay time from onset of symptoms 
to admission in the ED was 16 hours, and only 31.6% accessed the ED in <2 
hours. Analysis showed that the appearance of nonmotor symptoms as the 
primary symptom and nonuse of the 911 system were significant predictors of 
delay >2 hours. Someone other than the patient made the decision to seek 
treatment in 66% of the cases.113
• Spanish-speaking Hispanics are less likely to know all stroke symptoms than 
English-speaking Hispanics, non-Hispanic blacks, and non-Hispanic whites. 
Lack of English proficiency is strongly associated with lack of stroke knowledge 
among Hispanics.114
Aftermath
(See Charts 14-9 through 14-12.)
• Stroke is a leading cause of serious long-term disability in the United States 
(Survey of Income and Program Participation, a survey of the US Bureau of the 
Census).115
• Among Medicare patients discharged from the hospital after stroke, ≈45% return 
directly home, 24% are discharged to inpatient rehabilitation facilities, and 31% 
are discharged to skilled nursing facilities. Of stroke patients returning directly 
home, 32% use home healthcare services. 116 For Medicare patients (including, 
but not limited to, stroke survivors), the likelihood of receiving inpatient 
rehabilitation facility care versus skilled nursing facility care is substantially 
influenced by the distance to and availability of inpatient rehabilitation facility 
beds.117
• Approximately one third of stroke survivors experience poststroke depression.118
• In the NHLBI’s FHS, among ischemic stroke survivors who were ≥65 years of 
age, the following disabilities were observed at 6 months after stroke119:
– 50% had some hemiparesis
– 30% were unable to walk without some assistance
– 46% had cognitive deficits
– 35% had depressive symptoms
– 19% had aphasia
– 26% were dependent in activities of daily living
– 26% were institutionalized in a nursing home
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• Data from the BRFSS (CDC) 2005 survey on stroke survivors in 21 states and 
the District of Columbia found that 30.7% of stroke survivors received outpatient 
rehabilitation. The findings indicated that the prevalence of stroke survivors 
receiving outpatient stroke rehabilitation was lower than would be expected if 
clinical practice guideline recommendations for all stroke patients had been 
followed.120
• After stroke, women have greater disability than men. A cross-sectional analysis 
of 5888 community-living elderly people (>65 years of age) in the CHS who 
were ambulatory at baseline found that women were half as likely to be 
independent in activities of daily living after stroke, even after controlling for 
age, race, education, and marital status. 121 A prospective study from a 
Michigan-based stroke registry found that women had a 63% lower probability 
of achieving independence in activities of daily living 3 months after discharge, 
even after controlling for age, race, subtype, prestroke ambulatory status, and 
other patient characteristics.122
• Black stroke survivors had greater limitations in ambulation than did white 
stroke survivors, after adjustment for age, sex, and educational attainment but not 
stroke subtype, according to data from the NHIS (2000–2001, NCHS) as 
analyzed by the CDC.123 A national study of inpatient rehabilitation after first 
stroke found that blacks were younger, had a higher proportion of hemorrhagic 
stroke, and were more disabled on admission. Compared with non-Hispanic 
whites, blacks and Hispanics also had a poorer functional status at discharge but 
were more likely to be discharged to home rather than to another institution, even 
after adjustment for age and stroke subtype. After adjustment for the same 
covariates, compared with non-Hispanic whites, blacks also had less 
improvement in functional status per inpatient day.124
Hospital Discharges/Ambulatory Care Visits
(See Table 14-1.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with stroke as the first-listed diagnosis remained about the same, with discharges 
of 981 000 and 1 015 000, respectively (NHDS, NHLBI tabulation).
• Data from 2010 from the NHDS of the NCHS showed that the average length of 
stay for discharges with stroke as the first-listed diagnosis was 6.1 days 
compared with 9.5 days in 1990.
• In 2010, men and women accounted for roughly the same number of hospital 
stays for stroke in the 18- to 44-year-old age group. Among people 45 to 64 
years of age, 57.1% of stroke patients were men. After 65 years of age, women 
were the majority. Among people 65 to 84 years of age, 53.4% of stroke patients 
were women, whereas among those ≥85 years of age, women constituted 66.2% 
of all stroke patients.125
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• A first-ever county-level Atlas of Stroke Hospitalizations Among Medicare 
Beneficiaries was released in 2008 by the CDC in collaboration with the Centers 
for Medicare & Medicaid Services. It found that the stroke hospitalization rate 
for blacks was 27% higher than for the US population in general, 30% higher 
than for whites, and 36% higher than for Hispanics. In contrast to whites and 
Hispanics, the highest percentage of strokes in blacks (42.3%) occurred in the 
youngest Medicare age group (65–74 years of age).41
• In 2009, there were 768 000 ED visits and 127 000 outpatient department visits 
with stroke as the first-listed diagnosis. In 2010, physician office visits for a first-
listed diagnosis of stroke totaled 2 207 000 (NHAMCS, unpublished NHLBI 
tabulation).126
Stroke in Children
• On the basis of pathogenic differences, pediatric strokes are typically classified 
as either perinatal (occurring at ≤28 days of life and including in utero strokes) or 
(later) childhood.
• Estimates of the overall annual incidence of stroke in US children are 6.4 per 100 
000 children (0 to 15 years) in 1999 in the GCNKSS127 and 4.6 per 100 000 
children (0 to 19 years) in 1997 to 2003 according to data from Kaiser 
Permanente of Northern California, a large, integrated healthcare delivery 
system.128 Approximately half of all incident childhood strokes are 
hemorrhagic.127–129
• The prevalence of perinatal strokes is 29 per 100 000 live births, or 1 per 3500 
live births in the 1997–2003 Kaiser Permanente of Northern California 
population.128
• A history of infertility, preeclampsia, prolonged rupture of membranes, and 
chorioamnionitis are independent maternal risk factors for perinatal arterial 
ischemic stroke.130 However, maternal health and pregnancies are normal in 
most cases.131
• The most common cause of arterial ischemic stroke in children is a cerebral 
arteriopathy, found in more than half of all cases.132,133
• Children with cardiac disease are at 16-fold increased risk of arterial ischemic 
stroke compared with children in the general population; those with single-
ventricle physiology are at highest risk.134
• Thrombophilias (genetic and acquired) are risk factors for childhood stroke, with 
summary ORs ranging from 1.6 to 8.8 in a meta-analysis.135
• In a prospective Swiss registry, 136 atherosclerotic risk factors were less common 
in children with arterial ischemic stroke than in young adults; the most common 
of these factors in children was hyperlipidemia (15%). However, an analysis of 
the Nationwide Inpatient Sample suggests a low but rising prevalence of these 
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factors among US adolescents and young adults hospitalized for ischemic stroke 
(1995 versus 2008).137
• From 1979 to 1998 in the United States, childhood mortality resulting from 
stroke declined by 58% overall, with reductions in all major subtypes.138
• The incidence of stroke in children has been stable over the past 10 years, 
whereas 30-day case fatality rates declined from 18% in 1988–1989 to 9% in 
1993–1994 and 9% in 1999 in the GCNKSS population.127
• Compared with girls, boys have a 1.28-fold higher risk of stroke.139 Compared 
with white children, black children have a 2-fold risk of both incident stroke and 
death attributable to stroke.138,139 The increased risk among blacks is not fully 
explained by the presence of sickle cell disease, nor is the excess risk among 
boys fully explained by trauma.139
• At a mean follow-up time of 2.1 years, 37% of 123 childhood ischemic stroke 
survivors had full recovery, 20% had mild deficits, 26% had moderate deficits, 
and 16% had severe deficits.140 Concomitant involvement of the basal ganglia, 
cerebral cortex, and posterior limb of the internal capsule predicts a persistent 
hemiparesis.141
• Despite current treatment, 1 of 10 children with ischemic or hemorrhagic stroke 
will have a recurrence within 5 years.142,143 The 5-year recurrence risk is as high 
as 60% among children with cerebral arteriopathy. The recurrence risk after 
perinatal stroke, however, is negligible.144
• More than 25% of survivors of perinatal ischemic strokes develop delayed 
seizures within 3 years; children with larger strokes are at higher risk.145
• Sickle cell disease is the most important cause of ischemic stroke among black 
children. The Stroke Prevention Trial in Sickle Cell Anemia (STOP) 
demonstrated the efficacy of blood transfusions for primary stroke prevention in 
children with sickle cell disease identified as high-risk by transcranial Doppler; 
STOP II demonstrated that stopping transfusions after 30 months of treatment 
was associated with a high risk of stroke.146
• The Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) trial 
recently reported that chronic blood transfusion therapy remains the superior 
option (over hydroxyurea) for secondary stroke prevention in children with sickle 
cell disease.147 A similar trial of hydroxyurea as an alternative for primary stroke 
prevention is under way.
Stroke in the Very Elderly
• Stroke patients >85 years of age make up 17% of all stroke patients.148
• Very elderly patients have a higher risk-adjusted mortality, 148,149 have longer 
hospitalizations,149 receive less evidenced-based care,150,151 and are less likely 
to be discharged to their original place of residence.149,152
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Barriers to Stroke Care
• On the basis of NHIS data, the inability to afford medications among stroke 
survivors increased significantly from 8.1% to 12.7% between 1997 and 2004, 
totaling 76 000 US stroke survivors in 2004. Compared with stroke survivors 
able to afford medications, those unable to afford them more frequently reported 
lack of transportation, no health insurance, no usual place of care, income <$20 
000, and out-of-pocket medical expenses ≥$2000.153
• In 2002, ≈21% of US counties did not have a hospital, 31% lacked a hospital 
with an ED, and 77% did not have a hospital with neurological services.154
• Of patients with ischemic stroke in the California Acute Stroke Pilot Registry, 
23.5% arrived at the ED within 3 hours of symptom onset, and 4.3% received 
thrombolysis. If all patients had called 911 immediately, the expected overall rate 
of thrombolytic treatment within 3 hours would have increased to 28.6%. If all 
patients with known onset had arrived within 1 hour and had been treated 
optimally, 57% could have received thrombolytic treatment.155
• Data from the Paul Coverdell National Acute Stroke Registry were analyzed 
from the 142 hospitals that participated in the 4 registry states. More patients 
were transported by ambulance than by other means (43.6%). Time of stroke 
symptom onset was recorded for 44.8% of the patients. Among these patients, 
48% arrived at the ED within 2 hours of symptom onset. Significantly fewer 
blacks (42.4%) arrived within 2 hours of symptom onset than did whites 
(49.5%), and significantly fewer nonambulance patients (36.2%) arrived within 2 
hours of symptom onset than did patients transported by ambulance (58.6%).156
• NHIS data from 1998–2002 found that younger stroke survivors (45–64 years) 
self-reported worse access to physician care and medication affordability than 
older stroke survivors. Compared with older patients, younger stroke survivors 
were more likely to be male (52% versus 47%), to be black (19% versus 10%), 
and to lack health insurance (11% versus 0.4%). Lack of health insurance was 
associated with reduced access to care.157
• Results from the BASIC project found that women were less likely to arrive at 
the ED within 3 hours of stroke symptom onset than men (OR, 0.7; 95% CI, 0.5–
0.9). Mexican Americans were 40% less likely to arrive by emergency medical 
services (EMS) than non-Hispanic whites, even after adjustment for age, 
National Institutes of Health Stroke Scale score, education, history of stroke, and 
insurance status. Language fluency was not associated with time to hospital 
arrival or use of EMS. The receipt of tissue-type plasminogen activator was low 
(1.5%) but did not differ by sex or race.158
• A national study of academic medical centers found no change in the proportion 
of patients with stroke arriving at hospitals within 2 hours of symptom onset 
between 2001 and 2004 (37% versus 38%); however, the rate of intravenous 
tissue-type plasminogen activator use increased over this time period (14% to 
38%), which suggests system-level improvements in the organization of in-
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hospital care. In risk-adjusted analyses, black patients were 45% less likely to 
arrive within 2 hours than white patients.159
Operations and Procedures
(See Chart 14-13.)
• In 2010, an estimated 100 000 inpatient endarterectomy procedures were 
performed in the United States. Carotid endarterectomy is the most frequently 
performed surgical procedure to prevent stroke (NHDS, NHLBI tabulation).
• Although rates of carotid endarterectomy in the Medicare population decreased 
slightly between 1998 and 2004, the use of carotid artery stenting increased 
dramatically.160
• The practice of carotid stenting in the United States is expanding, from <3% of 
all carotid artery revascularization procedures in 1998 to 13% in 2008.161
• The randomized Carotid Revascularization Endarterectomy versus Stenting Trial 
(CREST) compared carotid endarterectomy and stenting for symptomatic and 
asymptomatic carotid stenosis. There was no overall difference in the primary 
end point of stroke, MI, or death; however, carotid endarterectomy showed 
superiority with increasing age, with the crossover point at approximately age 
70, and was associated with fewer strokes, which had a greater impact on quality 
of life than MI.162,163
Cost
(See Table 14-1.)
The direct and indirect cost of stroke in 2009 was $38.6 billion (MEPS, NHLBI tabulation).
• The estimated direct medical cost of stroke for 2009 is $22.8 billion. This 
includes hospital outpatient or office-based provider visits, hospital inpatient 
stays, ED visits, prescribed medicines, and home health care.164
• The mean expense per person for stroke care in the United States in 2009 was 
estimated at $6018.164 The mean lifetime cost of ischemic stroke in the United 
States is estimated at $140 048. This includes inpatient care, rehabilitation, and 
follow-up care necessary for lasting deficits. (All numbers were converted to 
1999 dollars by use of the medical component of the Consumer Price Index.)165
• The estimated cost of acute pediatric stroke in the United States was $42 million 
in 2003. The mean cost of short-term hospital care was $20 927 per discharge.166
• After adjustment for routine healthcare costs, the average 5-year cost of a 
neonatal stroke was $51 719 and that of a childhood stroke was $135 161. Costs 
among children with stroke continued to exceed those in age-matched control 
children even in the fifth year by an average of $2016.167
• In a study of stroke costs within 30 days of an acute event between 1987 and 
1989 in the Rochester Stroke Study, the average cost was $13 019 for mild 
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ischemic strokes and $20 346 for severe ischemic strokes (4 or 5 on the Rankin 
Disability Scale).168
• Inpatient hospital costs for an acute stroke event account for 70% of first-year 
poststroke costs.128
• The largest components of short-term care costs were room charges (50%), 
medical management (21%), and diagnostic costs (19%).169
• Death within 7 days, subarachnoid hemorrhage, and stroke while hospitalized for 
another condition are associated with higher costs in the first year. Lower costs 
are associated with mild cerebral infarctions or residence in a nursing home 
before the stroke.168
• Demographic variables (age, sex, and insurance status) are not associated with 
stroke cost. Severe strokes (National Institutes of Health Stroke Scale score >20) 
cost twice as much as mild strokes, despite similar diagnostic testing. 
Comorbidities such as ischemic HD and AF predict higher costs.169,170
• The total cost of stroke from 2005 to 2050, in 2005 dollars, is projected to be 
$1.52 trillion for non-Hispanic whites, $313 billion for Hispanics, and $379 
billion for blacks. The per capita cost of stroke estimate is highest in blacks ($25 
782), followed by Hispanics ($17 201) and non-Hispanic whites ($15 597). Loss 
of earnings is expected to be the highest cost contributor in each race/ethnic 
group.171
• In adjusted models that controlled for relevant covariates, the attributable 1-year 
cost of poststroke aphasia was estimated at $1703 in 2004 dollars.172
• Average cost for outpatient stroke rehabilitation services and medications the 
first year after inpatient rehabilitation discharge was $11 145. The corresponding 
average yearly cost of medication was $3376, whereas the average cost of yearly 
rehabilitation service utilization was $7318.173
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15. Congenital Cardiovascular Defects and Kawasaki Disease
ICD-9 745 to 747, ICD-10 Q20 to Q28. See Tables 15-1 through 15-4.
Congenital cardiovascular defects, also known as congenital heart defects, are structural 
problems that arise from abnormal formation of the heart or major blood vessels. ICD-9 lists 
25 congenital heart defects codes, of which 21 designate specific anatomic or hemodynamic 
lesions.
Defects range in severity from tiny pinholes between chambers that may resolve 
spontaneously to major malformations that can require multiple surgical procedures before 
school age and may result in death in utero, in infancy, or in childhood. The common 
complex defects include the following:
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• Tetralogy of Fallot (TOF)
• Transposition of the great arteries (TGA)
• Atrioventricular (AV) septal defects
• Coarctation of the aorta
• Hypoplastic left heart syndrome (HPLHS)
Congenital heart defects are serious and common conditions that have a significant impact 
on morbidity, mortality, and healthcare costs in children and in adults.1–4 As health 
outcomes improve and survival increases for children living with congenital HD, the burden 
of care is shifting toward adult populations.5
Incidence
The most commonly reported incidence of congenital heart defects in the United States is 
between 4 and 10 per 1000, clustering around 8 per 1000 live births.6,7 Continental 
variations in birth prevalence have been reported, from 6.9 per 1000 births in Europe to 9.3 
per 1000 in Asia.8 Variations in reported number of incident cases are largely accounted for 
by the age at detection and the method of diagnosis. Major defects may be apparent in the 
prenatal or neonatal period, but minor defects may not be detected until adulthood. 
Detection rates have increased since the advent of cardiac ultrasound.4 Thus, true measures 
of the incidence of congenital HD would need to record new cases of defects that present 
from fetal life onward. Because most estimates are available for new cases detected between 
birth and the first year of life, birth prevalence is the best proxy for incident congenital heart 
defects. These are typically reported as cases per 1000 live births per year and do not 
distinguish between tiny defects that resolve without treatment and major malformations. To 
distinguish more serious defects, some studies also report new cases of sufficient severity to 
require an invasive procedure or that result in death within the first year of life. Despite the 
absence of true incidence figures, some data are available and are provided in Table 15-2.
Abbreviations Used in Chapter 15
ASD atrial septal defect
AV atrioventricular
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CI confidence interval
DM diabetes mellitus
HD heart disease
HPLHS hypoplastic left heart syndrome
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MACDP Metropolitan Atlanta Congenital Defects Program
NCHS National Center for Health Statistics
NH non-Hispanic
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NHLBI National Heart, Lung, and Blood Institute
RR relative risk
TGA transposition of the great arteries
TOF tetralogy of Fallot
VSD ventricular septal defect
• Using population-based data from the Metropolitan Atlanta Congenital Defects 
Program (MACDP) in metropolitan Atlanta, GA, congenital heart defects 
occurred in 1 of every 111 to 125 births (live, still, or >20 weeks’ gestation) from 
1995 to 1997 and from 1998 to 2005, with variations in sex and racial 
distribution of some lesions.4,6
• Data collected in Alberta, Canada, found the total prevalence of CHD to be 12.42 
per 1000 total births (live, still, or >20 weeks’ gestation).9
• The National Birth Defects Prevention Network for 13 states from 2004 to 2006 
showed the average prevalence of 21 selected major birth defects. These data 
indicated that there are >6100 estimated annual cases of 5 cardiovascular defects: 
truncus arteriosus (0.7/10 000 births), TGA (3.0/10 000 births), TOF (4.0/10 000 
births), AV septal defect (4.7/10 000 births), and HPLHS (2.3/10 000 births).10
• Analysis of contemporary birth cohorts with MACDP data revealed that the most 
common defects at birth were ventricular septal defect (VSD; 4.2/1000 births), 
atrial septal defect (ASD; 1.3/1000 births), valvar pulmonic stenosis (0.6/1000 
births); TOF (0.5/1000 births), aortic coarctation (0.4/1000 births), AV septal 
defect (0.4/1000 births), and TGA (0.2/1000 births).6,11
• An estimated minimum of 32 000 infants are expected to be affected with 
congenital HD each year in the United States. Of these, an approximate 25%, or 
2.4 per 1000 live births, require invasive treatment in the first year of life.1
• Estimates also are available for bicuspid aortic valves, which occur in 13.7 per 
1000 people; these defects may not require treatment in infancy but can cause 
problems later in adulthood.12
Prevalence
(See Tables 15-1 through 15-3.)
The 32nd Bethesda Conference estimated that the total number of adults living with 
congenital HD in the United States in 2000 was 800 000.2,3 In the United States, 1 in 150 
adults are expected to have some form of congenital HD.3 In population data from Canada, 
the measured prevalence of congenital cardiac defects in the general population was 11.89 
per 1000 children and 4.09 per 1000 adults in the year 2000.13 Extrapolated to the US 
population in the same year, this yields published estimates of 859 000 children and 850 000 
adults for the year 2000.11 The expected growth rates of the congenital heart defects 
population vary from 1% to 5% per year depending on the age and distribution of 
lesions.2,13
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Estimates of the distribution of lesions in the congenital heart defects population using 
available data vary with assumptions made. If all those born with lesions between 1940 and 
2002 were treated, there would be 750 000 survivors with simple lesions, 400 000 with 
moderate lesions, and 180 000 with complex lesions; in addition, there would be 3.0 million 
subjects alive with bicuspid aortic valves.14 Without treatment, the number of survivors in 
each group would be 400 000, 220 000, and 30 000, respectively. The actual numbers 
surviving are projected to be between these 2 sets of estimates as of 1 decade ago.14 Using 
measurements from population data in Canada, the prevalence of severe forms of congenital 
heart defects increased 85% in adults and 22% in children from 1985 to 2000.13 The most 
common types of defects in children are (at a minimum) VSD, 620 000 people; ASD, 235 
000 people; valvular pulmonary stenosis, 185 000 people; and patent ductus arteriosus, 173 
000 people.14 The most common lesions seen in adults are ASD and TOF.2
Risk Factors
• Numerous intrinsic and extrinsic nongenetic risk factors contribute to CHD.15
• Attributable risks or fractions have been shown to include paternal anesthesia in 
TOF (3.6%), sympathomimetic medication for coarctation of the aorta (5.8%), 
pesticides for VSD (5.5%), and solvents for HPLHS (4.6%).16
• A study of infants born with heart defects unrelated to genetic syndromes who 
were included in the National Birth Defects Prevention Study found that women 
who reported smoking in the month before becoming pregnant or in the first 
trimester were more likely to give birth to a child with a septal defect. Compared 
with the infants of mothers who did not smoke during pregnancy, infants of 
mothers who were heavy smokers (≥25 cigarettes daily) were twice as likely to 
have a septal defect.17
• Data from the Baltimore-Washington Infant Study reported that maternal 
smoking during the first trimester of pregnancy was associated with at least a 
30% increased risk of the following lesions in the fetus: ASD, pulmonary valvar 
stenosis, truncus arteriosus, and TGA.18
• Associations between exposure to air pollutants during first-trimester pregnancy 
and risks of congenital heart defects were documented from 1986 to 2003 by the 
MACDP that related carbon monoxide, nitrogen dioxide, and sulfur dioxide 
measurements to the risk of ASD, VSD, TGA, and TOF.19
• The results of a population-based study examining pregnancy obesity found a 
weak to moderate positive association of maternal obesity with 7 of 16 categories 
of birth defects, including heart defects.20
• Although folic acid supplementation is recommended during pregnancy to 
potentially reduce the risk of congenital heart defects,15 there has been only 1 US 
population-based case-control study, performed with the Baltimore-Washington 
Infant Study between 1981 and 1989, that showed an inverse relationship 
between folic acid use and the risk of TGA.21 A study from Quebec, Canada, 
that analyzed 1.3 million births from 1990 to 2005 found a significant 6% per 
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year reduction in severe congenital heart defects using a time-trend analysis 
before and after public health measures were instituted that mandated folic acid 
fortification of grain and flour products in Canada.22
• Pregestational DM was significantly associated with cardiac defects, both 
isolated and multiple. Gestational DM was associated with a limited group of 
birth defects.23
• Paternal risk of occupational exposure was addressed in a study published in 
2012 documenting a higher incidence of congenital HD with paternal exposure 
to phthalates.24
Mortality
(See Table 15-1.)
Mortality related to congenital cardiovascular defects in 2009 was 3189 deaths. Any-
mention mortality related to congenital cardiovascular defects in 2009 was 5051 deaths.21
• In 2009, congenital cardiovascular defects were the most common cause of 
infant death resulting from birth defects; 26.6% of infants who died of a birth 
defect had a heart defect.25
• The death rate attributable to congenital heart defects in the United States has 
continued to decline from 1979 to 1997 and from 1999 to 2006. Age-adjusted 
death rates attributable to all congenital heart defects declined 21% to 39%, and 
deaths tended to occur at progressively older ages. Nevertheless, mortality in 
infants <1 year of age continues to account for nearly half of the deaths.18, 26
• When CDC data on multiple causes of death were used to examine mortality in 
cyanotic and acyanotic lesions between 1979 and 2005, all-age death rates had 
declined by 60% for VSD and 40% for TOF.27
• In population-based data from Canada, 8123 deaths occurred in 71 686 
congenital HD patients followed up for nearly 1 million patient-years. Overall 
mortality decreased by 31%, and the median age of death increased from 2 to 23 
years between 1987 and 2005.28
• The 2009 age-adjusted death rate (deaths/100 000 people) attributable to 
congenital cardiovascular defects was 1.0. Death rates were 1.1 for white males, 
1.4 for black males, 0.9 for white females, and 1.2 for black females. Crude 
infant mortality rates (<1 year of age) were 31.4 for white infants and 42.2 for 
black infants.25
• Mortality after congenital heart surgery also differs between races/ethnicities 
after adjustment for access to care. The risk of in-hospital mortality for minority 
patients compared with white patients is 1.22 (95% CI, 1.05–1.41) for Hispanics, 
1.27 (95% CI, 1.09–1.47) for non-Hispanic blacks, and 1.56 (95% CI, 1.37–1.78) 
for other non-Hispanics.29
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• According to CDC multiple-cause death data, from 1999 to 2006, sex differences 
in mortality over time varied with age. Between the ages of 18 and 34 years, 
mortality over time decreased significantly in females but not in males.30
• On the basis of data from the Healthcare Cost and Utilization Project’s Kids’ 
Inpatient Database from 2000, 2003, and 2006, male children had more 
congenital heart defect surgeries in infancy, more high-risk surgeries, and more 
procedures to correct multiple congenital heart defects. Female infants with high-
risk congenital heart defects had a 39% higher adjusted mortality.26
• In 2007, 189 000 life-years were lost before 55 years of age because of deaths 
attributable to congenital cardiovascular defects. This is almost as many life-
years as were lost from leukemia and asthma combined (NHLBI tabulation of 
NCHS mortality data).
• Data from the Pediatric Heart Network conducted in 15 North American centers 
revealed that even in lesions associated with the highest mortality among 
congenital lesions, such as HPLHS, aggressive palliation can lead to an increase 
in the 12-month survival rate, from 64% to 74%.31
• Data analysis for the Society of Thoracic Surgeons’ Congenital Heart Surgery 
Database, a voluntary registry with self-reported data for a 4-year cycle (2007–
2010) from 103 centers performing congenital heart surgery (98 from the United 
States, 3 from Canada, and 1 from Japan),32 showed that of 95 357 total 
operations, the overall aggregate hospital discharge mortality rate was 3.5%.33 
Specifically, the mortality rate was 10.1% for neonates (0–30 days of age),34 
2.9% for infants (31 days to 1 year of age),35 1.1% for children (>1 year to 18 
years of age),36 and 1.9% for adults (>18 years of age).37
• Using the Nationwide Inpatient Sample 1988–2003, mortality was examined for 
12 congenital heart defect procedures. A total of 30 250 operations were 
identified, which yielded a national estimate of 152 277±7875 operations. Of 
these, 27% were performed in patients ≥18 years of age. The overall in-hospital 
mortality rate for adult patients with congenital heart defects was 4.71% (95% 
CI, 4.19%–5.23%), with a significant reduction in mortality observed when 
surgery was performed on such adult patients by pediatric versus nonpediatric 
heart surgeons (1.87% versus 4.84%; P<0.0001).38
Hospitalizations
(See Table 15-1.)
In 2004, birth defects accounted for >139 000 hospitalizations, representing 47.4 stays per 
100 000 people. Cardiac and circulatory congenital anomalies accounted for 34% of all 
hospital stays for birth defects. Although the most common congenital lesions were shunts, 
including patent ductus arteriosus, VSDs, and ASDs, TOF accounted for a higher proportion 
of in-hospital death than any other birth defect. Between 1997 and 2004, hospitalization 
rates increased by 28.5% for cardiac and circulatory congenital anomalies.39
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Cost
• From data from the Healthcare Cost and Utilization Project 2003 Kids’ Inpatient 
Database and 2003 information on birth defects in the Congenital Malformations 
Surveillance Report, it was found that the most expensive average neonatal 
hospital charges were for 2 congenital heart defects: HPLHS ($199 597) and 
common truncus arteriosus ($192 781). Two other cardiac defects, coarctation of 
the aorta and TGA, were associated with average hospital charges in excess of 
$150 000. For the 11 selected cardiovascular congenital defects (of 35 birth 
defects considered), there were 11 578 hospitalizations in 2003 and 1550 in-
hospital deaths (13.4%). Estimated total hospital charges for these 11 conditions 
were $1.4 billion.40
• In 2004, hospital costs for congenital cardiovascular defect conditions totaled 
$2.6 billion. The highest aggregate costs were for stays related to cardiac and 
circulatory congenital anomalies, which accounted for ≈$1.4 billion, more than 
half of all hospital costs for birth defects.39
• Data from 1941 neonates with HPLHS showed a median cost of $99 070 for 
stage 1 palliation (Norwood or Sano procedure), $35 674 for stage 2 palliation 
(Glenn procedure), $36 928 for stage 3 palliation (Fontan procedure), and $289 
292 for transplantation.41
• In 2124 patients undergoing congenital heart operations between 2001 and 2007, 
total costs for the surgeries were $12 761 (ASD repair), $18 834 (VSD repair), 
$28 223 (TOF repair), and $55 430 (arterial switch operation).42
Kawasaki Disease
ICD-9 446.1; ICD-10 M30.3.
Mortality—5. Any-mention mortality—7.
• The incidence of Kawasaki disease is rising worldwide, including in the United 
States, where the hospitalization rate rose from 17.5/100 000 children aged <5 
years to 20.8/100 000 children <5 years in 2006.43 In 2010, Japan experienced its 
highest-ever incidence rate of 239.6 cases per 100 000 children aged <4 years.44
• US states with higher Asian American populations have higher rates of Kawasaki 
disease; for example, rates are 2.5-fold higher in Hawaii than in the continental 
United States.45
• Boys have a 1.5-fold higher incidence of Kawasaki disease than girls.45
• An estimated 5523 hospitalizations for Kawasaki disease occurred in the United 
States in 2006, with a mean patient age of 3 years. Race-specific incidence rates 
indicate that Kawasaki disease is most common among Americans of Asian and 
Pacific Island descent (30.3/100 000 children <5 years of age), occurs with 
intermediate frequency in non-Hispanic blacks (17.5/100 000 children <5 years 
of age) and Hispanics (15.7/100 000 children <5 years of age), and is least 
common in whites (12.0/100 000 children <5 years of age).46
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• Kawasaki disease is more common during the winter and early spring months, 
except in Hawaii, where no clear seasonal trend is seen47; it occurs more often in 
boys than girls at a ratio of ≈1.5:1, and 76.8% of children with Kawasaki disease 
are <5 years of age.43,45,46
• Data from the Kids’ Inpatient Database45 show a hospitalization rate for 
Kawasaki disease for children <5 years of
– 19 per 100 000 in 2009
– 20.8 per 100 000 in 2006
– 17.3 per 100 000 in 2003
– 17.5 per 100 000 in 2000
• Addition of prednisolone to the standard regimen of intravenous immunoglobulin 
for patients with severe Kawasaki disease appears to result in a substantial 
reduction in the incidence of coronary artery anomalies (RR, 0.20; 95% CI, 
0.12–0.28).48
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16. Disorders of Heart Rhythm
See Table 16-1.
Bradyarrhythmias
ICD-9 426.0, 426.1, 427.81; ICD-10 I44.0 to I44.3, I49.5.
Mortality—791. Any-mention mortality—4678. Hospital discharges— 110 000.
AV Block
Prevalence and Incidence
• The prevalence of first-degree AV block in NHANES III is 3.7% (313 of 8434 
participants with electrocardiographic data readable for PR interval).1
• In a healthy sample of subjects from the ARIC study (mean age 53 years), the 
prevalence of first-degree AV block was 7.8% in black men, 3.0% in black 
women, 2.1% in white men, and 1.3% in white women.2 Lower prevalence 
estimates were noted in the relatively younger population (mean age 45 years) of 
the CARDIA study at its year 20 follow-up examination: 2.6% in black men, 
1.9% in black women, 1.2% in white men, and 0.1% in white women.2
• Mobitz II second-degree AV block is rare in healthy individuals (≈0.003%), 
whereas Mobitz I (Wenckebach) is observed in 1% to 2% of healthy young 
people, especially during sleep.3
• The prevalence of third-degree AV block in the general adult population is 
≈0.02% to 0.04%.4,5
• Third-degree AV block is very rare in apparently healthy individuals. Johnson et 
al6 found only 1 case among >67 000 symptom-free individuals; Rose et al,7 in 
their study of >18 000 civil servants, did not find any cases. On the other hand, 
among 293 124 patients with DM and 552 624 with hypertension enrolled with 
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Veterans Health Administration hospitals, third-degree AV block was present in 
1.1% and 0.6% of those patients, respectively.8
• Congenital complete AV block is estimated to occur in 1 of 15 000 to 25 000 live 
births.3
Abbreviations Used in Chapter 16
AED automated external defibrillator
AHA American Heart Association
AF atrial fibrillation
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities study
AV atrioventricular
BMI body mass index
BP blood pressure
CABG cardiac revascularization (coronary artery bypass graft)
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EMS emergency medical services
FHS Framingham Heart Study
GWTG Get With The Guidelines
HCM hypertrophic cardiomyopathy
HD heart disease
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MI myocardial infarction
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAR population attributable risk
PVT polymorphic ventricular tachycardia
RR relative risk
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SBP systolic blood pressure
SNP single nucleotide polymorphism
SVT supraventricular tachycardia
TdP torsade de pointes
VF ventricular fibrillation
VT ventricular tachycardia
Risk Factors
• Although first-degree AV block and Mobitz type I second-degree AV block can 
occur in apparently healthy individuals, presence of Mobitz II second-degree or 
third-degree AV block usually indicates underlying HD, including CHD and HF.3
• Reversible causes of AV block include electrolyte abnormalities, drug-induced 
AV block, perioperative AV block attributable to hypothermia, or inflammation 
near the AV conduction system after surgery in this region. Some conditions may 
warrant pacemaker implantation because of the possibility of disease progression 
even if the AV block reverses transiently (eg, sarcoidosis, amyloidosis, and 
neuromuscular diseases).9
• Long sinus pauses and AV block can occur during sleep apnea. In the absence of 
symptoms, these abnormalities are reversible and do not require pacing.10
Prevention
• Detection and correction of reversible causes of acquired AV block could be of 
potential importance in preventing symptomatic bradycardia and other 
complications of AV block.9
• In utero detection of congenital AV block is possible by echocardiography.11
Aftermath
• In the FHS, PR interval prolongation (>200 ms) was associated with an increased 
risk of AF (HR, 2.06; 95% CI, 1.36–3.12),12,13 pacemaker implantation (HR, 
2.89; 95% CI, 1.83–4.57),13 and all-cause mortality (HR, 1.44; 95% CI, 1.09–
1.91).13 Compared with individuals with a PR ≤200 ms, individuals with PR 
interval >200 ms had an absolute increased risk per year of 1.04% for AF, 0.55% 
for pacemaker implantation, and 2.05% for death.
• Patients with abnormalities of AV conduction may be asymptomatic or may 
experience serious symptoms related to bradycardia, ventricular arrhythmias, or 
both.
• Decisions about the need for a pacemaker are influenced by the presence or 
absence of symptoms directly attributable to bradycardia. Permanent pacing 
improves survival in patients with third-degree AV block, especially if syncope 
has occurred.9 Nevertheless, the overall prognosis depends to a large extent on 
the underlying HD.
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• Although there is little evidence to suggest that pacemakers improve survival in 
patients with isolated first-degree AV block,14 it is now recognized that marked 
first-degree AV block (PR >300 ms) can lead to symptoms even in the absence of 
higher degrees of AV block.15
Prognosis
• Investigators at Northwestern University compared older adult (age >60 years) 
outpatients with (n=470) and without (n=2090) asymptomatic bradycardia. Over 
a mean follow-up of 7.2 years, patients with asymptomatic bradycardia had a 
higher adjusted incidence of pacemaker insertion (HR, 2.14; 95% CI, 1.30–3.51; 
P=0.003), which appeared after a lag time of 4 years. However, the absolute rate 
of pacemaker implantation was low (<1% per year), and asymptomatic 
bradycardia was not associated with a higher risk of death.16
Sinus Node Dysfunction
Prevalence and Incidence
• The prevalence of sinus node dysfunction has been estimated to be between 403 
and 666 per million, with an incidence rate of 63 per million per year requiring 
pacemaker therapy.17
• Sinus node dysfunction occurs in 1 of every 600 cardiac patients >65 years of 
age and accounts for ≈50% of implantations of pacemakers in the United 
States.18,19
• Sinus node dysfunction is commonly present with other causes of 
bradyarrhythmias (carotid sinus hypersensitivity in 33% of patients and advanced 
AV conduction abnormalities in 17%).20,21
Risk Factors
• The causes of sinus node dysfunction can be classified as intrinsic (secondary to 
pathological conditions involving the sinus node) or extrinsic (caused by 
depression of sinus node function by external factors such as drugs or autonomic 
influences).22
• Sinus node dysfunction may occur at any age but is primarily a disease of the 
elderly, with the average being ≈68 years of age.18
• Idiopathic degenerative disease is probably the most common cause of sinus 
node dysfunction.23
• Collected data from 28 different studies on atrial pacing for sinus node 
dysfunction showed a median annual incidence of complete AV block of 0.6% 
(range, 0%–4.5%) with a total prevalence of 2.1% (range, 0%–11.9%). This 
suggests that the degenerative process also affects the specialized conduction 
system, although the rate of progression is slow and does not dominate the 
clinical course of disease.24
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• Ischemic HD can be responsible for one third of cases of sinus node dysfunction. 
Transient sinus node dysfunction can complicate MI, which is common during 
inferior MI, and is caused by autonomic influences. Cardiomyopathy, long-
standing hypertension, infiltrative disorders (eg, amyloidosis and sarcoidosis), 
collagen vascular disease, and surgical trauma can also result in sinus node 
dysfunction.25,26
Aftermath
• The course of sinus node dysfunction is typically progressive, with 57% of 
patients experiencing symptoms over a 4-year period if untreated, and a 23% 
prevalence of syncope over the same time frame.27
• Approximately 50% of patients with sinus node dysfunction develop tachy-brady 
syndrome over a lifetime; such patients have a higher risk of stroke and death. 
The survival of patients with sinus node dysfunction appears to depend primarily 
on the severity of underlying cardiac disease and is not significantly changed by 
pacemaker therapy.28–30
• In a retrospective study,31 patients with sinus node dysfunction who had 
pacemaker therapy were followed up for 12 years; at 8 years, mortality among 
those with ventricular pacing was 59% compared with 29% among those with 
atrial pacing. This discrepancy may be attributed to selection bias. For instance, 
the physiological or anatomic disorder (eg, fibrosis of conductive tissue) that led 
to the requirement for the particular pacemaker may have influenced prognosis, 
rather than the type of pacemaker used.
• The incidence of sudden death is extremely low, and sinus node dysfunction does 
not appear to affect survival whether untreated or treated with pacemaker 
therapy.9
• Supraventricular tachycardia (SVT) including AF occurs in 47% to 53% of 
patients with sinus node dysfunction.30,32
• On the basis of records from the NHDS, age-adjusted pacemaker implantation 
rates increased progressively from 370 per million in 1990 to 612 per million in 
2002. This escalating implantation rate is attributable to increasing implantation 
for isolated sinus node dysfunction; implantation for sinus node dysfunction 
increased by 102%, whereas implantation for all other indications did not 
increase.33
SVT (Excluding AF and Atrial Flutter)
ICD-9 427.0; ICD-10 I47.1.
Mortality—130. Any-mention mortality—1220. Hospital discharges— 23 000.
Prevalence and Incidence
• Data from the Marshfield Epidemiologic Study Area in Wisconsin suggested the 
incidence of documented paroxysmal SVT is 35 per 100 000 person-years. The 
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mean age at SVT onset was 57 years, and both female sex and age >65 years 
were significant risk factors.34
• A review of ED visits from 1993 to 2003 revealed that 550 000 visits were for 
SVT (0.05% of all visits; 95% CI, 0.04%–0.06%), or ≈50 000 visits per year. Of 
these patients, 24% (95% CI, 15%–34%) were admitted to the hospital, and 44% 
(95% CI, 32%–56%) were discharged without specific follow-up.35
• The prevalence of SVT that is clinically undetected is likely much greater than 
the estimates from ED visits and electrophysiology procedures would suggest. 
For example, among a random sample of 604 participants in Finland, 7 (1.2%) 
fulfilled the diagnostic criteria for inappropriate sinus tachycardia.36
• Of 1383 participants in the Baltimore Longitudinal Study of Aging undergoing 
maximal exercise testing, 6% exhibited SVT during the test; increasing age was a 
significant risk factor. Only 16% exhibited >10 beats of SVT, only 4% were 
symptomatic, and the SVT participants were more likely to develop spontaneous 
SVT or AF.37
• From the surface ECG, the prevalence of atrial tachycardia is estimated to be 
0.34% in asymptomatic patients and 0.46% in symptomatic patients.38
Aftermath
• The primary consequence of SVT for the majority of patients is a decline in 
quality of life.39 However, rare cases of incessant SVT can lead to a tachycardia-
induced cardiomyopathy, 40 and rare cases of sudden death attributed to SVT as a 
trigger have been described.41
Specific Types
• Among those presenting for invasive electrophysiological study and ablation, AV 
nodal reentrant tachycardia (a circuit that requires 2 AV nodal pathways) is the 
most common mechanism of SVT42,43 and usually represents the majority of 
cases (56% of 1 series of 1754 cases from Loyola University Medical Center).43
• AV reentrant tachycardia (an arrhythmia that requires the presence of an 
extranodal connection between the atria and ventricles or specialized conduction 
tissue) is the second most common42,43 (27% in the Loyola series43), and atrial 
tachycardia is the third most common (17% in the Loyola series43).
• In the pediatric population, AV reentrant tachycardia is the most common SVT 
mechanism, followed by AV nodal reentrant tachycardia and then atrial 
tachycardia.44
• AV reentrant tachycardia prevalence decreases with age, whereas AV nodal 
reentrant tachycardia and atrial tachycardia prevalences increase with advancing 
age.43
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• The majority of AV reentrant tachycardia patients in the Loyola series were men 
(55%), whereas the majority of patients with AV nodal reentrant tachycardia 
(70%) or atrial tachycardia (62%) were women.43
• Multifocal atrial tachycardia is an arrhythmia that is commonly confused with 
AF and is characterized by 3 distinct P-wave morphologies, irregular R-R 
intervals, and a rate >100 beats per minute. It is uncommon in both children45 
and adults,46 with a prevalence in hospitalized adults estimated at 0.05% to 
0.32%.46,47 The average age in adults is 70 to 72 years. Adults with multifocal 
atrial tachycardia have a mortality rate that is high, with estimates around 45%, 
but this is generally ascribed to the underlying condition(s).46,47
Wolff-Parkinson-White Syndrome
• Wolff-Parkinson-White syndrome, a diagnosis reserved for those with both 
ventricular preexcitation (evidence of an anterograde conducting AV accessory 
pathway on a 12-lead ECG) and tachyarrhythmias,39 deserves special attention 
because of the associated risk of sudden death. Sudden death is generally 
attributed to rapid heart rates in AF conducting down an accessory pathway and 
leading to ventricular fibrillation (VF).48,49 Of note, AF is common in Wolff-
Parkinson-White patients, and surgical or catheter ablation of the accessory 
pathway often results in elimination of the AF.50
• Ventricular preexcitation with or without tachyarrhythmia was observed in 
0.11% of 47 358 ECGs in adults participating in 4 large Belgian epidemiological 
studies51 and in 0.17% of 32 837 Japanese high school students in ECGs 
obtained by law before the students entered school.52
• Asymptomatic adults with ventricular preexcitation appear to be at no increased 
risk of sudden death compared with the general population,53–56 although certain 
characteristics found during invasive electrophysiological study (including 
inducibility of AV reentrant tachycardia or AF, accessory pathway refractory 
period, and the shortest R-R interval during AF) can help risk stratify these 
patients.49,57
• In a meta-analysis of 20 studies involving 1869 asymptomatic patients with a 
Wolff-Parkinson-White ECG pattern followed up for a total of 11 722 person-
years, the risk of sudden death in a random effects model that was used because 
of heterogeneity across studies was estimated to be 1.25 (95% CI, 0.57–2.19) per 
1000 person-years. Risk factors for sudden death included male sex, inclusion in 
a study of children (<18 years of age), and inclusion in an Italian study.58
• Symptomatic adult patients with the Wolff-Parkinson-White syndrome are at a 
higher risk of sudden death. In a study of 60 symptomatic patients in Olmsted 
County, Minnesota, including some who underwent curative surgery, 2 (3.3%) 
experienced sudden death over a 13-year period. Of 690 Wolff-Parkinson-White 
syndrome patients referred to a single hospital in the Netherlands, 15 (2.2%) had 
aborted sudden death, and VF was the first manifestation of the disease in 8 
patients.59
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• Of 379 Wolff-Parkinson-White patients with induced AV reentrant tachycardia 
during electrophysiology study who did not undergo ablation, 29 (8%) exhibited 
a “malignant presentation” over a mean 3.6 years of follow-up: syncope/
presyncope in 25 patients, rapid preexcited AF causing hemodynamic collapse in 
3 patients, and VF in 1 patient.60 Those with such a presentation were more often 
male, had a shorter accessory pathway effective refractory period during 
electrophysiology study, more often had AV reentrant tachycardia that triggered 
AF during electrophysiology study, and more often had >1 accessory pathway.
• Although some studies in asymptomatic children with ventricular preexcitation 
suggest a benign prognosis,55,61 others suggest that electrophysiological testing 
can identify a group of asymptomatic children with a risk of sudden death or VF 
as high as 11% over 19 months of follow-up.62
Subclinical Atrial Tachyarrhythmias
Pacemakers and defibrillators have increased clinician awareness of the frequency of 
subclinical AF and atrial high-rate episodes in individuals without a documented history of 
AF. Several studies have suggested that device-detected high-rate atrial tachyarrhythmias are 
surprisingly frequent and are associated with an increased risk of AF,63 
thromboembolism,63,64 and total mortality.63
• Investigators in the ASSERT study (Asymptomatic Atrial Fibrillation and Stroke 
Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial 
Pacing Trial) prospectively enrolled 2580 patients with a recent pacemaker or 
defibrillator implantation who were ≥65 years of age, had a history of 
hypertension, and had no history of AF. They classified individuals by presence 
versus absence of subclinical atrial tachyarrhythmias (defined as atrial rate >190 
beats per minute for >6 minutes in the first 3 months) and conducted follow-up 
for 2.5 years.65 Subclinical atrial tachyarrhythmias in the first 3 months occurred 
in 10.1% of the patients and were associated with the following:
– An almost 6-fold higher risk of clinical AF (HR, 5.56; 95% CI, 3.78–
8.17; P<0.001)
– A more than doubling in the adjusted risk of the primary end point, 
ischemic stroke or systemic embolism (HR, 2.50; 95% CI, 1.28–4.89; 
P<0.008)
– An annual ischemic stroke or systemic embolism rate of 1.69% (versus 
0.69% in those without)
– A 13% PAR for ischemic stroke or systemic embolism
• Over the subsequent 2.5 years of follow-up, an additional 34.7% of the patients 
had subclinical atrial tachyarrhythmias, which were 8-fold more frequent than 
clinical AF episodes.
• The appropriate therapy of subclinical atrial tachyarrhythmias has not been 
rigorously studied.
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AF and Atrial Flutter
ICD-9 427.3; ICD-10 I48.
Prevalence
• Estimates of the prevalence of AF in the United States ranged from ≈2.7 to 6.1 
million in 2010, and AF prevalence is expected to rise to between ≈5.6 and 12 
million in 2050.66,67
• Data from a California health plan suggest that compared with whites, blacks 
(OR, 0.49; 95% CI, 0.47–0.52), Asians (OR, 0.68; 95% CI, 0.64–0.72), and 
Hispanics (OR, 0.58; 95% CI, 0.55–0.61) have significantly lower adjusted 
prevalences of AF.68
• Data from the NHDS/NCHS (1996–2001) on cases that included AF as a 
primary discharge diagnosis found the following:
– Approximately 44.8% of patients were men.
– The mean age for men was 66.8 years versus 74.6 years for women.
– The racial breakdown for admissions was 71.2% white, 5.6% black, and 
2.0% other races (20.8% were not specified).
– Black patients were much younger than patients of other races.
• Among Medicare patients aged ≥65 years, diagnosed from 1993 to 2007, the 
prevalence of AF increased ≈5% per year, from ≈41.1 per 1000 beneficiaries to 
85.5 per 1000 beneficiaries.69
Incidence
• Data from the NHDS/NCHS (1996–2001) on cases that included AF as a 
primary discharge diagnosis found the following:
– The incidence in men ranged from 20.6 per 100 000 people per year for 
patients between 15 and 44 years of age to 1077.4 per 100 000 people 
per year for patients ≥85 years of age.
– In women, the incidence ranged from 6.6 per 100 000 people per year 
for patients between 15 and 44 years of age to 1203.7 per 100 000 
people per year for those ≥85 years of age.
• In Olmsted County, Minnesota:
– The age-adjusted incidence of clinically recognized AF in a white 
population increased by 12.6% between 1980 and 2000.67,70
– The incidence of AF was greater in men (incidence ratio for men over 
women 1.86) and increased markedly with older age.67
• In a Medicare sample, the incidence of AF was ≈28 per 1000 person-years and 
did not change substantively between 1993 and 2007. Of individuals with 
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incident AF in 2007, ≈55% were women, 91% were white, 84% had 
hypertension, 36% had HF, and 30% had cerebrovascular disease.69
Mortality
• In 2009, AF was mentioned on 100 196 US death certificates and was the 
underlying cause in 15 434 of those deaths (NCHS, NHLBI).
• In adjusted analyses from the FHS, AF was associated with an increased risk of 
death in both men (OR, 1.5; 95% CI, 1.2–1.8) and women (OR, 1.9; 95% CI, 
1.5–2.2).71 Furthermore, there was an interaction with sex, such that AF 
appeared to diminish the survival advantage typically observed in women.
• In Medicare beneficiaries ≥65 years of age with new-onset AF, mortality 
decreased modestly but significantly between 1993 and 2007. In 2007, the age-
and sex-adjusted mortality at 30 days was 11%, and at 1 year, it was 25%.69
• A study of >4600 patients diagnosed with first AF showed that risk of death 
within the first 4 months after the AF diagnosis was high. The most common 
causes of CVD death were CAD, HF, and ischemic stroke, which accounted for 
22%, 14%, and 10%, respectively, of the early deaths (within the first 4 months) 
and 15%, 16%, and 7%, respectively, of the late deaths.70
• AF is also associated with mortality in individuals with other cardiovascular 
conditions and procedures, including HF,72,73 MI,74,75 CABG,76,77 and stroke,78 
and with noncardiovascular conditions such as sepsis79 and noncardiac surgery.80
Lifetime Risk and Cumulative Risk
• Participants in the NHLBI-sponsored FHS study were followed up from 1968 to 
1999. At 40 years of age, remaining lifetime risks for AF were 26.0% for men 
and 23.0% for women. At 80 years of age, lifetime risks for AF were 22.7% for 
men and 21.6% for women. In further analysis, counting only those who had 
development of AF without prior or concurrent HF or MI, lifetime risk for AF 
was ≈16%.81
• By 80 years of age, investigators from the NHLBI-sponsored ARIC study 
observed that the cumulative risk of AF was 21% in white men, 17% in white 
women, and 11% in African Americans of both sexes.82
Risk Factors
• Standard risk factors
– Both ARIC83 and FHS (http://www.framinghamheartstudy.org/risk/
atrial.html)12,84 have developed risk prediction models to predict new-
onset AF. Predictors of increased risk of new-onset AF include 
advancing age, European ancestry, body size (greater height and BMI), 
electrocardiography features (left ventricular hypertrophy, left atrial 
enlargement), DM, BP (SBP and hypertension treatment), and presence 
of CVD (CHD, HF, valvular HD).
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– Other consistently reported risk factors for AF include clinical and 
subclinical hyperthyroidism,85,86 CKD,87 and heavy alcohol 
consumption.88
• Family history
– Although unusual, early-onset familial lone AF has long been 
recognized as a risk factor.89,90
– In the past decade, the heritability of AF in the community has been 
appreciated. In studies from the FHS:
♦ Adjusted for coexistent risk factors, having at least 1 parent 
with AF was associated with a 1.85-fold increased risk of AF 
in the adult offspring (multivariable-adjusted 95% CI, 1.12–
3.06; P=0.02).91
♦ A history of a first-degree relative with AF also was associated 
with an increased risk of AF (HR, 1.40; 95% CI, 1.13–1.74).76 
The risk was greater if the firstdegree relative’s age of onset 
was ≤65 years (HR, 2.01; 95% CI, 1.49–2.71) and with each 
additional affected first-degree relative (HR, 1.24; 95% CI, 
1.05–1.46).92
• Genetics
– Mutations in genes coding channels (sodium and potassium), gap 
junction proteins, and signaling have been described, often in lone AF 
or familial AF series, but they are responsible for few cases of AF in the 
community.93
– Meta-analyses of genome-wide association studies have revealed SNPs 
on chromosomes 4q25 (upstream of PITX2),94–96 16q22 (ZFHX3),95,97 
and 1q21 (KCNN3),96 as well as 6 other novel susceptibility loci (near 
PRRX1, CAV1, C9orf3, SYNPO2L, SYNE2, and HCN4).98 Although 
an area of intensive inquiry, the causative SNPs and the functional basis 
of the associations have not been revealed.
Awareness
• In a US national biracial study of individuals with AF, compared with whites, 
blacks had approximately one third the likelihood (OR, 0.32; 95% CI, 0.20–0.52) 
of being aware that they had AF.99
Prevention
• Data from the ARIC study indicated that having at least 1 elevated risk factor 
explained 50% and having at least 1 borderline risk factor explained 6.5% of 
incident AF cases. The estimated overall incidence rate per 1000 person-years at 
a mean age of 54.2 years was 2.19 for those with optimal risk, 3.68 for those 
with borderline risk, and 6.59 for those with elevated risk factors.100
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• Hypertension accounted for ≈14%101 to 22%100 of AF cases.
• Observational data from the CHS suggested that moderate-intensity exercise 
(such as regular walking) was associated with a lower risk of AF (HR, 0.72).102 
However, data from many studies suggested that vigorous-intensity exercise 5 to 
7 days a week was associated with a slightly increased risk of AF (HR, 1.20; 
P=0.04).103
• Meta-analyses have suggested that renin-angiotensin system blockers may be 
useful in primary and secondary (recurrences) prevention of AF in trials of 
hypertension, after MI, in HF, and after cardioversion.104,105 However, the 
studies were primarily secondary or post hoc analyses, and the results were fairly 
heterogeneous. Recently, in an analysis of the EMPHASIS-HF trial (Eplerenone 
in Mild Patients Hospitalization And SurvIval Study in Heart Failure), in one of 
many secondary outcomes, eplerenone was nominally observed to reduce the 
incidence of new-onset AF.106
• Although heterogeneous in their findings, modest-sized short-term studies 
suggested that the use of statins might prevent AF; however, larger longer-term 
studies do not provide support that statins are effective in AF prevention.107
• The NHLBI sponsored a workshop highlighting important research areas to 
advance the prevention of AF.108
Aftermath
• Hospitalization
– Hospital discharges—479 000
♦ From 1996 to 2001, hospitalizations with AF as the first-listed 
diagnosis increased by 34%.109
♦ On the basis of Medicare and MarketScan databases, annually, 
individuals with AF (37.5%) are approximately twice as likely 
to be hospitalized as age- and sex-matched control subjects 
(17.5%).110
• Stroke
– Stroke rates per 1000 patient-years declined in AF patients taking 
anticoagulants, from 46.7 in 1992 to 19.5 in 2002, for ischemic stroke 
but remained fairly steady for hemorrhagic stroke (1.6–2.9).111
– When standard stroke risk factors were accounted for, AF was 
associated with a 4-to 5-fold increased risk of ischemic stroke.112
– Although the RR of stroke associated with AF did not vary (≈3–5-fold 
increased risk) substantively with advancing age, the proportion of 
strokes attributable to AF increased significantly. In FHS, AF accounted 
for ≈1.5% of strokes in individuals 50 to 59 years of age and ≈23.5% in 
those 80 to 89 years of age.112
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– Paroxysmal, persistent, and permanent AF all appeared to increase the 
risk of ischemic stroke to a similar degree.113
– AF was also an independent risk factor for ischemic stroke severity, 
recurrence, and mortality.78 In one study, people who had AF and were 
not treated with anticoagulants had a 2.1-fold increase in risk for 
recurrent stroke and a 2.4-fold increase in risk for recurrent severe 
stroke.114
– Studies have demonstrated an underutilization of warfarin therapy. In a 
recent meta-analysis, men and individuals with prior stroke were more 
likely to receive warfarin, whereas factors associated with lower use 
included alcohol and drug abuse, noncompliance, warfarin 
contraindications, dementia, falls, both gastrointestinal and intracranial 
hemorrhage, renal impairment, and advancing age.115
• Cognition
– Individuals with AF have an adjusted 2-fold increased risk of 
dementia.116
– A meta-analysis suggested that the risk was consistently high in the 7 
studies of patients with recent stroke and a history of AF (OR, 2.4; 95% 
CI, 1.7–3.5; P<0.001; I2=87%). There was significant heterogeneity in 
the 7 studies of individuals without a history of stroke (OR, 1.6; 95% 
CI, 1.0–2.7; P=0.05; I2=87%).117
– In individuals with AF in Olmsted County, Minnesota, the cumulative 
rate of dementia at 1 and 5 years was 2.7% and 10.5%, respectively.97
• Heart failure
– AF and HF share many antecedent risk factors, and ≈40% of 
individuals with either AF or HF will develop the other condition.72
– In the community, estimates of the incidence of HF in individuals with 
AF ranged from ≈3.372 to 4.4118 per 100 person-years of follow-up.
Cost—Investigators examined Medicare and MarketScan databases (2004–2006) to 
estimate costs attributed to AF in 2008 US dollars:
• Annual total direct costs for AF patients were ≈$20 670 versus ≈$11 965 in the 
control group, for an incremental per-patient cost of $8705.110
• Extrapolating to the US population, it is estimated that the incremental cost of 
AF was ≈$26 billion, of which $6 billion was attributed to AF, $9.9 billion to 
other cardiovascular expenses, and $10.1 billion to noncardiovascular 
expenses.110
Tachycardia
ICD-9 427.0, 1, 2; ICD-10 I47.0, I47.1, I47.2, I47.9.
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Mortality—607. Any-mention mortality—5902. Hospital discharges— 78 000.
Monomorphic Ventricular Tachycardia
Prevalence and Incidence
• Of 150 consecutive patients with wide-complex tachycardia subsequently studied 
by invasive electrophysiological study, 122 (81%) had ventricular tachycardia 
(VT; the remainder had SVT).119
• Of patients with ventricular arrhythmias presenting for invasive 
electrophysiological studies, 11% to 21% had no structural HD, and the majority 
of those with structural HD had CAD.120,121
• In 634 patients with implantable cardioverter-defibrillators who had structural 
HD (including both primary and secondary prevention patients) followed up for a 
mean 11±3 months, ≈80% of potentially clinically relevant ventricular 
tachyarrhythmias were attributable to VT amenable to antitachycardia pacing 
(implying a stable circuit and therefore monomorphic VT).122 Because therapy 
may have been delivered before spontaneous resolution occurred, the proportion 
of these VT episodes with definite clinical relevance is not known.
• Of those with VT in the absence of structural HD, right ventricular outflow tract 
VT is the most common form.123
Aftermath
• Although the prognosis of those with VT or frequent premature ventricular 
contractions in the absence of structural HD is good,120,123 a potentially 
reversible cardiomyopathy may develop in patients with very frequent premature 
ventricular contractions,124,125 and some cases of sudden death attributable to 
short-coupled premature ventricular contractions have been described.126,127
Polymorphic VT
Prevalence and Incidence
• The true prevalence and incidence of polymorphic VT (PVT) in the US general 
population is not known.
• During ambulatory cardiac monitoring, PVT prevalence ranged from 0.01% to 
0.15%128,129; however, among patients who developed sudden cardiac death 
during ambulatory cardiac monitoring, PVT was detected in 30% to 43%.129–131
• A prevalence range of 15% to 19% was reported during electrophysiological 
study in patients resuscitated from cardiac arrest.131–133
• In the setting of AMI, the prevalence of PVT ranged from 1.2% to 2%.134,135
• Out-of-hospital PVT is estimated to be present in ≈25% of all cardiac arrest 
cases involving VT.136,137
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Risk Factors
• PVT in the setting of a normal QT interval is most frequently seen in the context 
of acute ischemia or MI.135,138
• Less frequently, PVT with a normal QT interval can occur in patients without 
apparent structural HD. Catecholaminergic PVT, which is discussed under 
inherited arrhythmic syndromes, is one such disorder.
• A prolonged QT, whether acquired (drug induced) or congenital, is a common 
cause of PVT. Drug-induced prolongation of QT causing PVT is discussed under 
torsade de pointes (TdP), whereas congenital prolonged QT is discussed under 
inherited arrhythmic syndromes.
Aftermath
• The presentation of PVT can range from a brief, asymptomatic, self-terminating 
episode to recurrent syncope or sudden cardiac death.139
• The overall hospital discharge rate (survival) of PVT has been estimated to be 
≈28%.140
Prevention
• Prompt detection and correction of myocardial ischemia would potentially 
minimize the risk of PVT with normal QT in the setting of AMI.
Torsade de Pointes
Prevalence and Incidence
• The true incidence and prevalence of drug-induced TdP in the US general 
population is largely unknown.
• By extrapolating data from non-US registries,141 it has been estimated that 12 
000 cases of drug-induced TdP occur annually in the United States.142
• The prevalence of drug-induced prolongation of QT and TdP is 2 to 3 times 
higher in women than in men.143
• With the majority of QT-prolonging drugs, drug-induced TdP may occur in 3% 
to 15% of patients.124
• Antiarrhythmic drugs with QT-interval–prolonging potential carry a 1% to 3% 
risk of TdP over 1 to 2 years of exposure.144
Risk Factors
• TdP is usually related to administration of QT-prolonging drugs.145 An up-to-
date list of drugs with the potential to cause TdP may be found at http://
www.azcert.org/medical-pros/drug-lists/drug-lists.cfm, a Web site maintained by 
the University of Arizona Center for Education and Research on Therapeutics.
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• Specific risk factors for drug-induced TdP include prolonged QT, female sex, 
advanced age, bradycardia, hypokalemia, hypomagnesemia, left ventricular 
systolic dysfunction, and conditions that lead to elevated plasma concentrations 
of causative drugs, such as kidney disease, liver disease, drug interactions, or 
some combination of these.142,146,147
• Predisposition was also noted in patients who had a history of ventricular 
arrhythmia and who experienced a recent symptomatic increase in the frequency 
and complexity of ectopy.148
• Drug-induced TdP rarely occurs in patients without concomitant risk factors. An 
analysis of 144 published articles describing TdP associated with noncardiac 
drugs revealed that 100% of the patients had at least 1 risk factor, and 71% had at 
least 2 risk factors.149
Aftermath
• Drug-induced TdP may result in morbidity that requires hospitalization and in 
mortality attributable to sudden cardiac death in up to 31% of patients.142,150
• Patients with advanced HF with a history of drug-induced TdP had a 
significantly higher risk of sudden cardiac death during therapy with amiodarone 
than amiodarone-treated patients with no history of drug-induced TdP (55% 
versus 15%).151 Current use of antipsychotic drugs was associated with a 
significant increase in the risk of sudden cardiac death attributable to TdP (OR, 
3.3; 95% CI, 1.8–6.2).152
• Hospitalization was required in 47% and death occurred in 8% of patients with 
QT prolongation and TdP caused by administration of methadone.153
Prevention
• Keys to reducing the incidence of drug-induced cardiac arrhythmias include 
increased awareness among the medical, pharmaceutical, and nursing professions 
of the potential problems associated with the use of certain agents.
• Appropriate monitoring when a QT-prolonging drug is administered is essential. 
Also, prompt withdrawal of the offending agent should be initiated.154
VF and Ventricular Flutter
ICD-9 427.4; ICD-10 I49.0.
Mortality—1037. Any-mention mortality—9154.
Out-of-Hospital Cardiac Arrest: Adults
Out-of-hospital cardiac arrest is defined as a sudden and unexpected pulseless condition 
attributable to cessation of cardiac mechanical activity.155 There are wide variations in the 
reported incidence of and outcomes for out-of-hospital cardiac arrest. These differences are 
caused in part by differences in definition and ascertainment of cardiac arrest data, as well as 
differences in treatment after the onset of cardiac arrest.
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For additional details on out-of-hospital cardiac arrest treatment, please refer to Chapter 21, 
Quality of Care.
Incidence—(See Table 16-1.)
• The incidence of nontraumatic EMS-assessed, EMS-treated cardiac arrest and 
bystander-witnessed VF among individuals of any age during 2011 in the United 
States is best characterized by an ongoing registry from the Resuscitation 
Outcomes Consortium.
• The total resident population of the United States is 313 794 637 individuals 
(www.census.gov, accessed on June 22, 2012). Extrapolation of the incidence 
and case-fatality rate of EMS-assessed out-of-hospital cardiac arrest reported by 
the Resuscitation Outcomes Consortium (Resuscitation Outcomes Consortium 
Investigators, unpublished data, June 20, 2012) to the total population of the 
United States suggests that each year, 359 400 (quasi CI, 350 200–368 200) 
people experience EMS-assessed out-of-hospital cardiac arrests in the United 
States.
• Approximately 60% of out-of-hospital cardiac arrests are treated by EMS 
personnel.156
• 25% of those with EMS-treated out-of-hospital cardiac arrest have no symptoms 
before the onset of arrest.157
• Among EMS-treated out-of-hospital cardiac arrests, 23% have an initial rhythm 
of VF or VT or are shockable by an automated external defibrillator.158
• The incidence of cardiac arrest with an initial rhythm of VF is decreasing over 
time; however, the incidence of cardiac arrest with any initial rhythm is not 
decreasing.159
Risk Factors
• A study conducted in New York City found the age-adjusted incidence of out-of-
hospital cardiac arrest per 10 000 adults was 10.1 among blacks, 6.5 among 
Hispanics, and 5.8 among whites.160
• Prior HD is a major risk factor for cardiac arrest. A study of 1275 health 
maintenance organization enrollees 50 to 79 years of age who had cardiac arrest 
showed that the incidence of out-of-hospital cardiac arrest was 6.0 per 1000 
person-years in subjects with any clinically recognized HD compared with 0.8 
per 1000 person-years in subjects without HD. In subgroups with HD, incidence 
was 13.6 per 1000 person-years in subjects with prior MI and 21.9 per 1000 
person-years in subjects with HF.161
• A family history of cardiac arrest in a first-degree relative is associated with an 
≈2-fold increase in risk of cardiac arrest.162,163
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• In a study of 81 722 women in the Nurses’ Health Study, the PAR of sudden 
death associated with 4 lifestyle factors (smoking, PA, diet, and weight) was 81% 
(95% CI, 52%–93%).164
Aftermath
• Survival to hospital discharge in 2010, after EMS-treated nontraumatic cardiac 
arrest with any first recorded rhythm was 9.5% (95% CI, 8.8%–10.2%) for 
patients of any age, 9.8% (95% CI, 9.0%–10.6%) for adults, and 7.8% (4.2%–
11.5%) for children (Resuscitation Outcomes Consortium Investigators, 
unpublished data, June 20, 2012). Survival after bystander-witnessed VF was 
28.4% (95% CI, 25.1%–31.8%) for patients of any age, 28.4% (95% CI, 25.1%–
31.8%) for adults, and 57.1% (95% CI, 20.4%–93.8%) for children 
(Resuscitation Outcomes Consortium Investigators, unpublished data, June 20, 
2012).
• A study conducted in New York City found the age-adjusted survival to 30 days 
after discharge was more than twice as poor for blacks as for whites, and survival 
among Hispanics was also lower than among whites.160
• Seventy-nine percent of the lay public are confident that they know what actions 
to take in a medical emergency; 98% recognize an automated external 
defibrillator as something that administers an electric shock to restore a normal 
heartbeat among victims of sudden cardiac arrest; and 60% are familiar with 
cardiopulmonary resuscitation (Harris Interactive survey conducted on behalf of 
the AHA among 1132 US residents ≥18 years of age, January 8, 2008–January 
21, 2008).
Out-of-Hospital Cardiac Arrest: Athletics
• Among 10.9 million registered participants in 40 marathons and 19 half 
marathons, the overall incidence of cardiac arrest was 0.54 per 100 000 
participants (95% CI, 0.41–0.70).165 Those with cardiac arrest were more often 
male and were running a marathon versus a half marathon. Seventy-one percent 
of those with cardiac arrest died; those who died were younger (mean 39±9 years 
of age) than those who did not die (mean 49±10 years of age), were more often 
male, and were more often running a full marathon.
Out-of-Hospital Cardiac Arrest: Children
(See Table 16-1.)
• The incidence of nontraumatic EMS-treated cardiac arrest and bystander-
witnessed VF among individuals <18 years of age in the United States is best 
characterized by an ongoing registry. Survival to hospital discharge among 
children with EMS-treated, nontraumatic cardiac arrest is 7.8% (95% CI, 4.2%–
11.5%; Resuscitation Outcomes Consortium Investigators, unpublished data, 
June 20, 2011) and that of bystander-witnessed VF is 57.1% (95% CI, 20.4%–
93.8%).
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• Most sudden deaths in athletes were attributable to CVD (56%). Of the 
cardiovascular deaths that occurred, 29% occurred in blacks, 54% in high school 
students, and 82% with physical exertion during competition/training; only 11% 
occurred in females, although this proportion has increased over time.166
• A longitudinal study of students 17 to 24 years of age participating in National 
Collegiate Athletic Association sports showed that the incidence of nontraumatic 
out-of-hospital cardiac arrest was 1 per 22 903 athlete participant-years. The 
incidence of cardiac arrest tended to be higher among blacks than among whites 
and among men than among women.167
In-Hospital Cardiac Arrest
• Extrapolation of the incidence of in-hospital cardiac arrest reported by Get With 
The Guidelines (GWTG)–Resuscitation to the total population of hospitalized 
patients in the United States suggests that each year, 209 000 (quasi CI, 192 000–
211 000) people are treated for in-hospital cardiac arrest.168
• According to the GWTG-Resuscitation Investigators (unpublished data, June 22, 
2012), 24.2% (95% CI, 23.5%–24.9%) of patients of any age or 23.9% (95% CI, 
23.2%–24.6%) of adults and 40.2% (95% CI, 34.2%–46.2%) of children 
(excluding neonates who experienced in-hospital cardiac arrest with any first 
recorded rhythm) in 2011 survived to discharge.
• In 2011, 17.6% (95% CI, 17.0%–18.3%) of patients of any age or 17.7% (95% 
CI, 17.1%–18.4%) of adults and 14.1% (95% CI, 9.8%–18.3%) of children 
(excluding neonates) had in-hospital cardiac arrest with VF or pulseless VT as 
the first recorded rhythm. Of these, 43.0% (95% CI, 41.0%–45.0%) of adults and 
52.8% (95% CI, 36.5%–69.1%) of children (excluding neonates) survived to 
discharge (GWTG-Resuscitation Investigators unpublished data, June 22, 2012). 
For additional details on in-hospital arrest treatment, please refer to Chapter 21, 
Quality of Care.
Monogenic Inherited Syndromes Associated With Sudden Cardiac Death
Long-QT Syndrome
• The hereditary long-QT syndrome is a genetic channelopathy characterized by 
prolongation of the QT interval (typically >460 ms) and susceptibility to 
ventricular tachyarrhythmias that lead to syncope and sudden cardiac death. 
Investigators have identified mutations in 13 genes leading to this phenotype 
(LQT1 through LQT13). LQT1 (KCNQ1), LQT2 (KCNH2), and LQT3 
(SCN5A) mutations account for the majority (≈80%) of the typed 
mutations.169,170
• Prevalence of long-QT syndrome is estimated at 1 per 2000 live births from 
ECG-guided molecular screening of ≈44 000 mostly white infants born in 
Italy.171 A similar prevalence was found among nearly 8000 Japanese school 
children screened by use of an ECG-guided molecular screening approach.172
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• Long-QT syndrome has been reported among those of African descent, but its 
prevalence is not well assessed.173
• There is variable penetrance and a sex-time interaction for long-QT syndrome 
symptoms. Risk of cardiac events is higher among boys than girls (21% among 
boys and 14% among girls by age 12 years). Risk of events during adolescence is 
equivalent between sexes (≈25% for both sexes from ages 12–18 years). 
Conversely, risk of cardiac events in young adulthood is higher among women 
than men (39% among women from ages 18 to 40 years and 16% among 
men).170
• In addition to age and sex, the clinical course is influenced by prior syncope or 
aborted cardiac arrest, family history, QT-interval duration, genotype, number of 
mutations, and congenital deafness.169,170,174
• Risk of cardiac events is decreased during pregnancy but increased during the 9-
month postpartum period.175
• The mainstay of therapy and prevention is β-blockade treatment.170,174 
Implantable defibrillators are considered for high-risk individuals.176
Short-QT Syndrome
• Short-QT syndrome is a recently described inherited mendelian condition 
characterized by shortening of the QT interval (typically QT <320 ms) and 
predisposition to AF and ventricular tachyarrhythmias and sudden death. 
Mutations in 5 ion channel genes have been described (SQT1–SQT5).177
• In a population of 41 767 young predominantly male Swiss transcripts, 0.02% of 
the population had a QT interval shorter than 320 ms.178
• Among 53 patients from the European Short QT Syndrome Registry (75% males, 
median age 26 years), a familial or personal history of cardiac arrest was present 
in 89%. Twenty-four patients received an implantable cardioverter-defibrillator, 
and 12 received long-term prophylaxis with hydroquinidine. During a median 
follow-up of 64 months, 2 patients received an appropriate implantable 
cardioverter-defibrillator shock, and 1 patient experienced syncope. 
Nonsustained PVT was recorded in 3 patients.179
The Brugada Syndrome
• The Brugada syndrome is an inherited channelopathy characterized by persistent 
ST-segment elevation in the precordial leads (V1–V3), right bundle-branch block, 
and susceptibility to ventricular arrhythmias and sudden cardiac death.180
• Mutations in several ion channel–related genes have been identified that lead to 
Brugada syndrome.180
• Prevalence is estimated at 1 to 5 per 10 000 individuals. Prevalence is higher in 
Southeast Asian countries, including Thailand and the Philippines. There is a 
strong male predominance (80% male).180–185
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• Cardiac event rates for Brugada syndrome patients followed up prospectively in 
northern Europe (31.9 months) and Japan (48.7 months) were similar: 8% to 
10% in patients with prior aborted sudden death, 1% to 2% in those with history 
of syncope, and 0.5% in asymptomatic patients.186,187 Predictors of poor 
outcome included family history of sudden death and early repolarization pattern 
on ECG.186,187
Catecholaminergic PVT
• Catecholaminergic PVT is a familial condition characterized by adrenergically 
induced ventricular arrhythmias associated with syncope and sudden death. It is 
associated with frequent ectopy, bidirectional VT, and PVT with exercise or 
catecholaminergic stimulation (such as emotion, or medicines such as 
isoproterenol).
• Mutations in genes encoding the ryanodine type 2 receptor (RYR2)188,189 are 
found in the majority, and mutations in genes encoding calsequestrin 2 
(CASQ2)190,191 are found in a small minority.192 However, a substantial 
proportion of individuals with catecholaminergic PVT do not have an identified 
mutation.
• Statistics regarding catecholaminergic PVT are primarily from case series. Of 
101 patients with catecholaminergic PVT, the majority had experienced 
symptoms before 21 years of age.192
• In small series (n=27 to n=101) of patients followed up over a mean of 6.8 to 7.9 
years, 27% to 62% experienced cardiac symptoms, and fatal or near-fatal events 
occurred in 13% to 31%.192–194
• Risk factors for cardiac events included younger age of diagnosis and absence of 
β-blocker therapy. A history of aborted cardiac arrest and absence of β-blocker 
therapy were risk factors for fatal or near-fatal events.192
Arrhythmogenic Right Ventricular Cardiomyopathy
• Arrhythmogenic right ventricular cardiomyopathy is a form of genetically 
inherited structural HD that presents with fibrofatty replacement of the 
myocardium, with clinical presentation of palpitations, syncope, and sudden 
death.195
• Twelve arrhythmogenic right ventricular cardiomyopathy loci have been 
described (ARVC1–ARVC12). Disease-causing genes for 8 of these loci have 
been identified, the majority of which are in desmosomally related proteins.195
• Prevalence is estimated at 2 to 10 per 10 000 individuals. 195,196 Of 100 patients 
reported on from the Johns Hopkins Arrhythmogenic Right Ventricular 
Dysplasia Registry, 51 were men, and 95 were white, with the rest being of 
black, Hispanic, or Middle Eastern origin. Twenty-two percent of index cases 
had evidence of the familial form of arrhythmogenic right ventricular 
cardiomyopathy.197
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• The most common presenting symptoms were palpitations (27%), syncope 
(26%), and sudden cardiac death (23%).197
• During a median follow-up of 6 years, 47 patients received an implantable 
cardioverter-defibrillator, 29 of whom received appropriate implantable 
cardioverter-defibrillator shocks. At the end of follow-up, 66 patients were alive. 
Twenty-three patients died at study entry, and 11 died during follow-up (91% of 
deaths were attributable to sudden cardiac arrest).197 Similarly, the annual 
mortality rate was 2.3% for 130 patients with arrhythmogenic right ventricular 
cardiomyopathy from Paris, France, who were followed up for a mean of 8.1 
years.198
Hypertrophic Cardiomyopathy—(Please refer to Chapter 19, Cardiomyopathy and 
Heart Failure, for statistics regarding the general epidemiology of HCM.)
• Over a mean follow-up of 8±7 years, 6% of HCM patients experienced sudden 
cardiac death.199
• Among 1866 sudden deaths in athletes between 1980 and 2006, HCM was the 
most common cause of cardiovascular sudden death (in 251 cases, or 36% of the 
690 deaths that could be reliably attributed to a cardiovascular cause).166
• The risk of sudden death increases with increasing maximum left ventricular 
wall thickness,200,201 and the risk for those with wall thickness ≥30 mm is 18.2 
per 1000 patient-years (95% CI, 7.3–37.6),200 or approximately twice that of 
those with maximal wall thickness <30 mm.200,201 Of note, an association 
between maximum wall thickness and sudden death has not been found in every 
HCM population.202
• Nonsustained VT is a risk factor for sudden death,203,204 particularly in younger 
patients. Nonsustained VT in those ≤30 years of age is associated with a 4.35-
greater odds of sudden death (95% CI, 1.5–12.3).203
• A history of syncope is also a risk factor for sudden death in these patients,205 
particularly if the syncope was recent before the initial evaluation and not 
attributable to a neurally mediated event.206
• The presence of left ventricular outflow tract obstruction ≥30 mm Hg appears to 
increase the risk of sudden death by ≈2-fold.207,208 The presence of left 
ventricular outflow tract obstruction has a low positive predictive value (7%–8%) 
but a high negative predictive value (92%–95%) for predicting sudden 
death.207,209
• The rate of malignant ventricular arrhythmias detected by implantable 
cardioverter-defibrillators appears to be similar between those with a family 
history of sudden death in ≥1 first-degree relatives and those with at least 1 of the 
risk factors described above.210
• The risk of sudden death increases with the number of risk factors.211,212
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17. Subclinical Atherosclerosis
(See Table 17-1 and Chart 17-1 through 17-6).
Atherosclerosis, a systemic disease process in which fatty deposits, inflammation, cells, and 
scar tissue build up within the walls of arteries, is the underlying cause of the majority of 
clinical cardiovascular events. Individuals who develop atherosclerosis tend to develop it in a 
number of different types of arteries (large and small arteries and those feeding the heart, 
brain, kidneys, and extremities), although they may have much more in some parts of the 
body than others. In recent decades, advances in imaging technology have allowed for 
improved ability to detect and quantify atherosclerosis at all stages and in multiple different 
vascular beds. Two modalities, computed tomography (CT) of the chest for evaluation of 
CAC and B-mode ultrasound of the neck for evaluation of carotid artery IMT, have been 
used in large studies with outcomes data and may help define the burden of atherosclerosis 
in individuals before they develop clinical events such as heart attack or stroke. Another 
commonly used method for detecting and quantifying atherosclerosis in the peripheral 
arteries is the ankle-brachial index (ABI), which is discussed in Chapter 20. Data on 
cardiovascular outcomes are starting to emerge for additional modalities that measure 
anatomic and functional measures of subclinical disease, including brachial artery reactivity 
testing, aortic and carotid magnetic resonance imaging, and tonometric methods of 
measuring vascular compliance or microvascular reactivity. Further research may help to 
define the role of these techniques in cardiovascular risk assessment. Some guidelines have 
recommended screening for subclinical atherosclerosis, especially by CAC, or IMT may be 
appropriate in people at intermediate risk for HD (eg, 10-year estimated risk of 10% to 20%) 
but not for lower-risk general population screening or for people with preexisting HD or 
most other high-risk conditions.1,2 However, a recent guideline notes those with DM who 
are ≥40 years of age may be suitable for screening of risk by coronary calcium. There are 
still limited data demonstrating whether screening with these and other imaging modalities 
can improve patient outcomes or whether it only increases downstream medical care costs. 
A recently published report in a large cohort randomly assigned to coronary calcium 
screening or not showed such screening to result in an improved risk factor profile without 
increasing downstream medical costs.3
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Abbreviations Used in Chapter 17
AAC aortic artery calcification
ABI ankle-brachial index
ACS acute coronary syndrome
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
CAC coronary artery calcification
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CONFIRM Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry
CT computed tomography
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
EISNER Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research
FHS Framingham Heart Study
FMD flow-mediated dilation
FRS Framingham Risk Score
HBP high blood pressure
HDL high-density lipoprotein
HD heart disease
HR hazard ratio
IMT intima-media thickness
LDL low-density lipoprotein
MESA Multi-Ethnic Study of Atherosclerosis
NHLBI National Heart, Lung, and Blood Institute
RR relative risk
SBP systolic blood pressure
Coronary Artery Calcification
Background
• CAC is a measure of the burden of atherosclerosis in the heart arteries and is 
measured by CT. Other components of the atherosclerotic plaque, including fatty 
(eg, cholesterol-rich components) and fibrotic components, often accompany 
CAC and may be present even in the absence of CAC.
• The presence of any CAC, which indicates that at least some atherosclerotic 
plaque is present, is defined by an Agatston score >0. Clinically significant 
plaque, frequently an indication for more aggressive risk factor management, is 
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often defined by an Agatston score ≥100 or a score ≥75th percentile for one’s 
age and sex. An Agatston score ≥400 has been noted to be an indication for 
further diagnostic evaluation (eg, exercise testing or myocardial perfusion 
imaging) for CAD.
• Current guidelines provide for a modest Class IIa, Level of Evidence B 
recommendation for screening for coronary calcium in people at intermediate 
risk (eg, 10%–20% 10-year CHD risk) or with DM; a Class IIb, Level of 
Evidence B recommendation for those at low intermediate risk (6%–10% 10-
year CHD risk); but a contraindication (Class III, Level of Evidence B) for 
screening those at lower risk.2
Prevalence—(See Table 17-1 and Charts 17-1 and Chart 17-2.)
• The NHLBI’s FHS reported CAC measured in 3238 white adults in age groups 
ranging from <45 years of age to ≥75 years of age.4
– Overall, 32.0% of women and 52.9% of men had prevalent CAC.
– Among participants at intermediate risk according to FRS, 58% of 
women and 67% of men had prevalent CAC.
• The NHLBI’s CARDIA study measured CAC in 3043 black and white adults 33 
to 45 years of age (at the CARDIA year 15 examination).5
– Overall, 15.0% of men and 5.1% of women, 5.5% of those 33 to 39 
years of age and 13.3% of those 40 to 45 years of age, had prevalent 
CAC. Overall, 1.6% of participants had an Agatston score that exceeded 
100.
– The prevalence of CAC was lower in black men than in white men but 
was similar in black and white women at these ages.
• The NHLBI’s MESA measured CAC in 6814 participants 45 to 84 years of age, 
including white (n=2619), black (n=1898), Hispanic (n=1494), and Chinese 
(n=803) men and women.6
– The prevalence and 75th percentile levels of CAC were highest in white 
men and lowest in black and Hispanic women. Significant ethnic 
differences persisted after adjustment for risk factors, with the RR of 
coronary calcium being 22% less in blacks, 15% less in Hispanics, and 
8% less in Chinese than in whites.
– Table 17-1 shows the 75th percentile levels of CAC by sex and race at 
selected ages. These might be considered cut points above which more 
aggressive efforts to control risk factors (eg, elevated cholesterol or BP) 
could be implemented and/or at which treatment goals might be more 
aggressive (eg, LDL cholesterol <100 mg/dL instead of <130 mg/dL).
• The prevalence of CAC varies widely according to FRS. In a report from 
MESA,7 the prevalence of CAC among individuals with very low FRS (10-year 
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risk <5%) was low. These findings may have important implications for 
population screening for subclinical atherosclerosis.
• Investigators from the NHLBI’s CARDIA study examined the association 
between neighborhood attributes and subclinical atherosclerosis in younger adult 
populations. Using 2000 US Census block-group–level data, among women, 
higher odds of CAC were associated with higher neighborhood deprivation and 
lower neighborhood cohesion. Among all men, neither neighborhood deprivation 
nor neighborhood cohesion was associated with CAC, whereas among men in 
deprived neighborhoods, low cohesion was associated with higher odds of CAC.8
CAC and Incidence of Coronary Events—(See Chart 17-3 and 17-4.)
• The NHLBI’s MESA recently reported on the association of CAC scores with 
first CHD events over a median follow-up of 3.9 years among a population-based 
sample of 6722 men and women (39% white, 27% black, 22% Hispanic, and 
12% Chinese).9
– People with CAC scores of 1 to 100 had ≈4 times greater risk and those 
with CAC scores >100 were 7 to 10 times more likely to experience a 
coronary event than those without CAC.
– CAC provided similar predictive value for coronary events in whites, 
Chinese, blacks, and Hispanics (HRs ranging from 1.15–1.39 for each 
doubling of coronary calcium).
• In another report of a community-based sample, not referred for clinical reasons, 
the South Bay Heart Watch examined CAC in 1461 adults (average age 66 years) 
with coronary risk factors, with a median of 7.0 years of follow-up.10
• In a study of healthy adults 60 to 72 years of age who were free of clinical CAD, 
predictors of the progression of CAC were assessed. Predictors tested included 
age, sex, race/ethnicity, smoking status, BMI, family history of CAD, C-reactive 
protein, several measures of DM, insulin levels, BP, and lipids. Insulin resistance, 
in addition to the traditional cardiac risk factors, independently predicts 
progression of CAC.11 Clinically, however, it is not yet recommended to conduct 
serial scanning of CAC to measure effects of therapeutic interventions.
• A recent publication from MESA also used CAC, in particular, and carotid IMT 
to stratify CHD and CVD event risk in people with metabolic syndrome and DM; 
those with low levels of CAC or carotid IMT have CHD and CVD event rates as 
low as many people without metabolic syndrome and DM. Those with DM who 
have CAC scores <100 have annual CHD event rates of <1%.12
• It is noteworthy, as recently demonstrated in MESA in 5878 participants with a 
median of 5.8 years of follow-up, that the addition of CAC to standard risk 
factors resulted in significant improvement of classification of risk for incident 
CHD events, placing 77% of people in the highest or lowest risk categories 
compared with 69% based on risk factors alone. An additional 23% of those who 
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experienced events were reclassified as high risk, and 13% with events were 
reclassified as low risk.13
• The contribution of CAC to risk prediction has also been observed in other 
cohorts, including both the Heinz Nixdorf Recall study14 and the Rotterdam 
study.15
• In MESA, among 6603 people aged 45 to 84 years (1686 or 25% with metabolic 
syndrome without DM and 881 or 13% with DM), subclinical atherosclerosis 
assessed by CAC was more severe in people with metabolic syndrome and DM 
than in those without these conditions, and the extent of CAC was a strong 
predictor of CHD and CVD events in these groups, with CAC increasing the C 
statistic significantly (P<0.001) over other risk factors in each of these groups.12
CAC Progression and Risk
• A recent report in 4609 individuals who had baseline and repeat cardiac CT 
found that progression of CAC in predicting future all-cause mortality provided 
only incremental information over baseline score, demographics, and 
cardiovascular risk factors.16
• Furthermore, in MESA, among 5662 subjects aged 45 to 84 years who received 
baseline and follow-up CT scans, the progression of CAC was greater in people 
with metabolic syndrome and DM than in those without, and greater progression 
of CAC in these groups was also associated with greater risk for CHD events.17
Abdominal Aortic Calcification and Multisite Atherosclerosis
• Abdominal aortic calcification (AAC) can be measured by CT and at most age 
groups is at a higher prevalence than CAC. In MESA, AAC prevalence ranged 
from 34% in those aged 45 to 54 years to 94% in those aged 75 to 84 years. 
Prevalence was significantly higher in Caucasians (79%) and lowest in blacks 
(62%). The prevalence of CAC, increased carotid IMT, and abnormal ABI was 
also greater in those with versus without AAC, and by age 65 years, 97% of men 
and 91% of women had either AAC, CAC, increased carotid IMT, or low ABI. 
Three or more of these conditions (“multisite atherosclerosis”) were present in 
20% of women and 30% of men.18
• In addition, AAC was significantly associated with cigarette smoking and 
dyslipidemia, whereas CAC showed much weaker associations; age and 
hypertension were associated similarly and significantly with AAC and CAC. 
AAC was more strongly correlated with most CVD risk factors than was CAC.19
• At present, however, no recommendations exist for screening of AAC for 
assessment of cardiovascular risk because of the limited data available.
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Carotid IMT
Background
• Carotid IMT measures the thickness of 2 layers (the intima and media) of the 
wall of the carotid arteries, the largest conduits of blood going to the brain. 
Carotid IMT is thought to be an even earlier manifestation of atherosclerosis than 
CAC, because thickening precedes the development of frank atherosclerotic 
plaque. Carotid IMT methods are still being refined, so it is important to know 
which part of the artery was measured (common carotid, internal carotid, or 
bulb) and whether near and far walls were both measured. This information can 
affect the average-thickness measurement that is usually reported.
• Unlike CAC, everyone has some thickness to the layers of their arteries, but 
people who develop atherosclerosis have greater thickness. Ultrasound of the 
carotid arteries can also detect plaques and determine the degree of narrowing of 
the artery they may cause. Epidemiological data, including the data discussed 
below, have indicated that high-risk levels of thickening might be considered as 
those in the highest quartile or quintile for one’s age and sex, or ≥1 mm.
• Although ultrasound is commonly used to diagnose plaque in the carotid arteries 
in people who have had strokes or who have bruits (sounds of turbulence in the 
artery), guidelines are limited as to screening of asymptomatic people with 
carotid IMT to quantify atherosclerosis or predict risk. However, some 
organizations have recognized that carotid IMT measurement by B-mode 
ultrasonography may provide an independent assessment of coronary risk.20 For 
those at intermediate CHD risk (eg, 10%–20% 10-year CHD risk), a Class IIa, 
Level of Evidence B recommendation has been noted for the use of carotid IMT 
in screening asymptomatic people.2
Prevalence and Association With Incident Cardiovascular Events—(See Chart 
17-5 and 17-6.)
• The Bogalusa Heart Study measured carotid IMT in 518 black and white men 
and women at a mean age of 32±3 years. These men and women were healthy 
but overweight.21
– Men had significantly higher carotid IMT in all segments than women, 
and blacks had higher common carotid and carotid bulb IMTs than 
whites.
– Even at this young age, after adjustment for age, race, and sex, carotid 
IMT was associated significantly and positively with waist 
circumference, SBP, DBP, and LDL cholesterol. Carotid IMT was 
inversely correlated with HDL cholesterol levels. Participants with 
greater numbers of adverse risk factors (0, 1, 2, 3, or more) had 
stepwise increases in mean carotid IMT levels.
• In a subsequent analysis, the Bogalusa investigators examined the association of 
risk factors measured since childhood with carotid IMT measured in these young 
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adults.22 Higher BMI and LDL cholesterol levels measured at 4 to 7 years of age 
were associated with increased risk for being >75th percentile for carotid IMT in 
young adulthood. Higher SBP and LDL cholesterol and lower HDL cholesterol 
in young adulthood were also associated with having high carotid IMT. These 
data highlight the importance of adverse risk factor levels in early childhood and 
young adulthood in the early development of atherosclerosis.
• Among both women and men in MESA, blacks had the highest common carotid 
IMT, but they were similar to whites and Hispanics in internal carotid IMT. 
Chinese participants had the lowest carotid IMT, in particular in the internal 
carotid, of the 4 ethnic groups.23
• The NHLBI’s CHS reported follow-up of 4476 men and women ≥65years of age 
(mean age 72 years) who were free of CVD at baseline.24
– Mean maximal common carotid IMT was 1.03±0.20 mm, and mean 
internal carotid IMT was 1.37±0.55 mm.
– After a mean follow-up of 6.2 years, those with maximal combined 
carotid IMT in the highest quintile had a 4-to 5-fold greater risk for 
incident heart attack or stroke than those in the bottom quintile. After 
adjustment for other risk factors, there was still a 2- to 3-fold greater 
risk for the top versus the bottom quintile.
• A study of 441 individuals ≤65 years of age without a history of CAD, DM, or 
hyperlipidemia who were examined for carotid IMT found 42% had high-risk 
carotid ultrasound findings (carotid IMT ≥75th percentile adjusted for age, sex, 
and race or presence of plaque). Among those with an FRS ≤5%, 38% had high-
risk carotid ultrasound findings.25
• Conflicting data have been reported on the contribution of carotid IMT to risk 
prediction. In 13 145 participants in the NHLBI’s ARIC study, the addition of 
carotid IMT combined with identification of plaque presence or absence to 
traditional risk factors reclassified risk in 23% of individuals overall, with a net 
reclassification improvement of 9.9%. There was a modest but statistically 
significant improvement in the area under the receiver operating characteristic 
curve, from 0.742 to 0.755.26 In contrast, data reported recently from the Carotid 
Atherosclerosis Progression Study observed a net reclassification improvement 
of −1.4% that was not statistically significant.27
CAC and Carotid IMT
• In the NHLBI’s MESA, a study of white, black, Chinese, and Hispanic adults 45 
to 84 years of age, carotid IMT and CAC were found to be commonly associated, 
but patterns of association differed somewhat by sex and race.23
– Common and internal carotid IMT were greater in women and men 
who had CAC than in those who did not, regardless of ethnicity.
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– Overall, CAC prevalence and scores were associated with carotid IMT, 
but associations were somewhat weaker in blacks than in other ethnic 
groups.
– In general, blacks had the thickest carotid IMT of all 4 ethnic groups, 
regardless of the presence of CAC.
– Common carotid IMT differed little by race/ethnicity in women with 
any CAC, but among women with no CAC, IMT was higher among 
blacks (0.86 mm) than in the other 3 groups (0.76–0.80 mm).
• In a more recent analysis from the NHLBI’s MESA, the investigators reported on 
follow-up of 6698 men and women in 4 ethnic groups over 5.3 years and 
compared the predictive utility of carotid IMT and CAC.28
– CAC was associated more strongly than carotid IMT with the risk of 
incident CVD.
– After adjustment for each other (CAC score and IMT) and for 
traditional CVD risk factors, the HR for CVD increased 2.1-fold for 
each 1-standard deviation increment of log-transformed CAC score 
versus 1.3-fold for each 1-standard deviation increment of the 
maximum carotid IMT.
– For CHD events, the HRs per 1-standard deviation increment increased 
2.5-fold for CAC score and 1.2-fold for IMT.
– A receiver operating characteristic curve analysis also suggested that 
CAC score was a better predictor of incident CVD than was IMT, with 
areas under the curve of 0.81 versus 0.78, respectively.
– Investigators from the NHLBI’s CARDIA and MESA studies examined 
the burden and progression of subclinical atherosclerosis among adults 
<50 years of age. Ten-year and lifetime risks for CVD were estimated 
for each participant, and the participants were stratified into 3 groups: 
(1) those with low 10-year (<10%) and low lifetime (<39%) predicted 
risk for CVD; (2) those with low 10-year (<10%) but high lifetime 
(≥39%) predicted risk; and (3) those with high 10-year risk (>10%). 
The latter group had the highest burden and greatest progression of 
subclinical atherosclerosis. Given the young age of those studied, ≈90% 
of participants were at low 10-year risk, but of these, half had high 
predicted lifetime risk. Compared with those with low short-term/low 
lifetime predicted risks, those with low short-term/high lifetime 
predicted risk had significantly greater burden and progression of CAC 
and significantly greater burden of carotid IMT, even at these younger 
ages. These data confirm the importance of early exposure to risk 
factors for the onset and progression of subclinical atherosclerosis.29
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CT Angiography
CT angiography is widely used by cardiologists to aid in the diagnosis of CAD, particularly 
when other test results may be equivocal. It is also of interest because of its ability to detect 
and possibly quantitate overall plaque burden and certain characteristics of plaques that may 
make them prone to rupture, such as positive remodeling or low attenuation.
• In a study of 1059 subjects undergoing CT angiography, those who exhibited 
both positive remodeling and low-attenuation plaques <30 Hounsfield units on 
CT had the greatest risk of developing future ACS.30
However, because of the limited outcome data in asymptomatic people, as well as the 
associated expense and risk of CT angiography (including generally higher radiation levels 
than CT scanning to detect CAC), current guidelines do not recommend its use as a 
screening tool for assessment of cardiovascular risk in asymptomatic people (Class III, Level 
of Evidence C).2
• In symptomatic individuals, however, the CONFIRM registry (Coronary CT 
Angiography Evaluation for Clinical Outcomes: An International Multicenter 
Registry) showed that even if the CAC score was 0, obstructive CAD was 
possible and was associated with an increased risk of cardiovascular events (HR 
of 5.7 in those with ≥50% stenosis versus no obstructive CAD when the CAC 
score was 0).31
• In addition, a recent meta-analysis of 11 studies that included 7335 people with 
suspected CAD showed those with at least 1 significant coronary stenosis from 
CT angiography had an annualized event rate of 11.9% and an HR of 10.7 for 
incident cardiovascular events, which was not attenuated by adjustment for 
coronary calcium.32
Measures of Vascular Function and Incident CVD Events
Background
• Measures of arterial tonometry (stiffness) are based on the concept that pulse 
pressure has been shown to be an important risk factor for CVD. Arterial 
tonometry offers the ability to directly and noninvasively measure central pulse 
wave velocity in the thoracic and abdominal aorta.
• Brachial FMD is a marker for nitric oxide release from the endothelium that can 
be measured by ultrasound. Impaired FMD is an early marker of CVD.
• Recommendations have not been specific, however, as to which, if any, measures 
of vascular function may be useful for CVD risk stratification in selected patient 
subgroups. Because of the absence of significant prospective data relating these 
measures to outcomes, latest guidelines do not currently recommend measuring 
either FMD (Class III, Level of Evidence B) or arterial stiffness (Class III, Level 
of Evidence C) for cardiovascular risk assessment in asymptomatic adults.2
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Arterial Tonometry and CVD
• The Rotterdam Study measured arterial stiffness in 2835 elderly participants 
(mean age 71 years).33 They found that as aortic pulse wave velocity increased, 
the hazard risk of CHD was 1.72 (second versus first tertile) and 2.45 (third 
versus first tertile). Results remained robust even after accounting for carotid 
IMT, ABI, and pulse pressure.
• A study from Denmark of 1678 individuals 40 to 70 years of age found that each 
1–standard deviation increment in aortic pulse wave velocity increased CVD risk 
by 16% to 20%.34
• The FHS measured several indices of arterial stiffness, including pulse wave 
velocity, wave reflection, and central pulse pressure.35 They found that not only 
was higher pulse wave velocity associated with a 48% increased risk of incident 
CVD events, but pulse wave velocity additionally improved CVD risk prediction 
(integrated discrimination improvement of 0.7%, P<0.05).
FMD and CVD—MESA measured FMD in 3026 participants (mean age 61 years) who 
were free of CVD. As FMD increased (ie, improved brachial function), the risk of CVD was 
16% lower.36 FMD also improved CVD risk prediction compared with the FRS by 
improving net reclassification by 29%.
Impact of Subclinical Disease Screening on Behavior and Risk—There are 
limited observational and clinical trial data to show whether screening for subclinical disease 
can result in initiation of beneficial lifestyle or preventive therapies.
• In a 1996 study of 703 men and women who underwent coronary calcium 
scanning, after adjustment for age, sex, preexisting high cholesterol, HBP, 
cigarette smoking, and a positive family history of CAD, the natural log of total 
calcium score remained associated with new aspirin usage, new cholesterol 
medication usage, consultation with a physician, weight loss, and decreases in 
dietary fat.37
• More recently, among 980 people referred for coronary calcium scanning, in 
multivariable analysis, greater baseline CAC score was strongly associated with 
initiation of aspirin therapy, dietary changes, and increased exercise.38
• A recent study examining the effects of an office-based ultrasound screening 
intervention in 355 subjects aged ≥40 years with at least 1 risk factor showed that 
the presence of an abnormal carotid ultrasound significantly altered physicians’ 
prescription of aspirin and cholesterol medicine and subjects’ awareness of CVD 
risk and intentions to make exercise and diet changes and quit smoking; an 
abnormal carotid ultrasound also predicted reduced dietary sodium and increased 
fiber intake.39
• In the only large-scale randomized clinical trial to date involving CAC scanning, 
the EISNER study (Early Identification of Subclinical Atherosclerosis by 
Noninvasive Imaging Research), among 2137 adults randomized 2:1 to scanning 
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versus no scanning, those scanned showed a net favorable change in SBP, LDL 
cholesterol, and waist circumference among those with abnormal waist girth and 
no change in FRS compared with an increase in FRS in those who were not 
scanned. In addition, the higher the baseline CAC score, the greater the 
improvement in BP, total and LDL cholesterol, triglycerides, weight, and FRS. 
Importantly, downstream medical testing and costs were comparable between 
groups.3
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18. Coronary Heart Disease, Acute Coronary Syndrome, and Angina 
Pectoris
Coronary Heart Disease
ICD-9 410 to 414, 429.2; ICD-10 I20 to I25; see Glossary (Chapter 25) for details and 
definitions. See Tables 18-1 and 18-2. See Charts 18-1 through 18-10.
Prevalence—(See Table 18-1 and Charts 18-1 and 18-2.)
• On the basis of data from NHANES 2007–2010 (NHLBI tabulation), an 
estimated 15.4 million Americans ≥20 years of age have CHD.
– Total CHD prevalence is 6.4% in US adults ≥20 years of age. CHD 
prevalence is 7.9% for men and 5.1% for women.
– Among non-Hispanic whites, CHD prevalence is 8.2% for men and 
4.6% for women.
– Among non-Hispanic blacks, CHD prevalence is 6.8% for men and 
7.1% for women.
– Among Mexican Americans, CHD prevalence is 6.7% for men and 
5.3% for women.
• On the basis of data from the 2011 NHIS:
– Among Hispanic or Latino individuals ≥18 years of age, CHD 
prevalence is 5.9%.1
– Among American Indian/Alaska Natives ≥18 years of age, it is 
estimated that 7.2% have CHD, and among Asians ≥18 years of age, the 
estimate is 4.3%.1
• According to data from NHANES 2007–2010 (NHLBI tabulation), the overall 
prevalence for MI is 2.9% in US adults ≥20 years of age. MI prevalence is 4.2% 
for men and 1.7% for women.
– Among non-Hispanic whites, MI prevalence is 4.4% for men and 1.5% 
for women.
– Among non-Hispanic blacks, MI prevalence is 3.9% for men and 2.3% 
for women.
– Among Mexican Americans, MI prevalence is 3.6% for men and 1.7% 
for women.
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• Data from the BRFSS 2011 survey indicated that 4.3% of respondents had been 
told that they had had an MI. The highest prevalence was in Arkansas (6.4%) and 
West Virginia (6.2%). The lowest prevalence was in Colorado (2.7%) and Utah 
(3.0%). In the same survey, 4.2% of respondents were told that they had angina 
or CHD. The highest prevalence was in West Virginia (6.6%), and the lowest was 
in Colorado (2.4%).2
• Projections show that by 2030, prevalence of CHD will increase ≈18% from 
2013 estimates (AHA computation, based on methodology described in 
Heidenreich et al3).
Abbreviations Used in Chapter 18
AP angina pectoris
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CABG coronary artery bypass graft
CAD coronary artery disease
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early 
Implementation of the ACC/AHA Guidelines
CVD cardiovascular disease
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EHS-ACS-II Second Euro Heart Survey on Acute Coronary Syndromes
EMS emergency medical services
FHS Framingham Heart Study
GRACE Global Registry of Acute Coronary Events
GWTG Get With The Guidelines
HD heart disease
HDL-C high-density lipoprotein cholesterol
HF heart failure
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
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NHDS National Hospital Discharge Survey
NHIS National Health Interview Study
NHLBI National Heart, Lung, and Blood Institute
NRMI National Registry of Myocardial Infarction
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PCI percutaneous coronary intervention
SBP systolic blood pressure
STEMI ST-segment–elevation myocardial infarction
UA unstable angina
WISE Women’s Ischemia Syndrome Evaluation
Incidence—(See Table 18-1 and Charts 18-3 through 18-5.)
• Approximately every 44 seconds, an American will have an MI (AHA 
computation).
• On the basis of data from the ARIC study4 of the NHLBI:
– This year, ≈635 000 Americans will have a new coronary attack 
(defined as first hospitalized MI or CHD death), and ≈280 000 will 
have a recurrent attack. It is estimated that an additional 150 000 silent 
MIs occur each year. That assumes that ≈21% of the 715 000 first and 
recurrent MIs are silent.5,6
– The estimated annual incidence of MI is 525 000 new attacks and 190 
000 recurrent attacks.
– Average age at first MI is 64.7 years for men and 72.2 years for women.
• On the basis of the NHLBI-sponsored FHS:
– CHD makes up more than half of all cardiovascular events in men and 
women <75 years of age.5
– The lifetime risk of developing CHD after 40 years of age is 49% for 
men and 32% for women.7
– The incidence of CHD in women lags behind men by 10 years for total 
CHD and by 20 years for more serious clinical events such as MI and 
sudden death.5
• In the NHLBI-sponsored ARIC study, in participants 35 to 74 years of age, the 
average age-adjusted first MI or fatal CHD rates per 1000 population were as 
follows: white men, 3.9; black men, 5.5; white women, 1.7; and black women, 
3.4 (unpublished data from ARIC Surveillance 1987–2009, NHLBI).
• Incidence rates for MI in the NHLBI-sponsored ARIC study are displayed in 
Charts 18-3 and 18-4, stratified by age, race, and sex. The annual age-adjusted 
rates per 1000 population of first MI (1987–2009) in ARIC Surveillance 
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(NHLBI) were 5.0 in black men, 3.0 in white men, 2.0 in black women, and 1.6 
in white women (unpublished data from ARIC Surveillance 1987–2009, 
NHLBI).
• Analysis of more than 40 years of physician-validated AMI data in the FHS 
study of the NHLBI found that AMI rates diagnosed by electrocardiographic 
criteria declined ≈50%, with a concomitant 2-fold increase in rates of AMI 
diagnosed by blood markers. These findings may explain the paradoxical 
stability of AMI rates in the United States despite concomitant improvements in 
CHD risk factors.8
• Among American Indians 65 to 74 years of age, the annual rates per 1000 
population of new and recurrent MIs were 7.6 for men and 4.9 for women.9 
Analysis of data from NHANES III (1988–1994) and NHANES 1999–2002 
(NCHS) showed that in adults 20 to 74 years of age, the overall distribution of 
10-year risk of developing CHD changed little during this time. Among the 3 
racial/ethnic groups, blacks had the highest proportion of participants in the 
high-risk group.10
• On the basis of data from the NHDS, since the mid-1990s, the rate of 
hospitalization for MI and in-hospital case fatality rates have decreased.11
• From 2002 to 2007, the rates of hospitalization for MI decreased among 
Medicare beneficiaries; however, the degree of reduction was more significant in 
whites than African Americans.12
Trends in Incidence
• In the FHS, incidence rates of AMI diagnosed by electrocardiographic criteria 
decreased significantly in men 50 to 59 years of age and 70 to 79 years of age 
and in women 70 to 79 years of age from the period 1960–1969 to 1990– 1999. 
In contrast, incidence rates of AMI diagnosed by serum biomarkers increased 
significantly in men 50 to 59 years of age and 70 to 79 years of age and in 
women 70 to 79 years of age.13
• Data from the Worcester Heart Attack Study showed that incidence rates for 
AMI were 277 per 100 000 person-years in 1975 and 209 per 100 000 person-
years in 2005 (P=0.42 for overall trend). The incidence rate rose from 1975 to 
1981, decreased from 1981 to 1988, increased from 1981 to 2001, and decreased 
from 2001 to 2005.14
• In Olmsted County, Minnesota, no significant change in the overall age- and sex-
adjusted incidence rate for hospitalized MI was noted (186 per 100 000 person-
years in 1987 and 180 per 100 000 person-years in 2006; P=0.171), but a 
significant decline in the age- and sex-adjusted incidence rate for hospitalized MI 
based on creatine kinase/creatine kinase-MB markers, to 141 per 100 000 
person-years (P=0.020), was observed in 2006, which represents a 20% decrease 
during the study period.15
et al. Page 242
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• Data from Kaiser Permanente Northern California showed that the age- and sex-
adjusted incidence rate of hospitalizations for MI changed from 274 per 100 000 
person-years in 1999 to 208 per 100 000 person-years in 2008. Furthermore, the 
age- and sex-adjusted incidence rate of hospitalizations for STEMI changed from 
133 per 100 000 person-years in 1999 to 50 per 100 000 person-years in 2008 (P 
linear trend <0.001). The trajectory of the age- and sex-adjusted incidence rate of 
hospitalizations for NSTEMI did not change significantly.16
• From 1987 to 2008, the age- and biomarker-adjusted incidence rates of 
hospitalization for AMI or fatal CHD decreased by 4.9% per year (95% CI, 
5.3%–4.5%) among white men, 3.9% per year (95% CI, 4.5%–3.4%) among 
white women, 1.8% per year (95% CI, 2.6%–1.0%) among black men, and 3.5% 
per year (95% CI, 4.4%–2.6%) among black women in the ARIC study.17
Mortality
• CHD caused ≈1 of every 6 deaths in the United States in 2009. CHD mortality 
was 386 324.18
• CHD any-mention mortality was 549 233. MI mortality (ICD-10 I21 to I22) was 
125 464. MI any-mention mortality was 162 443 (NCHS, NHLBI tabulation).18
• In 2009, the overall CHD death rate was 116.1. From 1999 to 2009, the annual 
death rate attributable to CHD declined 40.3% and the actual number of deaths 
declined 27.1% (AHA computation).19 The death rates were 155.9 for white 
males and 181.1 for black males; for white females, the rate was 84.9, and for 
black females, it was 110.3.19
• Approximately every 34 seconds, an American will experience a coronary event, 
and approximately every minute, someone will die of one (AHA computation).
• Approximately 34% of the people who experience a coronary attack in a given 
year will die of it, and ≈15% who experience a heart attack (MI) will die of it 
(AHA computation).
• The percentage of CHD deaths that occurred out of the hospital in 2009 was 
73%. According to NCHS mortality data, 281 000 CHD deaths occur out of the 
hospital or in hospital EDs annually (2009, ICD-10 codes I20 to I25; NCHS, 
AHA tabulation).
• A study of 1275 health maintenance organization enrollees 50 to 79 years of age 
who had cardiac arrest showed that the incidence of out-of-hospital cardiac arrest 
was 6.0/1000 subject-years in subjects with any clinically recognized HD 
compared with 0.8/1000 subject-years in subjects without HD. In subgroups with 
HD, incidence was 13.6/1000 subject- years in subjects with prior MI and 
21.9/1000 subject-years in subjects with HF.20
• Approximately 80% of people who die of CHD are ≥65 years of age (NCHS; 
AHA computation).
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• The estimated average number of years of life lost because of an MI is 16.6 
(NCHS, NHLBI tabulation).
• On the basis of data from the FHS of the NHLBI5:
– Fifty percent of men and 64% of women who die suddenly of CHD 
have no previous symptoms of this disease. Between 70% and 89% of 
sudden cardiac deaths occur in men, and the annual incidence is 3 to 4 
times higher in men than in women; however, this disparity decreases 
with advancing age.
– People who have had an MI have a sudden death rate 4 to 6 times that 
of the general population.
• Researchers investigating variation in hospital-specific 30-day risk-stratified 
mortality rates for patients with AMI found teaching status, number of hospital 
beds, AMI volume, cardiac facilities available, urban/rural location, geographic 
region, hospital ownership type, and socioeconomic status profile of the patients 
were all significantly associated with mortality rates. However, a substantial 
proportion of variation in outcomes for patients with AMI between hospitals 
remains unexplained by measures of hospital characteristics.21
Temporal Trends in CHD Mortality
• The decline in CHD mortality rates in part reflects the shift in the pattern of 
clinical presentations of AMI. In the past decade, there has been a marked 
decline in STEMI (from 133 to 50 cases per 100 000 person-years).16
• According to data from the National Registry of Myocardial Infarction22:
– From 1990 to 1999, in-hospital AMI mortality declined from 11.2% to 
9.4%.
– Mortality rate increases for every 30 minutes that elapses before a 
patient with ST-segment elevation is recognized and treated.
• Other studies also reported declining case fatality rates after MI:
– In Olmsted County, Minnesota, the age- and sex-adjusted 30-day case-
fatality rate decreased by 56% from 1987 to 2006.15
– In Worcester, MA, the hospital case fatality rates, 30-day postadmission 
case fatality rates, and 1-year postdischarge case fatality rates for 
STEMI were 11.1%, 13.2%, and 10.6%, respectively, in 1997 and 
9.7%, 11.4%, and 8.4%, respectively, in 2005. The hospital case fatality 
rates, 30-day postadmission case fatality rates, and 1-year postdischarge 
case fatality rates for NSTEMI were 12.9%, 16.0%, and 23.1%, 
respectively, in 1997 and 9.5%, 14.0%, and 18.7%, respectively, in 
2005.23
– Among enrollees of the Kaiser Permanente Northern California 
healthcare delivery system, the age- and sex-adjusted 30-day mortality 
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rate for MI dropped from 10.5% in 1999 to 7.8% in 2008, and the 30-
day mortality rate for NSTEMI dropped from 10.0% in 1999 to 7.6% in 
2008.16
• CHD death rates have fallen from 1968 to the present. Analysis of NHANES 
(NCHS) data compared CHD death rates between 1980 and 2000 to determine 
how much of the decline in deaths attributable to CHD over that period could be 
explained by the use of medical and surgical treatments versus changes in CVD 
risk factors (resulting from lifestyle/behavior). After 1980 and 2000 data were 
compared, it was estimated that ≈47% of the decrease in CHD deaths was 
attributable to treatments, including the following24:
– Secondary preventive therapies after MI or revascularization (11%)
– Initial treatments for AMI or UA (10%)
– Treatments for HF (9%)
– Revascularization for chronic angina (5%)
– Other therapies (12%), including antihypertensive and lipid-lowering 
primary prevention therapies
• It was also estimated that a similar amount of the reduction in CHD deaths, 
≈44%, was attributable to changes in risk factors, including the following24:
– Lower total cholesterol (24%)
– Lower SBP (20%)
– Lower smoking prevalence (12%)
– Decreased physical inactivity (5%)
– Nevertheless, these favorable improvements in risk factors were offset 
in part by increases in BMI and in DM prevalence, which accounted for 
an increased number of deaths (8% and 10%, respectively).
• Between 1980 and 2002, death rates attributable to CHD among men and women 
≥65 years of age fell by 52% in men and 49% in women. Among men, the death 
rate declined on average by 2.9% per year in the 1980s, 2.6% per year during the 
1990s, and 4.4% per year from 2000 to 2002. Among women, death rates fell by 
2.6%, 2.4%, and 4.4%, respectively. However, when stratified by age, among 
men 35 to 54 years of age, the average annual rate of death fell by 6.2%, 2.3%, 
and 0.5%, respectively. Among women 35 to 54 years of age, the average annual 
rate of death fell by 5.4% and 1.2% and then increased by 1.5%, respectively. 
This increase was not statistically significant; however, in even younger women 
(35–44 years of age), the rate of death has been increasing by an average of 1.3% 
annually between 1997 and 2002, which is statistically significant.25
• An analysis of 28 studies published from 1977 to 2007 found that 
revascularization by CABG or PCI in conjunction with medical therapy in 
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patients with nonacute CAD is associated with significantly improved survival 
compared with medical therapy alone.26
• A recent analysis of Centers for Medicare & Medicaid Services data suggests 
that between 1995 and 2006, the 30-day mortality rate attributable to MI 
decreased, as did hospital variation in mortality attributable to MI.27
• Data from the Nationwide Inpatient Sample database suggest that mortality 
attributable to MI has decreased since 1988.28
Risk Factors
• Risk factors for CHD act synergistically to increase CHD risk, as shown in the 
example in Charts 18-6 and 18-7.
Awareness of Warning Signs and Risk Factors for HD
• Data from the Women Veterans Cohort showed that 42% of women ≥35 years of 
age were concerned about HD. Only 8% to 20% were aware that CAD is the 
major cause of death for women.29
• Among people in 14 states and Washington, DC, participating in the 2005 
BRFSS, only 27% were aware of 5 heart attack warning signs and symptoms (1, 
pain in jaw, neck, or back; 2, weak, lightheaded, or faint; 3, chest pain or 
discomfort; 4, pain or discomfort in arms or shoulder; and 5, shortness of breath) 
and indicated that they would first call 911 if they thought someone was having a 
heart attack or stroke. Awareness of all 5 heart attack warning signs and 
symptoms and the need to call 911 was higher among non-Hispanic whites 
(30.2%), women (30.8%), and those with a college education or more (33.4%) 
than among non-Hispanic blacks and Hispanics (16.2% and 14.3%, respectively), 
men (22.5%), and those with less than a high school education (15.7%), 
respectively. By state, awareness was highest in West Virginia (35.5%) and 
lowest in Washington, DC (16.0%).30
• A 2004 national study of physician awareness and adherence to CVD prevention 
guidelines showed that fewer than 1 in 5 physicians knew that more women than 
men die each year of CVD.31 Women’s awareness that CVD is their leading 
cause of death increased from 30% in 1997 to 54% in 2009. The percentages of 
women identifying warning signs for a heart attack were as follows: pain in the 
chest, neck, shoulder, and arm—56%; shortness of breath—29%, chest tightness
—17%, nausea—15%; and fatigue—7%. Compared with 1997, however, little 
change in knowledge of warning signs was noted. The 3 most commonly cited 
HD prevention strategies were getting adequate sleep (94%), consuming fish oil/
omega 3 fatty acids (82%), and taking aspirin regularly (78%). The most 
common preventive actions taken by women during the preceding year were 
having BP checked (84%), trying to manage stress better (74%), seeing a doctor 
or other healthcare provider (73%), decreasing consumption of unhealthy foods 
(71%), and having cholesterol checked (66%).32
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Delays Between Symptom Onset and Arrival at Hospital
• A recent community surveillance study in 4 US communities reported that in 
2000, the overall proportion of people with delays of ≥4 hours from onset of 
AMI symptoms to hospital arrival was 49.5%. The study also reported that from 
1987 to 2000, there was no statistically significant change in the proportion of 
patients whose delays were ≥4 hours, which indicates that there has been little 
improvement in the speed at which patients with MI symptoms arrive at the 
hospital after symptom onset. Although the proportion of patients with MI who 
arrived at the hospital by EMS increased over this period, from 37% in 1987 to 
55% in 2000, the total time between onset and hospital arrival did not change 
appreciably.33
• Data from CRUSADE (Can Rapid Risk Stratification of Unstable Angina 
Patients Suppress Adverse Outcomes With Early Implementation of the 
ACC/AHA Guidelines) and the National Cardiovascular Data Registry ACTION 
Registry–GWTG showed a longer median time to hospital presentation in men (3 
hours) than women (2.8 hours; P<0.001). From 2002 to 2007, presentation time 
did not change significantly in men or women.13
• Individuals with documented CHD have 5 to 7 times the risk of having a heart 
attack or dying as the general population. Survival rates improve after a heart 
attack if treatment begins within 1 hour; however, most patients are admitted to 
the hospital 2.5 to 3 hours after symptoms begin. More than 3500 patients 
surveyed with a history of CHD were asked to identify possible symptoms of 
heart attack. Despite their history of CHD, 44% had low knowledge levels. In 
this group, who were all at high risk of future AMI, 43% assessed their risk as 
less than or the same as others their age. More men than women perceived 
themselves as being at low risk, at 47% versus 36%, respectively.34
• Data from Worcester, MA, indicate that the average time from symptom onset to 
hospital arrival has not improved and that delays in hospital arrival are associated 
with less receipt of guidelines-based care. Mean and median prehospital delay 
times from symptom onset to arrival at the hospital were 4.1 and 2.0 hours in 
1986 and 4.6 and 2.0 hours in 2005, respectively. Compared with those arriving 
within 2 hours of symptom onset, those with prolonged prehospital delay were 
less likely to receive thrombolytic therapy and PCI within 90 minutes of hospital 
arrival.35
• In an analysis from ARIC, low neighborhood household income (OR, 1.46; 95% 
CI, 1.09–1.96) and being a Medicaid recipient (OR, 1.87; 95% CI, 1.10–3.19) 
were associated with increased odds of having prolonged prehospital delays from 
symptom onset to hospital arrival for AMI compared with individuals with 
higher neighborhood household income and other insurance providers, 
respectively.36
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Aftermath
• Depending on their sex and clinical outcome, people who survive the acute stage 
of an MI have a chance of illness and death 1.5 to 15 times higher than that of the 
general population. Among these people, the risk of another MI, sudden death, 
AP, HF, and stroke—for both men and women—is substantial (FHS, NHLBI).5
• On the basis of pooled data from the FHS, ARIC, and CHS studies of the 
NHLBI, within 1 year after a first MI:
– At ≥45 years of age, 19% of men and 26% of women will die.
– At 45 to 64 years of age, 5% of white men, 8% of white women, 14% 
of black men, and 9% of black women will die.
– At ≥65 years of age, 25% of white men, 30% of white women, 25% of 
black men, and 30% of black women will die.
– In part because women have MIs at older ages than men, they are more 
likely to die of MIs within a few weeks.
• Within 5 years after a first MI:
– At ≥45 years of age, 36% of men and 47% of women will die.
– At 45 to 64 years of age, 11% of white men, 18% of white women, 22% 
of black men, and 28% of black women will die.
– At ≥65 years of age, 46% of white men, 53% of white women, 54% of 
black men, and 58% of black women will die.
• Of those who have a first MI, the percentage with a recurrent MI or fatal CHD 
within 5 years is:
– At 45 to 64 years of age, 15% of men and 22 of women
– At ≥65 years of age, 22% of men and women
– At 45 to 64 years of age, 14% of white men, 18% of white women, 22% 
of black men, and 28% of black women
– At ≥65 years of age, 21% of white men and women, 33% of black men, 
and 26% of black women
• The percentage of people with a first MI who will have HF in 5 years is:
– At 45 to 64 years of age, 8% of men and 18% of women
– At ≥65 years of age, 20% of men and 23% of women
– At 45 to 64 years of age, 7% of white men, 15% of white women, 13% 
of black men, and 25% of black women
– At ≥65 years of age, 19% of white men, 23% of white women, 31% of 
black men, and 24% of black women
• The percentage of people with a first MI who will have a stroke within 5 years is:
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– At 45 to 64 years of age, 2% of men and 6% of women
– At ≥65 years of age, 5% of men and 8% of women
– At 45 to 64 years of age, 2% of white men, 4% of white women, 3% of 
black men, and 10% of black women
– At ≥65 years of age, 5% of white men, 8% of white women, 9% of 
black men, and 10% of black women
• The median survival time (in years) after a first MI is:
– At 55 to 64 years of age, 17.0 for men and 13.3 for women
– At 65 to 74 years of age, 9.3 for men and 8.8 for women
– At ≥75 years of age, 3.2 for men and 3.2 for women
• A Mayo Clinic study found that cardiac rehabilitation after an MI is underused, 
particularly in women and the elderly. Women were 55% less likely than men to 
participate in cardiac rehabilitation, and older study patients were less likely to 
participate than younger participants. Only 32% of men and women ≥70 years of 
age participated in cardiac rehabilitation compared with 66% of those 60 to 69 
years of age and 81% of those <60 years of age.37
• Among survivors of an MI, in 2005, 34.7% of BRFSS respondents participated 
in outpatient cardiac rehabilitation. The prevalence of cardiac rehabilitation was 
higher among older age groups (≥50 years of age), among men versus women, 
among Hispanics, among those who were married, among those with higher 
education, and among those with higher levels of household income.38
• A recent analysis of Medicare claims data revealed that only 13.9% of Medicare 
beneficiaries enroll in cardiac rehabilitation after an AMI, and only 31% enroll 
after CABG. Older people, women, nonwhites, and individuals with 
comorbidities were less likely to enroll in cardiac rehabilitation programs.39
Hospital Discharges and Ambulatory Care Visits—(See Table 18-1 and Chart 18-8.)
• From 2000 to 2010, the number of inpatient discharges from short-stay hospitals 
with CHD as the first-listed diagnosis decreased from 2 165 000 to 1 346 000 
(NHDS, NHLBI tabulation).
• In 2009, there were 14 044 000 ambulatory care visits with CHD as the first-
listed diagnosis (NCHS, NAMCS, NHAMCS). There were 12 816 000 physician 
office visits, 639 000 ED visits, and 589 000 outpatient department visits with a 
primary diagnosis of CHD (NHAMCS, NHLBI tabulation). The majority of 
these visits (77.7%) were for coronary atherosclerosis.40
• The age-adjusted hospitalization rate for MI was 215 per 100 000 people in 1979 
to 1981, increased to 342 in 1985 to 1987, stabilized for the next decade, and 
then declined after 1996 to 242 during the period from 2003 to 2005. Rates for 
men were almost twice those of women. Trends were similar for men and 
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women. Hospitalization rates increased with age and were the highest among 
those ≥85 years of age.11
• Most hospitalized patients >65 years of age are women. For MI, 28.4% of 
hospital stays for people 45 to 64 years of age were for women, but 63.7% of 
stays for those ≥85 years of age were for women. Similarly, for coronary 
atherosclerosis, 32.7% of stays among people 45 to 64 years of age were for 
women; this figure increased to 60.7% of stays among those ≥85 years of age. 
For nonspecific chest pain, women were more numerous than men among 
patients <65 years of age. Approximately 54.4% of hospital stays among people 
45 to 64 years of age were for women. Women constituted 73.9% of hospital 
stays for nonspecific chest pain among patients ≥85 years of age, higher than for 
any other condition examined. For AMI, one third more women than men died in 
the hospital: 9.3% of women died in the hospital compared with 6.2% of men.41
Operations and Procedures
• In 2010, an estimated 954 000 inpatient PCI procedures, 397 000 inpatient 
bypass procedures, 1 029 000 inpatient diagnostic cardiac catheterizations, 97 
000 inpatient implantable defibrillator procedures, and 370 000 pacemaker 
procedures were performed for inpatients in the United States. (NHLBI 
tabulation).
Cost—(See Table 18-1.)
• The estimated direct and indirect cost of CHD in 2009 is $195.2 billion (MEPS, 
NHLBI tabulation).
• In 2006, $11.7 billion was paid to Medicare beneficiaries for in-hospital costs 
when CHD was the principal diagnosis ($14 009 per discharge for AMI, $12 977 
per discharge for coronary atherosclerosis, and $10 630 per discharge for other 
ischemic HD).34,42
• Between 2013 and 2030, medical costs of CHD (real 2010$) are projected to 
increase by ≈100%:
– Indirect costs for all CVD (real 2010$) are projected to increase 52% 
(from $202.5 billion to $308.2 billion) between 2013 and 2030. Of 
these indirect costs, CHD is projected to account for ≈43% and has the 
largest indirect costs (AHA computation, based on methodology 
described in Heidenreich et al3).
Acute Coronary Syndrome
ICD-9 codes 410, 411; ICD-10 I20.0, I21, I22
The term ACS is increasingly used to describe patients who present with either AMI or UA. 
(UA is chest pain or discomfort that is accelerating in frequency or severity and may occur 
while at rest but does not result in myocardial necrosis.) The discomfort may be more severe 
and prolonged than typical AP or may be the first time a person has AP. UA, NSTEMI, and 
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STEMI share common pathophysiological origins related to coronary plaque progression, 
instability, or rupture with or without luminal thrombosis and vasospasm.
• A conservative estimate for the number of discharges with ACS from hospitals in 
2010 is 625 000. Of these, an estimated 363 000 are males and 262 000 are 
females. This estimate is derived by adding the first-listed inpatient hospital 
discharges for MI (595 000) to those for UA (30 000; NHDS, NHLBI).
• When secondary discharge diagnoses in 2010 were included, the corresponding 
number of inpatient hospital discharges was 1 141 000 unique hospitalizations 
for ACS; 653 000 were males, and 488 000 were females. Of the total, 813 000 
were for MI alone, 322 000 were for UA alone, and 6000 hospitalizations 
received both diagnoses (NHDS, NHLBI).
Decisions about medical and interventional treatments are based on specific findings noted 
when a patient presents with ACS. Such patients are classified clinically into 1 of 3 
categories according to the presence or absence of ST-segment elevation on the presenting 
ECG and abnormal (“positive”) elevations of myocardial biomarkers, such as troponins, as 
follows:
• STEMI
• NSTEMI
• UA
The percentage of ACS or MI cases with ST-segment elevation varies in different registries/
databases and depends heavily on the age of patients included and the type of surveillance 
used. According to the National Registry of Myocardial Infarction 4 (NRMI-4), ≈29% of 
patients with MI are patients with STEMI.43 The AHA GWTG project found that 32% of 
the patients with MI in the CAD module are patients with STEMI (personal communication 
from AHA GWTG staff, October 1, 2007). The Global Registry of Acute Coronary Events 
(GRACE) study, which includes US patient populations, found that 38% of ACS patients 
have STEMI, whereas the second Euro Heart Survey on ACS (EHS-ACS-II) reported that 
≈47% of patients with ACS have STEMI.44
In addition, the percentage of ACS or MI cases with ST-segment elevation appears to be 
declining. In an analysis of 46 086 hospitalizations for ACS in the Kaiser Permanente 
Northern California study, the percentage of MI cases with ST-segment elevation decreased 
from 48.5% to 24% between 1999 and 2008.16
• Analysis of data from the GRACE multinational observational cohort study of 
patients with ACS found evidence of a change in practice for both 
pharmacological and interventional treatments in patients with either STEMI or 
non–ST-segment–elevation ACS. These changes have been accompanied by 
significant decreases in the rates of in-hospital death, cardiogenic shock, and new 
MI among patients with non–ST-segment–elevation ACS. The use of evidence-
based therapies and PCI interventions increased in the STEMI population. This 
increase was matched by a statistically significant decrease in the rates of death, 
cardiogenic shock, and HF or pulmonary edema.45
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• A study of patients with non–ST-segment–elevation ACS treated at 350 US 
hospitals found that up to 25% of opportunities to provide American College of 
Cardiology (ACC)/AHA guideline–recommended care were missed in current 
practice. The composite guideline adherence rate was significantly associated 
with in-hospital mortality.45
• A study of hospital process performance in 350 centers of nearly 65 000 patients 
enrolled in the CRUSADE National Quality Improvement Initiative found that 
ACC/AHA guideline–recommended treatments were adhered to in 74% of 
eligible instances.46
• After adjustment for clinical differences and the severity of CAD by angiogram, 
30-day mortality after ACS is similar in men and women.47
Angina Pectoris
ICD-9 413; ICD-10 I20.1 to I20.9.
Prevalence—(See Table 18-2 and Chart 18-9.)
• A study of 4 national cross-sectional health examination studies found that 
among Americans 40 to 74 years of age, the age-adjusted prevalence of AP was 
higher among women than men. Increases in the prevalence of AP occurred for 
Mexican American men and women and African American women but were not 
statistically significant for the latter.48
Incidence—(See Table 18-2 and Chart 18-10.)
• Only 18% of coronary attacks are preceded by long-standing AP (NHLBI 
computation of FHS follow-up since 1986).
• The annual rates per 1000 population of new episodes of AP for nonblack men 
are 28.3 for those 65 to 74 years of age, 36.3 for those 75 to 84 years of age, and 
33.0 for those ≥85 years of age. For nonblack women in the same age groups, the 
rates are 14.1, 20.0, and 22.9, respectively. For black men, the rates are 22.4, 
33.8, and 39.5, and for black women, the rates are 15.3, 23.6, and 35.9, 
respectively (CHS, NHLBI).49
• On the basis of 1987 to 2001 data from the ARIC study of the NHLBI, the 
annual rates per 1000 population of new episodes of AP for nonblack men are 
8.5 for those 45 to 54 years of age, 11.9 for those 55 to 64 years of age, and 13.7 
for those 65 to 74 years of age. For nonblack women in the same age groups, the 
rates are 10.6, 11.2, and 13.1, respectively. For black men, the rates are 11.8, 
10.6, and 8.8, and for black women, the rates are 20.8, 19.3, and 10.0, 
respectively.49
Mortality
• A small number of deaths resulting from CHD are coded as being attributable to 
AP. These are included as a portion of total deaths attributable to CHD.
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Cost
• For women with nonobstructive CHD enrolled in the Women’s Ischemia 
Syndrome Evaluation (WISE) study of the NHLBI, the average lifetime cost 
estimate was ≈$770 000 and ranged from $1.0 to $1.1 million for women with 1-
vessel to 3-vessel CHD.50
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19. Cardiomyopathy and Heart Failure
See Table 19-1 and Charts 19-1 through 19-3.
Cardiomyopathy
ICD-9 425; ICD-10 I42.
Mortality—23 831. Any-mention mortality—47 323. Hospital discharges—34 000.
• Since 1996, the NHLBI-sponsored Pediatric Cardiomyopathy Registry has 
collected data on all children with newly diagnosed cardiomyopathy in New 
England and the Central Southwest (Texas, Oklahoma, and Arkansas).1
– The overall incidence of cardiomyopathy is 1.13 cases per 100 000 
among children <18 years of age.
– Among children <1 year of age, the incidence is 8.34, and among 
children 1 to 18 years of age, it is 0.70 per 100 000.
– The annual incidence is lower in white than in black children, higher in 
boys than in girls, and higher in New England (1.44 per 100 000) than 
in the Central Southwest (0.98 per 100 000).
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• HCM is the most common inherited heart defect, occurring in 1 of 500 
individuals. In the United States, ≈500 000 people have HCM, yet most are 
unaware of it.2 See Chapter 16, Disorders of Heart Rhythm, for statistics 
regarding sudden death in HCM.
• In a recent report of the Pediatric Cardiomyopathy Registry, the overall annual 
incidence of HCM in children was 4.7 per 1 million children. There was a higher 
incidence in the New England than in the Central Southwest region, in boys than 
in girls, and in children diagnosed at <1 year of age than in older children.3
• Dilated cardiomyopathy is the most common form of cardiomyopathy. The 
Pediatric Cardiomyopathy Registry recently reported an annual incidence of 
dilated cardiomyopathy in children <18 years of age of 0.57 per 100 000 overall. 
The annual incidence was higher in boys than in girls (0.66 versus 0.47 cases per 
100 000), in blacks than in whites (0.98 versus 0.46 cases per 100 000), and in 
infants (<1 year of age) than in children (4.40 versus 0.34 cases per 100 000). 
The majority of children (66%) had idiopathic disease. The most common known 
causes were myocarditis (46%) and neuromuscular disease (26%).4
• Risk factors for death and transplantation in children varied by cause of dilated 
cardiomyopathy. For idiopathic dilated cardiomyopathy, increased left 
ventricular end-diastolic dimension was associated with increased transplantation 
risk but not mortality. Short stature was significantly related to death but not 
transplantation.5
• The 5-year incidence rate of sudden cardiac death among children with dilated 
cardiomyopathy is 3%.6
• Tachycardia-induced cardiomyopathy develops slowly and appears reversible, 
but recurrent tachycardia causes rapid decline in left ventricular function and 
development of HF. Sudden death is possible.7
• Data from Kaiser Permanente indicate that the incidence of peripartum 
cardiomyopathy is 4.84 per 10 000 live births (95% CI, 3.98–5.83) and is 
associated with higher maternal and neonatal death rates and worse neonatal 
outcomes.8
Abbreviations Used in Chapter 19
ABC Aging, Body and Composition
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults Study
CHS Cardiovascular Health Study
CI confidence interval
CVD cardiovascular disease
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DM diabetes mellitus
EF ejection fraction
FHS Framingham Heart Study
HbA1c hemoglobin A1c
HCM hypertrophic cardiomyopathy
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PAR population attributable risk
Heart Failure
ICD-9 428; ICD-10 I50.
Prevalence—(See Table 19-1 and Chart 19-1.)
• On the basis of data from NHANES 2007–2010, an estimated 5.1 million 
Americans ≥20 years of age have HF (NHLBI tabulation).
• Projections show that by 2030, the prevalence of HF will increase 25% from 
2013 estimates (AHA computation based on methodology described in 
Heidenreich et al9).
Incidence—(See Table 19-1 and Chart 19-2.)
• Data from the NHLBI-sponsored FHS10 indicate the following:
– HF incidence approaches 10 per 1000 population after 65 years of age.
– Seventy-five percent of HF cases have antecedent hypertension.
– At 40 years of age, the lifetime risk of developing HF for both men and 
women is 1 in 5. At 80 years of age, remaining lifetime risk for 
development of new HF remains at 20% for men and women, even in 
the face of a much shorter life expectancy.
– At 40 years of age, the lifetime risk of HF occurring without antecedent 
MI is 1 in 9 for men and 1 in 6 for women.
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– The lifetime risk for people with BP >160/90 mm Hg is double that of 
those with BP <140/90 mm Hg.
• The annual rates per 1000 population of new HF events for white men are 15.2 
for those 65 to 74 years of age, 31.7 for those 75 to 84 years of age, and 65.2 for 
those ≥85 years of age. For white women in the same age groups, the rates are 
8.2, 19.8, and 45.6, respectively. For black men, the rates are 16.9, 25.5, and 
50.6,* and for black women, the estimated rates are 14.2, 25.5, and 44.0,* 
respectively (CHS, NHLBI).11
• In MESA, African Americans had the highest risk of developing HF, followed by 
Hispanic, white, and Chinese Americans (4.6, 3.5, 2.4, and 1.0 per 1000 person-
years, respectively). This higher risk reflected differences in the prevalence of 
hypertension, DM, and socioeconomic status. African Americans had the highest 
proportion of incident HF not preceded by clinical MI (75%).12
• In Olmsted County, Minnesota, the incidence of HF did not decline between 
1979 and 2000.13
• In the ARIC study of the NHLBI, the age-adjusted incidence rate per 1000 
person-years was 3.4 for white women, less than for all other groups, that is, 
white men (6.0), black women (8.1), and black men (9.1). The 30-day, 1-year, 
and 5-year case fatality rates after hospitalization for HF were 10.4%, 22%, and 
42.3%, respectively. Blacks had a greater 5-year case fatality rate than whites 
(P<0.05). HF incidence rates in black women were more similar to those of men 
than of white women. The greater HF incidence in blacks than in whites is 
explained largely by blacks’ greater levels of atherosclerotic risk factors.14
• Data from Kaiser Permanente indicated an increase in the incidence of HF 
among the elderly, with the effect being greater in men.15
• Data from hospitals in Worcester, MA, indicate that during 2000, the incidence 
and attack rates for HF were 219 per 100 000 and 897 per 100 000, respectively. 
HF was more frequent in women and the elderly. The hospital fatality rate was 
5.1%.16
• In the CARDIA study, HF before 50 years of age was more common among 
blacks than whites. Hypertension, obesity, and systolic dysfunction are important 
risk factors that may be targets for prevention.17
Mortality—(See Table 19-1.)
• In 2009, HF any-mention mortality was 274 601 (123 661 males and 150 940 
females). HF was the underlying cause in 56 410 of those deaths in 2009 (NCHS, 
NHLBI). Table 19-1 shows the numbers of these deaths that are coded for HF as 
the underlying cause.
• The 2009 overall any-mention death rate for HF was 82.3. Any-mention death 
rates were 98.3 for white males, 104.5 for black males, 72.2 for white females, 
and 79.7 for black females (NCHS, NHLBI).
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• One in 9 deaths has HF mentioned on the death certificate (NCHS, NHLBI).
• The number of any-mention deaths attributable to HF was approximately as high 
in 1995 (287 000) as it was in 2009 (275 000; NCHS, NHLBI).
• Survival after HF diagnosis has improved over time, as shown by data from the 
FHS18 and the Olmsted County Study.13 However, the death rate remains high: 
≈50% of people diagnosed with HF will die within 5 years.13,19
• In the elderly, data from Kaiser Permanente indicate that survival after the onset 
of HF has also improved.15
• In the CHS, depression and amino-terminal pro-B-type natriuretic peptide were 
independent risk factors for CVD-related and all-cause mortality.20
• Among Medicare beneficiaries, the overall 1-year mortality rate declined slightly 
over the past decade but remains high.21 Changes were uneven across states.
Risk Factors
• In the NHLBI-sponsored FHS, hypertension is a common risk factor for HF, 
followed closely by antecedent MI.18 B-type natriuretic peptide, urinary 
albumin-to-creatinine ratio, and elevated serum γ-glutamyl transferase were also 
identified as risk factors for HF.22,23
• In the Framingham Offspring Study, among 2739 participants, increased 
circulating concentrations of resistin were associated with incident HF 
independent of prevalent coronary disease, obesity, insulin resistance, and 
inflammation.24
• Among 20 900 male physicians in the Physicians Health Study, the lifetime risk 
of HF was higher in men with hypertension; healthy lifestyle factors (normal 
weight, not smoking, regular exercise, moderate alcohol intake, consumption of 
breakfast cereals, and consumption of fruits and vegetables) were related to 
lower risk of HF.25
• Among 2934 participants in the Health Aging, Body and Composition (ABC) 
study, the incidence of HF was 13.6 per 1000 person-years. Men and black 
participants were more likely to develop HF. Coronary disease (PAR 23.9% for 
white participants, 29.5% for black participants) and uncontrolled BP (PAR 
21.3% for white participants, 30.1% for black participants) had the highest PARs 
in both races. There was a higher overall proportion of HF attributable to 
modifiable risk factors in black participants than in white participants (67.8% 
versus 48.9%). Hospitalizations were higher among black participants.26 
Inflammatory markers (interleukin-6 and tumor necrosis factor-α) and serum 
albumin levels were also associated with HF risk.27,28
• In the CHS, baseline cardiac troponin and changes in cardiac troponin levels 
measured by a sensitive assay were significantly associated with incident HF.29 
Circulating individual and total omega-3 fatty acid concentrations were 
associated with lower incidence of HF.30
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• In the ARIC study, white blood cell count, C-reactive protein, albuminuria, 
HbA1c among individuals without ventricular premature complexes, and 
socioeconomic position over the life course were all identified as risk factors for 
HF.18,31–35
Left Ventricular Function
• Data from Olmsted County, Minnesota, indicate that:
– Among asymptomatic individuals, the prevalence of left ventricular 
diastolic dysfunction was 21% for mild diastolic dysfunction and 7% 
for moderate or severe diastolic dysfunction. The prevalence of systolic 
dysfunction was 6%. The presence of any left ventricular dysfunction 
(systolic or diastolic) was associated with an increased risk of 
developing overt HF, and diastolic dysfunction was predictive of all-
cause death.36 After 4 years of follow-up, the prevalence of diastolic 
dysfunction increased to 39.2%. Diastolic dysfunction was associated 
with development of HF during 6 years of subsequent follow-up after 
adjustment for age, hypertension, DM, and CAD (HR, 1.81; 95% CI, 
1.01–3.48).37
– Among individuals with symptomatic HF, the prevalence of left 
ventricular diastolic dysfunction was 6% for mild diastolic dysfunction 
and 75% for moderate or severe diastolic dysfunction.38 The proportion 
of people with HF and preserved EF increased over time. Survival 
improved over time among individuals with reduced EF but not among 
those with preserved EF.39
Hospital Discharges/Ambulatory Care Visits—(See Table 19-1 and Chart 19-3.)
• Hospital discharges for HF were essentially unchanged from 2000 to 2010, with 
first-listed discharges of 1.008 million and 1.023 million, respectively (NHDS, 
NHLBI tabulation).
• In 2010, there were 1.801 million physician office visits with a primary diagnosis 
of HF. In 2009, there were 668 000 ED visits and 293 000 outpatient department 
visits for HF (NHAMCS, NHLBI tabulation).
• Among 1077 patients with HF in Olmsted County, Minnesota, hospitalizations 
were common after HF diagnosis, with 83% patients hospitalized at least once 
and 43% hospitalized at least 4 times. More than one half of all hospitalizations 
were related to noncardiovascular causes.40
• Among Medicare beneficiaries, the overall HF hospitalization rate declined 
substantially from 1998 to 2008 but at a lower rate for black men.21 Changes 
were uneven across states.
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Cost
• Projections show that by 2030, the total cost of HF will increase almost 120% to 
$70 billion from the 2013 estimated total cost of $32 billion (unpublished AHA 
computation based on methodology described in Heidenreich et al9).
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20. Valvular, Venous, Aortic, and Peripheral Artery Diseases
See Tables 20-1 and 20-2 and Charts 20-1 through 20-3.
Mortality and any-mention mortality in this section are for 2009. “Mortality” is the number 
of deaths in 2009 for the given underlying cause based on ICD-10. Prevalence data are for 
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2006. Hospital discharge data are from the NHDS/NCHS; data include inpatients discharged 
alive, dead, or status unknown. Hospital discharge data for 2009 are based on ICD-9 codes.
Valvular Heart Disease
(See Table 20-1.)
ICD-9 424; ICD-10 I34 to I38.
Mortality—22 144. Any-mention mortality—45 285. Hospital discharges—85 000.
Two important factors have contributed to the changing epidemiology of valvular heart 
disease in the United States over the past few decades: aging of the population and the 
increased ability to diagnose valvular heart disease by echocardiography.
• A large population-based epidemiological study with systematic use of 
echocardiography on 16 501participants from Olmsted County, Minnesota, 
showed an overall age-adjusted prevalence of clinically diagnosed (moderate or 
greater) valvular heart disease of 1.8%.1
• Prevalence of any valve disease increased with age1:
– 18 to 44 years: 0.3% (95% CI, 0.2%–0.3%)
– 45 to 54 years: 0.7% (95% CI, 0.6%–0.9%)
– 55 to 64 years: 1.6% (95% CI, 1.4%–1.9%)
– 65 to 75 years: 4.4% (95% CI, 3.9%–4.9%)
– ≥75 years: 11.7% (95% CI, 11.0%–12.5%)
• Pooled echocardiographic data from 11 911 participants from CARDIA (4351), 
ARIC (2435), and CHS (5125) demonstrated a similar increase in prevalence 
with age (Table 20-1)1:
– 18 to 44 years: 0.7% (95% CI, 0.5%–1.0%)
– 45 to 54 years: 0.4% (95% CI, 0.1%–1.3%)
– 55 to 64 years: 1.9% (95% CI, 1.2%–2.8%)
– 65 to 75 years: 8.5% (95% CI, 7.6%–9.4%)
– ≥75 years: 13.3% (95% CI, 11.7%–15.0%)
• Adjusted to the entire US population, these data suggest that the prevalence of 
any valve disease is 2.5% (95% CI, 2.2%–2.7%), with no difference between 
men (2.4% [95% CI, 2.1%–2.8%]) and women (2.5% [95% CI, 2.1%–2.9%]). 
Within this sample, 0.4% had aortic stenosis, 0.5% had aortic regurgitation, 0.1% 
had mitral stenosis, and 1.7% had mitral regurgitation.1
• In CARDIA, ARIC, and CHS, survival of participants with valve disease was 
79% (standard error 2%) at 5 years and 68% (1.9%) at 8 years, compared with 
93% (0.2%) and 86% (0.4%) in participants without valve disease. In Olmsted 
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County, valve disease was associated with a 75% increased risk of death through 
8 years of follow-up (95% CI, 1.61–1.90).
• Echocardiography data from FHS of 1696 men and 1893 women (mean 
[standard deviation] age 54 [10] years) were used to assess the prevalence of 
valvular regurgitation. Mitral regurgitation or tricuspid regurgitation of more than 
or equal to mild severity was seen in 19.0% and 14.8% of men and 19.1% and 
18.4% of women, respectively. Aortic regurgitation of more than or equal to trace 
severity was present in 13.0% of men and 8.5% of women.3
Abbreviations Used in Chapter 20
AAA abdominal aortic aneurysm
ABI ankle brachial index
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CKD chronic kidney disease
CT computed tomography
CVD cardiovascular disease
DM diabetes mellitus
DVT deep vein thrombosis
ECG electrocardiogram
FHS Framingham Heart Study
HD heart disease
HR hazard ratio
ICD International Classification of Diseases
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IE infective endocarditis
IRAD International Registry of Acute Aortic Dissection
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAD peripheral artery disease
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PE pulmonary embolism
REACH Reduction of Atherothrombosis for Continued Health
RR relative risk
SOURCE United Kingdom SAPIEN Aortic Bioprosthesis European Outcome registry
TAVI United Kingdom Transcatheter Aortic Valve Implantation registry
TAVR transcatheter aortic valve replacement
TIA transient ischemic attack
VTE venous thromboembolism
VSS venous stasis syndrome
WHO World Health Organization
WONDER Wide-ranging Online Data for Epidemiologic Research
Aortic Valve Disorders
ICD-9 424.1; ICD-10 I35.
Mortality—14 703 Any-mention mortality—29 730. Hospital discharges—55 000.
• The prevalence of moderate or severe aortic stenosis in patients ≥75 years old is 
2.8% (95% CI, 2.1%–3.7%), and the prevalence of moderate or severe aortic 
regurgitation in patients ≥75 years is 2.0% (95% CI, 1.4%–2.7%).1
• Congenitally malformed bicuspid or unicuspid valve appeared to be at least as 
common (56%) as so-called degenerative tricuspid aortic valve disease (45%; 1% 
undetermined) in a large (n=932 patients aged 26–91 years) single-center 
experience of patients who presented with isolated aortic valve replacement.4
• Aortic regurgitation prevalence in patients presenting for aortic valve 
replacement suggests that cusp prolapse (type II aortic regurgitation) is a 
common cause of aortic regurgitation, on the basis of data from a large study 
from a single center in Belgium (n=163 patients; mean [standard deviation] age 
58 [14] years)5:
– Type I: enlargement of the aortic root with normal cusps (25.2%)
– Type II: cusp prolapse or fenestration (38.0%)
– Type III: poor cusp tissue quality or quantity (36.8%)
• In MESA participants aged 45 to 84 years (n=5880), aortic valve calcium was 
quantified with serial CT images. During a mean follow-up of 2.4 years, 210 
(4.1%) of the 5142 participants with no aortic valve calcium had a mean 
incidence rate of progression of 1.7% per year, which increased with age. 
Incident aortic valve calcium was associated with several conventional 
cardiovascular risk factors, including age, male sex, BMI, and smoking.6
• Approximately 50% of patients with severe aortic stenosis are referred for 
cardiothoracic surgery, and ≈40% undergo aortic valve replacement according to 
data from 10 US centers of various sizes and geographic distribution. Reasons 
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for not undergoing aortic valve replacement included high perioperative risk, 
age, lack of symptoms, and patient/family refusal.7
Aortic Valve Interventions
• Lipid-lowering therapy does not appear to reduce aortic stenosis progression on 
the basis of any echocardiographic measures of aortic stenosis, as reported by a 
meta-analysis of 4 randomized controlled trials by Teo and colleagues.8
• Transcatheter aortic valve replacement (TAVR) has emerged as an innovative 
technology for treatment of aortic stenosis in patients at high risk for 
perioperative complications.
– Data from the UK Transcatheter Aortic Valve Implantation (TAVI) 
Registry on 877 patients (through December 2009) with 100% follow-
up demonstrate survival rates of 92.9% at 30 days, 78.6% at 1 year, and 
73.7% at 2 years.9
– Safety of TAVR appeared to be improving from 2008– 2009 to 2009–
2010 in the United Kingdom SAPIEN Aortic Bioprosthesis European 
Outcome (SOURCE) Registry, with lower rates of >2+ aortic 
regurgitation (4.5% versus 2.1%, P=0.01) and conversion to open 
surgery (3.7% versus 1.5%, P=0.03) between the respective study 
periods. Pacemaker implantation (7.7% versus 6.7%), stroke (2.4% 
versus 2.6%), and 30-day mortality rates (10.8% versus 10.7%) did not 
change.10
– Thirty-day stroke/TIA rates appear higher with TAVR than with 
surgical aortic valve replacement (5.5% versus 2.4%, P=0.04).11
Mitral Valve Disorders
ICD-9 424.0; ICD-10 I34.
Mortality—2280. Any-mention mortality—5250. Hospital discharges—22 000.
Prevalence—(See Table 20-1.)
• In pooled data from CARDIA, ARIC, and CHS, mitral valve disease was the 
most common valvular lesion. At least moderate mitral regurgitation occurred at 
a frequency of 1.7% as adjusted to the US adult population of 2000, increasing 
from 0.5% in participants aged 18 to 44 years to 9.3% in participants aged ≥75 
years.1
• A systematic review by de Marchena and colleagues12 found that in the US 
population, the prevalence of mitral regurgitation according to Carpentier’s 
functional classification system was as follows:
– Type I (congenital mitral regurgitation and endocarditis): <20 per 1 
million
– Type II (myxomatous mitral regurgitation): 15 000 per 1 million
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– Type IIIa (rheumatic HD, systemic lupus erythematosus, 
antiphospholipid syndrome): 10 520 per 1 million
– Type IIIb (ischemic mitral regurgitation, left ventricular dysfunction, 
dilated cardiomyopathy): 23 250 per 1 million
• Data from the Framingham Offspring Study demonstrated that the prevalence of 
classic (1.3%) and nonclassic (1.1%) mitral valve prolapse was similar. The 
average degree of mitral regurgitation in both types of mitral valve prolapse was 
trace or mild. The frequencies of chest pain, dyspnea, and ECG abnormalities 
were similar among participants with and without prolapse.13
Pulmonary Valve Disorders
ICD-9 424.3; ICD-10 I37.
Mortality—14. Any-mention mortality—35.
Tricuspid Valve Disorders
ICD-9 424.2; ICD-10 I36.
Mortality—12. Any-mention mortality—95.
Rheumatic Fever/Rheumatic HD
(See Table 20-2 and Chart 20-1.)
ICD-9 390 to 398; ICD-10 I00 to I09.
Mortality—3234. Any-mention mortality—6085. Hospital discharges—20 000.
• Rheumatic HD is uncommon in high-income countries such as the United States 
but remains endemic in Africa, Asia, and the Pacific, affecting >15 million 
individuals and causing 233 000 deaths annually.14
• The reported prevalence of rheumatic HD is increasing in all regions of the world 
except Europe.15
• Recent echocardiography-based screening studies in schoolchildren have 
demonstrated rheumatic HD prevalence rates ranging from 14.8 (95% CI, 7.3–
22.3) per 1000 (Uganda)16 to 20.4 (95% CI, 16.9–23.9) per 1000 in northern 
India17 to 21.5 (95% CI, 16.8–26.2) per 1000 in Cambodia and 30.4 (95% CI, 
23.2–37.6) per 1000 (Mozambique).18
– Echocardiography reveals a 3- to 10-fold higher prevalence of 
rheumatic HD than clinical examination16,18
• Acute rheumatic fever incidence is decreasing in all WHO regions except for the 
Americas, where it appears to be increasing slightly, and the Western Pacific, 
where it appears to be increasing steadily.15
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• In 1950, ≈15 000 Americans (adjusted for changes in ICD codes) died of 
rheumatic fever/rheumatic HD compared with ≈3100 annually in the present era 
(NCHS/NHLBI).
• The 2009 overall death rate for rheumatic fever/rheumatic HD was 1.1 per 100 
000. Death rates varied across race/ethnic groups but were generally low: white, 
1.2 per 100 000; black or African American, 0.7 per 100 000; Asian or Pacific 
Islander, 0.6 per 100 000; American Indian or Alaska Native, 0.6 per 100 000; 
and Hispanic or Latino origin individuals, 0.4 per 100 000.19
Bacterial Endocarditis
ICD-9 421.0; ICD-10 I33.0.
Mortality—1119. Any-mention mortality—2289. Hospital discharges—34 000, primary plus 
secondary diagnoses.
• The 2007 AHA guidelines on prevention of infective endocarditis (IE)15 state 
that IE is thought to result from the following sequence of events: (1) Formation 
of nonbacterial thrombotic endocarditis on the surface of a cardiac valve or 
elsewhere that endothelial damage occurs; (2) bacteremia; and (3) adherence of 
the bacteria in the bloodstream to nonbacterial thrombotic endocarditis and 
proliferation of bacteria within a vegetation. Viridans group streptococci are part 
of the normal skin, oral, respiratory, and gastrointestinal tract flora, and they 
cause ≥50% of cases of community-acquired native valve IE not associated with 
intravenous drug use.20
• Although the absolute risk for acquiring IE from a dental procedure is impossible 
to measure precisely, the best available estimates are as follows: If dental 
treatment causes 1% of all cases of viridans group streptococcal IE annually in 
the United States, the overall risk in the general population is estimated to be as 
low as 1 case of IE per 14 million dental procedures. The estimated absolute risk 
rates for acquiring IE from a dental procedure in patients with underlying cardiac 
conditions are as follows21:
– Mitral valve prolapse: 1 per 1.1 million procedures
– CHD: 1 per 475 000
– Rheumatic HD: 1 per 142 000
– Presence of a prosthetic cardiac valve: 1 per 114 000
– Previous IE: 1 per 95 000 dental procedures
• Cessation of antibiotic prophylaxis for IE before dental procedures has not led to 
a change in pediatric cases of endocarditis. Using 2003 to 2010 data from 37 
centers in the Pediatric Health Information Systems Database, Pasquali and 
colleagues22 did not demonstrate a significant difference in the number of IE 
hospitalizations after the guidelines were implemented in 2007 (1.6% difference 
after versus before guideline implementation; 95% CI, −6.4% to 10.3%; P=0.7).
et al. Page 270
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
• Cardiac device IE appears to be present in 6.4% (95% CI, 5.5%–7.4%) of 
patients with definite IE, according to data from the International Collaboration 
on Endocarditis–Prospective Cohort Study (2000–2006). Nearly half (45.8%; 
95% CI, 38.3%–53.4%) of such cases are associated with healthcare-associated 
infection. In-hospital and 1-year mortality rates for these patients were 14.7% 
(26/177; 95% CI, 9.8%–20.8%) and 23.2% (41/177; 95% CI, 17.2%–30.1%), 
respectively.23
Endocarditis, Valve Unspecified
ICD-9 424.9; ICD-10 I38.
Mortality—5135. Any-mention mortality—10 414.
Venous Thromboembolism Epidemiology (Including Deep Vein Thrombosis and 
Pulmonary Embolism)24
Pulmonary Embolism—ICD-9 415.1; ICD-10 I26.
Mortality—7040. Any-mention mortality—28 404. Hospital discharges—186 000.
Deep Vein Thrombosis—ICD-9 451.1; ICD-10 I80.2.
Mortality—2452. Any-mention mortality—12 439.
Incidence
• Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT; 
typically involving deep veins of the leg or pelvis) and its complication, 
pulmonary embolism (PE).
• The average annual incidence of VTE among whites is 108 per 100 000 person-
years, with ≈250 000 incident cases occurring annually among US whites.
• VTE incidence appears to be similar or higher among African Americans and 
lower among Asian Americans and Native Americans than among whites.
• After adjustment for the different age and sex distribution of African Americans, 
VTE incidence is ≈78 per 100 000, which suggests that 27 000 incident VTE 
cases occur annually among US blacks.
• VTE incidence has not changed significantly over the past 25 years.
• Incidence rates increase exponentially with age for both men and women and for 
both DVT and PE.
• Incidence rates are higher in women during childbearing years, whereas 
incidence rates after age 45 years are higher in men.
• PE accounts for an increasing proportion of VTE with increasing age in both 
sexes.
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• VTE event type (DVT versus PE) has a common familial background and shared 
genetic susceptibility.25
Survival
• Observed survival after VTE is significantly worse than expected survival for age 
and sex, and survival after PE is much worse than after DVT alone.
• For almost one quarter of PE patients, the initial clinical presentation is sudden 
death.
• Thirty-day VTE survival is 74.8% (DVT alone, 96.2%; PE with or without DVT, 
59.1%).26
• PE is an independent predictor of reduced survival for up to 3 months.
• Because most PE deaths are sudden and usually attributed to underlying disease 
(eg, cancer, other chronic heart, lung, or renal disease), secular trends in VTE 
survival are confounded by autopsy rates.
Recurrence
• VTE is a chronic disease with episodic recurrence; ≈30% of patients develop 
recurrence within the next 10 years.
• The hazard of recurrence varies with the time since the incident event and is 
highest within the first 6 to 12 months.
• Independent predictors of early (within 180 days) recurrence include active 
cancer, proportion of time spent taking heparin with a heparin level ≥0.2 anti-Xa 
U/mL, and proportion of time spent taking warfarin with an international 
normalized ratio ≥2. Two-week case fatality for recurrent DVT alone and 
recurrent PE with or without DVT is 2% and 11%, respectively.27
• Independent predictors of long-term recurrence include age, BMI, neurological 
disease with leg paresis, active cancer, lupus anticoagulant or antiphospholipid 
antibody, antithrombin, protein C or protein S deficiency, and persistently 
increased plasma fibrin D-dimer.
• Idiopathic incident VTE, incident PE, and male sex may predict a higher risk of 
recurrence, but reports are conflicting.28–30
• Oncology patients with incidentally discovered PE have similarly high rates of 
recurrence and reduced survival compared with oncology patients with 
symptomatic PE.31
Complications
• VTE complications include venous stasis syndrome (also called postthrombotic 
syndrome) and venous ulcer, as well as chronic thromboembolic pulmonary 
hypertension.
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• The 20-year cumulative incidence of venous stasis syndrome and venous ulcer 
after proximal DVT is ≈40% and 3.7%, respectively.
• The incidence of chronic thromboembolic pulmonary hypertension is 6.5 per 
million person-years; ≈1400 incident cases occur annually among US whites.
Risk Factors
• Independent VTE risk factors include increasing patient age, surgery, trauma/
fracture, hospital or nursing home confinement, active cancer, central vein 
catheterization or transvenous pacemaker, prior superficial vein thrombosis, 
infection, varicose veins, and neurological disease with leg paresis, and among 
women, use of oral contraceptives, pregnancy/postpartum period, and hormone 
therapy.32
• Together, these risk factors account for >75% of all incident VTE that occurs in 
the community.
• Compared with residents in the community, hospitalized residents have a >130-
fold higher VTE incidence (71 versus 9605 per 100 000 person-years).33
• Hospitalization and nursing home residence together account for almost 60% of 
incident VTE events that occur in the community.
• Among patients hospitalized for acute medical illness, independent risk factors 
for VTE include prior VTE, thrombophilia, cancer, age >60 years, leg paralysis, 
immobilization ≥7 days, and admission to an intensive care unit or coronary care 
unit.34
• Among cancer patients beginning chemotherapy, tumor site, BMI, hemoglobin, 
platelet and white blood cell count, and plasma D-dimer and soluble P-selectin 
levels are predictors of VTE in the next 6 months.35
• Pregnancy-associated VTE incidence is 200 per 100 000 woman-years; 
compared with nonpregnant women of childbearing age, the RR is increased ≈4-
fold.
• VTE risk during the postpartum period is ≈5-fold higher than during pregnancy.
• VTE is highly heritable and follows a complex mode of inheritance that involves 
environmental interaction.
• Inherited thrombophilias (eg, inherited antithrombin, protein C, or protein S 
deficiency; factor V Leiden; prothrombin G20210A; ABO blood type non-O) 
interact with such clinical risk factors (ie, environmental “exposures”) as oral 
contraceptives, pregnancy, hormone therapy, and surgery to compound VTE risk.
• Similarly, genetic interaction compounds the risk of incident and recurrent VTE.
Arteries, Diseases of
ICD-9 440 to 448; ICD-10 I70 to I78. Includes PAD.
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Penetrating Aortic Ulcers
• A single-center evaluation of 388 penetrating aortic ulcers found on CT 
angiography (2003–2009) demonstrated penetrating aortic ulcers in the aortic 
arch (6.8%), descending thoracic aorta (61.2%), and abdominal aorta (29.7%). 
Nearly 2 of every 3 penetrating aortic ulcers (57.7%) did not have a saccular 
aneurysm or intramural hematoma, whereas ≈1 in 4 (27.8%) had associated 
saccular aneurysms, and ≈1 in 7 (14.4%) had an associated intramural 
hematoma. Rupture was present in ≈1 in 25 (4.1%) penetrating aortic ulcers.36
Aortic Aneurysm—ICD-9 441; ICD-10 I71.
Mortality—10 597. Any-mention mortality—17 215. Hospital discharges—64 000.
• Although the definition varies somewhat by age and body surface area, generally 
an AAA is considered to be present when the anteroposterior diameter of the 
aorta reaches 3.0 cm.37
• The prevalence of AAAs that are 2.9 to 4.9 cm in diameter ranges from 1.3% in 
men 45 to 54 years of age to 12.5% in men 75 to 84 years of age. For women, the 
prevalence ranges from 0% in the youngest to 5.2% in the oldest age groups.37
• Between 1997 and 2009, age-adjusted mortality attributable to AAA declined 
from 40.4 to 25.7 per 100 000 in England and Wales and from 30.1 to 20.8 per 
100 000 population in Scotland.38
• A meta-analysis of 15 475 individuals from 18 studies on small AAAs (3.0–5.4 
cm) demonstrated that mean aneurysm growth rate was 2.21 mm per year and 
was independent of age and sex. Growth rates were higher in smokers (by 0.35 
mm/y) and lower in patients with DM (by 0.51 mm/y).39
• Rupture rates range from 0.71 to 11.03 per 1000 person-years, with higher 
rupture rates in smokers (pooled HR, 2.02; 95% CI, 1.33–3.06) and women 
(pooled HR, 3.76; 95% CI, 2.58–5.47).39
• Data from the International Registry of Acute Aortic Dissection (IRAD) suggest 
that patients with acute type B aortic dissection have heterogenous in-hospital 
outcomes. In-hospital mortality in patients with and without complications (such 
as mesenteric ischemia, renal failure, limb ischemia, or refractory pain) was 
20.0% and 6.1%, respectively. In complicated patients, in-hospital mortality 
associated with surgical and endovascular repair was 28.6% and 10.1% 
(P=0.006), respectively.40
AAA Treatment
• After multivariable adjustment, Medicare patients who underwent open AAA 
repair had higher risk of all-cause mortality (HR, 1.24; 95% CI, 1.05–1.47) and 
AAA-related mortality (HR, 4.37; 95% CI, 2.51–7.66) at 1 year than patients 
who underwent endovascular repair.41
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Peripheral Artery Disease—(See Charts 20-2 and 20-3.)
ICD-9: 440.20 to 440.24, 440.30 to 440.32, 440.4, 440.9, 443.9, 445.02; ICD-10: I70.2, 
I70.9, I73.9, I74.3, I74.4.
Mortality—13 893. Any-mention mortality—64 469. Hospital discharges—146 000.
• PAD affects ≈8.5 million Americans aged ≥40 years and is associated with 
significant morbidity and mortality.42 PAD prevalence is higher in older 
individuals and appears to disproportionately affect African Americans.42
• The age- and sex-standardized prevalence (standard error) of PAD in the United 
States is 4.6% (0.3%) based on data from NHANES 1999–2004. The highest 
prevalence of PAD was observed among elderly people, non-Hispanic blacks, 
and women. In a multivariable age-, sex-, and race/ethnicity-adjusted regression 
model, hypertension, DM, CKD, and smoking were associated with incident 
PAD (P≤0.05 for each).43
• In the general population, only ≈10% of people with PAD have the classic 
symptom of intermittent claudication. Approximately 40% do not complain of 
leg pain, whereas the remaining 50% have a variety of leg symptoms different 
from classic claudication.44,45 Data from NHANES 1999–2002 suggest that up 
to two thirds of US adults with PAD who are ≥40 years old are asymptomatic, 
with one fourth having severe PAD (ABI <0.7).46 In an older, disabled 
population of women, as many as two thirds of individuals with PAD had no 
exertional leg symptoms.47
• The risk factors for PAD are similar but not identical to those for CHD. DM and 
cigarette smoking are stronger risk factors for PAD than for CHD.37 ORs for 
associations of DM and smoking with symptomatic PAD are ≈3.0 to 4.0. Most 
studies suggest that the prevalence of PAD is similar in men and women.48
• Pooled data from 11 studies in 6 countries found that PAD (defined by ABI <0.9) 
is a marker for systemic atherosclerotic disease. The pooled age-, sex-, risk 
factor–, and CVD-adjusted RR for all-cause death was 1.60 (95% CI, 1.32–1.95), 
the RR for cardiovascular mortality was 1.96 (95% CI, 1.46–2.64), the RR for 
CHD was 1.45 (95% CI, 1.08–1.93), and the RR for stroke was 1.35 (95% CI, 
1.10–1.65).49
• A 2008 meta-analysis of 24 955 men and 23 339 women demonstrated that the 
association of the ABI with mortality has a reverse J-shaped distribution in 
which participants with an ABI of 1.11 to 1.40 are at lowest risk for mortality. 50 
Low ABI (≤0.9) carried a 3-fold (RR, 3.33; 95% CI, 2.74–4.06) risk of all-cause 
death compared with men with normal ABI (1.11–1.40) and a similar risk in 
women (RR, 2.71; 95% CI, 2.03–3.62).50
• Among 508 patients (449 men) identified from 2 vascular laboratories in San 
Diego, CA, a decline in ABI of >0.15 within a 10-year period was associated 
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with a subsequent increased risk of all-cause mortality (RR, 2.4; 95% CI, 1.2–
4.8) and CVD mortality (RR, 2.8; 95% CI, 1.3–6.0) at 3 years’ follow-up.51
• Among 440 patients with PAD, male sex and smoking were more associated with 
aortoiliac (proximal) disease than with infrailiac (distal) disease. In addition, 
aortoiliac disease was associated with an increased risk of mortality or 
cardiovascular events compared with infrailiac disease (adjusted HR, 3.28; 95% 
CI, 1.87–5.75).52
• People with PAD have impaired function and quality of life. This is true even for 
people who do not report leg symptoms. Furthermore, patients with PAD, 
including those who are asymptomatic, experience a significant decline in lower-
extremity functioning over time.53–55
• Among patients with established PAD, higher PA levels during daily life are 
associated with better overall survival rate, a lower risk of death because of 
CVD, and slower rates of functional decline.56,57 In addition, better 6-minute 
walk performance and faster walking speed are associated with lower rates of all-
cause mortality, cardiovascular mortality, and mobility loss.58,59
• A cross-sectional, population-based telephone survey of >2500 adults ≥50 years 
of age, with oversampling of blacks and Hispanics, found that 26% expressed 
familiarity with PAD. Of these, half were not aware that DM and smoking 
increase the risk of PAD. One in 4 knew that PAD is associated with increased 
risk of MI and stroke, and only 14% were aware that PAD could lead to 
amputation. All knowledge domains were lower in individuals with lower 
income and education levels.60
Interventions
• Data from the Reduction of Atherothrombosis for Continued Health (REACH) 
Registry of 8273 PAD participants suggest that only 70% of PAD patients receive 
lipid-lowering therapy and only 82% receive antiplatelet therapy for secondary 
CVD prevention.61
• A 2011 systematic review evaluated lower-extremity aerobic exercise against 
usual care and demonstrated a range of benefits, including the following62:
– Increased claudication time by 71 seconds (79%) to 918 seconds 
(422%).
– Increased claudication distance by 15 m (5.6%) to 232 m (200%).
– Increased walking distance/time by 67% to 101% after 40 minutes of 
walking 2 to 3 times per week.
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21. Quality of Care
See Tables 21-1 through 21-13.
The Institute of Medicine defines quality of care as “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are 
consistent with current professional knowledge.”1 The Institute of Medicine has defined 6 
specific domains for improving health care, including care that is safe, effective, patient-
centered, timely, efficient, and equitable.
In the following sections, data on quality of care will be presented based on the 6 domains of 
quality as defined by the Institute of Medicine. This is intended to highlight current care and 
to stimulate efforts to improve the quality of cardiovascular care nationally. Where possible, 
data are reported from recently published literature or standardized quality indicators from 
quality-improvement registries (ie, those consistent with the methods for quality 
performance measures endorsed by the ACC and the AHA).2 Additional data on aspects of 
quality of care, such as adherence to ACC/AHA clinical practice guidelines, are also 
included to provide a spectrum of quality-of-care data. The data selected are meant to 
provide examples of the current quality of care as reflected by the Institute of Medicine 
domains and are not meant to be comprehensive given the sheer number of publications 
yearly.
Abbreviations Used in Chapter 21
ACC American College of Cardiology
ACEI angiotensin-converting enzyme inhibitor
ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes Network
ACS acute coronary syndrome
AED automated external defibrillator
AF atrial fibrillation
AHA American Heart Association
AMA-PCPI American Medical Association–Physician Consortium for Performance Improvement
AMI acute myocardial infarction
ARB angiotensin receptor blocker
BMI body mass index
BP blood pressure
CABG coronary artery bypass grafting
CAD coronary artery disease
CHF congestive heart failure
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CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and AGgressive drug Evaluation trial
CPR cardiopulmonary resuscitation
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early 
Implementation of the ACC/AHA Guidelines
D2B Door-to-Balloon Alliance
DM diabetes mellitus
DVT deep vein thrombosis
ED emergency department
EF ejection fraction
EMS emergency medical services
GWTG Get With The Guidelines
GWTG-HF Get With The Guidelines–Heart Failure
HbA1c hemoglobin A1c
HF heart failure
HIQR Hospital Inpatient Quality Reporting
HR hazard ratio
IV intravenous
LDL low-density lipoprotein
LV left ventricular
LVEF left ventricular ejection fraction
LVSD left ventricular systolic dysfunction
MI myocardial infarction
N/A not available or not applicable
NCDR National Cardiovascular Data Registry
NHANES National Health and Nutrition Examination Survey
NM not measured
NSTEMI non–ST-elevation myocardial infarction
OR odds ratio
PAD peripheral artery disease
PCI percutaneous coronary intervention
PINNACLE Practice Innovation and Clinical Excellence
RR relative risk
SBP systolic blood pressure
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial
SD standard deviation
STEMI ST-elevation myocardial infarction
TAVR transcatheter aortic valve replacement
tPA tissue-type plasminogen activator
UFH unfractionated heparin
VF ventricular fibrillation
VHA Veterans Health Administration
VT ventricular tachycardia
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• The safety domain has been defined as avoiding injuries to patients from the care 
that is intended to help them. The following are several publications that have 
focused on safety issues:
– In a small, single-center study conducted over a 2-month period in the 
cardiac care unit of a tertiary center, Rahim et al3 demonstrated that 
iatrogenic adverse events were common (99 of 194 patients), of which 
bleeding (27%) was the most common preventable iatrogenic adverse 
event.
– Using the NCDR (National Cardiovascular Data Registry) CathPCI 
Registry, Tsai et al4 found that almost one fourth of dialysis patients 
undergoing PCI (n=22 778) received a contraindicated antithrombotic 
agent, specifically enoxaparin, eptifibatide, or both. Patients who 
received a contraindicated antithrombotic agent had an increased risk of 
in-hospital bleeding (OR, 1.63; 95% CI, 1.35–1.98) and a trend toward 
increased mortality (OR, 1.15; 95% CI, 0.97–1.36).4
– Using data from the ACTION Registry-GWTG, Mathews and 
colleagues developed a contemporary model to stratify in-hospital 
bleeding risk for patients after STEMI and NSTEMI.5 The 12 factors 
associated with major bleeding in the model were heart rate, baseline 
hemoglobin, female sex, baseline serum creatinine, age, 
electrocardiographic changes, HF or shock, DM, PAD, body weight, 
SBP, and home warfarin use. The risk model discriminated well in the 
derivation (C statistic= 0.73) and validation (C statistic=0.71) cohorts, 
and the risk score for major bleeding corresponded well with observed 
bleeding.5
– In a random sample of medical and surgical long-term care adult 
patients in Massachusetts hospitals, López et al6 assessed the 
association between disclosure of an adverse event and patients’ 
perception of quality of care. Overall, only 40% of adverse events were 
disclosed. Higher quality ratings were associated with disclosure of an 
adverse event. Conversely, lower patient perception of quality of care 
was associated with events that were preventable and with events that 
caused discomfort.6
– Using prospective propensity-matched cohort analysis of 7 newly 
introduced cardiovascular devices, Resnic et al7 showed the feasibility 
of automated prospective surveillance to identify low-frequency safety 
signals in a cardiovascular registry. In this study, 3 of the 21 safety 
alerts triggered sustained alerts in 2 implantable devices.7
• Effective care has been defined as providing services based on scientific 
knowledge to all who could benefit and refraining from providing services to 
those not likely to benefit. It also encompasses monitoring results of the care 
provided and using them to improve care for all patients.1 There are many 
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quality-improvement registries that have been developed for inpatient 
cardiovascular/stroke care, and the data on these are provided in subsequent 
tables. Similar efforts are under way for quality-of-care registries in the 
outpatient setting. In 2011, the AHA published a policy statement for expanding 
the applications of existing and future clinical registries.8 This statement 
discusses recommendations on ensuring high-quality data, linking clinical 
registries with supplemental data, integrating registries with electronic health 
records, safeguarding privacy, securing adequate funding, and developing a 
business model to initiate and sustain these registries.
– In the CRUSADE registry, 1 in 10 patients (10.3%) had a documented 
contraindication to reperfusion. Primary reasons for contraindications 
were identified as absence of an ischemic indication (53.8%), bleeding 
risk (16.7%), patient-related reasons (25.3%), and other (4.2%). 
Conversely, 7.2% of patients with STEMI without a reperfusion 
contraindication did not have reperfusion therapy administered, and this 
was associated with greater in-hospital mortality.9
– According to data from NHANES 1988–1994 and 1999–2008, rates of 
hypertension have increased from 23.9% in 1988–1994 to 29.0% in 
2007–2008, and hypertension control has increased from 27.3% in 
1988–1994 to 50.1% in 2007–2008. In addition, among patients with 
hypertension, BP has decreased from 143.0/80.4 to 135.2/74.1 mm 
Hg.10
– Weintraub et al11 reported results from a comparative effectiveness 
study of PCI versus CABG using observational data among patients 
≥65 years of age with 2- or 3-vessel CAD without AMI. Their results 
showed that at 1 year, there was no significant difference in adjusted 
mortality between groups (6.24% in the CABG group versus 6.55% in 
the PCI group). At 4 years, there was lower mortality in the CABG 
group than in the PCI group (16.4% versus 20.8%; RR, 0.79; 95% CI, 
0.76–0.82).11
– Appel et al12 reported results of a randomized controlled trial 
comparing the effectiveness of 2 behavioral weight loss interventions 
with controls. The interventions included either remote weight loss 
intervention (delivered through the telephone, a study-specific Web site, 
and e-mail) or in-person support (individual and group sessions along 
with the 3 means of remote support). At 24 months, the mean change in 
weight from baseline was −0.8 kg in the control group, −4.6 kg in the 
group with remote support only (P<0.001 for comparison with the 
control group), and −5.1 kg in the group receiving in-person support 
(P<0.001 for comparison with the control group). The change in weight 
from baseline did not differ significantly between the 2 intervention 
groups at the end of the trial.
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– Choudhry et al13 reported results of a cluster randomized trial that 
evaluated the impact of eliminating out-of-pocket costs (full 
prescription coverage) on medication adherence and cardiovascular 
outcomes in patients discharged after MI. Compared with the usual 
prescription coverage, rates of adherence to statins, β-blockers, 
angiotensin-converting enzyme inhibitors, and angiotensin receptor 
blockers were on average 4% to 6% higher in the full-coverage group. 
There was no significant difference in the primary outcome (first major 
vascular event or revascularization) between the 2 groups (17.6 per 100 
person years in the full-coverage group versus 18.8 in the usual-
coverage group; HR, 0.93; 95% CI, 0.82–1.04). The rates of secondary 
outcomes of total major vascular events or revascularization were 
significantly reduced in the full-coverage group (21.5 versus 23.3; HR, 
0.89; 95% CI, 0.90–0.99), as was the rate of first major vascular event 
(11 versus 12.8; HR, 0.86; 95% CI, 0.74–0.99). The elimination of 
copayments did not increase total spending, although patient costs were 
reduced for drugs and other services.
– Data from the ACC PINNACLE (Practice Innovation and Clinical 
Excellence) outpatient registry14 of patients with CAD (n=38 775) 
showed that 77.8% of the patients (30 160) were prescribed statins, 
2042 (5.3%) were treated only with nonstatin lipid-lowering 
medications, and 6573 (17%) were not taking any lipid-lowering 
medication. Lack of medical insurance (RR, 0.94; 95% CI, 0.89–1.00) 
was associated with a lower likelihood of statin treatment, whereas 
male sex (RR, 1.10; 95% CI, 1.07–1.13), coexisting hypertension (RR, 
1.07; 95% CI, 1.02–1.12), prior CABG (RR, 1.09; 95% CI, 1.05–1.14), 
and prior PCI (RR, 1.11; 95% CI, 1.06–1.16) were associated with a 
higher likelihood of statin treatment.
– In patients recently hospitalized with HF, a randomized clinical trial did 
not show improvement in the primary end point (readmission for any 
reason or death of any cause within 180 days after enrollment) or the 
secondary end points (hospitalization for HF, number of days in the 
hospital, and number of hospitalizations) with the use of 
telemonitoring.15 Similar results were seen in a randomized clinical 
trial of remote telemedical management in patients with chronic HF.16
– Heisler et al17 reported results of a prospective, multisite, cluster 
randomized trial that evaluated the effectiveness of a pharmacist-led 
intervention that targeted medication management and adherence 
counseling to improve BP control in patients with DM in 2 high-
performing integrated healthcare systems. Although the mean SBP of 
patients in the intervention arm was 2.4-mm Hg lower (95% CI, –3.4 to 
–1.5; P<0.001) immediately after the intervention than that of patients 
in the control arm, the mean SBP decrease from 6 months before to 6 
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months after the intervention (primary outcome) was similar in 
magnitude (≈9 mm Hg) in both arms.17
– Outcome measures of 30-day mortality and 30-day readmission after 
hospitalization for AMI or HF have been developed that adjust for 
patient mix (eg, comorbidities) so that comparisons can be made across 
hospitals.18–21 Using national Medicare data from July 2006 through 
June 2009, the median (10th, 90th percentile) hospital risk-standardized 
mortality rate was 16% (13.9%, 17.8%) for AMI and 10.8% (8.9%, 
12.7%) for HF. The median risk-standardized readmission rate was 
19.9% (18.5%, 21.2%) for AMI and 24.5% (22.2%, 27.1%) for HF. 
Distinct regional patterns were seen for both measures and both 
conditions.18
– A study of 30 947 patients admitted with ischemic strokes showed that 
admission to a designated stroke center compared with admission to a 
nondesignated hospital was associated with more frequent use of 
thrombolytic therapy (4.8% versus 1.7%, P<0.001), and lower 30-day 
all-cause mortality (10.1% versus 12.5%, P<0.001).22
– A study of 458 hospitals participating in the Society of Thoracic 
Surgeons National Cardiac Database showed that an intervention of 
receiving quality-improvement educational material designed to 
influence the prescription rates of 4 medication classes (aspirin, β-
blockers, lipid-lowering therapy, and angiotensin-converting enzyme 
inhibitors) after CABG discharge in addition to site-specific feedback 
reports led to a significant improvement in adherence for all 4 
secondary prevention medications at the intervention sites compared 
with the control sites.23
– In 2011, the ACC Foundation/AHA/American Medical Association–
Physician Consortium for Performance Improvement (AMA-PCPI) 
published a joint report on performance measures for CAD and 
hypertension.24 The 9 performance measures for CAD care included BP 
control, lipid control, symptom and activity assessment, symptom 
management, tobacco use (screening, cessation, and intervention), 
antiplatelet therapy, β-blocker therapy, angiotensin-converting enzyme 
inhibitor/ angiotensin receptor blocker therapy, and cardiac 
rehabilitation patient referral from an outpatient setting. For 
hypertension care, the performance measures included BP control. This 
set was an update to the 2005 ACC Foundation/AHA performance 
measures for CAD and hypertension and included modifications to 7 of 
the 2005 performance measures. Screening for DM was retired from the 
CAD set published in 2005, whereas symptom management and cardiac 
rehabilitation referral were added to the 2011 CAD set. Similarly, the 
ACC Foundation/AHA/AMA-PCPI published a report on performance 
measures for HF,25 which was an update to the 2005 report.26 Eight 
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measures from the 2005 report were retired, β-blocker use in patients 
with HF was expanded as a performance measure for the inpatient 
setting, symptom management and counseling about implantable 
cardioverter-defibrillators were added as new quality metrics, and 
patient education was changed from a performance measure to a quality 
metric.
– Inpatient ACS, HF, and stroke quality-of-care measures data, including 
trends in care data, where available from national registries, are given in 
Tables 21-1 through 21-6.
– Selected outpatient quality-of-care measures from the National 
Committee for Quality Assurance for 2010 appear in Table 21-7.
– Quality-of-care measures for patients who had out-of hospital cardiac 
arrest and were enrolled in the Resuscitation Outcomes Consortium 
cardiac arrest registry in 2010 (Resuscitation Outcomes Consortium 
Investigators, unpublished data, June 20, 2012) are given in Table 21-8.
– Quality-of-care measures for patients who had inhospital cardiac arrest 
and were enrolled in the AHA’s GWTG-Resuscitation quality-
improvement project in 2011 (GWTG-Resuscitation Investigators, 
unpublished data, June 20, 2012) are given in Table 21-9.
• Patient-centered care has been defined as the provision of care that is respectful 
of and responsive to individual patient preferences, needs, and values and that 
ensures that patient values guide all clinical decisions. Dimensions of patient-
centered care include the following: (1) Respect for patients’ values, preferences, 
and expressed needs; (2) coordination and integration of care; (3) information, 
communication, and education; (4) physical comfort; (5) emotional support; and 
(6) involvement of family and friends. Studies that focused on some of these 
aspects of patientcentered care are highlighted below.
– The COURAGE trial,27 which investigated a strategy of PCI plus 
optimal medical therapy versus optimal medical therapy alone, 
demonstrated that both groups had significant improvement in health 
status during follow-up. By 3 months, health status scores had increased 
in the PCI group compared with the medical therapy group, to 76±24 
versus 72±23 for physical limitation (P=0.004), 77±28 versus 73±27 for 
angina stability (P=0.002), 85±22 versus 80±23 for angina frequency 
(P<0.001), 92±12 versus 90±14 for treatment satisfaction (P<0.001), 
and 73±22 versus 68±23 for quality of life (P<0.001). The PCI plus 
optimal medical therapy group had a small but significant incremental 
benefit compared with the optimal medical therapy group early on, but 
this benefit disappeared by 36 months.
– In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)28 of 
single-lead implantable cardioverter-defibrillator versus amiodarone for 
moderately symptomatic HF, patients with implantable cardioverter-
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defibrillators had improvement in quality of life compared with medical 
therapy patients at 3 and 12 months but not at 30 months. Implantable 
cardioverter-defibrillator shocks in the month preceding a scheduled 
assessment were associated with a decrease in quality of life in multiple 
domains. The authors concluded that the presence of a single-lead 
implantable cardioverter-defibrillator was not associated with any 
detectably adverse quality of life during 30 months of follow-up.
– Peikes et al29 reported on 15 care-coordination programs as part of a 
Medicare demonstration project for patients with CHF, CAD, DM, and 
other conditions. Thirteen of the 15 programs did not show a difference 
in hospitalization rates, and none of the programs demonstrated net 
savings. The interventions tested varied significantly, but the majority 
of the interventions included patient education to improve adherence to 
medication, diet, exercise, and self-care regimens and improving care 
coordination through various approaches. These programs overall had 
favorable effects on none of the adherence measures and only a few of 
the many quality-of-care indicators examined. The authors concluded 
that programs with substantial in-person contact that target moderately 
to severely ill patients can be cost-neutral and improve some aspects of 
care.
– Hernandez et al30 showed that patients with outpatient follow-up within 
7 days of discharge for an HF hospitalization were less likely to be 
readmitted within 30 days in the GWTG-HF registry of patients who 
were ≥65 years of age. The median length of stay was 4 days 
(interquartile range, 2–6 days), and 21.3% of patients were readmitted 
within 30 days. At the hospital level, the median percentage of patients 
who had early follow-up after discharge from the index hospitalization 
was 38.3% (interquartile range, 32.4%–44.5%).
– Smolderen et al31 assessed whether health insurance status affects 
decisions to seek care for AMI. Uninsured and insured patients with 
financial concerns were more likely to delay seeking care during AMI 
and had prehospital delays of >6 hours (48.6% of uninsured patients 
and 44.6% of insured patients with financial concerns compared with 
39.3% of insured patients without financial concerns). Lack of health 
insurance and financial concerns about accessing care among those with 
health insurance were each associated with delays in seeking 
emergency care for AMI.
– Using a cohort (n=192) nested within a randomized trial at a university-
affiliated ambulatory practice, Murray et al32 demonstrated that refill 
adherence of <40% was associated with a 3-fold higher incidence of HF 
hospitalization than refill adherence of ≥80% (P=0.002). In 
multivariable analysis, prescription label–reading skills were associated 
with a lower incidence of HF-specific emergency care (incidence rate 
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ratio, 0.76; 95% CI, 0.19–0.69), and participants with adequate health 
literacy had a lower risk of HF hospitalization (incidence rate ratio, 
0.34; 95% CI, 0.15–0.76).
– Reynolds et al33 reported results on health-related quality of life after 
TAVR in inoperable patients with severe aortic stenosis compared with 
those receiving standard therapy. Health-related quality of life was 
assessed at baseline and at 1, 6, and 12 months with the Kansas City 
Cardiomyopathy Questionnaire and the 12-item Short Form-12 General 
Health Survey. Although the Kansas City Cardiomyopathy 
Questionnaire summary scores improved in both groups, the extent of 
improvement was greater in the TAVR group than in the standard-care 
group at 1 month (mean between-group difference, 13 points; 95% CI, 
8–19), with larger benefits at 6 months (mean difference, 21 points; 
95% CI, 15–27 points) and 12 months (mean difference, 26 points; 95% 
CI, 19– 33). At 12 months, TAVR patients also reported higher physical 
and mental health scores on the 12-item Short Form-12 General Health 
Survey, with a mean difference of 5.7 and 6.4 points, respectively 
(P<0.001 for both comparisons) compared with standard care.33
– In 2012, the AHA published a scientific statement on decision making 
in advanced HF. This statement discusses the clinical trajectory of HF, 
importance and process of shared decision making in advanced HF, 
timing of discussion, discussion on outcomes beyond survival (ie, major 
adverse events, symptom burden, functional limitations, loss of 
independence, quality of life, and obligations for caregivers), 
discussions regarding end-of-life issues, and assessment and integration 
of emotional readiness of the patient and family in these discussions.34
– In 2012, the ACC Foundation published a policy statement on patient-
centered care in cardiovascular medicine. This policy statement 
discusses and provides recommendations on topics such as enhanced 
clinician-patient communication, health literacy, clinician-directed 
patient education, assessment of patient-centered outcomes, process of 
shared decision making, collaborative care planning and goal setting, 
and patient empowerment and self-management. The policy statement 
also discusses newer paradigms and challenges in patient-centered care, 
such as the impact of technology, complexity of care strategies with 
self-care, a systemic approach to episodic care, and barriers to patient-
centered care.35
• The timely care domain relates to reducing waits and sometimes harmful delays 
for both those who receive and those who give care. Timeliness is an important 
characteristic of any service and is a legitimate and valued focus of improvement 
in health care and other industries.
– Data from the CRUSADE national quality-improvement initiative 
showed that median delay from onset of symptoms to hospital 
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presentation for patients presenting with NSTEMI was 2.6 hours and 
was significantly associated with in-hospital mortality but did not 
change over time from 2001 to 2006.36
– Bradley et al37 demonstrated that participation in the Door-to-Balloon 
(D2B) Alliance led to a reduction in door-to-balloon time to within 90 
minutes for patients with STEMI. By March 2008, >75% of patients 
had door-to-balloon times of ≤90 minutes compared with only 
approximately one fourth of patients in April 2005.
– Using data between 2005 and 2007 from the NCDR CathPCI Registry, 
Wang et al38 demonstrated that among STEMI patients, only 10% of 
the transfer patients received PCI within 90 minutes (versus 63% for 
direct-arrival patients; P<0.0001).
– Glickman et al39 showed that a year-long implementation of 
standardized protocols as part of a statewide regionalization program 
was associated with a significant improvement in median door-in–door-
out times among 436 STEMI patients who presented at non-PCI 
hospitals who required transfer (before intervention: 97 minutes, 
interquartile range 56–160 minutes; after intervention: 58 minutes, 
interquartile range 35–90 minutes; P<0.0001).
– Data on time to reperfusion for STEMI or ischemic stroke are provided 
from national registries in Table 21-10.
• Efficiency has been defined as avoiding waste, in particular waste of equipment, 
supplies, ideas, and energy. In an efficient healthcare system, resources are used 
to get the best value for the money spent.
– The AHA and ACC have jointly developed a scientific statement that 
outlines standards for measures to be used for public reporting of 
efficiency in health care. The group identified 4 standards important to 
the development of any efficiency performance measure, including (1) 
integration of quality and cost, (2) valid cost measurement and analysis, 
(3) no or minimal incentive to provide poor-quality care, and (4) no or 
proper attribution of the measure. In the statement, 4 examples were 
provided of hospital-based efficiency measures, as well as information 
on how each of the measures fared within the 4 domains recommended. 
The examples were length of stay, 30-day readmission, hospitalization 
costs, and nonrecommended imaging tests.40
– At an urban, tertiary care, academic medical center ED, elements of 
departmental work flow were redesigned to streamline patient 
throughput before implementation of a fully integrated ED information 
system with patient tracking, computerized charting and order entry, 
and direct access to patient historical data from the hospital data 
repository. Increasing the clinical information available at the bedside 
and improving departmental work flow through ED information system 
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implementation and process redesign led to decreased patient 
throughput times and improved ED efficiency (eg, the length of stay for 
all patients [from arrival to time patient left the ED] decreased by 1.94 
hours, from 6.69 [n=508] before the intervention to 4.75 [n=691] hours 
after the intervention; P<0.001).41
– Himmelstein et al42 analyzed whether more-computerized hospitals had 
lower costs of care or administration or better quality, to address a 
common belief that computerization improves healthcare quality, 
reduces costs, and increases administrative efficiency. They found that 
hospitals that increased computerization faster had more rapid 
administrative cost increases (P=0.0001); however, higher overall 
computerization scores correlated weakly with better quality scores for 
AMI (r=0.07, P=0.003) but not for HF, pneumonia, or the 3 conditions 
combined. In multivariate analyses, more-computerized hospitals had 
slightly better quality. The authors concluded that hospital computing 
might modestly improve process measures of quality but does not 
reduce administrative or overall costs.
– In a retrospective cohort study of cases (111 707) submitted to the 
NCDR ICD [implantable cardioverterdefibrillator] Registry between 
January 1, 2006, and June 30, 2009, 25 145 (22.5%) received non–
evidence-based implantable cardioverter-defibrillator therapy. Patients 
who received non–evidence-based implantable cardioverter-defibrillator 
therapy compared with those who received evidence-based implantable 
cardioverter-defibrillator therapy had a significantly higher risk of in-
hospital death (0.57% versus 0.18%, P<0.001) and any postprocedure 
complication (3.23% versus 2.41%, P<0.001).43
– In a multicenter study of patients within the NCDR undergoing PCI, 
Chan et al44 reported results of the appropriateness of PCI for both 
acute and nonacute indications. Among patients undergoing PCI for 
acute indications (71.1% of the cohort), 98.5% of the procedures were 
classified as appropriate, 0.3% as uncertain, and 1.1% as inappropriate. 
Among patients undergoing PCI for nonacute indications (28.9% of the 
cohort), 50.4% of the procedures were classified as appropriate, 38% as 
uncertain, and 11.6% as inappropriate. There was also substantial 
variation for inappropriate nonacute PCI across hospitals (median 
hospital rate 10.8%; interquartile range 6.0%–16.7%).
• Equitable care means the provision of care that does not vary in quality because 
of personal characteristics such as sex, ethnicity, geographic location, and 
socioeconomic status. The aim of equity is to secure the benefits of quality health 
care for all the people of the United States. With regard to equity in caregiving, 
all individuals rightly expect to be treated fairly by local institutions, including 
healthcare organizations.
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– Chan et al45 demonstrated that rates of survival to discharge were lower 
for black patients (25.2%) than for white patients (37.4%) after in-
hospital cardiac arrest. Lower rates of survival to discharge for blacks 
reflected lower rates of both successful resuscitation (55.8% versus 
67.4%) and postresuscitation survival (45.2% versus 55.5%). 
Adjustment for the hospital site at which patients received care 
explained a substantial portion of the racial differences in successful 
resuscitation (adjusted RR, 0.92; 95% CI, 0.88–0.96; P<0.001) and 
eliminated the racial differences in postresuscitation survival (adjusted 
RR, 0.99; 95% CI, 0.92–1.06; P=0.68). The authors concluded that 
much of the racial difference was associated with the hospital center in 
which black patients received care.
– Kapoor et al46 evaluated 99 058 HF admissions from 244 sites between 
January 2005 and September 2009. Patients were grouped on the basis 
of payer status (private/ health maintenance organization, no insurance, 
Medicare, or Medicaid). Compared with private/health maintenance 
organization group, the other 3 groups were less likely to receive 
evidence-based therapies (β-blockers, implantable cardioverter-
defibrillators, anticoagulation for AF, angiotensin-converting enzyme 
inhibitors, or angiotensin receptor blockers) and had longer hospital 
stays. Higher adjusted rates of in-hospital mortality were also seen in 
patients with Medicaid (OR, 1.22; 95% CI, 1.06–1.41) and in patients 
with reduced EF and no insurance (OR, 1.61; 95% CI, 1.15–2.25).
– Cohen et al47 demonstrated that among hospitals engaged in a national 
quality monitoring and improvement program, evidence-based care for 
AMI appeared to improve over time for patients irrespective of race/ 
ethnicity, and differences in care by race/ethnicity care were reduced or 
eliminated. They analyzed 142 593 patients with AMI (121 528 whites, 
10 882 blacks, and 10 183 Hispanics) at 443 hospitals participating in 
the GWTG-CAD program. Overall, defect-free care was 80.9% for 
whites, 79.5% for Hispanics (adjusted OR versus whites, 1.00; 95% CI, 
0.94–1.06; P=0.94), and 77.7% for blacks (adjusted OR versus whites, 
0.93; 95% CI, 0.87–0.98; P=0.01). A significant gap in defect-free care 
was observed for blacks during the first half of the study but was no 
longer present during the remainder of the study. Overall, progressive 
improvements in defect-free care were observed regardless of race/
ethnic groups.
– Thomas et al48 analyzed data among hospitals that voluntarily 
participated in the AHA’s GWTG-HF program from January 2005 
through December 2008. Relative to white patients, Hispanic and black 
patients hospitalized with HF were significantly younger (median age 
78, 63, and 64 years, respectively) but had lower EFs (mean EF 41.1%, 
38.8%, and 35.7%, respectively) with a higher prevalence of DM 
(40.2%, 55.7%, and 43.8%, respectively) and hypertension (70.6%, 
et al. Page 292
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
78.4%, and 82.8%, respectively). The provision of guideline-based care 
was comparable for white, black, and Hispanic patients. Black (1.7%) 
and Hispanic (2.4%) patients had lower in-hospital mortality than white 
patients (3.5%). Improvement in adherence to all-or-none HF measures 
increased annually from year 1 to year 3 for all 3 racial/ ethnic 
groups.48
– Al-Khatib et al49 analyzed implantable cardioverterdefibrillator use for 
primary prevention among 11 880 patients with a history of HF, left 
ventricular EF<35%, and age >65 years enrolled in the GWTG-HF 
registry from January 2005 through December 2009. From 2005 to 
2007, overall implantable cardioverter-defibrillator use increased from 
30.2% to 42.4% and then remained unchanged in 2008 to 2009. After 
adjustment for confounders, implantable cardioverter-defibrillator use 
increased significantly in the overall study population during 2005 to 
2007 (OR, 1.28; 95% CI, 1.11–1.48 per year; P=0.0008) and in black 
women (OR, 1.82; 95% CI, 1.28–2.58 per year; P=0.0008), white 
women (OR, 1.30; 95% CI, 1.06–1.59 per year; P=0.010), black men 
(OR, 1.54; 95% CI, 1.19–1.99 per year; P=0.0009), and white men 
(OR, 1.25; 95% CI, 1.06–1.48 per year; P=0.0072). The increase in 
implantable cardioverterdefibrillator use was greatest among blacks. 
They concluded that although previously described racial disparities in 
the use of implantable cardioverter-defibrillators were no longer present 
in their study by the end of the study period, a sex difference in their 
use persisted.49
– GWTG data by race, sex, and ethnicity are provided in Tables 21-11 
through 21-13.
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22. Medical Procedures
See Tables 22-1 and 22-2 and Charts 22-1 through 22-4.
Trends in Operations and Procedures
(See Charts 22-1 and 22-2.)
• The total number of inpatient cardiovascular operations and procedures increased 
28%, from 5 939 000 in 2000 to 7 588 000 in 2010 (NHLBI computation based 
on NCHS annual data). Data from the NHDS were examined for trends from 
1990 to 2004 for use of PCI and CABG and in-hospital mortality rate attributable 
to PCI and CABG by sex.1
– Discharge rates (per 10 000 population) for PCI increased 58%, from 
37.2 in 1990 to 1992 to 59.2 in 2002 to 2004.
– Discharge rates for CABG increased from 34.1 in 1990 to 1992 to 38.6 
in 1996 to 1998, then declined to 25.2 in 2002 to 2004.
– In 1990 to 1992, discharge rates for CABG were 53.5 for males and 
18.1 for females; these rates increased through 1996 to 1998, then 
declined to 38.8 and 13.6, respectively, in 2002 to 2004. The magnitude 
of these declines decreased by age decile and were essentially flat for 
both men and women ≥75 years of age.
– PCI discharge rates increased from 54.5 for males and 23.0 for females 
to 83.0 and 38.7, respectively, over the 15-year time interval. In 2002 to 
2004, discharge rates for men and women 65 to 74 years of age were 
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135.1 and 64.0, respectively. For those ≥75 years of age, the rates were 
128.7 and 69.0, respectively.
– In-hospital mortality rate (deaths per 100 CABG discharges) declined 
from 4.3 to 3.5 between 1990 to 1992 and 2002 to 2004 despite an 
increase in Charlson comorbidity index. The mortality rate declined in 
all age and sex subsets, but especially in women.
• Data from the Acute Care Tracker database were used to estimate the population-
based rates per 100 000 population for PCI and CABG procedures from 2002 to 
2005, standardized to the 2005 US population2:
– Adjusted for age and sex, the overall rate for coronary revascularization 
declined from 382 to 358 per 100 000. PCI rates during hospitalization 
increased from 264 to 267 per 100 000, whereas CABG rates declined 
from 121 to 94.
• Data from men and women enrolled in Medicare from 1992 to 2001 suggest that 
efforts to eliminate racial disparities in the use of high-cost cardiovascular 
procedures (PCI, CABG, and carotid endarterectomy) were unsuccessful.3
– In 1992, among women, the age-standardized rates of carotid 
endarterectomy were 1.59 per 1000 enrollees for whites and 0.64 per 
1000 enrollees for blacks. By 2002, the rates were 2.42 per 1000 
enrollees among white women and 1.15 per 1000 enrollees among 
black women. For men, the difference in rates between whites and 
blacks remained the same. In 1992, the rates were 3.13 per 1000 
enrollees among white men and 0.82 per 1000 enrollees among black 
men; in 2001, the rates were 4.42 and 1.44, respectively.
Abbreviations Used in Chapter 22
CABG coronary artery bypass graft
CHF congestive heart failure
D2B Door-to-Balloon Alliance
GWTG-CAD Get With The Guidelines–Coronary Artery Disease
HD heart disease
HPLHS hypoplastic left heart syndrome
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PCI percutaneous coronary intervention
PTCA percutaneous transluminal coronary angioplasty
STEMI ST-segment–elevation myocardial infarction
TOF tetralogy of Fallot
VSD ventricular septal defect
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Cardiac Catheterization and PCI
• From 2000 to 2010, the number of cardiac catheterizations decreased slightly, 
from 1 221 000 to 1 029 000 annually (NHDS, NHLBI tabulation).
• In 2010, an estimated 492 000 patients underwent PCI (previously referred to as 
percutaneous transluminal coronary angioplasty, or PTCA) procedures in the 
United States (NHDS, NHLBI tabulation).
• In 2010, ≈67% of PCI procedures were performed on men, and ≈51% were 
performed on people ≥65 years of age (NHDS, NHLBI tabulation).
• In-hospital death rates for PCI have remained stable, although comorbidities 
increased for patients who received the procedure.1
• In 2010, ≈75% of stents implanted during PCI were drug-eluting stents 
compared with 25% that were bare-metal stents (NHDS, NHLBI computation).
• In a study of nontransferred patients with STEMI treated with primary PCI from 
July 2006 to March 2008, there was significant improvement over time in the 
percentage of patients receiving PCI within 90 minutes, from 54.1% from July to 
September 2006 to 74.1% from January to March 2008, among hospitals 
participating in the GWTG-CAD program. This improvement was seen whether 
or not hospitals joined the D2B Alliance during that period.4
• The rate of any cardiac stent procedure rose by 61% from 1999 to 2006, then 
declined by 27% between 2006 and 2009.5
Cardiac Open Heart Surgery
The NHDS (NCHS) estimates that in 2010, in the United States, 219 000 patients underwent 
a total of 397 000 coronary artery bypass procedures (defined by procedure codes). CABG 
volumes have declined nationally since 1998. Risk-adjusted mortality for CABG has 
declined significantly over the past decade.
• Data from the Society of Thoracic Surgeons’ National Adult Cardiac Database, 
which voluntarily collects data from ≈80% of all hospitals that perform CABG 
in the United States, indicate that a total of 158 008 procedures involved CABG 
in 2010.6
• Data from the Society of Thoracic Surgeons’ National Adult Cardiac Database 
document a 50% decline in the risk-adjusted mortality rate despite a significant 
increase in preoperative surgical risk.7
Congenital Heart Surgery, 1998 to 2002 (From Society of Thoracic Surgeons)
There were 103 664 procedures performed from July 2006 to June 2010. The in-hospital 
mortality rate was 3.2% in 2010. The 5 most common diagnoses were the following: patent 
ductus arteriosus (7.4%); HPLHS (6.9%); VSD, type 2 (6.3%); cardiac, other (5.3%); and 
TOF (4.9%).8
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Congenital Heart Surgery, 1998 to 2002 (From Society of Thoracic Surgeons)
There were 16 920 procedures performed from 1998 to 2002 at 18 centers. In 2002, there 
were 4208 procedures performed. The in-hospital mortality rate ranged from 5.7% in 1998 
to 4.3% in 2002. Of these procedures, ≈46% were performed in children >1 year old, ≈32% 
in infants between 29 days and 1 year of age, and ≈22% in neonates (<29 days old). The 
conditions for which these procedures were most commonly performed were the following: 
patent ductus arteriosus (6.5%), VSD (6.4%), and TOF (6.0%).
Heart Transplantations
(See Charts 22-3 and 22-4.)
In 2011, 2322 heart transplantations were performed in the United States (Chart 22-3). There 
are 246 transplant hospitals in the United States, 128 of which performed heart 
transplantations (based on Organ Procurement and Transplantation Network data as of April 
24, 2012).
• Of the recipients in 2011, 68.7% were male, and 65.8% were white; 20.9% were 
black, whereas 9.6% were Hispanic. Heart transplantations by recipient age are 
shown in Chart 22-4.
• As of April 18, 2012, for transplants that occurred between 2007 and 2008, the 
1-year survival rate was 89.4% for males and 87.8% for females; the 5-year rates 
between 2003 and 2008 were 76.1% for males and 72.6% for females; and the 
10-year rates between 1998 and 2008 were 57.0% for males and 54.7% for 
females. The 1-, 5-, and 10-year survival rates for white cardiac transplant 
patients were 89.5%, 77.4%, and 58.8%, respectively. For black patients, they 
were 85.7%, 65.8%, and 44.8%, respectively. For Hispanic patients, they were 
91.5%, 76.2%, and 62.5%, respectively.
• As of April 24, 2012, 3151 patients were on the transplant waiting list for a heart 
transplant, and 52 patients were on the list for a heart/lung transplant.
Cardiovascular Healthcare Expenditures
An analysis of claims and enrollment data from the Continuous Medicare History Sample 
and from physician claims from 1995 to 2004 was used to evaluate the conditions that 
contributed to the most expensive 5% of Medicare beneficiaries.8
• Ischemic HD, CHF, and cerebrovascular disease, respectively, constituted 13.8%, 
5.9%, and 5.7% of the conditions of all beneficiaries in 2004. In patients in the 
top 5% overall for all expenditures, the respective figures were 39.1%, 32.7%, 
and 22.3% for these cardiovascular conditions.
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23. Economic Cost of Cardiovascular Disease
See Tables 23-1 and 23-2 and Charts 23-1 through 23-4.
The annual direct and indirect cost of CVD and stroke in the United States is an estimated 
$312.6 billion (Table 23-1; Chart 23-1). This figure includes $192.1 billion in expenditures 
(direct costs, which include the cost of physicians and other professionals, hospital services, 
prescribed medication, and home health care, but not the cost of nursing home care) and 
$120.5 billion in lost future productivity attributed to premature CVD and stroke mortality in 
2009 (indirect costs).
The direct costs for CVD and stroke are the healthcare expenditures for 2009 available on 
the Web site of the nationally representative MEPS of the Agency for Healthcare Research 
and Quality.1 Details on the advantages or disadvantages of using MEPS data are provided 
in the Heart Disease and Stroke Statistics–2011 Update.2 Indirect mortality costs are 
estimated for 2009 by multiplying the number of deaths that year attributable to CVD and 
strokes, in age and sex groups, by estimates of the present value of lifetime earnings for 
those age and sex groups as of 2009. Mortality data are from the National Vital Statistics 
System of the NCHS.3 The present values of lifetime earnings are unpublished estimates 
furnished by the Institute on Health and Aging, University of California at San Francisco, by 
Wendy Max, PhD, on April 25, 2012. Those estimates have a 3% discount rate, the 
recommended percentage.4 The discount rate removes the effect of inflation in income over 
the lifetime of earnings.
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The indirect costs exclude lost productivity costs attributable to CVD and stroke illness 
during 2009 among workers, people keeping house, people in institutions, and people unable 
to work. Those morbidity costs were substantial in very old studies, but an adequate update 
could not be made.
Most Costly Diseases
(See Table 23-2 and Chart 23-2.)
CVD and stroke accounted for 15% of total health expenditures in 2009, more than any 
major diagnostic group.1,5 That is also the case for indirect mortality costs. By way of 
comparison, CVD total direct and indirect costs shown in Table 23-1 are higher than the 
official National Cancer Institute estimates for cancer and benign neoplasms in 2008, which 
were cited as $228 billion total ($93 billion in direct costs, $19 billion in indirect morbidity 
costs, and $116 billion in indirect mortality costs).6
Table 23-2 shows direct and indirect costs for CVD by sex and by 2 broad age groups. Chart 
23-2 shows total direct costs for the 14 leading chronic diseases in the MEPS list. HD is the 
most costly condition.1
Abbreviations Used in Chapter 23
AHA American Heart Association
CHD coronary heart disease
CHF congestive heart failure
COPD chronic obstructive pulmonary disease
CVD cardiovascular disease
GI gastrointestinal
HBP high blood pressure
HD heart disease
HF heart failure
MEPS Medical Expenditure Panel Survey
NCHS National Center for Health Statistics
Projections
(See Charts 23-3 and 23-4.)
The AHA developed methodology to project future costs of care for HBP, CHD, HF, stroke, 
and all other CVD.7 By 2030, 40.8% of the US population is projected to have some form of 
CVD. Between 2013 and 2030, total direct medical costs of CVD are projected to increase 
from $320 billion to $818 billion. Indirect costs (attributable to lost productivity) for all 
CVDs are estimated to increase from $203 billion in 2013 to $308 billion in 2030, an 
increase of 52%. These data indicate that CVD prevalence and costs are projected to 
increase substantially. It is important to underscore that differences exist between these 
estimates and those stated above. These apparent discrepancies largely reflect 
methodological differences and emphasize that the importance of cost projections resides in 
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the documentation of profoundly adverse trends, which constitute an urgent call to action 
and must be reversed, rather than in the calculation of precise numbers.
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24. At-a-Glance Summary Tables
See Tables 24-1 through 24-4.
Sources: See the following summary tables and charts for complete details:
• Smoking—Table 3-1
• Physical activity —Table 4-1
• Overweight/obesity—Table 6-1; Chart 6-1
• Blood cholesterol—Table 8-1
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• High blood pressure—Table 9-1
• Diabetes mellitus—Table 10-1
• Total cardiovascular diseases—Table 13-1
• Stroke—Table 14-1
• Congenital heart defects—Table 15-1
• Coronary heart disease—Table 18-1
• Heart failure—Table 19-1
25. Glossary
Age-adjusted rates Used mainly to compare the rates of ≥2 communities or population groups or the 
nation as a whole over time. The American Heart Association (AHA) uses a 
standard population (2000), so these rates are not affected by changes or 
differences in the age composition of the population. Unless otherwise noted, all 
death rates in this publication are age adjusted per 100 000 population and are 
based on underlying cause of death.
Agency for Healthcare Research 
and Quality
A part of the US Department of Health and Human Services, this is the lead agency 
charged with supporting research designed to improve the quality of health care, 
reduce the cost of health care, improve patient safety, decrease the number of 
medical errors, and broaden access to essential services. The Agency for 
Healthcare Research and Quality sponsors and conducts research that provides 
evidence-based information on healthcare outcomes, quality, cost, use, and access. 
The information helps healthcare decision makers (patients, clinicians, health 
system leaders, and policy makers) make more informed decisions and improve the 
quality of healthcare services. The Agency for Healthcare Research and Quality 
conducts the Medical Expenditure Panel Survey (MEPS; ongoing).
Bacterial endocarditis An infection of the heart’s inner lining (endocardium) or of the heart valves. The 
bacteria that most often cause endocarditis are streptococci, staphylococci, and 
enterococci.
Body mass index (BMI) A mathematical formula to assess body weight relative to height. The measure 
correlates highly with body fat. It is calculated as weight in kilograms divided by 
the square of the height in meters (kg/m2).
Centers for Disease Control and 
Prevention/National Center for 
Health Statistics (CDC/NCHS)
CDC is an agency within the US Department of Health and Human Services. The 
CDC conducts the Behavioral Risk Factor Surveillance System (BRFSS), an 
ongoing survey. The CDC/NCHS conducts or has conducted these surveys (among 
others):
• — National Health Examination Survey (NHES I, 1960– 1962; 
NHES II, 1963–1965; NHES III, 1966–1970)
• — National Health and Nutrition Examination Survey I (NHANES I; 
1971–1975)
• — National Health and Nutrition Examination Survey II (NHANES 
II; 1976–1980)
• — National Health and Nutrition Examination Survey III (NHANES 
III; 1988–1994)
• — National Health and Nutrition Examination Survey (NHANES; 
1999 to …) (ongoing)
• — National Health Interview Survey (NHIS) (ongoing)
• — National Hospital Discharge Survey (NHDS) (1965–2010)
• — National Ambulatory Medical Care Survey (NAMCS) (ongoing)
• — National Hospital Ambulatory Medical Care Survey (NHAMCS) 
(ongoing)
• — National Nursing Home Survey (periodic)
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• — National Home and Hospice Care Survey (periodic)
Centers for Medicare & 
Medicaid Services, formerly 
Health Care Financing 
Administration
The federal agency that administers the Medicare, Medicaid, and Child Health 
Insurance programs.
Comparability ratio Provided by the NCHS to allow time-trend analysis from one International 
Classification of Diseases (ICD) revision to another. It compensates for the 
“shifting” of deaths from one causal code number to another. Its application to 
mortality based on one ICD revision means that mortality is “comparability 
modified” to be more comparable to mortality coded to the other ICD revision.
Coronary heart disease (CHD) 
(ICD-10 codes I20–I25)
This category includes acute myocardial infarction (I21– I22), other acute ischemic 
(coronary) heart disease (I24), angina pectoris (I20), atherosclerotic cardiovascular 
disease (I25.0), and all other forms of chronic ischemic CHD (I25.1–I25.9).
Death rate The relative frequency with which death occurs within some specified interval of 
time in a population. National death rates are computed per 100 000 population. 
Dividing the total number of deaths by the total population gives a crude death rate 
for the total population. Rates calculated within specific subgroups, such as age-
specific or sex-specific rates, are often more meaningful and informative. They 
allow well-defined subgroups of the total population to be examined. Unless 
otherwise stated, all death rates in this publication are age adjusted and are per 100 
000 population.
Diseases of the circulatory 
system (ICD codes I00-I99)
Included as part of what the AHA calls “cardiovascular disease.” (“Total 
cardiovascular disease” in this Glossary.)
Diseases of the heart Classification the NCHS uses in compiling the leading causes of death. Includes 
acute rheumatic fever/chronic rheumatic heart diseases (I00–I09), hypertensive 
heart disease (I11), hypertensive heart and renal disease (I13), CHD (I20-I25), 
pulmonary heart disease and diseases of pulmonary circulation (I26–I28), heart 
failure (I50), and other forms of heart disease (I29–I49, I50.1–I51). “Diseases of 
the heart” are not equivalent to “total cardiovascular disease,” which the AHA 
prefers to use to describe the leading causes of death.
Health Care Financing 
Administration
See Centers for Medicare & Medicaid Services.
Hispanic origin In US government statistics, “Hispanic” includes people who trace their ancestry to 
Mexico, Puerto Rico, Cuba, Spain, the Spanish-speaking countries of Central or 
South America, the Dominican Republic, or other Spanish cultures, regardless of 
race. It does not include people from Brazil, Guyana, Suriname, Trinidad, Belize, 
or Portugal, because Spanish is not the first language in those countries. Most of 
the data in this update are for Mexican Americans or Mexicans, as reported by 
government agencies or specific studies. In many cases, data for all Hispanics are 
more difficult to obtain.
Hospital discharges The number of inpatients (including newborn infants) discharged from short-stay 
hospitals for whom some type of disease was the first-listed diagnosis. Discharges 
include those discharged alive, dead, or “status unknown.”
International Classification of 
Diseases (ICD) codes
A classification system in standard use in the United States. The International 
Classification of Diseases is published by the World Health Organization. This 
system is reviewed and revised approximately every 10 to 20 years to ensure its 
continued flexibility and feasibility. The 10th revision (ICD-10) began with the 
release of 1999 final mortality data. The ICD revisions can cause considerable 
change in the number of deaths reported for a given disease. The NCHS provides 
“comparability ratios” to compensate for the “shifting” of deaths from one ICD 
code to another. To compare the number or rate of deaths with that of an earlier 
year, the “comparability-modified” number or rate is used.
Incidence An estimate of the number of new cases of a disease that develop in a population, 
usually in a 1-year period. For some statistics, new and recurrent attacks, or cases, 
are combined. The incidence of a specific disease is estimated by multiplying the 
incidence rates reported in community- or hospital-based studies by the US 
population. The rates in this report change only when new data are available; they 
are not computed annually.
Major cardiovascular diseases Disease classification commonly reported by the NCHS; represents ICD codes I00 
to I78. The AHA does not use “major cardiovascular diseases” for any calculations. 
See “Total cardiovascular disease” in this Glossary.
Metabolic syndrome The metabolic syndrome is defined* as the presence of any 3 of the following 5 
diagnostic measures: Elevated waist circumference (≥102 cm in men or ≥88 cm in 
women), elevated triglycerides (≥150 mg/dL [1.7 mmol/L] or drug treatment for 
elevated triglycerides), reduced high-density lipoprotein (HDL) cholesterol (<40 
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mg/dL [0.9 mmol/L] in men, <50 mg/dL [1.1 mmol/L] in women, or drug 
treatment for reduced HDL cholesterol), elevated blood pressure (≥130 mm Hg 
systolic blood pressure, ≥85 mm Hg diastolic blood pressure, or drug treatment for 
hypertension), and elevated fasting glucose (≥100 mg/dL or drug treatment for 
elevated glucose).
Morbidity Incidence and prevalence rates are both measures of morbidity (ie, measures of 
various effects of disease on a population).
Mortality Mortality data for states can be obtained from the NCHS Web site (http://cdc.gov/
nchs/), by direct communication with the CDC/NCHS, or from the AHA on 
request. The total number of deaths attributable to a given disease in a population 
during a specific interval of time, usually a year, are reported. These data are 
compiled from death certificates and sent by state health agencies to the NCHS. 
The process of verifying and tabulating the data takes ≈2 years.
National Heart, Lung, and Blood 
Institute (NHLBI)
An institute in the National Institutes of Health in the US Department of Health and 
Human Services. The NHLBI conducts such studies as the following:
• — Framingham Heart Study (FHS; 1948 to …) (ongoing)
• — Honolulu Heart Program (HHP) (1965–1997)
• — Cardiovascular Health Study (CHS; 1988 to …) (ongoing)
• — Atherosclerosis Risk in Communities (ARIC) study (1985 to …) 
(ongoing)
• — Strong Heart Study (SHS) (1989–1992, 1991–1998)
• — The NHLBI also published reports of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure and the Third Report of the Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III).
National Institute of 
Neurological Disorders and 
Stroke (NINDS)
An institute in the National Institutes of Health of the US Department of Health 
and Human Services. The NINDS sponsors and conducts research studies such as 
these:
• — Greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS)
• — Rochester (Minnesota) Stroke Epidemiology Project
• — Northern Manhattan Study (NOMAS)
• — Brain Attack Surveillance in Corpus Christi (BASIC) Project
Physical activity Any bodily movement produced by the contraction of skeletal muscle that increases 
energy expenditure above a basal level.
Physical fitness The ability to perform daily tasks with vigor and alertness, without undue fatigue, 
and with ample energy to enjoy leisure-time pursuits and respond to emergencies. 
Physical fitness includes a number of components consisting of cardiorespiratory 
endurance (aerobic power), skeletal muscle endurance, skeletal muscle strength, 
skeletal muscle power, flexibility, balance, speed of movement, reaction time, and 
body composition.
Prevalence An estimate of the total number of cases of a disease existing in a population 
during a specified period. Prevalence is sometimes expressed as a percentage of 
population. Rates for specific diseases are calculated from periodic health 
examination surveys that government agencies conduct. Annual changes in 
prevalence as reported in this statistical update reflect changes in the population 
size. Changes in rates can be evaluated only by comparing prevalence rates 
estimated from surveys conducted in different years. Note: In the data tables, which 
are located in the different disease and risk factor categories, if the percentages 
shown are age adjusted, they will not add to the total.
Race and Hispanic origin Race and Hispanic origin are reported separately on death certificates. In this 
publication, unless otherwise specified, deaths of people of Hispanic origin are 
included in the totals for whites, blacks, American Indians or Alaska Natives, and 
Asian or Pacific Islanders according to the race listed on the decedent’s death 
certificate. Data for Hispanic people include all people of Hispanic origin of any 
race. See “Hispanic origin” in this Glossary.
Stroke (ICD-10 codes I60–I69) This category includes subarachnoid hemorrhage (I60); intracerebral hemorrhage 
(I61); other nontraumatic intracranial hemorrhage (I62); cerebral infarction (I63); 
stroke, not specified as hemorrhage or infarction (I64); occlusion and stenosis of 
precerebral arteries not resulting in cerebral infarction (I65); occlusion and stenosis 
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of cerebral arteries not resulting in cerebral infarction (I66); other cerebrovascular 
diseases (I67); cerebrovascular disorders in diseases classified elsewhere (I68); and 
sequelae of cerebrovascular disease (I69).
Total cardiovascular disease 
(ICD-10 codes I00–I99, Q20– 
Q28)
This category includes rheumatic fever/rheumatic heart disease (I00–I09); 
hypertensive diseases (I10–I15); ischemic (coronary) heart disease (I20–I25); 
pulmonary heart disease and diseases of pulmonary circulation (I26– I28); other 
forms of heart disease (I30–I52); cerebrovascular disease (stroke) (I60–I69); 
atherosclerosis (I70); other diseases of arteries, arterioles, and capillaries (I71–I79); 
diseases of veins, lymphatics, and lymph nodes not classified elsewhere (I80–I89); 
and other and unspecified disorders of the circulatory system (I95–I99). When data 
are available, we include congenital cardiovascular defects (Q20–Q28).
Underlying cause of death or 
any-mention cause of death
These terms are used by the NCHS when defining mortality. Underlying cause of 
death is defined by the World Health Organization as “the disease or injury which 
initiated the train of events leading directly to death, or the circumstances of the 
accident or violence which produced the fatal injury.” Contributing cause of death 
would be any other disease or condition that the decedent may also have had and 
that was reported on the death certificate.
*According to criteria established by the American Heart Association/ National Heart, Lung, and Blood Institute and 
published in Circulation (Circulation. 2005;112:2735–2752).
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Chart 2-1. 
Prevalence (unadjusted) estimates for poor, intermediate, and ideal cardiovascular health for 
each of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals, 
US children aged 12 to 19 years, National Health and Nutrition Examination Survey 
(NHANES) 2009–2010* (available data as of June 1, 2012). *Healthy Diet Score reflects 
2007–2008 NHANES data.
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Chart 2-2. 
Age-standardized prevalence estimates for poor, intermediate, and ideal cardiovascular 
health for each of the 7 metrics of cardiovascular health in the American Heart Association 
2020 goals, among US adults aged ≥20 years, National Health and Nutrition Examination 
Survey (NHANES) 2009–2010* (available data as of June 1, 2012). *Healthy Diet Score 
reflects 2007–2008 NHANES data
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Chart 2-3. 
Proportion (unadjusted) of US children aged 12 to 19 years meeting different numbers of 
criteria for Ideal Cardiovascular Health, overall and by sex, National Health and Nutrition 
Examination Survey (NHANES) 2007–2008 (available data as of June 1, 2012).
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Chart 2-4. 
Age-standardized prevalence estimates of US adults aged ≥20 years meeting different 
numbers of criteria for Ideal Cardiovascular Health, overall and by age and sex subgroups, 
National Health and Nutrition Examination Survey (NHANES) 2007–2008 (available data 
as of June 1, 2012).
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Chart 2-5. 
Age-standardized prevalence estimates of US adults aged ≥20 years meeting different 
numbers of criteria for Ideal Cardiovascular Health, overall and in selected race subgroups 
from National Health and Nutrition Examination Survey (NHANES) 2007–2008 (available 
data as of June 1, 2012).
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Chart 2-6. 
Prevalence estimates of meeting at least 5 criteria for Ideal Cardiovascular Health, US adults 
aged ≥20 years (age-standardized), overall and by sex and race, and US children aged 12 to 
19 years (unadjusted), by sex, National Health and Nutrition Examination Survey 
(NHANES) 2007–2008 (available data as of June 1, 2012).
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Chart 2-7. 
Age-standardized prevalence estimates of US adults meeting different numbers of criteria 
for Ideal and Poor Cardiovascular Health, for each of the 7 metrics of cardiovascular health 
in the American Heart Association 2020 goals, among US adults aged ≥20 years, National 
Health and Nutrition Examination Survey (NHANES) 2007–2008 (available data as of June 
1, 2012).
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Chart 2-8. 
Trends in prevalence (unadjusted) of meeting criteria for Ideal Cardiovascular Health, for 
each of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals, 
among US children aged 12 to 19 years, National Health and Nutrition Examination Survey 
(NHANES) 1999–2000 through 2009–2010*† (available data as of June 1, 2012). *Due to 
changes in the physical activity questionnaire between different cycles of the NHANES 
survey, trends over time for this indicator should be interpreted with caution and statistical 
comparisons should not be attempted. †Data for the Healthy Diet Score, based on a 2-day 
average intake, was only available for the 2003–2004, 2005–2006, and 2007–2008 
NHANES cycles at the time of this analysis.
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Chart 2-9. 
Age-standardized trends in prevalence of meeting criteria for Ideal Cardiovascular Health, 
for each of the 7 metrics of cardiovascular health in the American Heart Association 2020 
goals, among US adults aged ≥20 years, National Health and Nutrition Examination Survey 
(NHANES) 1999–2000 through 2009–2010 (available data as of June 1, 2012). *Due to 
changes in the physical activity questionnaire between different cycles of the NHANES 
survey, trends over time for this indicator should be interpreted with caution and statistical 
comparisons should not be attempted. †Data for the Healthy Diet Score, based on a 2-day 
average intake, was only available for the 2003–2004, 2005–2006, and 2007–2008 
NHANES cycles at the time of this analysis.
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Chart 2-10. 
Prevalence of ideal, intermediate, and poor CV health metrics in 2006 (AHA 2020 Impact 
Goals baseline year) and 2020 projections assuming current trends continue. 2020 targets for 
each CV health metric, assuming a 20% relative increase in ideal CV health prevalence 
metrics and a 20% relative decrease in poor CV health prevalence metrics for men and 
women. Reprinted from Huffman et al2 with permission. Copyright © 2012, American Heart 
Association.
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Chart 2-11. 
US age-standardized death rates* from cardiovascular diseases, 2000–2009. *Directly 
standardized to the age distribution of the 2000 US standard population. †Total CVD 
(Cardiovascular Disease): ICD-10 I00-I99, Q20-Q28. §Stroke (All cerebrovascular disease): 
ICD-10 I60-I69. ¶CHD (Coronary Heart Disease): ICD-10 I20-I25. **Other CVD: ICD-10 
I00 −I15, I26 −I51, I70 −I78, I80 −I89, I95−I99. Source: Centers for Disease Control and 
Prevention, National Center for Health Statistics. Multiple Cause of Death 1999–2009 on 
CDC WONDER Online Database, released 2012. Data for year 2009 are compiled from the 
Multiple Cause of Death File 2009, Series 20 No. 2O, 2012, data for year 2008 are compiled 
from the Multiple Cause of Death File 2008, Series 20 No. 2N, 2011, data for year 2007 are 
compiled from the Multiple Cause of Death File 2007, Series 20 No. 2M, 2010, data for 
years 2005–2006 data are compiled from Multiple Cause of Death File 2005–2006, Series 
20, No. 2L, 2009, and data for years 1999–2004 are compiled from the Multiple Cause of 
Death File 1999–2004, Series 20, No. 2J, 2007. http://wonder.cdc.gov/mcd-icd10.html. 
Accessed October 9, 2012.
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Chart 2-12. 
Incidence of cardiovascular disease according to the number of ideal health behaviors and 
health factors. Reprinted with permission from Folsom et al.4
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Chart 3-1. 
Prevalence (%) of students in grades 9 to 12 reporting current cigarette use by sex and race/
ethnicity (Youth Risk Behavior Surveillance System, 2011). NH indicates non-Hispanic. 
Data derived from MMWR: Morbidity and Mortality Weekly Report.1
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Chart 3-2. 
Prevalence (%) of current smoking for adults >18 years of age by race/ethnicity and sex 
(National Health Interview Survey: 2008–2010). All percentages are age-adjusted. NH 
indicates non-Hispanic. *Includes both Hispanics and non-Hispanics. Data derived from 
Centers for Disease Control and Prevention/National Center for Health Statistics, Health 
Data Interactive.9
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Chart 4-1. 
Prevalence of students in grades 9 to 12 who did not participate in at least 60 minutes of 
physical activity on any day by race/ethnicity and sex (Youth Risk Behavior Surveillance: 
2011). NH indicates non-Hispanic. Data derived from MMWR Surveillance Summaries.1
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Chart 4-2. 
Percentage of students in grades 9 to 12 who used a computer for ≥3 hours a day by race/
ethnicity and sex (Youth Risk Behavior Surveillance: 2011). NH indicates non-Hispanic. 
Data derived from MMWR Surveillance Summaries.1
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Chart 4-3. 
Prevalence of students in grades 9 to 12 who met currently recommended levels of physical 
activity during the past 7 days by race/ethnicity and sex (Youth Risk Behavior Surveillance: 
2011). “Currently recommended levels” was defined as activity that increased their heart 
rate and made them breathe hard some of the time for a total of at least 60 minutes per day 
on 5 of the 7 days preceding the survey. NH indicates non-Hispanic. Data derived from 
MMWR Surveillance Summaries.1
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Chart 4-4. 
Prevalence of children 6 to 19 years of age who attained sufficient moderate-to-vigorous 
physical activity to meet public health recommendations (≥60 minutes per day on 5 or more 
of the 7 days preceding the survey), by sex and age (National Health and Nutrition 
Examination Survey: 2003–2004). Source: Troiano et al.5
et al. Page 326
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 4-5. 
Prevalence of meeting the 2008 Federal Physical Activity Guidelines among adults ≥18 
years of age by race/ethnicity and sex (National Health Interview Survey: 2010). NH 
indicates non-Hispanic. Percentages are age-adjusted. Meeting the 2008 Federal Physical 
Activity Guidelines is defined as engaging in moderate leisure-time physical activity for at 
least 150 minutes per week or vigorous activity at least 75 minutes per week or an equivalent 
combination. Source: Schiller et al.7
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Chart 5-1. 
Age-adjusted trends in macronutrients and total calories consumed by US adults (20–74 
years of age), 1971–2004. Data derived from National Center for Health Statistics. Health, 
United States 2007, With Chartbook on Trends in the Health of Americans.13
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Chart 5-2. 
Per-capita calories consumed from different beverages by US adults (≥19 years of age), 
1965–2002. Data derived from Nationwide Food Consumption Surveys (1965, 1977–1978), 
National Health and Nutrition Examination Survey (1988–1994, 1999–2002), and Duffey 
and Popkin.57
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Chart 5-3. 
Total US food expenditures away from home and at home, 1977 and 2007. Data derived 
from Davis et al.59
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Chart 6-1. 
Prevalence of overweight and obesity among students in grades 9 through 12 by sex and 
race/ethnicity. NH indicates non-Hispanic. Data derived from Youth Risk Behavior 
Surveillance—United States, 2011, Table 101.66
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Chart 6-2. 
Age-adjusted prevalence of obesity in adults 20 to 74 years of age by sex and survey year 
(National Health Examination Survey: 1960–1962; National Health and Nutrition 
Examination Survey: 1971–1974, 1976–1980, 1988–1994, 1999–2002, and 2007–2010). 
Obesity is defined as body mass index of 30.0 kg/m2. Data derived from Health, United 
States, 2011 (National Center for Health Statistics).67
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Chart 6-3. 
Trends in the prevalence of obesity among US children and adolescents by age and survey 
year (National Health and Nutrition Examination Survey: 1971–1974, 1976–1980, 1988–
1994, 1999–2002, 2003–2006 and 2007–2010). Data derived from Health, United States, 
2011 (National Center for Health Statistics).67
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Chart 8-1. 
Trends in mean total serum cholesterol among adolescents 12 to 17 years of age by race, 
sex, and survey year (National Health and Nutrition Examination Survey: 1988–1994,* 
1999–2004, and 2005-2010). Values are in mg/dL. NH indicates non-Hispanic; Mex. Am., 
Mexican American. *Data for Mexican Americans not available. Source: National Center 
for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-2. 
Trends in mean total serum cholesterol among adults ages ≥20 years old by race and survey 
year (National Health and Nutrition Examination Survey: 1988–1994, 1999–2002, 2003–
2006, and 2007–2010). Values are in mg/dL. NH indicates non-Hispanic. Source: National 
Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-3. 
Age-adjusted trends in the prevalence of total serum cholesterol ≥200 mg/dL in adults ≥20 
years of age by sex, race/ethnicity, and survey year (National Health and Nutrition 
Examination Survey 2005–2006, 2007–2008, and 2009–2010). NH indicates non-Hispanic; 
Mex. Am., Mexican American.
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Chart 9-1. 
Prevalence of high blood pressure in adults ≥20 years of age by age and sex (National Health 
and Nutrition Examination Survey: 2007–2010). Hypertension is defined as systolic blood 
pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, if the subject said “yes” to 
taking antihypertensive medication, or if the subject was told on 2 occasions that he or she 
had hypertension. Source: National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 9-2. 
Age-adjusted prevalence trends for high blood pressure in adults ≥20 years of age by race/
ethnicity, sex, and survey (National Health and Nutrition Examination Survey: 1988–1994, 
1999–2004, and 2005–2010). NH indicates non-Hispanic. Source: National Center for 
Health Statics and National Heart, Lung and Blood Institute.
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Chart 9-3. 
Extent of awareness, treatment, and control of high blood pressure by race/ethnicity 
(National Health and Nutrition Examination Survey: 2007–2010). NH indicates non-
Hispanic. Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
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Chart 9-4. 
Extent of awareness, treatment, and control of high blood pressure by age (National Health 
and Nutrition Examination Survey: 2005–2008). Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 9-5. 
Extent of awareness, treatment, and control of high blood pressure by race/ethnicity and sex 
(National Health and Nutrition Examination Survey: 2007–2010). NH indicates non-
Hispanic. Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
et al. Page 341
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 10-1. 
Age-adjusted prevalence of physician-diagnosed diabetes mellitus in adults ≥20 years of age 
by race/ethnicity and sex (National Health and Nutrition Examination Survey: 2007–2010). 
NH indicates non-Hispanic. Source: National Center for Health Statistics and National 
Heart, Lung, and Blood Institute.
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Chart 10-2. 
Age-adjusted prevalence of physician-diagnosed type 2 diabetes mellitus in adults ≥20 years 
of age by race/ethnicity and years of education (National Health and Nutrition Examination 
Survey: 2007–2010). NH indicates non-Hispanic. Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 10-3. 
Trends in diabetes mellitus prevalence in adults ≥20 years of age by sex (National Health 
and Nutrition Examination Survey: 1988–1994 and 2007–2010). Source: National Center for 
Health Statistics, National Heart, Lung, and Blood Institute.
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Chart 10-4. 
Diabetes mellitus awareness, treatment, and control (National Health and Nutrition 
Examination Survey: 2007–2010). Source: National Heart, Lung, and Blood Institute.
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Chart 13-1. 
Prevalence of cardiovascular disease in adults ≥20 years of age by age and sex (National 
Health and Nutrition Examination Survey: 2007–2010). Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute. These data include coronary heart 
disease, heart failure, stroke, and hypertension.
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Chart 13-2. 
Incidence of cardiovascular disease* by age and sex (Framingham Heart Study, 1980–2003). 
*Coronary heart disease, heart failure, stroke, or intermittent claudication. Does not include 
hypertension alone. Source: National Heart, Lung, and Blood Institute.4
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Chart 13-3. 
Deaths attributable to diseases of the heart (United States: 1900–2009). See Glossary 
(Chapter 25) for an explanation of “diseases of the heart.” Note: In the years 1900–1920, the 
International Classification of Diseases codes were 77 to 80; for 1925, 87 to 90; for 1930–
1945, 90 to 95; for 1950–1960, 402 to 404 and 410 to 443; for 1965, 402 to 404 and 410 to 
443; for 1970–1975, 390 to 398 and 404 to 429; for 1980–1995, 390 to 398, 402, and 404 to 
429; for 2000–2009, I00 to I09, I11, I13, and I20 to I51. Before 1933, data are for a death 
registration area and not the entire United States. In 1900, only 10 states were in the death 
registration area, and this increased over the years, so part of the increase in numbers of 
deaths is attributable to an increase in the number of states. Source: National Center for 
Health Statistics.
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Chart 13-4. 
Deaths attributable to cardiovascular disease (United States: 1900–2009). Cardiovascular 
disease (International Classification of Diseases, 10th Revision codes I00–I99) does not 
include congenital. Before 1933, data are for a death registration area and not the entire 
United States. Source: National Center for Health Statistics.
et al. Page 349
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 13-5. 
Percentage breakdown of deaths attributable to cardiovascular disease (United States: 2009). 
Source: National Heart, Lung, and Blood Institute from National Center for Health Statistics 
reports and data sets. *Not a true underlying cause. With any-mention deaths, heart failure 
accounts for 35% of cardiovascular disease deaths. Total may not add to 100 because of 
rounding. Coronary heart disease includes International Classification of Diseases, 10th 
Revision (ICD-10) codes I20 to I25; stroke, I60 to I69; heart failure, I50; high blood 
pressure, I10 to I15; diseases of the arteries, I70 to I78; and Other, all remaining ICD-10 I 
categories.
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Chart 13-6. 
Cardiovascular disease (CVD) deaths vs cancer deaths by age (United States: 2009). Source: 
National Center for Health Statistics. CVD includes International Classification of Diseases, 
10th Revision codes I00 to I99 and Q20 to Q28; cancer, C00 to C97.
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Chart 13-7. 
Cardiovascular disease (CVD) and other major causes of death: total, <85 years of age, and 
≥85 years of age. Deaths among both sexes, United States, 2009. CLRD indicates chronic 
lower respiratory disease. Heart disease includes International Classification of Diseases, 
10th Revision codes I00 to I09, I11, I13, and I20 to I51; stroke, I60 to I69; all other CVD, 
I10, I12, I15, and I70 to I99; cancer, C00 to C97; CLRD, J40 to J47; Alzheimer disease, 
G30; and accidents, V01 to X59 and Y85 to Y86. Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
et al. Page 352
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 13-8. 
Cardiovascular disease (CVD) and other major causes of death in males: total, <85 years of 
age, and ≥85 years of age. Deaths among males, United States, 2009. CLRD indicates 
chronic lower respiratory disease. Heart disease includes International Classification of 
Diseases, 10th Revision codes I00 to I09, I11, I13, and I20 to I51; stroke, I60 to I69; all 
other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; CLRD, J40 to J47; and 
accidents, V01 to X59 and Y85 to Y86. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 13-9. 
Cardiovascular disease (CVD) and other major causes of death in females: total, <85 years 
of age, and ≥85 years of age. Deaths among females, United States, 2009. CLRD indicates 
chronic lower respiratory disease. Heart disease includes International Classification of 
Diseases, 10th Revision codes I00 to I09, I11, I13, and I20 to I51; stroke, I60 to I69; all 
other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; CLRD, J40 to J47; and 
Alzheimer disease, G30. Source: National Center for Health Statistics and National Heart, 
Lung, and Blood Institute.
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Chart 13-10. 
Cardiovascular disease and other major causes of death for all males and females (United 
States: 2009). A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99, Q20–Q28); B, cancer 
(C00–C97); C, accidents (V01–X59, Y85–Y86); D, chronic lower respiratory disease (J40–
J47); E, diabetes mellitus (E10–E14); and F, Alzheimer disease (G30). Source: National 
Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-11. 
Cardiovascular disease and other major causes of death for white males and females (United 
States: 2009). A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99, Q20–Q28); B, cancer 
(C00–C97); C, accidents (V01–X59, Y85–Y86); D, chronic lower respiratory disease (J40–
J47); E, diabetes mellitus (E10–E14); and F, Alzheimer disease (G30). Source: National 
Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-12. 
Cardiovascular disease and other major causes of death for black males and females (United 
States: 2009). A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99, Q20–Q28); B, cancer 
(C00–C97); C, accidents (V01–X59, Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic 
lower respiratory disease (J40–J47); and F, nephritis (N00–N07, N17–N19, N25–N27). 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-13. 
Cardiovascular disease and other major causes of death for Hispanic or Latino males and 
females (United States: 2009). A indicates cardiovascular disease plus congenital 
cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–
I99, Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59, Y85–Y86); D, diabetes 
mellitus (E10–E14); E, chronic lower respiratory disease (J40–J47); and F, influenza and 
pneumonia (J09–J18). Source: National Center for Health Statistics and National Heart, 
Lung, and Blood Institute.
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Chart 13-14. 
Cardiovascular disease and other major causes of death for Asian or Pacific Islander males 
and females (United States: 2009). “Asian or Pacific Islander” is a heterogeneous category 
that includes people at high cardiovascular disease risk (eg, South Asian) and people at low 
cardiovascular disease risk (eg, Japanese). More specific data on these groups are not 
available. A indicates cardiovascular disease plus congenital cardiovascular disease 
(International Classification of Diseases, 10th Revision codes I00–I99, Q20–Q28); B, cancer 
(C00–C97); C, accidents (V01–X59, Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic 
lower respiratory disease (J40–J47); and F, influenza and pneumonia (J09–J18). Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-15. 
Cardiovascular disease and other major causes of death for American Indian or Alaska 
Native males and females (United States: 2009). A indicates cardiovascular disease plus 
congenital cardiovascular disease (International Classification of Diseases, 10th Revision 
codes I00–I99, Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59, Y85–Y86); D, 
diabetes mellitus (E10–E14); E, chronic liver disease (K70, K73–K74); and F, chronic lower 
respiratory disease (J40–J47). Source: National Center for Health Statistics.
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Chart 13-16. 
Age-adjusted death rates for coronary heart disease (CHD), stroke, and lung and breast 
cancer for white and black females (United States: 2009). CHD includes International 
Classification of Diseases, 10th Revision codes I20 to I25; stroke, I60 to I69; lung cancer, 
C33 to C34; and breast cancer, C50. Source: National Center for Health Statistics.
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Chart 13-17. 
Cardiovascular disease mortality trends for males and females (United States: 1979–2009). 
CVD excludes congenital cardiovascular defects (International Classification of Diseases, 
10th Revision codes I00–I99). The overall comparability for cardiovascular disease between 
the International Classification of Diseases, 9th Revision (1979–1998) and International 
Classification of Diseases, 10th Revision (1999–2009) is 0.9962. No comparability ratios 
were applied. Source: National Center for Health Statistics.
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Chart 13-18. 
US maps corresponding to state death rates (including the District of Columbia), 2009.
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Chart 13-19. 
Estimated average 10-year cardiovascular disease risk in adults 50 to 54 years of age 
according to levels of various risk factors (Framingham Heart Study). HDL indicates high-
density lipoprotein; BP, blood pressure. Data derived from D’Agostino et al48 with 
permission of the publisher. Copyright © 2008, American Heart Association.
et al. Page 364
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 13-20. 
Hospital discharges for cardiovascular disease (United States: 1970–2010). Hospital 
discharges include people discharged alive, dead, and “status unknown.” Source: National 
Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-21. 
Hospital discharges for the 10 leading diagnostic groups (United States: 2010). Source: 
National Hospital Discharge Survey/National Center for Health Statistics and National 
Heart, Lung, and Blood Institute.
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Chart 14-1. 
Prevalence of stroke by age and sex (National Health and Nutrition Examination Survey: 
2007–2010). Source: National Center for Health Statistics and National Heart, Lung, and 
Blood Institute.
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Chart 14-2. 
Annual age-adjusted incidence of first-ever stroke by race. Hospital plus out-of-hospital 
ascertainment, 1993 to 1994, 1999, and 2005. ICH indicates intracerebral hemorrhage; SAH, 
subarachnoid hemorrhage. Data derived from Kleindorfer et al.9
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Chart 14-3. 
Annual rate of first cerebral infarction by age, sex, and race (Greater Cincinnati/Northern 
Kentucky Stroke Study: 1999). Rates for black men and women 45 to 54 years of age and 
for black men ≥75 years of age are considered unreliable. Source: Unpublished data from 
the Greater Cincinnati/Northern Kentucky Stroke Study.
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Chart 14-4. 
Annual rate of all first-ever strokes by age, sex, and race (Greater Cincinnati/Northern 
Kentucky Stroke Study: 1999). Rates for black men and women 45 to 54 years of age and 
for black men ≥75 years of age are considered unreliable.
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Chart 14-5. 
Age-adjusted incidence of stroke/transient ischemic attack* by race and sex, ages 45 to 74 
years, Atherosclerosis Risk in Communities study cohort, 1987–2001. Data derived from the 
National Heart, Lung, and Blood Institute, Incidence and Prevalence: 2006 Chart Book.175
et al. Page 371
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 14-6. 
Age-adjusted death rates for stroke by sex and race/ethnicity, 2009. Death rates for the 
American Indian/Alaska Native and Asian or Pacific Islander populations are known to be 
underestimated. Stroke includes International Classification of Diseases, 10th Revision 
codes I60 to I69 (cerebrovascular disease). Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 14-7. 
Stroke death rates, 2000 through 2006. Adults ≥35 years of age, by county. Rates are 
spatially smoothed to enhance the stability of rates in counties with small populations. 
International Classification of Diseases, 10th Revision codes for stroke: I60–I69. Data 
source: National Vital Statistics System and the US Census Bureau.
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Chart 14-8. 
Estimated 10-year stroke risk in adults 55 to 84 years of age according to levels of various 
risk factors (Framingham Heart Study). AF indicates atrial fibrillation; CVD, cardiovascular 
disease. Data derived from Wolf et al176 with permission of the publisher. Copyright © 
1991, American Heart Association.
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Chart 14-9. 
Proportion of patients dead 1 year after first stroke. Source: Pooled data from the 
Framingham Heart Study, Atherosclerosis Risk in Communities study, and Cardiovascular 
Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-10. 
Proportion of patients dead within 5 years after first stroke. Source: Pooled data from the 
Framingham Heart Study, Atherosclerosis Risk in Communities study, and Cardiovascular 
Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-11. 
Proportion of patients with recurrent stroke in 5 years after first stroke. Source: Pooled data 
from the Framingham Heart Study, Atherosclerosis Risk in Communities study, and 
Cardiovascular Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-12. 
Trends in carotid endarterectomy procedures (United States: 1980–2010). Source: National 
Hospital Discharge Survey/National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 14-13. 
Trends in carotid revascularization procedures. MCBE indicates Medicare beneficiaries; 
CEA, carotid endarterectomy; and CAS, carotid artery stenting. Reproduced with permission 
from Goodney et al.160 Copyright © 2008, American Medical Association. All rights 
reserved.
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Chart 17-1. 
Prevalence (%) of coronary calcium: US adults 33 to 45 years of age. P<0.0001 across race-
sex groups. Data derived from Loria et al.5
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Chart 17-2. 
Prevalence (%) of coronary calcium: US adults 45 to 84 years of age. P<0.0001 across 
ethnic groups in both men and women. Data derived from Bild et al.6
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Chart 17-3. 
Hazard ratios for coronary heart disease (CHD) events associated with coronary calcium 
scores: US adults 45 to 84 years of age (reference group coronary artery calcification 
[CAC]=0). All hazard ratios P<0.0001. Major CHD events included myocardial infarction 
and death attributable to CHD; any CHD events included major CHD events plus definite 
angina or definite or probable angina followed by revascularization. Data derived from 
Detrano et al.9
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Chart 17-4. 
Hazard ratios for coronary heart disease events associated with coronary calcium scores: US 
adults (reference group coronary artery calcification [CAC]=0 and Framingham Risk Score 
<10%). Coronary heart disease events included nonfatal myocardial infarction and death 
attributable to coronary heart disease. Data derived from Greenland et al.10
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Chart 17-5. 
Mean values of carotid intima-media thickness (IMT) for different carotid artery segments in 
younger adults by race and sex (Bogalusa Heart Study). Data derived from Urbina et al.21
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Chart 17-6. 
Mean values of carotid intima-media thickness (IMT) for different carotid artery segments in 
older adults, by race. Data derived from Manolio et al.23
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Chart 18-1. 
Prevalence of coronary heart disease by age and sex (National Health and Nutrition 
Examination Survey: 2007–2010). Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 18-2. 
Prevalence of myocardial infarction by age and sex (National Health and Nutrition 
Examination Survey: 2007–2010). Myocardial infarction includes people who answered 
“yes” to the question of ever having had a heart attack or myocardial infarction. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
et al. Page 387
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 18-3. 
Annual number of adults having diagnosed heart attack or fatal coronary heart disease 
(CHD) by age and sex (Atherosclerosis Risk in Communities Surveillance: 2004–2009 and 
Cardiovascular Health Study). These data include myocardial infarction (MI) and fatal CHD 
but not silent MI. Source: National Heart, Lung, and Blood Institute.
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Chart 18-4. 
Incidence of heart attack or fatal coronary heart disease by age, sex, and race 
(Atherosclerosis Risk in Communities Surveillance: 2004–2009*). Source: National Heart, 
Lung, and Blood Institute. *2005–2009 for ages 75–84 years.
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Chart 18-5. 
Incidence of myocardial infarction* by age, sex, and race (Atherosclerosis Risk in 
Communities Surveillance: 2004–2009*). Source: Unpublished data from Atherosclerosis 
Risk in Communities study, National Heart, Lung, and Blood Institute. *2005–2009 for ages 
75–84 years.
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Chart 18-6. 
Estimated 10-year coronary heart disease risk in adults 55 years of age according to levels of 
various risk factors (Framingham Heart Study). HDL-C indicates high density lipoprotein-
cholesterol. Data derived from Wilson et al.51
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Chart 18-7. 
Prevalence of low coronary heart disease risk, overall and by sex (National Health and 
Nutrition Examination Survey: 1971–2006). Low risk is defined as systolic blood pressure 
<120 mm Hg and diastolic blood pressure <80 mm Hg; cholesterol <200 mg/dL; body mass 
index <25 kg/m2; currently not smoking cigarettes; and no prior myocardial infarction or 
diabetes mellitus. Source: Personal communication with the National Heart, Lung, and 
Blood Institute, June 28, 2007.
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Chart 18-8. 
Hospital discharges for coronary heart disease by sex (United States: 1970–2010). Hospital 
discharges include people discharged alive, dead, and “status unknown.” Source: National 
Hospital Discharge Survey/National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 18-9. 
Prevalence of angina pectoris by age and sex (National Health and Nutrition Examination 
Survey: 2007–2010). Angina pectoris includes people who either answered “yes” to the 
question of ever having angina or angina pectoris or were diagnosed with Rose Angina. 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
et al. Page 394
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 18-10. 
Incidence of angina pectoris* by age and sex (Framingham Heart Study 1980–2002/2003). 
*Angina pectoris deemed uncomplicated on the basis of physician interview of patient. 
(Rate for women 45–54 years of age considered unreliable.) Data derived from National 
Heart, Lung, and Blood Institute.8
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Chart 19-1. 
Prevalence of heart failure by sex and age (National Health and Nutrition Examination 
Survey: 2007–2010). Source: National Center for Health Statistics and National Heart, 
Lung, and Blood Institute.
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Chart 19-2. 
Incidence of heart failure (heart failure based on physician review of medical records and 
strict diagnostic criteria) by age and sex (Framingham Heart Study: 1980–2003). Source: 
National Heart, Lung, and Blood Institute.
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Chart 19-3. 
Hospital discharges for heart failure by sex (United States: 1980–2010). Note: Hospital 
discharges include people discharged alive, dead, and status unknown. Source: National 
Hospital Discharge Survey/National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 20-1. 
Rheumatic heart disease prevalence trends per 1000 people for each World Health 
Organization region: A, The Americas; B, Europe; C, Africa; D, Eastern Mediterranean; E, 
Western Pacific; and F, Southeast Asia. Reprinted from Seckeler et al15 with permission of 
the publisher.
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Chart 20-2. 
Peripheral artery disease prevalence estimates in males by age and ethnicity. NH indicates 
non-Hispanic; Amer., American. Source: Reprinted from Allison et al42 with permission of 
the publisher.
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Chart 20-3. 
Peripheral artery disease prevalence estimates in females by age and ethnicity. NH indicates 
non-Hispanic; Amer., American. Source: Reprinted from Allison et al42 with permission of 
the publisher.
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Chart 22-1. 
Trends in cardiovascular procedures, United States: 1979 to 2010. PCI indicates 
percutaneous coronary intervention. Note: Inpatient procedures only. Source: National 
Hospital Discharge Survey, National Center for Health Statistics, and National Heart, Lung, 
and Blood Institute.
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Chart 22-2. 
Number of surgical procedures in the 10 leading diagnostic groups, United States: 2010. 
Source: National Hospital Discharge Survey/National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
et al. Page 403
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 22-3. 
Trends in heart transplantations (United Network for Organ Sharing: 1975–2011). Source: 
United Network for Organ Sharing, scientific registry data.
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Chart 22-4. 
Heart transplantations in the United States by recipient age, 2011. Source: Organ 
Procurement and Transplantation Network data as of April 13, 2012.
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Chart 23-1. 
Direct and indirect costs of cardiovascular disease (CVD) and stroke (in billions of dollars), 
United States, 2009. Source: Prepared by the National Heart, Lung, and Blood Institute.1,3
et al. Page 406
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Chart 23-2. 
The 20 leading diagnoses for direct health expenditures, United States, 2008 (in billions of 
dollars). COPD indicates chronic obstructive pulmonary disease; GI, gastrointestinal. 
Source: National Heart, Lung, and Blood Institute; estimates are from the Medical 
Expenditure Panel Survey, Agency for Healthcare Research and Quality, and exclude 
nursing home costs.
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Chart 23-3. 
Projected total costs of cardiovascular disease (CVD), 2015–2030 (2010 $ in billions) in the 
United States. HBP indicates high blood pressure; CHD, coronary heart disease; and CHF, 
congestive heart failure. Unpublished data tabulated by the American Heart Association 
using methods described in Heidenreich et al7.
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Chart 23-4. 
Projected total (direct and indirect) costs of total cardiovascular disease by age (2010 $ in 
billions). Unpublished data tabulated by the American Heart Association using methods 
described in Heidenreich et al7.
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Table 2-1
Definitions of Poor, Intermediate, and Ideal Cardiovascular Health for Each Metric in the AHA 2020 Goals
Level of Cardiovascular Health for Each Metric
Poor Intermediate Ideal
Current smoking
 Adults ≥20 y of age Yes Former ≤12 mo Never or quit >12 mo
 Children 12–19 y of age Tried during the prior 30 
d
… Never tried; never smoked 
whole cigarette
BMI*
 Adults ≥20 y of age ≥30 kg/m2 25–29.9 kg/m2 <25 kg/m2
 Children 2–19 y of age >95th percentile 85th–95th percentile <85th percentile
PA
 Adults ≥20 y of age None 1–149 min/wk moderate or
1–74 min/wk vigorous or
1–149 min/wk moderate + 2×vigorous
≥150 min/wk moderate or
≥75 min/wk vigorous or
≥150 min/wk moderate 
+ 2×vigorous
 Children 12–19 y of age None >0 and <60 min of moderate or vigorous 
every day
≥60 min of moderate or 
vigorous every day
Healthy diet pattern, No. of 
components†
 Adults ≥20 y of age 0–1 2–3 4–5
 Children 5–19 y of age 0–1 2–3 4–5
Total cholesterol, mg/dL
 Adults ≥20 y of age ≥240 200–239 or treated to goal <200
 Children 6–19 y of age ≥200 170–199 <170
Blood pressure
 Adults ≥20 y of age SBP ≥140 mm Hg or 
DBP ≥90 mm Hg
SBP120–139 mm Hg or DBP 80–89 
mm Hg or treated to goal
<120 mm Hg/<80 mm Hg
 Children 8–19 y of age >95th percentile 90th–95th percentile or SBP ≥120 mm 
Hg or DBP ≥80 mm Hg
<90th percentile
Fasting plasma glucose, mg/dL
 Adults ≥20 y of age ≥126 100–125 or treated to goal <100
 Children 12–19 y of age ≥126 100–125 <100
AHA indicates American Heart Association; BMI, body mass index; PA, physical activity; SBP, systolic blood pressure; and DBP, diastolic blood 
pressure.
*
Represents appropriate energy balance, ie, appropriate dietary quantity and PA to maintain normal body weight.
†
In the context of a healthy dietary pattern that is consistent with a Dietary Approaches to Stop Hypertension [DASH]–type eating pattern, to 
consume ≥4.5 cups/d of fruits and vegetables, ≥2 servings/wk of fish, and ≥3 servings/d of whole grains and no more than 36 oz/wk of sugar-
sweetened beverages and 1500 mg/d of sodium.
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Table 2-3
Selected Secondary Metrics for Monitoring CVD, NHANES 2009–2010*
In the Presence of CVD In the Absence of CVD
N† % (SE)‡ N† % (SE)‡
Total 16 209 474 7.2 (0.4) 199 590 596 92.8 (0.4)
 CHD 6 916 012 3.2 (0.3)
 Stroke 5 717 759 2.7 (0.2)
 CHF 4 320 227 2.0 (0.3)
 Acute MI 6 929 905 3.2 (0.3)
Health behaviors
 Smoking
  Current smoker or smokers who quit <12 mo ago 3 127 273 37.2 (4.9) 40 760 066 20.1 (0.9)
 PA
  PA: intermediate or poor§ 11 813 011 74.1 (5.1) 115 561 988 58.4 (1.5)
  PA: none 10 598 908 64.5 (5.5) 93 459 556 47.3 (1.2)
 Diet, no. of metrics*
  Total diet score 0–3 of 5 12 665 860 100.00 (0.00) 161 370 154 99.71 (0.11)
  Total diet score 0–1 of 5 9 540 532 70.06 (4.69) 127 156 293 78.84 (1.42)
 Overweight/obesity
  Overweight or obese (BMI ≥25.0 kg/m2) 12 621 701 69.4 (4.1) 134 879 713 68.1 (1.3)
  Obese ≥30.0 kg/m2) (BMI 7 763 611 49.0 (5.2) 68 655 702 34.7 (1.0)
Health factors
 Hypertension
  Prevalence of BP ≥140/90 mm Hg or taking medications 10 591 170 51.0 (5.0) 53 523 895 28.5 (0.9)
  Awareness among those with hypertension 10 071 343 98.6 (0.3) 42 436 782 70.6 (3.2)
  Treatment those with hypertension 9 819 244 97.4 (0.4) 39 194 948 61.4 (2.9)
  BP control to <140/<90 mm Hg among treated 6 886 176 64.2 (9.5) 27 323 649 72.4 (2.4)
  BP control to <140/<90 mm Hg among hypertensive 6 886 176 62.3 (9.4) 27 323 649 43.3 (2.8)
 Hypercholesterolemia
  Prevalence of total cholesterol ≥240 mg/dL or taking medications 8 201 829 37.1 (4.2) 48 701 198 25.7 (0.7)
  Awareness among those with hypercholesterolemia 7 742 127 84.6 (8.0) 35 174 931 59.9 (2.6)
  Treatment among those with hypercholesterolemia 7 219 078 79.3 (8.5) 25 405 334 38.7 (2.4)
  Cholesterol control to <200 mg/dL among treated 6 659 732 95.0 (1.4) 22 804 724 90.4 (1.2)
  Cholesterol control to <200 mg/dL among hypercholesterolemia 6 659 732 75.0 (8.9) 22 804 724 34.7 (2.4)
 Diabetes mellitus
  Prevalence of fasting glucose ≥125 mg/dL or taking medications 4 769 759 15.2 (2.2) 21 078 443 10.3 (1.1)
  Awareness among diabetics 4 006 153 90.4 (2.3) 14 242 760 64.3 (4.6)
  Treatment among diabetics 3 935 446 87.1 (3.2) 13 391 291 58.4 (5.3)
  Blood glucose control among treated 1 527 151 32.6 (9.9) 5 878 676 45.0 (8.0)
  Blood glucose control among diabetics 1 527 151 27.2 (8.7) 5 878 676 25.5 (5.9)
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CVD indicates cardiovascular disease; NHANES, National Health and Nutrition Examination Survey; SE, standard error; CHD, coronary heart 
disease; CHF, congestive heart failure; MI, myocardial infarction; PA, physical activity; BMI, body mass index; and BP, blood pressure.
*
Dietary data are based on 2007–2008, the most recent data available at the time of this analysis.
†Weighted sample size.
‡Standardized to the age distribution of the 2000 US Standard population.
§
Moderate <150 min/wk AND Vigorous <75 min/wk AND Combined <150 min/wk.
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
et al. Page 415
Table 2-4
Evidence-Based Individual Approaches for Improving Health Behaviors and Health Factors in the Clinic 
Setting
• Set specific goals (Class IA). Set specific, proximal goals with the patient, including a personalized plan to achieve the goals (eg, 
over the next 3 mo, increase fish by 1 serving/wk, reduce smoking by half a pack per day, or walk 30 min 3 times per week).
• Establish self-monitoring (Class IA). Develop a strategy for self-monitoring, such as a dietary or physical activity diary or Web-
based or mobile applications.
• Schedule follow-up (Class IA). Schedule regular follow-up (in-person, telephone, written, and/or electronic), with clear frequency 
and duration of contacts, to assess success, reinforce progress, and set new goals as necessary.
• Provide feedback (Class IA). Provide feedback on progress toward goals, including using in person, telephone, and/or electronic 
feedback.
• Increase self-efficacy (Class IA). Increase the patient’s perception that they can successfully change their behavior.*
• Use motivational interviewing† (Class IA). Use motivational interviewing when patients are resistant or ambivalent about 
behavior change.
• Provide long-term support (Class IB). Arrange long-term support from family, friends, or peers for behavior change, such as in 
other workplace, school, or community-based programs.
• Use a multicomponent approach (Class IA). Combine 2 or more of the above strategies into the behavior change efforts.
*
Examples of approaches include mastery experiences (set a reasonable, proximal goal that the person can successfully achieve); vicarious 
experiences (have the person see someone with similar capabilities performing the behavior, such as walking on a treadmill or preparing a healthy 
meal); physiological feedback (explain to the patient when a change in their symptoms is related to worse or improved behaviors); and verbal 
persuasion (persuade the person that you believe in their capability to perform the behavior).
†
Motivational interviewing represents use of individual counseling to explore and resolve ambivalence toward changing behavior. Major principles 
include fostering the person’s own awareness and resolution of their ambivalence, as well as their own self-motivation to change, in a partnership 
with the counselor or provider.
Table adapted from Artinian et al.10
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Table 2-5
Evidence-Based Healthcare Systems Approaches to Support and Facilitate Improvements in Health Behaviors 
and Health Factors11–15
• Electronic systems for scheduling and tracking initial visits and regular follow-up contacts for behavior change and treatments.
• Electronic medical records systems to help assess, track, and report on specific health behaviors (diet, PA, tobacco, body weight) 
and health factors (BP, cholesterol, glucose), as well as to provide feedback and the latest guidelines to providers.
• Practical paper or electronic toolkits for assessment of key health behaviors and health factors, including during, before, and after 
provider visits.
• Electronic systems to facilitate provision of feedback to patients on their progress during behavior change and other treatment 
efforts.
• Education and ongoing training for providers on evidence-based behavior change strategies, as well as the most relevant 
behavioral targets, including training on relevant ethnic and cultural issues.
• Integrated systems to provide coordinated care by multidisciplinary teams of providers, including physicians, nurse practitioners, 
dieticians, PA specialists, and social workers.
• Reimbursement guidelines and incentives that reward efforts to change health behaviors and health factors. Restructuring of 
practice goals and quality benchmarks to incorporate health behavior (diet, PA, tobacco, body weight) and health factor (BP, 
cholesterol, glucose) interventions and targets for both primary and secondary prevention.
BP indicates blood pressure; PA, physical activity.
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Table 2-6
Summary of Evidence-Based Population Approaches for Improving Diet, Increasing Physical Activity, and 
Reducing Tobacco Use*
Diet
 Media and education Sustained, focused media and educational campaigns, using multiple modes, for increasing consumption of 
specific healthful foods or reducing consumption of specific less healthful foods or beverages, either alone (IIa 
B) or as part of multicomponent strategies (I B)†‡§
On-site supermarket and grocery store educational programs to support the purchase of healthier foods (IIa B)†
 Labeling and information Mandated nutrition facts panels or front-of-pack labels/icons as a means to influence industry behavior and 
product formulations (IIa B)†
 Economic incentives Subsidy strategies to lower prices of more healthful foods and beverages (I A)†
Tax strategies to increase prices of less healthful foods and beverages (IIa B)†
Changes in both agricultural subsidies and other related policies to create an infrastructure that facilitates 
production, transportation, and marketing of healthier foods, sustained over several decades (IIa B)†
 Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized 
educational curricula, trained teachers, supportive school policies, a formal PE program, healthy food and 
beverage options, and a parental/family component (I A)†
School garden programs, including nutrition and gardening education and hands-on gardening experiences (IIa 
A)†
Fresh fruit and vegetable programs that provide free fruits and vegetables to students during the school day (IIa 
A)†
 Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention 
components (IIa A)†
Increased availability of healthier food/beverage options and/or strong nutrition standards for foods and 
beverages served, in combination with vending machine prompts, labels, or icons to make healthier choices (IIa 
B)†
 Local environment Increased availability of supermarkets near homes (IIa B)†‡
 Restrictions and mandates Restrictions on television advertisements for less healthful foods or beverages advertised to children (I B)†
Restrictions on advertising and marketing of less healthful foods or beverages near schools and public places 
frequented by youths (IIa B)†
General nutrition standards for foods and beverages marketed and advertised to children in any fashion, 
including on-package promotion (IIa B)†
Regulatory policies to reduce specific nutrients in foods (eg, trans fats, salt, certain fats) (I B)†§
Physical activity
 Labeling and information Point-of-decision prompts to encourage use of stairs (IIa A)†
 Economic incentives Increased gasoline taxes to increase active transport/commuting (IIa B)†
 Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized 
educational curricula, trained teachers, supportive school policies, a formal PE program, serving of healthy food 
and beverage options, and a parental/family component (IIa A)†
Increased availability and types of school playground spaces and equipment (I B)†
Increased number of PE classes, revised PE curricula to increase time in at least moderate activity, and trained 
PE teachers at schools (IIa A/IIb A¶)†
Regular classroom physical activity breaks during academic lessons (IIa A)†§
 Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention 
components (IIa A)†
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Structured worksite programs that encourage activity and also provide a set time for physical activity during 
work hours (IIa B)†
Improving stairway access and appeal, potentially in combination with “skip-stop” elevators that skip some 
floors (IIa B)†
Adding new or updating worksite fitness centers (IIa B)†
 Local environment Improved accessibility of recreation and exercise spaces and facilities (eg, building of parks and playgrounds, 
increasing operating hours, use of school facilities during nonschool hours) (IIa B)†
Improved land-use design (eg, integration and interrelationships of residential, school, work, retail, and public 
spaces) (IIa B)†
Improved sidewalk and street design to increase active commuting (walking or bicycling) to school by children 
(IIa B)†
Improved traffic safety (IIa B)†
Improved neighborhood aesthetics (to increase activity in adults) (IIa B)†
Improved walkability, a composite indicator that incorporates aspects of land-use mix, street connectivity, 
pedestrian infrastructure, aesthetics, traffic safety, and/or crime safety (IIa B)†
Smoking
 Media and education Sustained, focused media and educational campaigns to reduce smoking, either alone (IIa B) or as part of larger 
multicomponent population-level strategies (I A)†
 Labeling and information Cigarette package warnings, especially those that are graphic and health related (I B)†‡§
 Economic incentives Higher taxes on tobacco products to reduce use and fund tobacco control programs (I A)†‡§
 Schools and workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention 
components (IIa A)†
 Local environment Reduced density of retail tobacco outlets around homes and schools (I B)†
Development of community telephone lines for cessation counseling and support services (I A)†
 Restrictions and mandates Community (city, state, or federal) restrictions on smoking in public places (I A)†
Local workplace-specific restrictions on smoking (I A)†‡§
Stronger enforcement of local school-specific restrictions on smoking (IIa B)†
Local residence-specific restrictions on smoking (IIa B)†§
Partial or complete restrictions on advertising and promotion of tobacco products (I B)†
PE indicates physical education.
*
The specific population interventions listed here are either a Class I or IIa recommendation with an evidence grade of either A or B. The American 
Heart Association evidence grading system for class of recommendation and level of evidence is summarized in Table 2. Because implementation 
of population-level strategies does not require perfect evidence but rather consideration of risks versus benefits, associated costs, and alternate 
approaches, the absence of any specific strategy herein does not mean it should not also be considered for implementation. See the more detailed 
tables and text below for further information on the evidence for each of these interventions, as well as other strategies that were reviewed.
†At least some evidence from studies conducted in high-income Western regions and countries (eg, North America, Europe, Australia, New 
Zealand).
‡At least some evidence from studies conducted in high-income non-Western regions and countries (eg, Japan, Hong Kong, South Korea, 
Singapore).
§At least some evidence from studies conducted in low- or middle-income regions and countries (eg, Africa, China, Pakistan, India).
||
Based on cross-sectional studies only; only 2 longitudinal studies have been performed, with no significant relations seen.
¶
Evidence IIa A for improving physical activity; evidence IIb B for reducing adiposity.
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Reprinted from Mozaffarian et al11 with permission. © 2012 American Heart Association, Inc.
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Table 2-7
Reduction in BP Required to Increase Prevalence of Ideal BP Among Adults ≥20 y of Age; NHANES 2009–
2010
%
Percent BP ideal among adults, 2009–2010 44.26
20% Relative increase 53.11
Percent of US adults whose BP would be ideal if population mean BP were lowered by*
 2 mm Hg 56.13
 3 mm Hg 59.49
 4 mm Hg 61.59
 5 mm Hg 65.31
Standardized to the age distribution of the 2000 US standard population.
BP indicates blood pressure; NHANES, National Health and Nutrition Examination Survey.
*
Reduction in BP=(observed average systolic-X mm Hg) AND (observed average diastolic-X mm Hg).
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Table 2-8
AHA Advocacy and Policy Strategies Related to the 2020 Impact Goals for Ideal Cardiovascular Health
Measure of Cardiovascular Health Advocacy/Policy Solutions
Smoking Status
 Ideal for cardiovascular health:
 Adults: Never smoked or quit more than a year ago
 Children: Never tried or never smoked a whole 
cigarette
Federal
• Support the full, authorized funding level for the FDA’s Center for 
Tobacco Products and advocate for comprehensive implementation of 
FDA regulation of tobacco.
• Implement clinical guidance and monitor health claims concerning 
smokeless tobacco and other “harm reduction” products.
• Support the Tobacco Tax Equity Act that closes tax loopholes to 
ensure that all tobacco products are taxed at levels similar to the 
current tax rate for cigarettes.
• Continue to advocate for ratification of WHO’s Framework 
Convention of Tobacco Control as part of the UN Political 
Declaration on Non-Communicable Diseases for implementation by 
all countries who are a party to the treaty.
State
• Establish, strengthen, and protect smoke-free air laws in compliance 
with the Fundamentals of Smokefree Workplace Laws guidelines.
• Support tobacco-free secondary school, college, university, and 
hospital campuses.
• Support significant increases in tobacco excise taxes on all tobacco 
products.
• Establish and protect sustainable funding for tobacco prevention and 
cessation programs to levels that meet or exceed the CDC 
recommendations.
• Provide comprehensive tobacco cessation benefits in Medicaid, 
Medicare, and private health insurance plans.
• Eliminate tobacco sales in pharmacies and other health-related 
institutions.
Physical Activity
 Ideal for cardiovascular health:
 Adults: At least 150 min of moderate or 75 min of 
vigorous PA each week
 Children: >60 min of moderate-vigorous PA per day
Federal
• Preserve funding for Safe Routes to School and Complete Streets in 
Transportation Reauthorization.
• Include PA in nutrition education funding for the Farm Bill 
Supplemental Nutrition Assistance Program.
• Incorporate PA into electronic medical records.
• Support implementation of the National Physical Activity Plan.
• Increase the quality of physical education in schools and advocate for 
Physical Education for Progress grants to increase funding to schools 
to improve their PE programs.
• Advocate for regular revision and update of the Physical Activity 
Guidelines for Americans.
State
• Implement shared use of school facilities within the community and 
support the construction of school fitness facilities.
• Increase sports, recreational opportunities, parks, and green spaces in 
the community.
• Support efforts to design workplaces, communities, and schools 
around active living and integrate PA opportunities throughout the 
day.
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Measure of Cardiovascular Health Advocacy/Policy Solutions
• Provide safe routes to schools and school sites that offer walking/
biking options for more students.
• Support the creation of complete streets.
• Support the use of zoning policy to increase access to safe places for 
recreation.
• Create and maintain comprehensive worksite wellness programs.
• Support the creation and implementation, through legislation and 
regulation (including licensing), of PA standards for preschool, day 
care, and other out-of-school care programs.
• Require quality, more frequent physical education in schools.
• Promote efforts within the school environment that will lead to 
increased PA.
BMI
 Ideal for cardiovascular health:
 Adults: between 18.5 and 25 kg/m2
 Children: between the 15th and 85th percentile
 Go to www.americanheart.org/obesitypolicy for 
additional policy resources
Federal
• Provide obesity counseling and treatment coverage in the healthcare 
environment.
• Provide robust surveillance and monitoring of obesity, diet, PA, and 
tobacco use.
State
• Provide robust coverage for guidelines-based prevention, diagnosis, 
and treatment of overweight and obesity in the healthcare 
environment.
• Implement and monitor strong local wellness policies in all schools.
• Ensure adequate funding and implementation of coordinated school 
health programs.
• Establish comprehensive obesity prevention strategies in early 
childhood and day care programs.
• Advocate for continued funding for obesity prevention research and 
work to ensure a strong evaluation component is a part of 
implementation of new laws and programs.
Healthy Diet
 Ideal for cardiovascular health:
 In the context of a DASH-type dietary pattern, adults 
and children should achieve at least 4 of the 5 following 
key components of a healthy diet:
• Fruits and vegetables: >4.5 cups/d
• Fish: More than two 3.5-oz servings/wk 
(preferably oily fish)
• Fiber-rich whole grains (>1.1 g of fiber 
per 10 g of carbohydrates): three 1-oz-
equivalent servings per day
Federal
• Work to eliminate food deserts and improve access and affordability 
of healthy foods.
• Strengthen nutrition standards in schools for meals and competitive 
foods and in all government nutrition assistance or feeding programs.
• Improve food labeling to make the labels easier to read and convey 
more accurately the content of added sugars, trans fats, sodium, and 
whole grains in foods.
• Implement menu labeling in restaurants.
• Continue to support and monitor the removal of industrially produced 
trans fats from the food supply and ensure the use of healthy 
replacement oils.
• Restrict the marketing and advertising of unhealthy food to children.
• Support robust implementation of nutrition education and promotion 
in schools.
• Reduce added sugar and sodium in the food supply.
• Support the implementation and dissemination of procurement 
standards across federal agencies.
• Ensure that diet counseling is a covered benefit in Medicare.
• Sodium: <1500 mg/d State
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Measure of Cardiovascular Health Advocacy/Policy Solutions
• Sugar-sweetened beverages: <450 kcal 
(36 oz) per week Go to 
www.americanheart.org/obesitypolicy for 
more specific policy resources
• Support the implementation of the reauthorization of the Federal 
Childhood Nutrition Act and new regulations concerning competitive 
foods and beverages and use all available techniques, including 
legislation, to encourage schools to take advantage of opportunities to 
provide even healthier options for children.
• Support improvements in the school food environment just outside of 
school property, including corner stores and food trucks
• Support the creation and implementation of nutrition standards, 
through legislation and regulation (including licensing), for preschool 
and day care and other out-of-school care program meals.
• Support opportunities for greater nutrition education in schools. 
Support opportunities to expand the availability of fruits, vegetables, 
and water, including policies that support expansion of school 
gardens and farm-to-school programs.
• Support strategies that reduce sodium in the food supply.
• Reduce trans fats in packaged foods, baked goods, restaurant meals, 
and school meal programs.
• Support the elimination of food deserts through policies such as 
Healthy Food Financing that increase the availability of fruits, 
vegetables, and water in underserved neighborhoods.
• Support the establishment of food procurement policies that meet the 
AHA or federal guidelines for government offices.
• Support policies identified to reduce children’s exposure to marketing 
and advertising for unhealthy food.
• Support policies that change relative prices of healthy versus 
unhealthy food items.
• Support on a pilot basis the taxation of sugar-sweetened beverages to 
assess impact on health and consumer behavior, including 6 minimum 
criteria (at least a portion of the money is dedicated for HD and stroke 
prevention and/or obesity prevention, the tax is structured so as to 
result in an increase in price for sugar-sweetened beverages, tax is at 
least 1 cent/oz, there is money dedicated for evaluation with guidance 
that ensures rigorous evaluation including health outcomes, there is a 
standard definition of “sugar-sweetened beverage,” and there is no 
sunset).
• Support policies designed to encourage retailers to increase access to 
healthy foods while decreasing access to unhealthy foods.
• Expand state participation in the Department of Defense Fresh Fruit 
and Vegetable program.
Total Cholesterol
 Ideal for cardiovascular health:
 Adults: Total cholesterol <200 mg/dL
 Children: <170 mg/dL
Federal and State
• Partner with Department of Health and Human Services to promote 
the Million Hearts Campaign through increased public awareness and 
partnership engagement, science and evaluation, clinical care 
improvement, patient outreach, and public policy.
• Ensure adequate healthcare coverage for prevention and treatment of 
dyslipidemia.
• Secure and protect dedicated state appropriations aligned with HD 
and stroke priorities and work to support appropriate program 
implementation. Support other public health initiatives and evaluation 
targeted at HD, stroke, and related risk factors, as well as the 
disparities that exist in these areas.
Blood Pressure
 Ideal for cardiovascular health:
 Adults: <120/80 mm Hg
 Children: <90th percentile
Federal
• Partner with the Department of Health and Human Services to 
promote the Million Hearts Campaign, as above.
• Implement the Institute of Medicine’s recommendations to reduce 
sodium in the food supply.
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Measure of Cardiovascular Health Advocacy/Policy Solutions
• Improve food labeling to increase consumer understanding of sodium 
levels in packaged foods.
• Advocate for robust sodium limits in procurement standards, nutrition 
standards in schools, and other government feeding programs.
State
• Promote public funding for Heart Disease and Stroke Prevention 
Programs.
• Ensure the availability of essential CVD preventive benefits in private 
insurance and public health programs.
Fasting Plasma Glucose
 Ideal for cardiovascular health:
 Children and Adults: Fasting blood glucose <100 
mg/dL
Federal and State
• Ensure adequate healthcare coverage for early treatment and 
prevention of diabetes mellitus.
For AHA advocacy resources, including fact sheets, policy briefs, published papers, and position statements, go to http://www.heart.org/
HEARTORG/Advocate/PolicyResources/Policy-Resources_UCM_001135_SubHomePage.jsp.
AHA indicates American Heart Association; FDA, Food and Drug Administration; WHO, World Health Organization; UN, United Nations; CDC, 
Centers for Disease Control and Prevention; PA, physical activity; PE, physical education; DASH, Dietary Approaches to Stop Hypertension; HD, 
heart disease; and CVD, cardiovascular disease.
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Table 3-1
Cigarette Smoking
Population Group Prevalence, 2011 Age ≥18 y*5 Cost16
Both sexes 43 821 000 (19.0%) $193 Billion per year
Males 24 138 000 (21.3%) …
Females 19 683 000 (16.7%) …
NH white males 22.8% …
NH white females 19.7% …
NH black males 23.3% …
NH black females 15.1% …
Hispanic or Latino males 16.2% …
Hispanic or Latino females 8.3% …
Asian only (both sexes) 9.6% …
American Indian/Alaska 26.7% …
Native only (both sexes)
Percentages are age adjusted. Estimates for Asian only and American Indian/Alaska Native only include non-Hispanic and Hispanic persons.
Ellipses (…) indicate data not available; NH, non-Hispanic.
*
Rounded to the nearest thousand.
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Table 4-1
Met 2008 Federal PA Guidelines for Adults
Population Group Prevalence, 2011 (Age ≥18 y), %
Both sexes 21.0
Males 24.9
Females 17.1
NH white only 23.0
NH black only 18.0
Hispanic or Latino 15.4
American Indian/Alaska Native only 17.0
Asian only 16.7
“Met 2008 Federal PA Guidelines for Adults” is defined as engaging in at least 150 minutes of moderate or 75 minutes of vigorous aerobic leisure-
time PA per week (or an equivalent combination) and engaging in leisure-time strengthening PA at least twice a week.
Data are age-adjusted for adults ≥18 y of age.
PA indicates physical activity; NH, non-Hispanic.
Source: National Health Interview Survey 2011 (National Center for Health Statistics).7
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Table 7-1
Odds Ratio for Combinations of Parental Heart Attack History
OR (95% CI)
No family history 1.00
One parent with heart attack ≥50 y of age 1.67 (1.55–1.81)
One parent with heart attack <50 y of age 2.36 (1.89–2.95)
Both parents with heart attack ≥50 y of age 2.90 (2.30–3.66)
Both parents with heart attack, one <50 y of age 3.26 (1.72–6.18)
Both parents with heart attack, both <50 y of age 6.56 (1.39–30.95)
OR indicates odds ratio; CI, confidence interval.
Data derived from Chow et al.4
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Table 7-2
Validated SNPs for MI, the Nearest Gene, and the OR From the CARDIoGRAM Consortium
SNP Chromosomal Region Gene Effect Size (OR) Minor Allele Frequency
rs599839 1p13.3 SORT1 1.11 0.22
rs17465637 1q41 MIA3 1.14 0.26
rs17114036 1p32.2 PPAP2B 1.17 0.09
rs11206510 1p32.3 PCSK9 1.08 0.18
rs6725887 2q33 WDR12 1.14 0.15
rs2306374 3q22.3 MRAS 1.12 0.18
rs17609940 6p21.31 ANKS1A 1.07 0.25
rs12526453 6p24.1 PHACTR1 1.10 0.33
rs12190287 6q23.2 TCF21 1.08 0.38
rs798220 6q25 LPA 1.51 0.02
rs11556924 7q32.2 ZC3HC1 1.09 0.38
rs4977574 9p21.3 CDKN2A, CDKN2B 1.29 0.46
rs579459 9q34.2 ABO 1.10 0.21
rs1746048 10q11 CXCL12 1.09 0.13
rs12413409 10q24.32 CYP17A1-CNNM2-NT5C2 1.12 0.11
rs964184 11q23.3 ZNF259-APOA5-A4-C3-A1 1.13 0.13
rs3184504 12q24 Sh2b3 1.07 0.44
rs4773144 13q34 COL4A1-COL4A2 1.07 0.44
rs2895811 14q32.2 HHIPL1 1.08 0.43
rs3825807 15q25.1 ADAMTS7 1.07 0.43
rs216172 17p13.3 SMG6-SRR 1.07 0.37
rs12936587 17p11.2 RASD1-SMCR3-PEMT 1.07 0.44
rs46522 17q21.32 UBE2Z-GIP-ATP5G1-SNF8 1.06 0.47
rs1122608 19q13.2 LDLR 1.14 0.23
rs9982601 21q22.11 MRPS6 1.18 0.15
SNPs indicates single-nucleotide polymorphisms; MI, myocardial infarction; OR, odds ratio; and CARDIoGRAM, Coronary Artery DIsease 
Genome-wide Replication And Meta-analysis Consortium.
Data derived from Schunkert et al.9
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Table 7-3
Heritability of CVD Risk Factors From the FHS
Trait Heritability
ABI 0.2122
SBP 0.4223
DBP 0.3923
Left ventricular mass 0.24 to 0.3224
BMI 0.37 (mean age 40 y) to 0.52 (mean age 60 y)25
Waist circumference 0.4126
Visceral abdominal fat 0.3627
Subcutaneous abdominal fat 0.5727
Fasting glucose 0.3428
HbA1c 0.2728
Triglycerides 0.4829
HDL cholesterol 0.5229
Total cholesterol 0.5729
LDL cholesterol 0.5929
Estimated GFR 0.3330
CVD indicates cardiovascular disease; FHS, Framingham Heart Study; ABI, ankle-brachial index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; BMI, body mass index; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and GFR, 
glomerular filtration rate.
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Table 8-1
High Total and LDL Cholesterol and Low HDL Cholesterol
Population Group
Prevalence of Total 
Cholesterol ≥200 
mg/dL, 2010 Age ≥20 y
Prevalence of Total 
Cholesterol ≥240 
mg/dL, 2010 Age ≥20 y
Prevalence of LDL 
Cholesterol ≥130 
mg/dL, 2010 Age ≥20 y
Prevalence of HDL 
Cholesterol <40 
mg/dL, 2010 Age ≥20 y
Both sexes* 98 900 000 (43.4%) 31 900 000 (13.8%) 71 000 000 (31.1%) 48 700 000 (21.8%)
Males* 45 300 000 (41.3%) 14 000 000 (12.7%) 35 200 000 (31.9%) 34 600 000 (31.8%)
Females* 53 600 000 (44.9%) 17 900 000 (14.7%) 35 800 000 (30.0%) 14 100 000 (12.3%)
NH white males, % 40.5 12.3 30.1 33.1
NH white females, % 45.8 15.6 29.3 12.4
NH black males, % 38.6 10.8 33.1 20.3
NH black females, % 40.7 11.7 31.2 10.2
Mexican-American males, % 48.1 15.2 39.9 34.2
Mexican-American females, % 44.7 13.5 30.4 15.1
Prevalence of total cholesterol ≥200 mg/dL includes people with total cholesterol ≥240 mg/dL. In adults, levels of 200 to 239 mg/dL are considered 
borderline high. Levels of ≥240 mg/dL are considered high.
LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; and NH, non-Hispanic.
*
Total data for total cholesterol are for Americans ≥20 y of age. Data for LDL cholesterol, HDL cholesterol, and all racial/ethnic groups are age 
adjusted for age ≥20 y.
Source for total cholesterol ≥200 mg/dL, ≥240 mg/dL, LDL, and HDL: National Health and Nutrition Examination Survey (2007–2010), National 
Center for Health Statistics, and National Heart, Lung, and Blood Institute. Estimates from National Health and Nutrition Examination Survey 
2007–2010 (National Center for Health Statistics) applied to 2010 population estimates.
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Table 9-1
High Blood Pressure
Population Group
Prevalence, 2010, Age ≥20 
y
Mortality,* 2009, All 
Ages
Hospital Discharges, 
2010, All Ages Estimated Cost, 2009
Both sexes 77 895 000 (33.0%) 61 762 488 000 $51.0 Billion
Males 37 195 000 (33.6%) 27 668 (44.8%)† 216 000 …
Females 40 700 000 (32.2%) 34 094 (55.2%)† 272 000 …
NH white males 33.4% 20 286 … …
NH white females 30.7% 26 201 … …
NH black males 42.6% 6574 … …
NH black females 47.0% 6951 … …
Mexican American males 30.1% … … …
Mexican American females 28.8% … … …
Hispanic or Latino 22.2%‡ 3733 … …
Asian 18.7%‡ 1471 … …
American Indian/Alaska Native 25.8%‡ 279 … …
Hypertension is defined in terms of National Health and Nutrition Examination Survey blood pressure measurements and health interviews. A 
subject was considered hypertensive if systolic blood pressure was ≥140 mm Hg or diastolic blood pressure was ≥90 mm Hg, if the subject said 
“yes” to taking antihypertensive medication, or if the subject was told on 2 occasions that he or she had hypertension. Ellipses (…) indicate data not 
available; NH, non-Hispanic.
*
Mortality data for the white, black, Asian or Pacific Islander, and American Indian/Alaska Native populations include deaths among persons of 
Hispanic and non-Hispanic origin. Numbers of deaths for the American Indian/Alaska Native and Asian or Pacific Islander populations are known 
to be underestimated.
†
These percentages represent the portion of total high blood pressure mortality that is for males vs females.
‡National Health Interview Survey (2010), National Center for Health Statistics; data are weighted percentages for Americans ≥18 years of age. 
Source: Schiller et al.21
Sources: Prevalence: National Health and Nutrition Examination Survey (2007–2010), National Center for Health Statistics) and National Heart, 
Lung, and Blood Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 y of age. Age-specific percentages are 
extrapolated to the 2010 US population estimates. Mortality: CDC/National Center for Health Statistics, 2009 Mortality Multiple Cause–US, 
version July 19, 2012. These data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, National 
Center for Health Statistics; data include those discharged alive, dead, or status unknown. Cost: Medical Expenditure Panel Survey data include 
estimated direct costs for 2009; indirect costs calculated by National Heart, Lung, and Blood Institute for 2009.
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Table 12-1
BP and the Adjusted Risk of ESRD Among 316 675 Adults Without Evidence of Baseline Kidney Disease
JNC V BP Category Adjusted RR (95% CI)
Optimal 1.00 (Reference)
Normal, not optimal 1.62 (1.27–2.07)
High normal 1.98 (1.55–2.52)
Hypertension
 Stage 1 2.59 (2.07–3.25)
 Stage 2 3.86 (3.00–4.96)
 Stage 3 3.88 (2.82–5.34)
 Stage 4 4.25 (2.63–6.86)
BP indicates blood pressure; ESRD, end-stage renal disease; JNC V, fifth report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure; RR, relative risk; and CI, confidence interval.
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Table 12-2
Multivariable Association Between BMI and Risk of ESRD Among 320 252 Adults
BMI, kg/m2 Adjusted RR (95% CI)
18.5–24.9 (Normal weight) 1.00 (Reference)
25.0–29.9 (Overweight) 1.87 (1.64–2.14)
30.0–34.9 (Class I obesity) 3.57 (3.05–4.18)
35.0–39.9 (Class II obesity) 6.12 (4.97–7.54)
≥40.0 (Extreme obesity) 7.07 (5.37–9.31)
BMI indicates body mass index; ESRD, end-stage renal disease; RR, relative risk; and CI, confidence interval.
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Table 12-3
Adjusted HR (95% CI) for Death of Any Cause, Cardiovascular Events, and Hospitalization Among 1 120 295 
Ambulatory Adults, According to eGFR*
eGFR, mL·min−1·1.73 m−2 Death of Any Cause Any Cardiovascular Event Any Hospitalization
≥60† 1.00 1.00 1.00
45–59 1.2 (1.1–1.2) 1.4 (1.4–1.5) 1.1 (1.1–1.1)
30–44 1.8 (1.7–1.9) 2.0 (1.9–2.1) 1.5 (1.5–1.5)
15–29 3.2 (3.1–3.4) 2.8 (2.6–2.9) 2.1 (2.0–2.2)
<15 5.9 (5.4–6.5) 3.4 (3.1–3.8) 3.1 (3.0–3.3)
HR indicates hazard ratio; CI, confidence interval; and eGFR, estimated glomerular filtration rate.
*
The analyses were adjusted for age, sex, income, education, use or nonuse of dialysis, and presence or absence of prior coronary heart disease, 
prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, 
dyslipidemia, a serum albumin level ≥3.5 g/dL, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior 
hospitalizations.
†
This group served as the reference group.
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Table 13-1
Cardiovascular Diseases
Population Group Prevalence, 2010: Age ≥20 y Mortality, 2009: All Ages*
Hospital Discharges, 
2010: All Ages Cost, 2009
Both sexes 83 600 000 (35.3%) 787 931 5 802 000 $312.6 Billion
Males 40 700 000 (36.7%) 386 436 (49.0%)† 3 021 000
Females 42 900 000 (34.0%) 401 495 (51.0%)† 2 781 000 …
NH white males 36.6% 329 565 … …
NH white females 32.4% 343 955 … …
NH black males 44.4% 46 334 … …
NH black females 48.9% 48 070 … …
Mexican American males 33.4% … … …
Mexican American females 30.7% … … …
Asian … 16 419‡ … …
American Indian/Alaska Native … 3588 … …
Ellipses (…) indicate data not available; NH, non-Hispanic.
*
Mortality data are for whites and blacks and include Hispanics.
†
These percentages represent the portion of total cardiovascular disease mortality that is attributable to males vs females.
‡
Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey 2007–2010, National Center for Health Statistics (NCHS) and National 
Heart, Lung, and Blood Institute (NHLBI). Percentages for racial/ethnic groups are age-adjusted for Americans ≥20 y of age. Age-specific 
percentages are extrapolated to the 2010 US population estimates. Mortality: Centers for Disease Control and Prevention/NCHS, 2009 Mortality 
Multiple Cause–US, version July 19, 2012. These data represent underlying cause of death only. Data include congenital cardiovascular disease 
mortality. Hospital discharges: National Hospital Discharge Survey, NCHS. Data include those inpatients discharged alive, dead, or of unknown 
status. Cost: NHLBI. Data include estimated direct and indirect costs for 2009.
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Table 13-3
International Death Rates (Revised February 2012): Death Rates (Per 100 000 Population) for Total CVD, 
CHD, Stroke, and Total Deaths in Selected Countries (Most Recent Year Available)
CVD Deaths CHD Deaths Stroke Deaths Total Deaths
Men ages 35–74 y
 Russian Federation (2009) 1185.4 658.5 307.5 2438.3
 Bulgaria (2008) 803.7 219.4 218.2 1554.3
 Lithuania (2009) 734.7 444.6 138.3 1842.3
 Romania (2010) 657.9 268.2 195.9 1548.4
 Hungary (2009) 605.6 319.1 121.1 1652.3
 Slovakia (2009) 553.2 318.3 117.1 1390.5
 Poland (2009) 492.7 166.1 95.4 1389.7
 Croatia (2009) 419.3 202.2 113.6 1184.7
 Czech Republic (2009) 386.6 198.6 64.4 1080.8
 Kuwait (2009) 319.6 187.0 62.1 563.9
 Finland (2009) 284.4 170.0 43.8 833.2
 United States (2009) 249.8 143.1 29.5 847.5
 Greece (2009) 251.6 136.7 50.8 721.6
 Germany (2010) 211.5 105.1 29.3 748.8
 Ireland (2009) 210.0 140.6 29.2 701.3
 Belgium (2005) 209.6 99.5 35.9 821.7
 Denmark (2006) 206.6 84.8 45.6 865.6
 New Zealand (2007) 204.2 135.6 29.1 635.7
 United Kingdom (2009) 202.0 125.8 29.9 687.6
 Canada (2004) 198.3 130.8 24.2 705.3
 Austria (2010) 189.5 114.2 23.3 724.9
 Portugal (2009) 168.7 61.3 62.1 825.3
 Spain (2008) 168.2 77.6 33.7 714.0
 Sweden (2010) 165.2 93.1 26.3 556.1
 Italy (2008) 157.7 74.6 30.4 613.0
 Norway (2009) 154.4 84.6 29.0 607.0
 Switzerland (2007) 150.4 78.2 16.6 587.5
 Netherlands (2010) 147.6 57.1 25.1 619.5
 Japan (2009) 145.2 46.5 52.2 605.0
 Australia (2006) 141.3 88.9 22.0 553.4
 France (2008) 140.1 54.0 25.7 765.8
 Korea, South (2009) 138.4 41.0 65.9 783.6
 Israel (2008) 133.1 71.7 24.2 621.2
Women ages 35–74 y
 Russian Federation (2009) 463.0 221.2 157.5 918.5
 Bulgaria (2008) 368.6 70.9 120.6 699.3
 Romania (2010) 312.2 105.7 111.4 692.4
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CVD Deaths CHD Deaths Stroke Deaths Total Deaths
 Lithuania (2009) 253.9 127.5 73.8 648.6
 Kuwait (2009) 246.1 94.8 56.1 568.1
 Hungary (2009) 239.2 113.7 56.0 719.4
 Slovakia (2009) 228.5 120.7 57.5 590.7
 Croatia (2009) 190.8 71.9 68.7 520.1
 Poland (2009) 180.6 48.0 48.1 564.5
 Czech Republic (2009) 164.3 69.9 34.8 506.6
 United States (2009) 123.7 55.5 22.3 535.6
 Denmark (2006) 100.0 32.4 32.1 557.8
 Greece (2009) 97.1 33.3 29.3 319.0
 Belgium (2005) 94.4 30.8 24.8 436.3
 New Zealand (2007) 89.8 43.9 21.7 418.2
 United Kingdom (2009) 88.1 38.5 22.5 438.5
 Ireland (2009) 86.8 40.9 21.9 419.8
 Germany (2010) 84.1 30.4 17.7 392.0
 Finland (2009) 83.4 36.1 23.0 377.8
 Canada (2004) 83.1 42.8 17.3 432.7
 Portugal (2009) 76.5 20.0 33.5 377.6
 Austria (2010) 74.9 32.7 17.9 362.3
 Netherlands (2010) 71.0 20.5 18.9 408.6
 Sweden (2010) 67.8 31.1 16.2 357.1
 Italy (2008) 64.0 20.4 18.5 320.7
 Korea, South (2009) 63.5 41.0 33.2 312.3
 Spain (2008) 62.4 18.7 17.8 304.4
 Israel (2008) 61.5 23.1 14.4 376.0
 Norway (2009) 60.5 26.3 15.2 377.0
 Australia (2006) 60.4 26.8 16.3 327.5
 Japan (2009) 54.4 12.8 22.7 266.9
 Switzerland (2007) 54.1 19.4 12.4 327.6
 France (2008) 51.4 11.9 14.2 349.9
CVD indicates cardiovascular disease; CHD, coronary heart disease.
Rates are adjusted to the European Standard population. International Classification of Diseases, 10th Revision (ICD-10) codes are used for all 
countries except Greece, for which International Classification of Diseases, 9th Revision (ICD-9) codes are used. For countries using ICD-9, the 
ICD-9 codes are 390 to 459 for CVD, 410 to 414 for CHD, and 430 to 438 for stroke. ICD-10 codes are I00 to I99 for CVD, I20 to I25 for CHD, 
and I60 to I69 for stroke. The following countries have been dropped from the table because data on number of deaths or population are no longer 
furnished to the World Health Organization: Argentina, China, Colombia, and Mexico.
Sources: The World Health Organization, National Center for Health Statistics, and National Heart, Lung, and Blood Institute.
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Table 13-4
Remaining Lifetime Risks for CVD and Other Diseases Among Men and Women Free of Disease at 40 and 70 
Years of Age
Diseases
Remaining Lifetime Risk at Age 40 y Remaining Lifetime Risk at Age 70 y
Men Women Men Women
Any CVD5a 2 in 3* 1 in 2* 2 in 3† 1 in 2
CHD6 1 in 2 1 in 3 1 in 3 1 in 4
AF17 1 in 4 1 in 4 1 in 4 1 in 4
CHF18 1 in 5 1 in 5 1 in 5 1 in 5
Stroke34 1 in 6‡ 1 in 5‡ 1 in 6 1 in 5
Dementia34 … … 1 in 7 1 in 5
Hip fracture32 1 in 20 1 in 6 … …
Breast cancer38,40 1 in 1000 1 in 8 … 1 in 14
Prostate cancer38 1 in 6 … … …
Lung cancer38 1 in 12 1 in 17 … …
Colon cancer38 1 in 16 1 in 17 … …
DM41 1 in 3 1 in 3 1 in 9 1 in 7
Hypertension36 9 in 10‡ 9 in 10‡ 9 in 10† 9 in 10†
Obesity37 1 in 3 1 in 3 … …
CVD indicates cardiovascular disease; ellipses (…), not estimated; CHD, coronary heart disease; AF, atrial fibrillation; CHF, congestive heart 
failure; DM, diabetes mellitus.
*Age 45.
†Age 65 y.
‡Age 55 y.
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Table 14-1
Stroke
Population Group
Prevalence, 
2010: Age ≥20 y
New and Recurrent 
Attacks, All Ages
Mortality, 2009: 
All Ages*
Hospital 
Discharges, 
2010: All Ages Cost, 2009
Both sexes 6 800 000 (2.8%) 795 000 128 842 1 015 000 $38.6 Billion
Males 3 000 000 (2.6%) 370 000 (46.5%)† 52 073 (40.4%)† 485 000 …
Females 3 800 000 (3.0%) 425 000 (53.5%)† 76 769 (59.6%)† 530 000 …
NH white males 2.4% 325 000‡ 43 190 … …
NH white females 2.9% 365 000‡ 65 574 … …
NH black males 4.3% 45 000‡ 6962 … …
NH black females 4.7% 60 000‡ 8916 … …
Mexican-American males 2.3% … … … …
Mexican-American females 1.4% … … … …
Hispanic or Latino 2.8%§ … 7065 … …
Asian 2.7%§ … 3639|| … …
Native Hawaiian and other Pacific 
Islander
§¶ … … … …
American Indian/Alaska Native 4.6%§ … 561 … …
NH indicates non-Hispanic. Ellipses (…) indicate data not available.
*
Mortality data for the white, black, Asian or Pacific Islander, and American Indian/Alaska Native populations include deaths of persons of 
Hispanic and non-Hispanic origin. Numbers of deaths for the American Indian/Alaska Native and Asian or Pacific Islander populations are known 
to be underestimated.
†
These percentages represent the portion of total stroke incidence or mortality that applies to males vs females.
‡
Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
§National Health Interview Survey (2011), National Center for Health Statistics; data are weighted percentages for Americans >18 years of 
age.174
||
Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
¶
Estimate considered unreliable or does not meet standards of reliability or precision.
Sources: Prevalence: National Health and Nutrition Examination Survey 2007–2010, National Center for Health Statistics and National Heart, 
Lung, and Blood Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are 
extrapolated to the 2010 US population. Incidence: Greater Cincinnati/Northern Kentucky Stroke Study/National Institutes of Neurological 
Disorders and Stroke data for 1999 provided on August 1, 2007. US estimates compiled by National Heart, Lung, and Blood Institute. See also 
Kissela et al.142 Data include children. Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2009 Mortality 
Multiple Cause–United States, version July 19, 2012. These data represent underlying cause of death only. Mortality data for white and black males 
and females include Hispanics. Hospital discharges: National Hospital Discharge Survey, National Center for Health Statistics. Data include those 
inpatients discharged alive, dead, or status unknown. Cost: National Heart, Lung, and Blood Institute. Data include estimated direct and indirect 
costs for 2009.
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Table 14-2
Modifiable Stroke Risk Factors
Factor Prevalence, % PAR, %* RR
Cigarette smoking
 Overall 19.8 12–14† 1.9
  Men 22.3
  Women 17.4
Hypertension ‡ 8
 Ages 20–34 y
  Men 13.4 99
  Women 6.2 98
 Ages 35–44 y
  Men 23.2 99
  Women 16.5 106
 Ages 45–54 y
  Men 36.2 100
  Women 35.9 103
 Ages 55–64 y
  Men 53.7 100
  Women 55.8 102
 Ages 65–74 y
  Men 64.7 100
  Women 69.6 101
 Ages ≥75 y
  Men 64.1 100
  Women 76.4 101
Diabetes 7.3 5–27 1.8–6.0
High total cholesterol Data calculated for highest quintile (20%) vs 
lowest quintile
9.1 (5.7–13.8) 1.5 (95% CI, 1.3–1.8)
Continuous risk for ischemic stroke … 1.25 per 1-mmol/L (38.7 mg/dL) 
increase
Low HDL cholesterol
 <40 mg/dL
  Men 35
  Women 15
Data calculated for highest quintile (20%) vs 
lowest quintile
23.7 0.4
 <35 mg/dL 26 20.6 (10.1–30.7) 2.00 (95% CI, 1.43–2.70)
Continuous risk for ischemic stroke ≈0.5–0.6 for each 1-mmol/L increase
AF (nonvalvular)
 Overall age, y
  50–59 0.5 1.5 4.0
  60–69 1.8 2.8 2.6
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Factor Prevalence, % PAR, %* RR
  70–79 4.8 9.9 3.3
  80–89 8.8 23.5 4.5
Asymptomatic carotid stenosis 2–8 2–7§ 2.0
Sickle cell disease 0.25 (of blacks) … 200–400||
Postmenopausal hormone therapy 25 (Women 50–74 y of age) 9 1.4
Oral contraceptive use 13 (women 25–44 y) 9.4 2.3
Dietary factors
 Na intake >2300 mg 75–90 Unknown Unknown
 K intake <4700 mg 90–99 Unknown Unknown
Physical inactivity 25 30 2.7
Obesity 1.39 Stroke death per increase of 5 
kg/m2
  Men 33.3
  Women 35.3
 CHD
  Men 8.4 5.8 1.73 (1.68–1.78)
  Women 5.6 3.9¶ 1.55 (1.17–2.07)
 Heart failure
  Men 2.6 1.4
  Women 2.1 1.1¶
Peripheral arterial disease 4.9 3.0¶
PAR indicates population attributable risk; RR, relative risk; CI, confidence interval; HDL, high-density lipoprotein; AF, atrial fibrillation; and 
CHD, coronary heart disease.
*
PAR is the proportion of ischemic stroke in the population that can be attributed to a particular risk factor (see Goldstein et al62 for formula).
†
PAR is for stroke deaths, not ischemic stroke incidence.
‡
PAR percent=100×{[prevalence (RR−1)/prevalence (RR−1) +1]}.
§Calculated on the basis of referenced data provided in the table or text.
||
Relative to stroke risk in children without sickle cell disease.
¶Calculated on the basis of point estimates of referenced data provided in the table. For peripheral arterial disease, calculation was based on average 
RR for men and women.
Adapted from Goldstein et al.62
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Table 15.1
Congenital Cardiovascular Defects
Population Group Estimated Prevalence, 2002, All Ages Mortality, 2009, All Ages
Hospital Discharges, 2009, All 
Ages
Both sexes 650 000 to 1.3 million14 3189 52 000
Males … 1754 (55.0%)* 25 000
Females … 1435 (45.0%)* 27 000
NH white males … 1370 …
NH white females … 1086 …
NH black males … 304 …
NH black females … 268 …
Asian … 126 …
American Indian/Alaska Native … 35 …
Ellipses (…) indicate data not available; NH, non-Hispanic.
*
These percentages represent the portion of total congenital cardiovascular mortality that is for males vs females.
Sources: Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2009 Mortality Multiple Cause—United 
States, version July 19, 2012. These data represent underlying cause of death only; data include Hispanics. Hospital discharges: National Hospital 
Discharge Survey, National Center for Health Statistics; data include those inpatients discharged alive, dead, or status unknown.
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Table 15.2
Annual Birth Prevalence of Congenital Cardiovascular Defects in the United States1,4,7,12,49,50
Type of Presentation Rate per 1000 Live Births Estimated Number (Variable With Yearly Birth Rate
Fetal loss Unknown Unknown
Invasive procedure during the first year 2.4 9200
Detected during first year* 8 36 000
Bicuspid aortic valve 13.7 54 800
*
Includes stillbirths and pregnancy termination at <20 weeks’ gestation; includes some defects that resolve spontaneously or do not require 
treatment.
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Table 15.4
Surgery for Congenital Heart Disease
Sample Population, Weighted
Surgery for congenital heart disease 14 888 25 831
Deaths 736 1253
Mortality rate, % 4.9 4.8
By sex (81 missing in sample)
 Male 8127 14 109
  Deaths 420 714
  Mortality rate, % 5.2 5.1
 Female 6680 11 592
  Deaths 315 539
  Mortality rate, % 4.7 4.6
By type of surgery
 ASD secundum surgery 834 1448
  Deaths 3 6
  Mortality rate, % 0.4 0.4
 Norwood procedure for HPLHS 161 286
  Deaths 42 72
  Mortality rate, % 26.1 25.2
ASD indicates atrial septal defect; HPLHS, hypoplastic left heart syndrome.
In 2003, 25 000 cardiovascular operations for congenital cardiovascular defects were performed on children <20 years of age. Inpatient mortality 
rate after all types of cardiac surgery was 4.8%. Nevertheless, mortality risk varies substantially for different defect types, from 0.4% for ASD 
repair to 25.2% for first-stage palliation for HPLHS. Fifty-five percent of operations were performed in males. In unadjusted analysis, mortality 
after cardiac surgery was somewhat higher for males than for females (5.1% vs 4.6%).
Source: Analysis of 2003 Kids’ Inpatient Database38 and personal communication with Kathy Jenkins, MD, Children’s Hospital of Boston, MA, 
October 1, 2006.
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Table 16-1
Incidence and Outcome of Out-of-Hospital Cardiac Arrest in the United States
Overall (95% CI) Adults (95% CI) Children (95% CI)
Incidence (per 100 000)
 EMS assessed 126.4 (124.0–128.8) 147.7 (144.8–150.7) 11.0 (9.6–12.4)
 EMS treated 63.8 (62.1–65.4) 80.1 (77.9–82.2) 8.8 (7.6–10.1)
 Bystander-witnessed shockable rhythm (including VT, VF, shockable 
by AED)
10.0 (9.4–10.6) 9.8 (9.0–10.6) 0.3 (0.1–0.5)
Survival to discharge, %
 EMS assessed 4.8 (4.4–5.2) 5.3 (4.9–5.7) 6.3 (3.3–9.3)
 EMS treated 9.5 (8.8–10.2) 9.8 (9.0–10.6) 7.8 (4.2–11.5)
 Bystander-witnessed shockable rhythm 28.4 (25.1–31.8) 28.4 (25.1–31.8) 57.1 (20.4–93.8)
CI indicates confidence interval; EMS, emergency medical services; VT, ventricular tachycardia; VF, ventricular fibrillation; and AED, automated 
external defibrillator. Source: Resuscitation Outcomes Consortium Investigators, unpublished data, June 20, 2012.
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Table 17-1
CAC Scores for the 75th Percentile of Men and Women of Different Race/Ethnic Groups, at Specified Ages
Age, y
75th Percentile CAC Scores*
Black Chinese Hispanic White
Women
 45 0 0 0 0
 55 0 2 0 1
 65 26 45 19 54
 75 138 103 116 237
Men
 45 0 3 0 0
 55 15 34 27 68
 65 95 121 141 307
 75 331 229 358 820
CAC indicates coronary artery calcification.
*
The 75th percentile CAC score is the score at which 75% of people of the same age, sex, and race have a score at or below this level and 25% of 
people of the same age, sex, and race have a higher score. (Source: MESA CAC Tools Web site.40)
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Table 18-2
Angina Pectoris
Population Group Prevalence, 2010, Age ≥20 y Incidence of Stable AP, Age ≥45 y Hospital Discharges, 2010, All Ages
Both sexes 7 800 000 (3.2%) 500 000 22 000
Males 3 700 000 (3.3%) 320 000 12 000
Females 4 100 000 (3.2%) 180 000 10 000
NH white males 3.3% … …
NH white females 2.8% … …
NH black males 2.4% … …
NH black females 5.4% … …
Mexican-American males 3.4% … …
Mexican-American females 3.3% … …
AP is chest pain or discomfort that results from insufficient blood flow to the heart muscle. Stable AP is predictable chest pain on exertion or under 
mental or emotional stress. The incidence estimate is for AP without myocardial infarction.
AP indicates angina pectoris; NH, non-Hispanic; and ellipses, data not available.
*
There were 56 000 days of care for discharges of patients with AP from short-stay hospitals in 2010.
Sources: Prevalence: National Health and Nutrition Examination Survey 2007–2010 (National Center for Health Statistics) and National Heart, 
Lung, and Blood Institute; percentages for racial/ethnic groups are age-adjusted for US adults ≥20 years of age. AP includes persons who either 
answered “yes” to the question of ever having angina or AP or who were diagnosed with Rose angina (the Rose questionnaire is only administered 
to survey participants >40 years of age). Estimates from National Health and Nutrition Examination Survey 2007–2010 (National Center for Health 
Statistics) were applied to 2010 population estimates (≥20 years of age). Incidence: AP uncomplicated by a myocardial infarction or with no 
myocardial infarction (Framingham Heart Study 1980 to 2001–2003 of the original cohort and 1980 to 1998–2001 of the Offspring Cohort, 
National Heart, Lung, and Blood Institute). Hospital discharges: National Hospital Discharge Survey, National Center for Health Statistics; data 
include those inpatients discharged alive, dead, or status unknown.
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Table 19-1
Heart Failure
Population Group
Prevalence, 2010, Age ≥20 
y
Incidence (New 
Cases), Age ≥45 y
Mortality, 2009, All 
Ages*
Hospital Discharges, 
2010, All Ages
Both sexes 5 100 000 (2.1%) 670 000 56 410 1 023 000
Males 2 700 000 (2.5%) 350 000 23 563 (41.8%)† 501 000
Females 2 400 000 (1.8%) 320 000 32 847 (58.2%)† 522 000
NH white males 2.2% … 20 815 …
NH white females 1.7% … 29 372 …
NH black males 4.1% … 2341 …
NH black females 3.0% … 2987 …
Mexican American males 1.9% … … …
Mexican American females 1.1% … … …
Asian … … 660 …
American Indian/Alaska Native … … 235 …
Heart failure includes persons who answered “yes” to the question of ever having congestive heart failure.
NH indicates non-Hispanic; and ellipses (…), data not available.
*
Mortality data are based on underlying cause and include Hispanics.
†
These percentages represent the portion of total mortality attributable to heart failure that is for males vs females.
Sources: Prevalence: National Health and Nutrition Examination Survey 2007–2010 (National Center for Health Statistics) and National Heart, 
Lung, and Blood Institute. Percentages are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2010 US 
population estimates. These data are based on self-reports. Incidence: Framingham Heart Study, 1980–2003 from National Heart, Lung, and Blood 
Institute Incidence and Prevalence Chart Book, 2006. Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 
2009 Mortality Multiple Cause–US, version July 19, 2012.
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Table 20-2
Rheumatic Fever/Rheumatic Heart Disease
Population Group Mortality, 2009: All Ages* Hospital Discharges, 2010: All Ages
Both sexes 3234 20 000
Males 1071 (33.1%)† 5000
Females 2163 (66.9%)† 15 000
NH white males 946 …
NH white females 1903 …
NH black males 89 …
NH black females 178 …
Asian 98 …
American Indian/Alaska Native 20 …
NH indicates non-Hispanic; ellipses (…), data not available.
*
Mortality data include Hispanics.
†
These percentages represent the portion of total mortality that is for males vs females.
Sources: Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2009 Mortality Multiple Cause–US, version 
July 19, 2012; data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, National Center for Health 
Statistics, and National Heart, Lung, and Blood Institute; data include those inpatients discharged alive, dead, or of unknown status.
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Table 21-1
Acute Coronary Syndrome Quality-of-Care Measures, 2011
Quality-of-Care Measure VHA*
National Data 
From HIQR 
Program† ACTION-GWTG STEMI‡ ACTION-GWTG NSTEMI‡
Aspirin within 24 h of admission 99 99 98.4 97.1
Aspirin at discharge 99 98.8 98.9 97.9
β-Blockers within 24 h of admission, among 
AMI and angina patients
96 R NM NM
β-Blockers at discharge 99 98.6 97.7 96.1
Lipid-lowering medication at discharge§ 98 96.8 99 98.1
Lipid therapy at discharge if LDL cholesterol 
>130 mg/dL
97 NM NM NM
ARB/ACEI at discharge for patients with LVEF 
<40%
95 96.8 90.4 85.7
ACEI at discharge for AMI patients NM NM 72.9 60.8
ARB at discharge for AMI patients NM NM 8.1 12.4
Adult smoking cessation advice/counseling 100 99.7 98.7 98.1
Cardiac rehabilitation referral for AMI patients NM NM 83.2 72
Values are percentages.
VHA indicates Veterans Health Administration; HIQR, Hospital Inpatient Quality Reporting; ACTION-GWTG, Acute Coronary Treatment and 
Intervention Outcomes Registry–Get With The Guidelines; STEMI, ST-elevation myocardial infarction; NSTEMI, non–ST-elevation myocardial 
infarction; AMI, acute myocardial infarction; R, retired in 2009; NM, not measured; LDL, low-density lipoprotein; ARB, angiotensin receptor 
blocker; ACEI, angiotensin-converting enzyme inhibitor; and LVEF, left ventricular ejection fraction.
*VHA: AMI patients.
†
HIQR Program includes data from all payers, including Medicare and Medicaid.
‡ACTION Registry: STEMI and NSTEMI patients are reported separately. Patients must be admitted with acute ischemic symptoms within the 
previous 24 hours, typically reflected by a primary diagnosis of STEMI or NSTEMI. Patients who are admitted for any other clinical condition are 
not eligible.
§
Denotes statin use at discharge. Use of nonstatin lipid-lowering agent was 9.7% for STEMI patients and 12.6% for NSTEMI patients in the 
ACTION registry.
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Table 21-2
HF Quality-of-Care Measures, 2011
Quality-of-Care Measure
National Data From HIQR 
Program* AHA GWTG-HF VHA
LVEF assessment 98.3 99.2 100
ARB/ACEI at discharge for patients with LVSD 95.3 95.4 96
Complete discharge instructions 91 93.5 97
Adult smoking cessation advice/counseling 98.9 99.2 99
β-Blockers at discharge for patients with LVSD, no contraindications NM 96.2 NM
Anticoagulation for atrial fibrillation or atrial flutter, no contraindications NM 75.4 95
Values are percentages.
In the GWTG registry, mechanical ventilation was required in 1.1% of patients. In-hospital mortality rate was 3.4%, and mean length of hospital 
stay was 5.7 days (median 4.0 days).
HF indicates heart failure; HIQR, Hospital Inpatient Quality Reporting; AHA GWTG-HF, American Heart Association’s Get With The 
Guidelines–Heart Failure; VHA, Veterans Health Administration; LVEF, left ventricular ejection fraction; ARB/ACEI, angiotensin receptor 
blocker/angiotensin-converting enzyme inhibitor; LVSD, left ventricular systolic dysfunction; and NM, not measured.
*
HIQR Program includes data from all payers, including Medicare and Medicaid.
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Table 21-6
Additional ACTION-GWTG Quality-of-Care Metrics for ACS Care, 2011
Quality Metrics Overall STEMI NSTEMI
ECG within 10 min of arrival 62.4 74.2 57.1
Aspirin within 24 h of arrival 97.6 98.4 97.1
Any anticoagulant use* 93.2 95.4 91.7
Dosing error
 UFH dose 48.6 47.5 49.4
 Enoxaparin dose 11.8 10.6 11.9
 Glycoprotein IIb/IIIa inhibitor dose 7.2 7.4 7.0
Aspirin at discharge 98.3 98.9 97.9
Prescribed statins on discharge 98.4 99 98.1
Adult smoking cessation advice/counseling 98.4 98.7 98.1
Cardiac rehabilitation referral 76.5 83.2 72
In-hospital mortality† (95% CI) 4.6 (4.4–4.7) 5.9 (5.7–6.2) 3.7(3.5–3.8)
Values are percentages.
ACTION-GWTG indicates Acute Coronary Treatment and Intervention Outcomes Registry–Get With The Guidelines; ACS, acute coronary 
syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; ECG, 
electrocardiogram; UFH, unfractionated heparin; and CI, confidence interval.
*
Includes UFH, low-molecular-weight heparin, or direct thrombin inhibitor use.
†
Excludes transfer-out patients.
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Table 21-7
National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care, 
2010
Commercial, % Medicare, % Medicaid, %
AMI
 β-Blocker persistence* 75.5 83.1 76.3
Cholesterol management for patients with cardiovascular disease
 Cholesterol screening 88.9 88.5 82.0
 LDL cholesterol control (<100 mg/dL) 59.9 56.7 42.8
Hypertension
 BP <140/90 mm Hg 63.4 61.9 55.6
DM
 HbA1c testing 89.9 90.4 82.0
 HbA1c>9.0% 27.3 25.9 44.0
 Eye examination performed 57.7 64.6 53.1
 LDL cholesterol screening 85.6 87.8 74.7
 LDL cholesterol <100 mg/dL 47.7 52.1 34.6
 Monitoring nephropathy 83.6 89.2 77.7
 BP <140/90 mm Hg 65.7 62.3 60.4
Advising smokers and tobacco users to quit 76.7 77.9 73.6
BMI percentile assessment in children and adolescents 35.2 N/A 37.3
Nutrition counseling (children and adolescents) 37.4 N/A 45.6
Counseling for physical activity (children and adolescents) 35.3 N/A 36.7
BMI assessment for adults 40.7 50.4 42.2
Physical activity discussion in older adults (65 and older) N/A 52.3 N/A
Values are percentages.
AMI indicates acute myocardial infarction; LDL, low-density lipoprotein; BP, blood pressure; DM, diabetes mellitus; HbA1c, hemoglobin A1c; 
BMI, body mass index; and N/A, not available or not applicable.
*β-Blocker persistence: Received persistent β-blocker treatment for 6 months after AMI hospital discharge.
Circulation. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
et al. Page 469
Table 21-8
Quality of Care for EMS-Treated Out-of-Hospital Cardiac Arrest
Overall Adults Children
Bystander CPR, mean (95% CI), % 40.1 (38.9–41.3) 40.1 (38.9–41.4) 55.9 (49.1–62.7)
Shocked by AED before EMS, mean (95% CI), % 1.8 (1.5–2.2) 1.9 (1.5–2.2) 1.0 (0–2.3)
Chest compression fraction during first 5 min of EMS CPR, mean (SD)* 0.79 (0.22) 0.79 (0.22) 0.80 (0.19)
Compression depth, mean (SD)* 39.2 (14.9) 39.3 (14.9) 31.9 (14.2)
Preshock pause duration, mean (SD)† 15.4 (24.3) 15.4 (24.4) 13 (N/A)
Time to first EMS defibrillator applied, mean (SD), min 7.4 (9.0) 7.4 (9.2) 6.7 (3.2)
EMS indicates emergency medical services; CPR, cardiopulmonary resuscitation; CI, confidence interval; AED, automated external defibrillator; 
and SD, standard deviation.
*
During first 10 minutes of resuscitation.
†Up to and including first 6 shocks.
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Table 21-9
Quality of Care for In-Hospital Cardiac Arrest
Overall
Time to first shock within 3 min* 92.1% (91.0%–93.2%)
Hypothermia after resuscitation maintained between 32°C and 34°C 35.6% (30.5%–40.7%)
*Among those with a first recorded rhythm of ventricular fibrillation, pulseless ventricular tachycardia, or shockable by automated external 
defibrillator.
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Table 21-10
Timely Reperfusion for ACS and Stroke, 2011
Quality-of-Care Measure
VHA* (for STEMI) 
or GWTG-Stroke 
(for Stroke)
National Data 
From HIQR 
Program† ACTION-GWTG STEMI‡
STEMI
 tPA within 30 min 50§ 58.1 46.8§
 PCI within 90 min 69 92.5 94.2
Stroke
 IV tPA in patients who arrived <2 h after symptom onset, 
treated ≤3 h
78.3 N/A N/A
 IV tPA in patients who arrived <3.5 h after symptom onset, 
treated ≤4.5 h
57.9 N/A N/A
 IV tPA door-to-needle time ≤60 min 33.8 N/A N/A
Values are percentages.
ACS indicates acute coronary syndrome; VHA, Veterans Health Administration; STEMI, ST-segment–elevation myocardial infarction; GWTG-
Stroke, Get With The Guidelines–Stroke; HIQR, Hospital Inpatient Quality Reporting; ACTION-GWTG, Acute Coronary Treatment and 
Intervention Outcomes Registry–Get With The Guidelines; tPA, tissue-type plasminogen activator; PCI, percutaneous coronary intervention; IV, 
intravenous; and N/A, not applicable.
*VHA: acute myocardial infarction patients.
†
HIQR Program includes data from all payers, including Medicare and Medicaid.
‡ACTION Registry: STEMI and NSTEMI patients are reported separately. Patients must be admitted with acute ischemic symptoms within the 
previous 24 hours, typically reflected by a primary diagnosis of STEMI or NSTEMI. Patients who are admitted for any other clinical condition are 
not eligible.
§
Indicates low number.
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Table 22-1
2010 National Healthcare Cost and Utilization Project Statistics: Mean Hospital Charges, In-Hospital Death 
Rates, and Mean Length of Stay for Various Cardiovascular Procedures
Procedure
Mean Hospital 
Charges, $
In-Hospital 
Death Rate, %
Mean Length 
of Stay, d ICD-9 CM Procedure Codes
Total vascular and cardiac surgery and 
procedures
71 330 3.00 6.2 35–39, 00.50–00.51, 00.53–00.55, 
00.61–00.66
Cardiac revascularization (bypass) 133 247 1.52 8.9 36.1–36.3
PCI 67 086 1.08 3.2 00.66
Cardiac catheterization 39 264 0.87 3.7 37.21–37.23
Pacemakers 65 538 1.12 5.0 37.7–37.8, 00.50, 00.53
Implantable defibrillators 146 941 0.62 5.4 37.94–37.99, 00.51, 00.54
Endarterectomy 35 189 0.22 2.6 38.12
Valves 186 622 4.22 10.9 35.1–35.2, 35.99
Heart transplantation 536 947 3.95 37.0 37.51
ICD-9-CM indicates International Classification of Diseases, Clinical Modification, 9th Revision; PCI, percutaneous coronary intervention. Data 
derived from the Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project Nationwide Inpatient Sample, 2010.9
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